Oral presentations  by unknown
S1
Oral presentations
Surveillance of resistance in M. tuberculosis
and potential impact of epidemiological
cut-off values
S6 The critical concentration is important
G. Skenders* (Stopini, LV)
There are two types of drug susceptibility testing − qualitative and
quantitative. Quantitative test Minimal Inhibitory Concentration (MIC),
the lowest drug concentration that completely inhibits bacterial growth
in vitro. Qualitative test gives only a suggested interpretation without
MIC. For M. tuberculosis qualitative tests have been developed without
correlation with MIC.
The critical concentration is deﬁned as the concentration which clearly
differentiates resistant clinical isolate from the susceptible one while
critical proportion for resistance is the percentage of resistant population
of an culture which separates out susceptible cultures from the resistant.
Originally these parameters were established by clinical trials and
recommended two or three drug concentrations and 1% or 10%
critical proportion for establishing resistance. To simplify the procedure
modiﬁcation was recommended with one critical concentration of drug
and 1% proportion. A culture which shows less than 1% growth on
a medium containing a test drug as compared growth on the control
is considered as susceptible while 1% or more growth is considered
as resistant for clinical purpose. This principle has been applied to
other culture based methods standardized against proportion method and
resistance ratio methods.
The proportion method using a deﬁned inoculum, growth on a growth
control is compared with the growth on culture medium containing
the critical concentration of the test anti-tuberculosis drug and then a
percentage is calculated. The test is to be read after 4 weeks.
The resistance ratio method where resistance ratio is deﬁned as ratio
of the MIC for the patient’s strain to the MIC for the drug susceptible
reference strain (H37Rv), both tested in same experiment. Reference
strain in this method standardizes the results. Reading after 4 weeks
of incubation, interpretation is given by determination of resistance ratio
between MIC of H37Rv and test strain as 2 or less for susceptible strains
and 8 or more for resistant strains.
In the absolute concentration method critical concentrations used were
similar to proposed for proportion method. Only one dilution of inoculum
is used for drug containing media and two drug free controls are used.
After 4 weeks of inoculation the inhibition of growth is reported if the
number of colonies is less than 20 on drug media with conﬂuent growth
on drug free control.
Clinical problems from parasitology
S12 Strongyloides hyperinfestation
F. Castelli*, M. Gulletta, L.R. Tomasoni, V. Del Punta, A. Melzani
(Brescia, IT)
Current estimates indicate that it affects 30 to 100 million people,
but accurate prevalence data are lacking. Although strongyloidiasis
is endemic in many tropical and subtropical countries (sub-Saharan
Africa, Latin America, Southeast Asia, and Northern Australia), foci
of low endemicity are also reported in temperate climates, such as the
Mediterranean coast, Eastern Europe, and the southeastern United States.
The asexual biological cycle of the human parasite Strongyloides
stercoralis in the body of the human host leads to continuous auto-
infestation lasting for decades or even for the whole life. In case
of immune depression, the auto-infestation cycle accelerates with the
production o fan increasing number of larvae mainly within the
intestinal or respiratory tracts (hyper-infestation). The clinical onset of
Strongyloides hyper-infestation may be acute or sub-acute, with malaise
and asthenia. In case of fever, bacterial co-infection should be suspected.
Gastrointestinal symptoms are exacerbated and may be complicated
by intestinal ulcerations with melena and presence of rabditoides and
ﬁlarioides larvae in the ulcers and in the stools. Protein-dispersing
enteropathy may arise with edemas, ascytis, hypo-kaliemia.
Respiratory symptoms: Alveolar or interstitial hemorrhagic pneumonia
may occur, as well as pleuritis and lung abscesses. Pre-existing COPD
may exacerbate. Rabditoides and ﬁlariod larvae are present in the
sputum, in bronco-alveolar ﬂuid and in lung biopsies. Mortality due
to acute lung failure is high (50−79%).
When also other body districts are involved, Strongyloides dissemination
is present.
Considering the high case-fatality rate, it has been proposed that
Strongyloides infestation should be excluded (and preliminary treated
with ivermectine if detected) in those patients who are expected to
undergo immunosuppressive therapy, in particular if steroid-based, as
it is the case for many rheumatologic diseases.
Antimicrobial peptides − update for
infectious disease physicians
S15 Antimicrobial peptides in the lung
P. Hiemstra* (Haarlem, NL)
The lung is exposed to large numbers of inhaled pathogens on a
daily basis due to the large volumes of air that are inhaled. An
efﬁcient innate and adaptive immune system that is operative in the
lung prevents the development of respiratory infections. Antimicrobial
peptides and proteins (AMPs) are an important element of the innate
immune system that protects the mucosal surface of the lung against
infection. AMPs are a structurally diverse family of molecules with
broad-spectrum antimicrobial activities, and are often characterized by
cationic, amphipathic properties. A large variety of AMPs are present in
human airway secretions, including a- and b-defensins, the cathelicidin
hCAP18/LL-37, lactoferrin, lysozyme and the cationic antimicrobial
serine protease inhibitors secretory leukocyte proteinase inhibitor (SLPI)
and elaﬁn. In this overview, the focus will be on the peptides in the AMPs
family: the defensins and hCAP18/LL-37.
Whereas the main cellular source of the a-defensins and hCAP18/LL-37
in the lung is the neutrophil, airway epithelial cells produce b-defensins
and smaller amounts of hCAP18/LL-37. Expression of b-defensins by
airway epithelial cells is mainly regulated by microbial exposure and
inﬂammation, whereas vitamin D is an important regulator of epithelial
expression of hCAP18/LL-37. AMPs are an attractive candidate for
the treatment of respiratory (bacterial) infections, in part because they
are active against bacteria that are resistant to conventional antibiotics.
Currently two strategies are employed to bring AMPs to the clinic:
(i) use of (synthetic) AMPs; and (ii) enhancing their expression using
e.g. vitamin D or butyrate analogues.
Interesting, AMPs not only display antimicrobial activity, but are also
involved in a range of other processes, including inﬂammation, immunity
and wound repair. These non-antimicrobial functions are thought to
contribute to the in vivo antimicrobial activity of AMPs that has
been demonstrated in a variety of animal models. However, excessive
production of AMPs may contribute to inﬂammation. Current studies
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indicate that not only production, but also local factors (host and
pathogen-derived) that regulate the activity of AMPs are important for
their role in host defence. Especially studies in cystic ﬁbrosis have
revealed a variety of mechanisms that may restrict the antimicrobial
activity of AMPs, despite abundant local production.
Rare in the North, frequent in the South:
infections from the Mediterranean Basin
S20 Visceral leishmaniasis
Y. Ozbel* (Izmir, TR)
Leishmaniasis is a major vector borne disease which besides being
endemic in 88 countries worldwide, is the only “tropical” vector-borne
disease being endemic for decades in Southern Europe. In the world,
12 millions of persons suffer from leishmaniasis and about 500,000
visceral leishmaniasis (VL) cases occur every year (more than 50,000
die). Visceral form of clinical leishmaniasis is a systemic disease and
caused by protozoan parasites of the Leishmania donovani complex
which consists of the species L. donovani and L. infantum. Transmission
of L. infantum from dogs or infected people to people via different
species of sand ﬂies is primary route of infection.
L. donovani and L. infantum differ in their distribution, pathology, sand
ﬂy vectors and reservoir hosts. L. donovani is considered to be more
“aggressive” than L. infantum and causes anthroponotic VL in East
Africa and the Indian subcontinent. L. infantum/chagasi is responsible
for zoonotic VL in all countries of the Mediterranean Basin and Latin
America. Dogs are the main reservoir hosts for L. infantum and humans
are considered to be accidental hosts.
VL is a serious human disease that may be fatal if untreated. In
Mediterranean, VL primarily affected young children and infants, but
it is also often a complication in adults infected with HIV or those
receiving immunosuppressive drugs. The latter is one of the major health
problems in southern Europe in last decades.
The predominant L. infantum zymodeme is MON-1 in all endemic areas
of Europe. But recently, ﬁrst autochthonous case of L. donovani (MON-
37) was detected in Cyprus. The risk of introduction of new species
from countries where non-European species are endemic should also be
considered. L. donovani which is transmitted by different species of sand
ﬂies outside Europe might be hosted by most European sand ﬂies.
The direct, serological and molecular tools are available for the diagnosis
of VL and pentavalent antimonials are being used for treatment. They
are toxic and have to be used parenterally for prolonged period. But,
the lipid formulations of amphotericin B are an important advance in
therapy even the cost is high. An oral drug, Miltefosine, has been found
to be highly active against VL.
This presentation critically addresses the speciﬁcations of VL as a
Phlebotomus-borne disease and currently available diagnostic, treatment
and control regimens for VL.
S21 Toscana virus infections and other sandﬂy-transmitted
phleboviruses in the Mediterranean
R.N. Charrel* (Marseille, FR)
A signiﬁcant number of sandﬂies associated phleboviruses have been
shown to infect humans and cause various diseases from mild self-
resolutive febrile illness to meningitis and severe encephalitis, sometimes
with a fatal outcome. Among these sandﬂy-transmitted viruses, Toscana
virus is the most prominent one, probably due to its capacity to cause
neuro-invasive infections as demonstrated ﬁrst in Italy at the end of
the 1990’s, more recently in Spain, France, Turkey, Portugal, Croatia.
In France, Toscana virus is in the top 3 viruses (with enteroviruses and
herpesviruses) causing meningitis during summertime. Intriguingly, there
is still little data on the medical impact of Toscana virus in countries
located south of the Mediterranean.
There are accumulating evidence that other sandﬂy-transmitted phle-
boviruses (viruses within the species Sandﬂy fever Naples virus [SFNV)
and Sicilian virus [SFSV], or related to but distinct from SFNV and
SFSV) circulate in sandﬂies and cause infections in humans in France
and Spain, but also in Algeria and Tunisia. Recent evidence suggests
that there remain many other phleboviruses, not recognized at this time,
circulating in the Mediterranean area and possibly involved in human
infections. To address these neglected issues research programs based
on multidisciplinary approaches combining virology, infectious diseases,
entomology, epidemiology, social sciences must urgently be developed
and promoted for funding.
New models for microbiology lab services
S27 Core labs and point-of-care microbiology labs
M. Drancourt* (Marseille, FR)
In microbiology, the availability of automats performing great series
of tests for the direct diagnosis by culture and molecular biology
and the indirect diagnosis by serology requires the concentration of
the laboratories. The economic context also goes in this direction.
These are the reasons why we are witnessing everywhere in Europe,
including European countries where microbiology has been broken up
into small laboratories as in France, the trend of concentration of
the microbiological diagnosis activities on large platforms and “core-
laboratories”. Simultaneously to this trend of laboratories concentration,
has raised the need for performing the microbiological diagnosis within
the time of care − i.e. in less than 3 hours, which is asked more and more
frequently by clinicians. We have set up the Point-of-Care laboratories
which perform a deﬁnite number of microbiological analyses in less
than 3 hours which result must modify the medical management of
patients in terms of hospitalization, isolation and prescription of speciﬁc
anti-infectious drugs. In conclusion, our laboratories must advance in
two complementary directions: ﬁrst is fusing into large core-laboratories
in order to make cost-effective routine diagnosis in large series, to set
up new diagnostic protocols, to ensure the staff training and to give
a place for innovation and development of new tools and techniques;
the second is the spread-out of Point-of-Care laboratories including the
Remote Point-of-Care laboratories remaining under the responsibility
and the supervision of the Core-Laboratory staff by using the new
communication technologies.
Molecular virology
O30 Cytokine gene polymorphism and its association with
Epstein-Barr virus infection outcome in paediatric liver
transplant recipients
B. Kasztelewicz*, I. Jankowska, J. Pawlowska, J. Teisseyre,
P. Kalicinski, M. Pronicki, K. Dzierzanowska-Fangrat (Warsaw, PL)
Objectives: Paediatric liver transplant (LTx) patients (pts) are at
particular risk of developing EBV associated complications, including
PTLD (posttransplant lymphoproliferative disorder). The risk of PTLD
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is higher in pts with high viremia. However, some pts with persistently
high EBV DNA load do not develop lymphoproliferations, so there
is a need for new prognostic markers to deﬁne pts at risk of serious
complications. Polymorphism in cytokine genes inﬂuence susceptibility
to, and progression of the disease. The aim of the study was to assess
cytokine gene polymorphism that may be involved in pathogenesis of
EBV infection, in relation to EBV DNA load and PTLD development
in children after LTx.
Methods: One hundred seventy three children after LTx were included
in the study (mean age at LTx 4.4±8.6 years, and mean follow up
32.4±24 months). EBV DNA positive pts (N = 108) were stratiﬁed into:
chronically high viral load (>4000 copies/ug DNA for at least 6 months,
CHVL; N= 33), high viral load (>2000 copies, HVL; N= 33), low viral
load (<2000 copies, LVL; N= 26) and PTLD (N= 9) group. EBV DNA
negative pts (N = 65) served as a control group. Polymorphism of IFNG
+874, CCR5del32, TNFA-308, IL-10 −1117, MCP1+1543, IL-1b −511
and IL-1RN VNTR, were determined in all pts and related to EBV DNA
load, and PTLD development.
Results: Increased frequency of IL-1RN VNTR allele 2 was found in
PTLD pts when compared to non-PTLD pts (44% vs. 19%, p< 0.01,
OR= 4.28, (95%CI: 1.56–11.75)). Interestingly, the frequency of this
allele was signiﬁcantly decreased in CHVL pts when compared to PTLD
(5% vs 45%, p< 0.001) as well as to HVL (22%, p< 0.01), LVL (18%,
p< 0.05) and controls (22%, p = 0.001). Moreover, CHVL pts had lower
frequency of IL-1B −511 T allele then pts with PTLD (17% vs 39%,
p< 0.05) or controls (34%, p< 0.01). Mean EBV DNA load during 1st
year after LTx was signiﬁcantly higher in: (i) pt with IL-1RN VNTR
allele 1 then allele 2 (p< 0.05), (ii) pt with IL-10 −1117 C/C then C/T
genotype (p< 0.005). There was no association between TNFA −308,
CCR5del32, MCP1+1543 and IFNG +874 polymorphism, and PTLD
development or EBV DNA load in pts after LTx.
Conclusions: Presence of IL-1RN VNTR allele 2 may be a risk factor
for PTLD. Polymorphism in IL-1RN and IL-1B genes may be a useful
prognostic marker of CHVL. EBV DNA load in children after LTx may
be inﬂuenced by IL-10 −1117 and IL-1RN VNTR polymorphism.
O31 Cytokine gene polymorphism and congenital cytomegalovirus
infection
B. Kasztelewicz, J. Czech-Kowalska, M. Bartoszewska-Kornacka,
J. Romanska-Kita, G. Biaszczyk, D. Dzierzanowska,
K. Dzierzanowska-Fangrat* (Warsaw, PL)
Objective: Cytomegalovirus (CMV) is one of the most common viral
cause of congenital infections, which are associated with neurological
squeal or hearing loss in children. Primary infected women have high
risk for viral transmission to their foetus. Polymorphism in cytokine
genes may inﬂuence the susceptibility to infection. The aim of this study
was to assess the cytokine genes polymorphism that may be involved in
pathogenesis of CMV infection in newborns and their mothers.
Material: Three hundred twenty seven newborns (mean age 12 days)
with suspicion of congenital CMV infection and 209 mothers were
included in this study. Congenital CMV infection (deﬁned as CMV
DNA detection in blood/urine and/or positive anty-CMV IgM within
ﬁrst 3 weeks of life) was conﬁrmed in 34 children. Sixteen out of 209
mothers were CMV-seronegative during pregnancy. Polymorphism of
CCR5del32, TNFA-308, IL-10 −1117, MCP1+1543, IL-1b −511 and
IL-1RN VNTR, were determined in all newborns and mothers, and
related to congenital CMV infection and CMV serological status in
mothers.
Results: Signiﬁcantly decreased frequency of MCP1 +1543 C genotype
was found in CMV-seronegative mothers when compared to CMV
seropositive mothers (16.67% vs 54.76%, p = 0.03). In children with
congenital CMV infection a tendency for decreased frequency of
TNF-A “high producer” genotype was observed when compared to non-
infected newborns (11% vs 37%. p = 0.1). There was no association
between CCR5del32, IL-10 −1117, IL-1b −511 and IL-1RN VNTR
polymorphism and congenital CMV infection, seronegativity in mothers
as well as no association between mother-child’s cytokine genotype and
risk for congenital CMV infection.
Conclusion: Genetic polymorphism in MCP1 +1543 may contribute to
CMV seronegativity in mothers and thus indirectly inﬂuence the risk for
CMV primary infection during pregnancy and virus transmission to the
foetus.
O32 Quantitation of human herpesvirus-6 and -7 DNAs in
different blood fractions from blood donors
A. Gautheret-Dejean*, B. Ge´raudie, M. Charrier, D. Heurte´,
M. Desmonet, M-A. Bartoletti, P. Bonnafous, C. Penasse, H. Agut
(Paris, FR)
Objectives: The diagnosis of human herpesvirus-6 (HHV-6) or -7
(HHV-7) infections is based on the quantitation of viral genomic DNA
in blood. The aim of our study was to deﬁne usual values of HHV-6
and HHV-7 loads in different blood fractions (whole blood [WB],
mononuclear cells [PBMCs], polymorphonuclear cells [PMNLs]) of
blood donors.
Methods: For 200 blood donors, 10mL of blood were sampled on
EDTA. After putting aside aliquots of WB, PBMCs and PMNLs were
separated using Ficoll and dextran gradients, respectively. Nucleic acids
were extracted using QIAamp® DNA blood mini kit. Quantitation of
HHV-6 and HHV-7 DNAs was carried out using real-time PCR assays
and viral loads were expressed as the number of viral genomic equivalent
copies per million of cells (EqCop/M).
Results: HHV-6 DNA was detected in 8% of WB, 10.5% of PMNLs and
16.5% of PBMCs samples, whereas HHV-7 DNA was detected 51.5%
of WB and PMNLs and 62% of PBMCs samples. Median loads were 81
EqCop/M in WB, 34.5 EqCop/M in PMNLs and 62 EqCop/M in PBMCs
for HHV-6, and 129 EqCop/M in WB, 62 EqCop/M in PMNLs and
225 EqCop/M in PBMCs for HHV-7. One subject had chromosomally
integrated HHV-6 with high viral loads: 2.23×106 EqCop/M in WB,
2.55×106 EqCop/M in PMNLs, 2.84×106 EqCop/M in PBMCs, and
3.21×106 in plasma.
Conclusion: These results conﬁrm that PBMCs are the main com-
partment for HHV-6 and -7 in blood, the presence of viral genome
in PMNL probably corresponding to phagocytosis phenomenon. These
results allow us to deﬁne usual median viral load values in WB, 100
EqCop/M for HHV-6, 150 EqCop/M for HHV-7, commonly encountered
in immunocompetent patients who control the viral infection. Finally, the
prevalence of chromosomally integrated HHV-6 in France is 0.5%.
O33 Simultaneous detection of inﬂuenza A and its subtypes
(H1, H3, 2009 H1N1), inﬂuenza B, and RSV A and B in
respiratory specimens on an automated, random access,
molecular platform
B. Buchan, N. Anderson, P. Jannetto, N. Ledeboer* (Milwaukee, US)
Introduction:Multiplexed molecular detection of inﬂuenza A and B and
RSV is becoming increasingly available with a number of commercial
assays on the market. However, there are no ‘sample-to-result’ platforms
that detect these viruses along with inﬂuenza A and RSV subtypes.
Numerous studies have demonstrated increased sensitivity of these
techniques compared to culture and antigen detection methods. This
study evaluated the sensitivity and speciﬁcity of Nanosphere’s Verigene
System, with the Processor SP, for the detection of these respiratory
viruses.
Methods: Nasopharyngeal specimens were collected at multiple sites
during the 2008−9 and 2009−10 respiratory seasons. The presence of
inﬂuenza A/B and RSV was determined using culture/DFA. Inﬂuenza
A and RSV subtypes were determined using bi-directional sequencing.
Discrepant results were resolved using bi-directional sequencing. The
culture/DFA and bi-directional sequencing results for the samples were
blinded to the investigators until the conclusion of the study.
Results: Of the 323 specimens enrolled in the clinical trial, 121 were
culture/DFA positive for Inﬂuenza A, 14 were positive for inﬂuenza B,
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33 were positive for RSV, and 155 specimens were culture/DFA negative.
In comparison to culture/DFA for inﬂuenza A, the RV+ assay was 100%
sensitive and 97.0% speciﬁc. For inﬂuenza B, the RV+ assay was 100%
sensitive and 100% speciﬁc. For RSV, the RV+ assay was 97.0% sensitive
and 99.3% speciﬁc. There were 9 discrepant specimens between RV+
and culture/DFA. Bidirectional sequencing revealed that the RV+ assay
resulted in 8 additional true positives which were otherwise negative
by culture/DFA, and 1 additional true negative which was resulted as
positive by culture/DFA. All positive inﬂuenza A samples were subtyped
as 2009 H1N1 by sequencing (n = 127). The RV+ assay performance for
this subtype was 99.2% sensitivity and 100% speciﬁcity. For the H1 and
H3 subtypes, the speciﬁcities ranged from 99.7–100%. For the RSV A
and B subtypes, the sensitivities and speciﬁcities were 100% and 100%,
respectively, for both subtypes.
Conclusion: The RV+ assay for detection and subtyping of respiratory
viruses offers a rapid result time of ~2.5 hours with sensitivity and
speciﬁcity equal to or greater than traditional culture-based detection
methods. Additionally, the fully automated platform allows simple, on-
demand assay set-up which permits workﬂow ﬂexibility and requires
minimal hands on time.
O34 Detection of drug-resistant hepatitis B virus mutant strains
using ultradeep pyrosequencing in patients with chronic
hepatitis B
S.Y. Ko*, H.B. Oh, C.W. Park, J.E. Lee (Seoul, KR)
Objectives: Current methods of detecting hepatitis B virus (HBV)
drug-resistance mutations are mainly direct sequencing and reverse
hybridization, but haplotype assessment is not allowed by both methods.
Therefore mutations detected cannot be conﬁrmed whether they exist
in the same virus strain. Massively parallel ultradeep pyrosequencing
(UDPS) by Roche GS-FLX 454 Genome Sequencer was used to
detect drug-resistance mutations in patients with chronic hepatitis B.
We developed a sequence analysis program exclusive for analyzing
haplotypes of HBV drug-resistance mutations.
Methods: Samples from 30 chronic hepatitis B patients were obtained;
25 antiviral drug-treated and 5 drug-naı¨ve. HBV DNA titers were
greater than 1.0×104 IU/mL in all samples. 8 primer pairs were used
to obtain partially overlapping amplicons covering most of the HBV
genome. Frequencies of drug-resistance mutations were estimated using
the sequence analysis program and the results were compared with that
of direct sequencing. Haplotypes of drug-resistance mutations in each
sample were identiﬁed and their clinical relevance was investigated.
Results: A total of 369,603 clonally ampliﬁed fragments (reads) were
obtained from UDPS on 30 samples and the average number of reads
covering drug-resistance mutation region per sample was 1735 (451–
4526). Almost whole genome of HBV except between nt1582-nt1736
was sequenced. UDPS detected additional drug-resistance mutations
that were not detected by direct sequencing in 19 samples which
frequencies were between 1.1% and 23.8%. Of the 25 patients with
history of entecavir treatment, 20 patients were found to have haplotypes
of entecavir-resistance mutations. Haplotypes of entecavir-resistance
mutations were identiﬁed in all patients who experienced virologic
breakthrough during entecavir treatment or who had reduced sensitivity
to entecavir treatment.
Conclusion: Drug-resistance mutation testing in chronic hepatitis B
patients by UDPS was sensitive and accurate, detecting mutations
with frequency as low as 1.1% and estimating the mutation frequency
by analyzing an average of 1735 reads per sample. Identiﬁcation
of haplotypes of HBV drug-resistance mutations using the sequence
analysis program developed in this study will be useful in interpreting
virologic breakthrough and reduced sensitivity to treatment.
O35 Real-time Epstein-Barr virus PCR for the diagnosis of
primary EBV infection
C. Gartzonika, E. Kapsali*, N. Zotos, E. Priavali, H. Sakkas,
D. Papamichail, E. Papapetrou, A. Mavridis, S. Levidiotou (Ioannina,
GR)
Objectives: Speciﬁc viral laboratory diagnosis of primary Epstein-Barr
Virus (EBV) infection is usually based on antibody-detection assays.
Nonetheless, despite the availability of several different serological
markers EBV status of some patients is not easily resolved. Thus EBV
PCR has been added as a diagnostic tool. The aim of the present
study was to investigate the diagnostic utility of EBV DNA detection in
primary EBV infection in comparison with serological diagnosis and to
determine the plasma level of EBV DNA.
Methods: Sera from patients referred for suspected primary EBV
infection, were tested for heterophile antibodies (Monospot test), IgM
antibodies against viral capsid antigen (VCA IgM) and IgG against
nuclear antigen (EBNA IgG). A quantitative real time EBV PCR assay
(Light Cycler EBV Quant kit) was simultaneously performed in plasma
of 118 patients, aged 1−47 years, with negative IgG antibobies for
EBNA. In eighteen EBV DNA positive patients follow-up samples in
the course of disease were obtained and investigated.
Results: Forty three out of 46 patients (93.5%) with serologically
conﬁrmed primary infection as shown by the presence of VCA IgM
and heterophile antibody, were EBV DNA positive and the measured
viral loads ranged from 4.56×102 to 7.6×104 copies/ml. The three
samples found negative by PCR were collected 13 to 15 days after
onset of symptoms. By performing real time RCR in the remaining
72 samples, twenty four extra cases with viral load ranging of 2.05×102
to 3.0×104 copies/ml were diagnosed: in 20 of them, mainly children,
with detectable VCA IgM, heterophilic antibodies could not be detected
and in the other four, VCA IgM antibodies were absent. EBV DNA
load was detectable in all samples withdrawn until day 12 after onset of
symptoms. Higher viral load levels were detected in younger patients.
Conclusion: According to our results, use of EBV PCR assay resulted in
an increase in deﬁnitive diagnosis of primary EBV infection, enhanced
overall diagnostic efﬁcacy by 20.3%. Real time PCR is a reliable tool for
diagnosis of primary EBV infection early in the course of disease and
may especially serve as a useful diagnostic supplement in serologically
unclear cases of EBV infection.
O36 Nucleotide variation of Dengue virus serotype 2 during viral
persistence after acute infection in adults
M. Sriprapun*, C. Laosakul, S. Krajiw, K. Arunyingmongkol,
P. Siriyasatien, W. Kulwichit (Bangkok, TH)
Objectives: Nucleotide variations during long-term virus infection are
reported in ﬂavivirus infections: hepatitis C and West Nile viruses.
Dengue is also a ﬂavivirus, regarded as the most important and
widespread arthropod-borne disease. In recent ECCMIDs, our group’s
oral presentations demonstrated extended presence, after acute infection,
of live and culturable dengue virus in several specimens including urine.
Here we performed a pilot study to see if nucleotide changes were present
during the time frame.
Methods: Blood (plasma and peripheral blood mononuclear cells
(PBMCs)) and non-blood (urine, saliva and buccal cells) samples were
collected during acute, convalescent and late convalescent periods from
5 adult patients infected with dengue serotype 2. Reverse transcription
(RT) nested-PCR using primers speciﬁc to dengue envelope (E) gene,
per a published protocol, was performed using RNA from the processed
samples. The expected PCR products of 434 bps were puriﬁed and
sequenced. Nucleotide sequences were translated into amino acid
sequences using ExPASy tools. Both nucleotide and amino acid sequence
variations were analyzed by CLUSTALX2.
Results: RT nested-PCR could detect dengue virus during acute,
convalescent and late convalescent periods of infection in certain
samples. The virus was detected in PBMCs as late as 21 and 27 days
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after the onset of illness, respectively. In the other 3 patients, the virus
was detected in urine as late as 14, 15, and 23 days after onset of
illness, respectively. Nucleotide sequence variations were present in late
convalescent PBMCs samples of both patients when compared with their
own sequences in acute and convalescent samples. The differences are at
1.80 and 0.77 percents, respectively. However, the sequences ampliﬁed
from urine samples of the other 3 patients did not show variation among
the periods of infection. There were no amino acid changes in all 5
patients when compared among different periods of infection.
Conclusion: Survival of dengue virus in different cell types may be
correlated with genetic variations. PBMCs is one of the principal sites
for dengue replication. The viruses may actively replicate in such
compartment which is highly exposed to and receives an impact from
immune pressure. This may contribute to more diversity in dengue virus
population. Future studies are warranted to delineate such phenomena.
O37 Genetic diversity of Crimean-Congo haemorrhagic fever
viruses in Turkey
A.T. Kalaycioglu*, R. Durmaz, A. O¨zkul, Y. Uyar, G. Korukluoglu,
M. Ertek (Ankara, TR)
Objectives: The aim of this study was to investigate the genetic diversity
of Crimean-Congo hemorrhagic fever viruses (CCHFVs) by exploiting
both partial S and M RNA segments. In particular, a part of the Gn
region of M segment RNA that was subjected in our study harbours
virus neutralising epitopes and it is also important for involving in virus
pathogenecity. The analysis of Gn region of M segment would lead us the
determine the critical nucleotide and aminoacid variations among virus
isolates that could also facilitate the appropriate selection of vaccine
candidate virus.
Methods: The present study was focused mainly in CCHFVs isolated
from a total of 48 patients sera from the several provinces within the
Kelkit Valley of Turkey between 2009 and 2010 years. A one step RT-
PCR was used to amplify a 536 bp region of partial ‘S’ and a 890 bp
region of partial M segments of CCHFV isolates that were then subjected
for sequencing. The phylogenetic analysis were generated using the
Neighbor-joining (NJ) method. Phylogenetic analyses were conducted
in MEGA4.
Results: The phylogenetic analysis based on both partial ‘S’ and M
segments revealed that the distribution of CCHFVs on phylogenetic trees
reﬂected their continental origin and all CCHFV isolates subjected for
this study were shown to place within the European lineage (Europa I). In
addition, It was observed from the both S and M segments analysis that
CCHFVs circulating in Turkey were classiﬁed in two main clusters (I
and II) that together with representatives of viruses including eastern
European viral strains (Drostov, Kashmanow) and western European
viruses (Hoti, Kosovo). In addition, the nucleotide variations observed in
Gn region of CCHFV isolates resulted in several amino acid variations
between 638 and 763 amino acids.
Conclusions: The phylogenetic analysis of partial S and M segments
of CCHFV isolates derived from infected humans have updated and
the detailed the genetic status of viruses circulating in Turkey. Our
results highlights the genetic stability of CCHFVs circulating in Turkey.
This could be an advantage for selecting appropriate vaccine strain
and enhance the success for the protective efﬁcacy of vaccines under
development. In addition, we could also suggest that CCHFVs are tend
to be region or continent speciﬁc.
O38 Characterisation of HIV-1 genetic diversity in established and
recent infections among intravenous drug users from Lisbon,
Portugal
A.P. Francisco*, R. Coutinho, R. Silva, E. Paixa˜o, A.F. Silva, E. Pa´dua
(Lisbon, PT)
Objectives: The increasing number of new human immunodeﬁciency
virus type 1 (HIV-1) genetic forms has drawn attention to their potential
differences in transmissibility and virulence, and has raised questions
concerning the possible impact of molecular changes in epidemiology
and spread of infection. The aim of this study was to characterize the
genetic diversity of HIV-1 strains in circulation among intravenous drug
users (IDU) who have acquired the infection in two speciﬁc periods of
time: one group before 1998 (Established Infections, EI), and the other
group between 2004 and 2006 (Recent Infections, RI).
Methods: Blood samples were collected from 46 HIV-1-infected IDU
living in the Lisbon area, Portugal, including 25 cases of EI and 21 cases
of RI. Viral sequences were ampliﬁed by nested PCR from proviral DNA
and four genomic regions were characterized: env C2V3C3 and gp41
ectodomain, partial gag and full-length nef genes. The assignment of a
viral subtype was achieved by phylogenetic inference and bootscanning
analysis. Putative amino acid sequences were determined and the
conservation/disruption of functional domains in Env and Nef target
regions was analyzed.
Results: Combined genetic data analysis showed a signiﬁcant dif-
ference between groups (p< 0,001). A high proportion of subtype
B strains (60%, n = 15) was found in EI group, while the majority
of RI genetic forms was identiﬁed as non-B subtypes (90%,
n = 19), namely, subtype A, recombinant form AG and the mosaic
genomes structures A/BJ/G/CRF02_AG/CRF14_BG, B/G/CRF14_BG,
and A/G/CRF02_AG/CRF14_BG. Subtype G and BG recombinant
forms were present in both groups.
The analysis of Env and Nef functional motifs revealed a high degree
of conservation and no signiﬁcant differences were found between both
groups. However, the presence of several signatures associated with B
and non-B subtypes was observed, including speciﬁc polymorphisms for
subtype G, AG and BG viral forms.
Conclusions: The genetic analysis of HIV-1 strains revealed a signiﬁcant
change in the molecular epidemiology of infection, regarding B and
non-B subtypes, with the introduction of new viral forms in this IDU
population between 1998 and 2004. HIV-1 genetic diversity and the
differences between the viral subtypes require further investigation in
order to evaluate the potential implications in treatment and progression
of infection.
O39 New microﬂuidic platforms for the simultaneous detection of
pathogens using TaqMan® probe-based real-time PCR
A. Ferlinz*, L. Healy, K. Warrington, J. Sherlock, J. Fryer, L. Young,
A. Gottleib (Berlin, DE; Potters Bar, Manchester, UK)
Over the past decade, nucleic acid ampliﬁcation tests have been
developed for a broad range of pathogens and increasingly replaced
traditional methods. The key drivers for this shift of technology are the
high sensitivity of TaqMan® probe based Real-time PCR Assays and
also the ability to multiplex several assays in one reaction vessel. Here
we introduce microﬂuidic tools (branded TaqMan® Array Cards) that
allow the simultaneous detection of up to 384 pathogens in one sample.
The validation of one application of this technology, the “TaqMan Array
Human Viral Screening Card”, will be documented in this study. We
ﬁrst tested a panel of ‘real-time’ quantitative PCR (qPCR) reagents for
their speciﬁcity and sensitivity using 96well plates. Single tube TaqMan®
Assays were designed against conserved regions of BKV, JCV, HIV-1,
HIV-2, HTLV-I, HTLV-II, HCV, HBV, HPV-16, SV40, HHV7, CMV,
Adenovirus C, HSV-1, HSV-2 and HHV4 genomes.
All assays successfully and speciﬁcally detected their respective synthetic
target sequence oligonucleotide (“artiﬁcial template”) down to the single
copy level. Sensitivity and speciﬁcity were also tested in dilution series
of nucleic acid extracted from cell cultures infected with those viruses.
In summary, all tested assays showed excellent linearity and efﬁciency
with a very high degree of speciﬁcity for their targets. No cross-reactivity
was detected between assays of viruses belonging to the same family.
TaqMan Assays for 15 pathogen targets plus one internal positive
control are pre-loaded on the TaqMan Array Human Viral Screening
Cards allowing the simultaneous assessment of these targets in triplicate
ampliﬁcations from 8 samples in parallel. We tested sensitivity and
speciﬁcity using both artiﬁcial templates and nucleic acid extracted
from cell cultures infected with those viruses on these cards. Again,
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all TaqMan Assays showed excellent linearity and efﬁciency and a very
high degree of speciﬁcity for their targets, even in such a small reaction
volume (2ml). In conclusion, the TaqMan Array Human Viral Screening
Cards will be used as invaluable tools in ensuring that for example human
ES cell cultures, particularly from novel sources, are pathogen-free.
Moreover, additional TaqMan Array Cards for the screening & detection
of viruses, bacteria and parasites are currently under development and
will be made available in the coming year.
Hospital antibiotic use: causing or coping
with multi-drug resistance?
O40 Clinical impact of unsolicited post-prescription antibiotic
review in surgical and medical wards: a randomised
controlled trial
P. Lesprit*, C. Landelle, F. He´mery, C. Brun-Buisson (Cre´teil, FR)
Objectives: To describe the clinical impact of an early review of
antibiotic prescriptions in hospital using unsolicited infectious disease
physician counselling (IDPC).
Methods: Patients hospitalized in surgical or medical wards and
receiving any of 15 selected antibiotics were randomized between day
3 and 5 to a control group (C), where IDPC was provided only
when requested by ward physicians, and an intervention (I) group,
where all prescriptions were systematically evaluated by the IDP.
Improved antibiotic use was sought by withdrawing or de-escalating
therapy, promoting oral switch or reducing duration of therapy whenever
appropriate. Clinical outcomes of patients were compared between the
2 groups using the following criteria: hospital length of stay (HLOS),
in hospital mortality or at 60 days after randomization, intensive care
admission (ICU) within 7 days after randomization, new course of
antibiotic therapy 7 days after completing the ﬁrst course and rate of
readmission with antibiotic therapy within 60 days after randomization.
Results: 753 patients were included (C = 377, I = 376), of which
32.4% had hospital-acquired infection. Microbiological documentation
of infection was obtained for 46.7%. Solicited IDP advices were
requested for only 11.9% of patients in the (C) group; while 83.8%
of antibiotic prescriptions in the (I) group prompted IDPC, including
shortening the duration of therapy (27.4%) stopping (26.1%) or de-
escalating (25.0%) therapy and encouraging an oral switch (15.2%),
or other (17.1%) recommendation (e.g., changing the dosing regimen
or increasing the duration). Most (83.2%) IDP recommendations were
adhered to by physicians. The overall duration (median; [interquartile
range]) of therapy was lower in the (I) group than in the (C) group
(7 [5−10] vs. 8 [6−11] days; p< 0.001). There was no difference in
clinical outcomes of patients between the (I) and (C) groups, whether
in HLOS (15 [9−25] vs. 15 [9−27] days; p = 0.95), or rates of ICU
admission (1.9% vs. 1.6%; p = 0.78), new antibiotic courses (4.5% vs.
6.6%; p = 0.21), readmission with antibiotics (7.7% vs. 10.6%; p = 0.34),
and deaths in the hospital (6.9% vs. 6.6%; p = 0.88) or at 60 days (9.8%
vs. 10.1%; p = 0.91).
Conclusions: Unsolicited antibiotic review of antibiotic prescriptions
by IDP was associated with high rates of counselling and physicians’
compliance, resulting in shorter courses of antibiotic therapy, with no
evidence of a detrimental effect on clinical outcomes of patients.
O41 Amikacin and tobramycin for Pseudomonas aeruginosa and
Acinetobacter baumannii complex according to PK/PD and
microbiological breakpoints: is there a difference to revise
antibiotic policies?
F. Cardoso*, S. Gomes, E. Alves, C. Cardoso, A. Ferreira (Rio de
Janeiro, BR)
Objectives: To compare amikacin (AMK) and tobramycin (TOB)
susceptibility against Pseudomonas aeruginosa (PA) and Acinetobacter
baumannii complex (ACN) considering the microbiological and phar-
macokinetics/pharmacodynamics (PK/PD) breakpoints (BP).
Methods: Consecutive non duplicate PA and ACN isolates collected
from a teaching hospital, after the species identiﬁcation by Vitek®
(BioMerieux), were tested by Kirby-Bauer method for AMK and TOB
using disk diffusion and e-test for MIC determination according to CLSI
2009. Only the susceptible bacteria detected by disk diffusion had MIC
determined by e-test. Susceptibility rates were recalculated by proposed
PK/PD BP of 4mg/mL for AMK and <2mg/mL for TOB.
Results: A total of 237 bacteria were obtained from September 2008
to May 2010, including 164 PA isolates from 64 blood cultures, 66
respiratory tract secretions and 34 urine, and 73 ACN isolates from 37
blood cultures, 27 respiratory tract secretions, 8 urine and 1 peritoneal
ﬂuid were tested. The great majority of samples was obtained after 48h
of patient admission. PA was susceptible to AMK in 89% and to TOB in
84% (p = 0.1), while ACN was susceptible to AMK in 70% and to TOB in
63% (p = 0.4) by disk diffusion method. However, analyzing the data with
lower BP showed an opposite trend, PA with MIC <4mg/mL for AMK
and MIC <2mg/mL for TOB were 57% and 76% susceptible (p = 0.05),
respectively; as ACN were only 40% and 46% susceptible (p = 0.4),
respectively. When MIC distributions were analyzed, the modal MIC
of TOB was 1mg/mL for both species and for AMK were 3−4 mg/mL
and 3mg/mL for PA and ACN, respectively. PA MIC90 was 2mg/mL for
TOB and 8mg/mL for AMK.
Conclusion: The decrease of susceptibility was greater to amikacin
when lower breakpoints were applied and MIC distributions an-
alyzed. Nonetheless, recommendations of higher doses of AMK
(25−30mg/kg/day) or TOB (7mg/kg/day) use based on PA MIC90
should be updated in this institution. Current BP (CLSI and EUCAST)
for aminoglycosides seem to be overvalued when compared to more
realistic PK/PD BP (TOB 1−2 mg/mL and AMK 2−4 mg/mL). To indicate
the best choice of drug and dosing for the empiric therapy of PA
and ACN infections that would provide adequate drug exposure and
enhanced bacterial killing, MIC distributions interpretation and new
reliable breakpoints for AMK and TOB should be available.
O42 The ECDC pilot Point-Prevalence Survey of healthcare-
associated infections and antimicrobial use: antimicrobial use
analysis
P. Zarb*, A. Muller, B. Coignard, J. Griskeviciene, K. Weist,
S. Hopkins, M. Goossens, S. Vaerenberg, B. Catry, V. Vankerckhoven,
H. Goossens, C. Suetens on behalf of the ECDC-PPS Study Group
Introduction: The ECDC pilot Point Prevalence Survey of healthcare
associated infections (HAI) and antimicrobial use (AU) in European
acute care hospitals (ECDC-pPPS) was coordinated by ECDC and
outsourced to a consortium led by the University of Antwerp (UA) in
collaboration with the French Institute for Public Health Surveillance
(InVS) and the Belgian Scientiﬁc Institute of Public Health (WIV-ISP).
Objectives: The objectives of the ECDC-pPPS were to test and ﬁnalize
a protocol to describe and estimate the prevalence of HAI and AU in
participating hospitals stratiﬁed by patients’ characteristics or invasive
procedures and to provide a standardized tool for hospitals to identify
targets for quality improvement.
Methods: All patients on ward at 8:00am and not discharged at the time
of survey were included. Each department was surveyed in one day.
A patient-based (PB) and a unit-based (UB) protocol were provided.
The UB protocol aggregated denominator data at ward level without
information on invasive procedures or severity. Most participants used a
web-based tool provided by UA for data collection and validation. This
study analyzed AU by McCabe score and invasive procedures (vascular
catheter, urinary catheter, mechanical ventilation (MV) or surgery) as
collected in the PB protocol.
Results: The prevalence of AU in the 66 participating hospitals was 35%.
Patient specialty signiﬁcantly correlated to proportion of treated patients:
intensive care [61%]; surgery [41%]; medicine [39%]; paediatrics [30%]
(p< 0.001). Penicillins and enzyme inhibitor (J01CR) was the most used
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class overall (18%), in treatment intent of community infections (20%)
and hospital infections (18%).
Fifty hospitals used the PB protocol and included 14 329 patients,
5 201 of whom received 7 359 antimicrobials. Patients with an
invasive procedure or with high McCabe score were prescribed more
antimicrobials (p< 0.001 see ﬁgure). With increasing McCabe score,
the top 5 drugs cumulative proportion decreased (42, 33 and 29%) while
wide-spectrum drugs ranked higher (e.g., meropenem [5th in McCabe
score 3]).
Conclusion: The PB protocol can help future surveys in analyzing trends
in AU since risk factors collected can be used to adjust comparisons
between hospitals with similar case-mix, helping local policy makers in
identifying targets for quality improvement.
O43 Initial antibiotic treatment patterns and failure rates among
hospitalised patients with complicated skin and skin structure
infections: a 4-year review within an integrated US healthcare
system
R. Adamson*, S. Amara, X. Huang (South Plainﬁeld, Jersey City, US)
Objectives: In 2005, the Infectious Diseases Society of America
published practice guidelines for the treatment of complicated skin
and skin structure infection (cSSSI). Changes in treatment patterns and
outcomes for hospitalised patients with cSSSI following implementation
of these guidelines are not well documented. This study assessed
changes in empiric cSSSI therapy and the associated outcomes following
publication of these guidelines.
Methods: The study was conducted at Saint Barnabas Health Care
System, a 3500-bed US healthcare system with 6 acute-care facilities.
Trendstar clinical billing and Cerner laboratory databases were used to
identify patients hospitalised for cSSSI and stratify them into 3 infection
cohorts: acute, chronic/ulcerative, and surgical-site infections. Data were
collected on patients admitted between 1/1/2006 and 12/31/2009 who
received parenteral antibiotic therapy for 48 hours beginning within 24
hours of admission. We studied patterns of initial (ie, within 24 hours of
admission) antibiotic therapy and failure rates for each treatment. Failure
was deﬁned as receipt of alternate antibiotic therapy providing broader/
different antimicrobial coverage not initiated within the ﬁrst 24 hours of
admission, drainage/debridement/amputation >72 hours from admission,
or transfer to an ICU.
Results: A total of 8162 patients (6254 acute, 615 chronic/ulcerative,
1293 surgical-site) were included in this analysis. From 2006 to 2009,
the top 5 regimens used empirically as monotherapy or part of a
multidrug regimen changed accordingly: vancomycin from 17.9% to
50.2%, levoﬂoxacin from 21.4% to 31.8%, piperacillin/tazobactam from
17% to 34.8%, ampicillin/sulbactam from 17.2% to 19.5%, and cefazolin
from 27.7% to 26.9%.
From 2006 to 2009, failure rates for each of the regimens increased:
vancomycin from 10.5% to 15.7%, levoﬂoxacin from 10.1% to 16.0%,
piperacillin/tazobactam from 9.4% to 13.2%, ampicillin/sulbactam from
5.8% to 10.1%, and cefazolin from 13.0% to 25.1%. Overall failure rates
for all regimens increased signiﬁcantly (chi-squared tests; p< 0.01).
Conclusion: Following implementation of the 2005 practice guidelines,
use of top regimens (containing vancomycin, levoﬂoxacin, piperacillin/
tazobactam, ampicillin/sulbactam) increased considerably. Failure rates
associated with all regimens rose signiﬁcantly. These results underscore
the need for new treatment alternatives to minimize the emergence of
drug-resistant bacteria.
O44 Development of national prescribing indicators for antimi-
crobials to support reduction in Clostridium difﬁcile infection
J. Sneddon, D. Nathwani*, A. Patton, W. Malcolm, E. Watson on behalf
of the Scottish Antimicrobial Prescribing Group
Objective: The Scottish Antimicrobial Prescribing Group (SAPG) is a
national multidisciplinary clinical forum formed to implement national
improvement initiatives via a network of NHS Board Antimicrobial
Management Teams (AMTs).
Reduction of Clostridium difﬁcile infection (CDI) is a priority in
Scotland and there is a national target of 50% reduction by March 2011.
SAPG were asked to develop measures related to antibiotic use to support
achievement of this target.
Method: A. Development of prescribing indicators. SAPG had issued
guidance to AMTs in July 2008 advising that antibiotics associated with
high risk of CDI should be restricted within local antibiotic policies
and this was used as the basis for development of prescribing indicators.
Following consultation with SAPG members and AMTs, three indicators
were agreed and announced in Chief Executive Letter from Scottish
Government in April 2009. Indicators and targets:
1. Indication recorded in notes and empirical antibiotic choice compliant
with local policy. Target 95% Compliance
2. Duration of surgical prophylaxis <24 hours and compliant with local
policy.
Target 95% Compliance
3. Seasonal variation in quinolone use in winter months compared with
summer months is <5%.
B. Data management. The Institute of Healthcare Improvement
methodology and data management system were chosen for the hospital
prescribing indictors and the primary care indicator was developed as a
standard report within the Prescribing Information System for Scotland.
C. Reporting. SAPG produces reports on national compliance with the
hospital indicators 3-monthly and for the primary care indicator annually.
AMTs can access their own ‘real time’ NHS Board data.
Results: 1. In acute admission units, national compliance with empirical
prescribing policy is currently 78% and compliance with indication
documented in notes is 91%.
2. In a sample of surgical specialties national compliance with surgical
prophylaxis policy is currently 95% and duration <24 hours is 100%.
3. Primary care seasonal variation of quinolones − 9 out of 14 NHS
Boards achieved the target of <5% for winter 2009−10 compared with
summer 2009.
Conclusion: National engagement and broad consultation has allowed
development of national prescribing indicators to support reduction in
CDI.
Use of quality improvement methodology and regular feedback of results
to prescribers has driven increasing compliance with the indicators.
O45 Nephrotoxicity of continuous infusion of vancomycin in
critically ill patients
H. Spapen*, K. Janssen van Doorn, W. Verbrugghe, R. Jacobs,
N. Dobbeleir, M. Diltoer, P. Honore´, P. Jorens (Brussels, Edegem, BE)
Objective: To determine the incidence and associated risk factors of
nephrotoxicity during continuous vancomycin treatment in critically ill
patients with Gram-positive pneumonia and/or bacteraemia.
Methods: Retrospective, observational, two-centre, cohort study. Pa-
tients with microbiologically documented Gram-positive pneumonia
and/or bacteraemia and normal baseline renal function were included.
Vancomycin was given as a 15mg/kg loading dose, followed by a
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continuous infusion of 30mg/kg/day. Vancomycin dose was adjusted
daily aiming at plateau concentrations of 15−25mg/L. Nephrotoxicity
was deﬁned according to the Acute Kidney Injury Network (AKI)
classiﬁcation as an increase in serum creatinine of 0.3mg/dL or a 1.5 to
2 times increase from baseline on at least two consecutive days following
initiation of vancomycin.
Results: 129 patients were studied of whom 38 (29.5%) developed
AKI. Patients with AKI had a higher lean body weight (77.3±15.0 vs.
70.5±15.2 kg; p = 0.02), had more diabetes (79% vs. 54%; p = 0.01) and
vasopressor need (87% vs. 59%; p = 0.002) and received vancomycin for
a longer time period (14.9±9.8 vs. 9.2±4.9 days; p = 0.05). Independent
variables contributing to nephrotoxicity were, in order of importance,
serum vancomycin levels, body weight, and SAPS 3 score. The incidence
of nephrotoxicity rose substantially when vancomycin levels exceeded
the target range. (<25mg/L (n = 3) vs. 25−30mg/L (n = 9); odds ratio
9.75; conﬁdence interval 2.41–39.52; p< 0.0001 and <30mg/L (n = 12)
vs. >30mg/L (n = 26); odds ratio 30.69; conﬁdence interval 10.49–89.83;
p< 0.0001).
Conclusion: Vancomycin concentrations exceeding 25mg/L during
continuous infusion are associated with increased nephrotoxicity.
Nephrotoxicity is more often seen in conditions that cause either acute
(shock) or chronic (diabetes) kidney injury. This study challenges the
concept that continuous vancomycin infusion might better reconcile
higher therapeutic efﬁcacy with less nephrotoxicity.
O46 Continuous versus intermittent infusion of vancomycin: the
eternal diatribe
M.A. Cataldo*, E. Grilli, M. Musso, E. Tacconelli, N. Petrosillo (Rome,
IT)
Objectives: International guidelines recommend the administration of
vancomycin by intermittent infusion (InI). Nevertheless, many clinicians
are used to administer it by continuous infusion (CI). Published studies
comparing the effectiveness and adverse effects of CI versus InI showed
inconclusive results. The main aim of this systematic review was
to summarise available evidence on the effect of CI of vancomycin
compared to the InI in patients with infections due to Gram-positive
bacteria.
Methods: MEDLINE and Cochrane databases were searched to identify
published studies (1956-November 2010) that compared the effect of
CI and InI of vancomycin on mortality, clinical cure, toxicity rates
and mean vancomycin serum concentration. Systematic review was
conducted combining and analyzing the relative risk (RR) and computing
a summary RR of the effects with 95% conﬁdence interval (CI). The
standardised mean difference (SDM) was calculated for continuous
outcomes. The I2 test was calculated to assess heterogeneity across
studies (signiﬁcant value considered for I2> 50%). Included studies were
appraised for methodological quality independently by two authors (RCT
for adequacy of randomization, allocation concealment, blinding, follow-
up, and use of intention to treat analyses; observational studies through
the Newcastle-Ottawa scale).
Results: One RCT and 5 observational studies were included in the
analysis with a total study population of 443 patients. The quality of
included studies was fairly good. Compared with InI, CI of vancomycin
signiﬁcantly reduced the risk of nephrotoxicity (RR 0.6, 95%CI
0.4−0.9, P = 0.02; I2 = 0) and was associated with a signiﬁcantly higher
vancomycin serum concentration (SDM 1.07, 95%CI 0.5−1.6, P< 0.001;
I2 = 83%). Overall mortality was not different in the two groups (RR
1.03, 95%CI 0.7−1.6, P = 0.9; I2 = 0). The effect of CI on clinical cure
and adverse effects rates was not assessed through a statistical approach
due to the lack of data. The Begg’s funnel plot and the Egger test
indicated no evidence of publication bias.
Conclusion: Our meta-analysis suggests that continuous vancomycin
infusion allows to reach an higher serum vancomycin concentration
with signiﬁcantly lower risk of nephrotoxicity. Evidence of a beneﬁt on
clinical success rates and mortality needs to be further explored through
RCT with adequate sample size, standardized methods of vancomycin
concentration measures and reliable deﬁnitions of outcomes.
O47 Are surgeons the only common denominator between
Clostridium difﬁcile infections, surgical site infections and poor
compliance to antibiotic prophylaxis in surgery guidance?
E. Byrne*, S. El-Sheikha, D. Fernandes, Z. Morad, A. Shaﬁq,
A. Hakeem-Habeeb, I. Sadasivam, E. Tingi, D. D’Silva, M. Przybylo,
A. Guleri (Blackpool, UK)
Background: Surgical site infections are associated with signiﬁcant
complications and an increase in mortality and length of stay. Literature
and guidelines suggest optimal prophylactic antibiotics decrease the risk
of post operative infections. Blackpool Victoria Hospital operates a
successful Clostridium difﬁcile infections (CDI) programme with high
emphasis on antibiotic stewardship and root cause analysis[RCA] of
CDIs. Inappropriate use of antibiotics has emerged as the key risk factor
undermining the program. We present ﬁndings from a comprehensive
multidisciplinary audit of compliance with trust antibiotic prophylaxis
in surgery guidelines − conducted by trainee doctors; associated key
ﬁndings from CDI-RCAs [joint microbiologist-infection control team
database] and remedial actions.
Methods: Prospective case review of 182 adult surgical in-patient
prescriptions including cardio-thoracic, general surgery, obstetrics & gy-
naecology, orthopaedics, urology and vascular cases between September
to November 2010.
Review of CDI root cause analysis database.
Results: Key ﬁndings from 182 surgical case prescriptions: Mean
age is 58y with 41% (74/182) females. 76% (107/132) of cases had
antibiotics prescribed appropriately. Compliance markedly varied (37–
100%) between specialities. The trust guidelines provide prophylactic
antibiotic recommendations in only 77% (139/182) of procedures.
Antibiotic prophylaxis guidance for cardiac and thoracic surgery is
absent. Antibiotic at induction time was appropriate in 29% (53/182).
Missing documentation in 40% (72/182); 11% (16/142) received post-
operative antibiotic treatment. 13% (18/141) cases had documented
antibiotic allergies.
CDI-RCAs: 113 cases of CDI were analysed. Inappropriate antibiotic
prescribing and non compliance to trust antibiotic guidance was
57%[64/113] each. Key ﬁndings − delayed sampling; prolonged/repeated
courses; poor documentation.
Discussion: Poor compliance to trust antibiotic guidelines, poor
documentation, gaps in trust antibiotic guidance, inappropriate use of
high risk antibiotics [co-amoxiclav, cephalosporins] are key ﬁndings from
this audit and CDI-RCAs. These were used to inform action plan and
strategy to address the CDI and HAI program. Some key steps include −
revised antibiotic guidance, joint ward rounds with microbiologists,
joint pharmacy-microbiologist antibiotic compliance audits, mandatory
infection prevention road shows, raising awareness teaching programme,
posters, performance management indicators, etc.
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O48 Procalcitonin-guided antibiotic stewardship in lower
respiratory tract infections. A real-life international
multicentre quality surveillance (ProREAL)
W.C. Albrich*, F. Dusemund, B. Bucher, S. Meyer, R. Thomann,
F. Ku¨hn, M. Sprenger, D. Amin, P. Hausfater, P. Schuetz, B. Mu¨ller
for the ProREAL study team
Objectives: Procalcitonin (PCT) safely and effectively reduced antibiotic
use in patients with lower respiratory tract infections (LRTIs) in
controlled study conditions, yet experience outside of study conditions
is limited. We report the results of an observational quality surveillance
including centers in Switzerland (n = 10), France (n = 3) and the USA
(n = 1).
Methods: Consecutive adults with clinical suspicion of LRTI presenting
to the emergency departments or outpatient ofﬁces were enrolled and
registered in a central website, which provided antibiotic treatment
guidelines according to a previously published PCT-guided algorithm.
PCT was measured at the local sites using sensitive assays (Kryptor®,
BRAHMS or Vidas®, BioMerieux). The primary endpoint was duration
of antibiotic therapy.
Results: Of 1562 enrolled patients (mean age 67.8±18.5y; 44.4%
female), 1391 (89.1%) had an LRTI (community-acquired pneumonia
(CAP) 62.3%, acute exacerbation of chronic obstructive pulmonary
disease (AECOPD) 20.4%, acute bronchitis 16.0%). Algorithm
compliance overall was 69.0% with signiﬁcant differences between
diagnoses (bronchitis 80.6%, AECOPD 71.8%, CAP 62.6%; p< 0.001)
and between outpatients (65.7%) and inpatients (86.6%; p< 0.001).
Algorithm-experienced centers had higher compliance (82.5%) than
algorithm-naı¨ve centers (57.9%; p< 0.001). Geographical differences
were detected with high compliance in the Swiss centers (75.8%),
intermediate compliance in the French centers (66.0%) and low
compliance in the US center (33.2%; p< 0.001). On admission, the most
common pre-speciﬁed criteria for prescribing antibiotics despite low PCT
were high clinical severity (19.3%) and respiratory instability (11.5%);
no pre-speciﬁed reason was given in 58.0%. Mean antibiotic duration
was 6.3±5.3 days with signiﬁcant differences between the diagnoses
(bronchitis: 2.8d, AECOPD: 3.5d, CAP: 8.2d; p for each comparison
0.001). In a Cox proportional hazards model, non-compliance with
the algorithm, inpatient treatment, diagnosis of CAP (vs bronchitis),
and being algorithm-naı¨ve were independently associated with longer
antibiotic courses.
Conclusion: Cultural differences in antibiotic prescribing apparently
affect compliance with antibiotic stewardship efforts. In general,
compliance with the algorithm is feasible outside study conditions but
has to be reinforced to achieve maximum beneﬁt in reducing antibiotic
use.
O49 Hospital antimicrobial consumption pattern in the era of
multidrug-resistant bacteria
E. Iosiﬁdis*, S. Boukouvala, V. Barbarousi, C. Antachopoulos,
E. Roilides (Thessaloniki, GR)
Objectives: To study antimicrobial (ABC) consumption pattern in a
general tertiary care hospital with high level of resistance mainly among
Gram-negative bacteria.
Methods: Annual study of ABC consumption rates in 15 adult hospital
departments (7 internal medicine and subspecialties, 7 surgical and
subspecialties including solid organ transplant unit and mixed ICU) from
2005 to 2009. Antibiotic consumption calculator version 3.1 (WHO) was
used and annual ABC consumptions were expressed as DDDs/100 bed-
days (DDDHBD).
Results: Mean ABC consumption of different hospital departments
increased from 120 DDDHBD in 2005 to 136 DDDHBD in
2009 (p = 0.02). Annual ABC pattern analysis at hospital level (all
departments) showed that penicillins were the most commonly used ABC
(33% of total ABC consumption), followed by cephalosporins (19%),
ﬂuoroquinolones (11%), colistin (7.7%) and carbapenems (7.4%). Less
commonly used ABC were aminoglycosides (6.8%), macrolides (5%)
and glycopeptides (2%).
Among different departments ABC consumption showed approximately
the same pattern with the hospital level except for ICU. In ICU colistin
was the 2nd most common ABC (mean annual consumption rate 98
DDDHBD with a constant increase from 70 in 2005 to 141 DDDHBD
in 2008, p = 0.009) followed by carbapenems (mean consumption rate
of 73 DDDHBD) and aminoglycosides (mean consumption rate of 39
DDDHBD). In ICU cephalosporin consumption constituted only 3% of
total ABC consumption.
Longitudinal ABC analysis at hospital level between 2005 and 2009
demonstrated an increase in mean departmental consumption of
ﬂuoroquinolones (from 11 to 16 DDDHBD, p = 0.004); colistin (from
7 to 14 DDDHBD, p = 0.02); and linezolid (from 1 to 3.5 DDDHBD,
p = 0.008). During the same period no signiﬁcant variations were
found in annual consumption rates of b-lactams. More speciﬁc, annual
consumption rates of penicillins ranged between 39 and 42DDDHBDN
(p = 0.16), and of carbapenems between 8.7 and 9.7 DDDHBD (p = 0.09).
A non-signiﬁcant trend of decrease was found in annual consumption
rates of cephalosporins (from 27 to 24DDDHBD). Consumptions of
glycopeptides and macrolides were relatively low (<7 DDDHBD) and
did not signiﬁcantly change.
Conclusions: During study period an increase of total antimicrobial
consumption rate was found at hospital level. Signiﬁcant consumption
increase of non-b lactam antimicrobial classes including polymyxins,
ﬂuoroquinolones and oxazolidinones is of great concern.
Infection control without borders
S57 The EuRegio experience of successful cross-border infection
control (NL−D)
A.W. Friedrich* (Mu¨nster, DE)
In a Europe without healthcare borders, differences in prevalence of
multiresistant microorganisms become a crucial burden for patients
seeking healthcare across the border. Infection prevention has become
a keystone in reducing the spread of hypertransmittable multiresistant
microorganisms and in consequence maintaining the effectiveness of
antibiotic treatment. In this sense, infection prevention includes by far
more than measures to avoid transmission, but also the rational use
of antibiotics. Independently from the species involved, it is about
facultative pathogenic bacteria of different virulence and different
epidemic power that are colonizing patients and spreading in hospitals
or the community. Molecular epidemiology showed that most of the
MRSA infections are caused by a few epidemic clonal lineages.
Although transmission dynamics is not fully understood, today 3 major
transmission ways are accepted, reﬂecting the transmission dynamics of
hospital-, community- and livestock-MRSA. As the ha-MRSA seem to
follow their carriers, analysis of patient movements showed that MRSA
spread inter-institutionally within a healthcare region. This becomes even
more evident in border regions, where some MRSA seem not to cross the
border other, but ha-MRSA seems not to do so. The difference of MRSA-
prevalence between the adjacent regions in Germany and the Netherlands
ﬁnd here one possible explanation. A Dutch–German quality network
(www.mrsa-net.eu) was set up in 2005 comprising hospitals, GPs, labs,
public health services and patient interest groups. Its main objective is
the MRSA prevention in the border area. In 2007, screening of risk
patients become part of an external quality assurance for the hospitals
supervised by the public health authorities. In parallel, a 12-month
MRSA decolonisation-management was introduced for all GPs in order
to reduce MRSA carriership in the regional population. Since 2009, the
activities are being extended to the whole Dutch–German border region
(www.eursafety).
Enhanced screening activity resulted in a higher prevalence of MRSA-
carriership. In 2009, 3250 carriers, in 2010, 2080 carriers were reported.
At the same time, the number of MRSAB-isolates reported was 45 in
2009 and 23 in 2010, respectively. Looking at the German part of the
EUREGIO, the MRSAB-incidence per 100.000 inhabitants was there
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in 2010 the lowest (3,4) within all North Rhine-Westphalia (mean 4,8;
range 3,4−6,3).
The EUREGIO activities show that the implementation of regional
infection control is possible and can be synchronized at the borders.
Since patient mobility across the borders will increase, tomorrow’s
Europe will face new challenges. Multiresistance will become crucial
for the difference of healthcare quality in a Europe without healthcare
borders. Preventive microbiology will foster regional and euregional
infection prevention throughout Europe.
S58 The WHO experience: worldwide “clean care is safer care”
B. Allegranzi* (Geneva, CH)
Background: The WHO “Clean Care is Safer Care” (CCiSC)
programme, launched in October 2005, aims at reducing healthcare-
associated infections (HAI) worldwide. To achieve its aim CCiSC have
set 3 objectives: (1) to raise global awareness about the importance
of HAI; (2) to galvanize political commitment by Member States;
(3) to promote best practices at the point of care.
Methods: To achieve these objectives, implemented actions were:
(1) networking and collaborations with international experts and
stakeholders; scientiﬁc publications and communications; educational
activities at national and international levels; (2) invitations to Ministries
of Health to sign a formal statement as a pledge of their commitment
to tackle HAI; (3) development and dissemination of guidelines and
technical tools. Promotion of hand hygiene (HH) in healthcare settings as
the most effective measure for HAI prevention has been the cornerstone
of CCiSC technical work. The feasibility of the WHO Guidelines on
HH and the effectiveness of its implementation strategies and tools were
demonstrated through testing in 8 pilot sites and in over 250 healthcare
settings worldwide. We evaluated the impact of CCiSC based on outputs
corresponding to the 3 main objectives.
Results and Conclusions: Following the WHO call for collaboration,
key national and international infection control (IC) institutions have
strongly supported the work of CCiSC. Country commitment has been
reﬂected in the pledge signature to reduce HAI by 124 Member States
and in the launch of 42 national/sub-national HH campaigns, allocation
of ﬁnancial and human resources to IC and development of new policies.
To raise awareness about the importance of HAI, systematic reviews were
conducted to establish the epidemiological burden of endemic HAI and
a meta-analysis on the situation in developing countries was published.
Following implementation of the WHO recommendations and strategies,
signiﬁcant increase of HH compliance was observed across all pilot sites,
as well as improvement in infrastructure for HH and healthcare workers’
perception and knowledge about the importance of HAI and HH. The
local production of the WHO alcohol-based handrub formulations was
shown to be feasible and at low cost (ranging from US$ 0.30 to 0.50
per 100ml). To support long-term HH improvement worldwide, the
new initiative “SAVE LIVES: Clean Your Hands”, was launched on
5 May 2009. As of December 2010, 12 152 hospitals from 144 countries
registered to be part of this initiative. Within the space of 5 years,
CCiSC has generated unprecedented global momentum by mobilizing
countries, stakeholders, patient organizations and technical experts to
support its objectives and its ultimate aim. Multimodal strategies have
been identiﬁed as the most effective strategies to improve HH and IC at
the point of care, with important lessons learned about adaptation and
feasibility in settings with limited resources.
Emergence of virulent and antibiotic-
resistant bacterial forms in the marine
environment: a public health concern
S61 Mobile genetic elements transferring virulence and antibiotic
resistance genes among marine bacteria
M.L. Lemos*, M. Balado, A.J. Rivas, A. Rodrı´guez-Blanco, C.R. Osorio
(Santiago de Compostela, ES)
Marine bacteria are receiving increasing interest from the scientiﬁc
community. In addition to their ecological importance, it is now clear
that many marine bacteria are themselves potential human pathogens,
and that these bacteria are also a huge reservoir of genes encoding
virulence factors and antibiotic resistance. In this review we show that
some virulence factors of marine bacteria, as toxins, hemolysins and
siderophore biosynthesis are encoded by mobile DNA elements and that
some of them can be horizontally transmitted, not only to marine bacteria
but also to other animal and human pathogens. As a model we have been
studying Photobacterium damselae, a Vibrionaceae member widespread
in the marine environment, that includes two subspecies, subsp. piscicida
and subsp. damselae. The subsp. piscicida is the causative agent of ﬁsh
pasteurellosis. Subsp. damselae affects a variety of marine animals and is
also an opportunistic human pathogen, being reported clinical cases with
fatal outcome. We have described in these bacteria several mobile genetic
elements that encode virulence factors and antibiotic resistance. In this
regard, we have demonstrated that siderophore biosynthesis in subsp.
piscicida is encoded by a gene cluster which is part of a pathogenicity
island (PAI) closely similar to a Yersinia enterocolitica PAI, that has also
homologues in V. cholerae strains. This cluster encodes the biosynthesis,
transport and utilization of a siderophore that has a relevant role in
the pathogenicity of subsp. piscicida. This PAI is part of a 70 kb
mobilizable plasmid (pPHDP70). Moreover, we showed that some strains
of subsp. piscicida possess an ICE element of the SXT family, ﬁrst
reported in V. cholerae, that encodes tetracycline resistance and that
can promote the mobilization of other genetic elements such as the
virulence plasmids pPHDP10 and pPHDP70. We found that similar ICE
elements are also present in a signiﬁcant proportion in other marine
vibrios. Besides antibiotic resistance, some ICE elements also encode
heavy metals resistance. Other virulence factor encoded within a mobile
element in P. damselae is the synthesis of hemolysins. A conjugative
plasmid of 150 kb encodes two hemolysins, damselysin and HlyA,
which greatly contribute to the virulence of this bacterium to ﬁsh and
mice. We were able to demonstrate that some of these elements can
be horizontally transmitted by conjugation to other animal and human
bacterial pathogens.
S62 Pathogenic effects of marine Vibrio strains on human cells
M. Lleo*, G. Caburlotto, J.B. Kaper (Verona, IT; Baltimore, US)
V. parahaemolyticus is an inhabitant of estuarine and marine environ-
ments that causes seafood-borne gastroenteritis worldwide and more
rarely wound infections and septicemia. Recently, a type 3 secretion
system (T3SS2) able to secrete and translocate virulence factors into
the eukaryotic cell has been identiﬁed in a pathogenicity island (VP-
PAI) located on the smaller chromosome. These virulence-related genes
have previously been detected only in clinical strains. Classical virulence
genes for this species (tdh/trh) are rarely detected in environmental
strains which are usually considered to lack virulence potential. However,
during screening of a collection of environmental V. parahaemolyticus
isolates obtained in the North Adriatic Sea in Italy, a number of marine
strains carrying virulence-related genes, including genes involved in the
T3SS2, were detected.
In this study we investigated the pathogenic potential of these marine
V. parahaemolyticus strains by studying their adherence ability, their
cytotoxicity, their effect on zonula occludin protein1 (ZO-1) of the tight
junctions and their effect on transepithelial resistance (TER) in infected
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Caco-2 cells. By performing a reverse transcription-PCR we also tested
the expression of the T3SS2 genes vopT and vopB2 encoding an effector
and a translocon protein, respectively.
Our results indicate that, similarly to clinical strains, marine V. para-
haemolyticus strains carrying vopT, vopB2 and other genes included
in the VP-PAI are capable of adhering to human cells and of causing
cytoskeletal disruption and loss of membrane integrity in infected cells.
On the basis of data here presented, environmental V. parahaemolyticus
strains should be included in coastal water surveillance plans as they
may represent a risk for human health.
S63 Fish farms: potential role as reservoirs of antibiotic resistant
bacteria and resistance genes
D. Verner-Jeffreys*, N.G.H. Taylor, C. Baker-Austin, D. McIntosh
(Weymouth, UK; Rio de Janeiro, BR)
Aquaculture now supplies more than half the ﬁsh and shellﬁsh that are
eaten globally. As with other farmed animals, they are affected by a
range of bacterial diseases. These can have severe impacts on both
productivity and their welfare. Despite the development in recent years of
improved vaccines that effectively control some important diseases, such
as furunculosis in Atlantic salmon, antimicrobials are still used to control
many conditions. These are typically applied either in feed or direct to
the culture water, with varying levels of controls in place to control
their useage in different countries worldwide. This use of antimicrobials
has very likely driven the development of resistance in the bacteria
associated with farmed ﬁsh and shellﬁsh. As well as posing a threat
to the sustainability of the use of these important chemotherapeutants to
treat infected ﬁsh, there is also concern that much of this resistance is
encoded by so-called ’mobile’ genetic elements that transfer the genes
from otherwise harmless types of bacteria. Together with the resistance
genes, come a whole host of genes of unknown function which may
confer an entirely different selectable phenotype. The reservoir of genes
which transfer under the selective pressure of antibiotic usage in the
aquatic environment is largely unknown. A large body of scientiﬁc
evidence shows that bacteria harbouring these mobile AMR genes are
widely disseminated, and often at high prevalence, in all environments
studied to date (e.g. soil, mining waste, livestock production sites, water
treatment efﬂuent, marine and freshwater water column and sediment
samples). The potential threat that these environmental ’reservoirs’ of
mobile AMR genes pose to human and animal (including ﬁsh) health
has not yet been ascertained, but is likely to be considerable. For this
presentation we will discuss the extent to which aquaculture practices are
affected by, as well as may contribute to, these signiﬁcant AMR issues.
S64 Monitoring and modeling the microbiological quality of water
and shellﬁsh
M. Pommepuy* (Plouzane, FR)
Microbiological contamination in the marine environment can occur
in all marine biota anytime sewage from human or animal origin
is discharged to coastal waters. Bacteria and viruses from humans
and animals can affect seawater quality and can accumulate in ﬁlter
feeding shellﬁsh. Microbiological contamination often results from urban
wastewater discharges or non-point source pollution and dilution as well.
To limit sanitary risk, European regulations have proposed standards for
the classiﬁcation of shellﬁsh waters (EC/113/2006) and shellﬁsh growing
areas (EC/854/2004 modiﬁed by regulation EC/1666/2006). However,
despite the legal controls shellﬁsh outbreaks are currently reported.
The European regulation on microbiological criteria for shellﬁsh quality
stipulates legal control based on the traditional bacterial indicators
(Escherichia coli). However Escherichia coli indicator does not perform
well for viruses, the main micro-organism involved in shellﬁsh associated
outbreaks in Europe. Gastroenteritis and Hepatitis A are the most
important microbial diseases transmitted to humans through shellﬁsh.
Thus many outbreaks, even recently have been associated with shellﬁsh
fully compliant with legal bacteriological standards. In some outbreaks,
multiple strains of a single virus such as NoV can be detected indicating
or faecal contamination. Analysis of shellﬁsh events leading to shellﬁsh-
related outbreaks has conﬁrmed this hypothesis sewage, and when
environmental data are available, sewage-related contamination is often
demonstrated.
Microbiological contamination can cause bathing zones to be closed
or shellﬁsh sales prohibited. Both have direct effects on the coastal
economy (tourist and shellﬁsh industries). Modelling approach allows to
put in place a tool for risk assessment in coastal zone and anticipate the
degradation of water quality and thus, the zones closures. An example of
application using the integrated SWAT and MARS models is presented.
These nested models allow to estimate the impact of catchments’
agricultural practices and wastewater discharges on the quality of the
aquatic environment in estuaries devoted to shellﬁsh culture. This
association of models has the ability to simulate E. coli concentrations
and virus from the catchment, via streams and watershed outlet, and
into the estuary. These models consider the dynamic processes, and
incorporate daily and variable pathogen ﬂuxes into the hydrodynamic
model. Models have the capability of predicting the special pattern
of various hydrological factors and contaminant outﬂows within a
watershed, and are thus widely used for simulating microbial fate and
transport in watersheds. They also propose management scenario to
improve the quality of water of shellﬁsh growing areas.
The role of PK/PD in the treatment of severe
infections
S65 MRSA, enterococci, Pseudomonas aeruginosa and
Acinetobacter spp: where are we going with resistance patterns?
S. Stefani* (Catania, IT)
Infections caused by MDR pathogens continue to challenge physicians
and to threaten patient’s lives. Despite some new drugs recently licensed
for treating infections sustained by Gram positive pathogens such as
MRSA, a growing problem in MDR enterococci, but, above all, in Gram-
negative bacteria is now emerging, not paralleled by the development of
novel antimicrobials.
MRSA is still a leading cause of severe infections: it is an extremely
ﬂexible pathogens in acquiring antibiotic resistance and virulence
traits. Recent results has demonstrated the isolation of hVISA and
VISA strains in which empirical glycopeptide therapy is proving to
be less effective or inappropriate. Even if, in this case, there is the
possibility to use alternative regimens, this is not always for MDR
enterococci, that, together with a diffuse natural unsusceptibility to
many families of drugs, have acquired resistance to many drugs. The
evolution of antibiotic resistance is reaching the most extreme level in
Gram negative pathogens. MDR or PDR microorganisms were found
among Enterobacteria (Klebsiella spp and E. coli) but also in non-
fermentative opportunistic pathogens such as P. aeruginosa and, above
all, A. baumannii.
Data from the NNISS report resistance rates among P. aeruginosa
isolates to imipenem and quinolones as approximately 21% and 30%
respectively; in ICUs the respective rates are higher (up to 51% for
ciproﬂoxacin, 31% for piperacillin/tazobactam, 38% imipenem, and 23%
ceftazidime). Relevant ﬁgures are emerging from Europe (EarsNet), in
some cases showing a worsening trend.
Multicenter surveillance studies on A. baumannii strains have reported
that resistance to carbapenems now accounts for more than 50%
of isolates in ICUs worldwide, with peaks in some south-European
countries as reported by the EarsNet.
We all know that antibiotic use leads to a change in the epidemiology
and in resistance patterns; at the same time, in this genetic age, we
are beginning to see and understand how bacteria defend themselves
through mutations, acquisition and development of new strategies against
antibiotic therapy. Together with this, there is also the bacterial potential
for dissemination of new mechanisms (bacterial tourism), such as the
recent example of the new Delhi MBL. Unless we have a global policy
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for antibiotic use and support research into drug development and studies
on mechanisms of resistance, we will not begin to control this dangerous
phenomenon.
ISF Symposium and Presentation of the
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S69 Mapping QTL associated with host susceptibility to Klebsiella
pneumoniae infection in the Collaborative Cross mouse
resource population
F. Iraqi*, K. Vered, I. Ofek, B. Yalcin, C. Durrant, R. Mott (Tel Aviv,
IL; Oxford, UK)
Objectives: Infectious diseases of the respiratory tract are the most
common causes of deaths worldwide in humans. Klebsiella pneumoniae
(Kp) is a common pulmonary pathogen causing severe pneumonia
often associated with sepsis. With the rise of antibiotic resistance in
bacteria, there is a need for alternative, effective and affordable control
methods. For this purpose we initiated studies aimed at mapping and
subsequently identifying the host susceptibility genes to Klebsiella
pneumoniae infection in a novel and high genetically diverse mouse
resource population, the Collaborative cross (CC).
Methods: In total, 434 mice of 73 CC lines were challenged by
intraperitoneally (IP) with 104 CFU of Klebsiella pneumoniae strain K2
(KP-2) and variety of traits, including mean survival time post infection,
body weight at different time points during the challenge and compared
with the initial body weight, were monitored for 15 days duration of the
challenge. High molecular genomic DNA of the CC lines was genotyped
with 620K single nucleotide polymorphic (SNP) of mouse diversity
array, and subsequently a QTL mapping was conducted using HAPPY
software.
Results: Survival analysis has shown that the different CC lines differed
signiﬁcantly (P< 0.05) with spectrum of mean survival time between 1
to 12 days post infection. “Broad sense” heritability (including epistatic,
but not dominance effects) of this trait in the CC mouse population was
high as of 0.45. Permutation test analysis determined the 50%, 90% and
95% threshold levels and found to be 6.2, 8.1 and 8.8, respectively. Two
signiﬁcant QTL were mapped on chromosome 1 and 2 with logP 13.2
and 10.3, respectively at 95% threshold level, with genomic regions
of less than 1Mb. Additional signiﬁcant QTL was mapped with logP
8.5 on chromosome 7. Three suggestive QTL were also mapped on
chromosomes 3, 9 and 11 with logP of 7.5, 7.2 and 7.1, respectively. A
number of candidate genes underlying the QTL are suggested.
Conclusion: These results has strongly conﬁrmed that host susceptibility
to Klebsiella pneumoniae is a complex trait and controlled by multiple
genetic factors and the CC mouse population is a powerful tool for
dissecting this trait and can be used of studying other infectious diseases.
S70 Pathophysiology: damage associated molecular patterns
T. van der Poll* (Amsterdam, NL)
Although inﬂammation is important for the eradication of invading
pathogens, uncontrolled or chronic inﬂammation accompanying infection
can be detrimental to the host. The mechanisms by which pathogens
initiate inﬂammation have been well studied. Several classes of receptors
are important for sensing microorganisms and for the subsequent
induction of pro-inﬂammatory responses; these receptors have been
collectively termed pattern recognition receptors (PRRs).
It is now evident that PRRs also recognize non-infectious material
released during cellular injury during infection. These endogenous
molecules have been termed damage-associated molecular patterns
(DAMPs). A common feature of DAMPs is that they are endogenous
factors that are normally sequestered intracellularly and are therefore
hidden from recognition by the immune system under normal
physiological conditions. However, under conditions of cellular stress or
injury, these molecules can be released into the extracellular environment
(e.g. HMGB1, DNA, RNA). In addition to DAMPs from an intracellular
source, there are also extracellularly located DAMPs, released by
extracellular matrix degradation during tissue injury (e.g. hyaluronan,
heparan sulphate and biglycan).
Several DAMPs have been implicated in the pathogenesis of sepsis. This
lecture discusses the role of DAMPs in sepsis and the host receptors
involved in their recognition.
S73 Is there a rationale to use immunostimulation to counteract
the altered immune status of sepsis and SIRS patients?
J.M. Cavaillon* (Paris, FR)
Due to persistent frustrations following experimental approaches aimed
to target inﬂammatory mediators in sepsis, it is now proposed that the
anti-inﬂammatory phase should be targeted with drugs able to boost
immunity. It is certainly appealing, but might still consist in treating
a consequence, or a symptom of the syndrome, rather than the cause.
Immunodepression, prior to the septic episode, is clearly a risk factor
for mortality, as determined by many epidemiological studies performed
during sepsis in humans. However, whether the modiﬁcation of the
immune status following sepsis or non-infectious systemic inﬂammatory
response syndrome (SIRS), known as “compensatory anti-inﬂammatory
response syndrome” (CARS), has serious consequences in terms of
survival, remains debatable. Of course, the increased frequency of
nosocomial infections in intensive care units (ICU), may have led to some
deaths, but those late deaths cannot explain the initial high mortality of
septic shock. In animal models, preventing apoptosis of immune cells
or boosting immune cells have been shown to be protective. But before
dying from anergy and apoptosis of their immune cells, don’t patients
rather die from shock, organ failure and ultimately from nosocomial
infections or withdrawal from intensive care? In addition, alteration of
immune cells has been mainly demonstrated in human blood and murine
lymphoid organs, but immune cells within the other tissues might not
be deactivated. For example, lung neutrophils are activated in murine
hemorrhagic shock or endotoxinemia, whereas this is not the case for
blood neutrophils. Or, in contrast to any other mononuclear phagocytes,
murine alveolar macrophages cannot be rendered tolerant to endotoxin,
while endotoxin tolerance has often been suggested to partially mimic
the state of hyporeactivity of circulating immune cells. Finally, even for
circulating cells, the alteration of their reactivity is not a global defect,
but rather a reprogramming that maintains certain functions intact while
down-regulating others, particularly, those involved in inﬂammation.
Indeed, all organs are affected by the systemic inﬂammatory process,
and behave speciﬁcally to the insult. In sepsis and SIRS there is not
a pro-inﬂammatory response followed by an anti-inﬂammatory one, but
rather both events are concomitant and compartmentalized. This rendered
the therapeutic approach quite challenging, and should therefore be taken
into consideration.
New diagnostic methods for invasive fungal
infections
S74 Non-culture based diagnosis of invasive aspergillosis
C. Lass-Flo¨rl* (Innsbruck, AT)
Invasive aspergillosis (IA) caused by the fungus Aspergillus species
is a frequent and life-threatening complication of chemotherapy and
bone marrow transplantation with high rates of mortality and morbidity.
The most common species of Aspergillus causing human disease are
Aspergillus fumigatus, A. ﬂavus, A. niger, and A. terreus. There is no
“gold standard” test for the diagnosis of IA, and detection currently
requires data from clinical and radiological sources and from mycology
and histopathology where feasible. Diagnosis is complex and problematic
and can only be conﬁrmed by identiﬁcation of the fungus in biopsy
samples. Capturing tissue for diagnosis is in itself hazardous, and
because of this many patients receive empirical antifungal treatment
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rather than undergo biopsy. Attempts have been made to develop speciﬁc
and sensitive diagnostic tests that can be used to track the early onset
of infection. Detection of one such signature molecule, galactomannan
(and associated galactomannoprotein molecules), forms the basis of the
commercial Platelia enzyme immunoassay (EIA), an assay that has found
widespread use in IA diagnosis. Speciﬁcity of the GM test ranges
from 66% to 100% and sensitivity from 57% to 100%. The reasons
for variability in performance likely encompass both biological and
epidemiological factors; including prophylactic and empirical antifungal
therapies that compromise the sensitivity of the GM immunoassay:
alternative strategies to diagnosis have been sought including detection
of the fungal cell wall component (1,3)-b-D-glucan and polymerase
chain reaction (PCR). Detection of BG relies on its ability to activate
factor G of the horseshoe crab coagulation cascade. While these tests
display sufﬁcient sensitivity, they lack sufﬁcient speciﬁcity or suffer
from interference under certain conditions. The kinetics of GM, BG,
and DNA release are less easily established in vivo, but comparisons of
the diagnostic potential of PCR, the Platelia GM immunoassay and BG
tests have been undertaken in patients with hematological disorders, with
contrasting results. The “one assay-ﬁts-all” approach to IA diagnostics is
unrealistic and accurate diagnosis will necessarily rely on complementary
diagnostic approaches.
S75 Latest developments in molecular detection of outbreaks
C.H. Klaassen*, M. Fishbach, N.D. Fedorova, J. Meis (Nijmegen,
NL; Rockville, US)
Conﬁrmation of suspected outbreaks of fungal infections require high
resolution molecular genotyping methods. A large variety of methods
have been reported in literature that differ in complexity, discriminatory
power, costs, turn-around-time, reproducibility and stability. In recent
years there is a growing tendency to use repeated DNA elements based
or sequence based typing methods since these allow generation of typing
data that is easily stored and exchanged between laboratories. However,
these methods are not readily available to laboratories with no access to
the specialized equipment needed for these kinds of analyses (usually a
capillary DNA analyzer) or with no or only little experience in molecular
typing. As a result, such laboratories often refrain from performing such
typing analyses.
In an attempt to develop a typing method that is more accessible to
non-specialized laboratories as well we chose to develop an entirely
new genotyping approach. In this approach we choose not to try to
determine if isolates may be identical or clonally related, but instead
we aim to show in a deﬁnitive manner that they are not. The choice of
typing targets allows easy and unambiguous genotyping. The real-time
PCR format without the use of expensive ﬂuorescent labeled probes
makes this approach far more accessible than methods currently in
use. Furthermore, compared to existing genotyping methods, the new
approach is extremely simple, fast and economical. The diversity index
evaluated on a collection of >200 isolates of various origin was 0.985.
This means that there is a chance of only 1.5% that any two randomly
tested isolates yield the same genotype. This approach thus provides
a rapid simple and accessible screening method to evaluate potential
outbreak situations.
S76 Rapid detection of Candida species and resistance from blood
cultures
J. Guinea Ortega* (Madrid, ES)
Despite the current expanded armamentarium of antifungal agents,
mortality due to candidemia remains extremely high. In patients with
candidemia, early initiation of antifungal treatment is desirable, because
it is associated with better outcome. The nonspeciﬁc clinical presentation
of candidemia and the increasing number of antifungal-resistant isolates
may lead to a delay in the initiation of adequate therapy. Therefore,
efforts to improve the diagnosis of candidemia and to reduce the time
to detecting antifungal-resistant Candida isolates are warranted.
Widespread use of sensitive and speciﬁc strategies (eg, PCR-based
procedures) able to decrease time to diagnosis of candidemia is still
hampered by the lack of standardization. Real-time PCR to detect
Candida DNA in blood samples from high-risk patients is promising
due to its high analytical sensitivity and low inter-sample cross-
contamination. In addition, few species of Candida have been included in
the panel of detectable microorganisms of some marketed real-time PCR
systems. Candida DNA can also be detected in blood culture bottles that
are positive for yeasts, thus anticipating the results of the conventional
identiﬁcation. Use of speciﬁc probes helps to avoid further sequencing
of amplicons and can reduce time to identiﬁcation.
Molecular detection of Candida isolates with antifungal resistance to
ﬂuconazole or echinocandins is based on two strategies. First, speciﬁc
mutations can be investigated in genes encoding the drug targets. The
technique can be performed on DNA extracted from clinical samples,
in blood culture bottles, or on cultured isolates. Second, application of
ﬂuorescence in situ hybridization (FISH) assays in blood culture bottles
in which yeasts can be observed in the Gram stain make it possible to
detect some species of Candida with intrinsic decreased of the antifungal
susceptibility. Finally, the Etest can be applied directly in blood culture
bottles containing yeasts, and antifungal susceptibility of the isolates can
be available within 24 hours.
In this presentation, I will review the above-mentioned procedures
and the clinical impact of their implementation in the microbiology
laboratory.
Antimicrobial pharmacology: from bench to
bedside
O78 Comparative analysis of the potential of polymyxin B and
gentamicin to cause apoptosis and necrosis in cultured
renal LLC-PK1 cells: concentration-dependent studies with
incubated and electroporated cells
M.-P. Mingeot-Leclercq*, P. Tulkens (Brussels, BE)
Objectives: Polymyxins and aminoglycoisdes are both known to be
associated with nephrotoxicity. In previous studies, we showed that
gentamicin causes concentration-dependent apoptosis and necrosis in
renal LCC-PK1 cells upon incubation at large concentrations (typically
above 0.5 and 1.5 g/L, respectively; Servais et al. Tox. Appl.
Pharmacol. 2005, 206:321−33). Delivery of the antibiotic into cells
by electroporation increases about 100-fold their susceptibility for both
alterations (Servais et al. AAC 2006, 50:1213−21). Our aim has been to
compare polymyxins to gentamicin in these models.
Methods: Polymyxin B was chosen as its clinical nephrotoxicity was
shown recently to be similar to that of colistin (polymyxin E; Oliveira
et al. Diagn Microbiol Infect Dis. 2009, 65:431−4). Gentamicin was the
clinical product complying with the European Pharmacopoeia. LLC-PK1
cells were from ATCC. Incubation: cells were continuously exposed to
drugs for 48 hours. Electroporation: cells were electroporated in the
presence of the drug, left for 15 min, and transferred to drug-free-
medium for 24 h at 37ºC. Necrosis was assessed by the release of lactate
dehydrogenase (a cytosolic enzyme), and apoptosis by microscopic
enumeration of condensed and fragmented nuclei after staining with
4’,6’-diamidine-2’-phenylindole.
Results: Concentration-response curves are shown in the Figure with
reference to the known renal (tissue) and serum concentrations for
electroporated and incubated cells, respectively. While gentamicin caused
apoptosis and necrosis in electroporated cells at concentrations pertinent
of the expected tissue concentrations, polymyxin B caused only necrosis.
For incubated cells, gentamicin caused apoptosis when the concentration
reached the human Cmax but no necrosis in the range of concentrations
investigated. Polymyxin B caused no apoptosis, but necrosis became
massive when it concentrations exceeded 10-fold the human Cmax.
Conclusions: Polymyxin B and gentamicin markedly differ in their
ability to cause apoptosis, but both agents cause necrosis when delivered
into the cytosol. With incubated cells, polymyxin B appears safe as long
S14 21st ECCMID/27th ICC, Oral presentations
as it concentration remains low, which call for caution against undue
increase of dosages. Extrapolation of these data to the human situation
and interpretation in terms of clinical toxic potential will need to be
further studied.
O79 Time-kill effect of levoﬂoxacin against multidrug-resistant
Pseudomonas aeruginosa isolated from patients with
ventilator-associated pneumonia
A. Savva, M. Mouktaroudi, D. Carrer, A. Safarika,
E.J. Giamarellos-Bourboulis* (Athens, GR)
Objectives: Former results of our group in a limited number of isolates
have shown that when used in vitro at concentrations within the range
to those achieved in the epithelial lining ﬂuid (ELF), levoﬂoxacin (LVF)
may be active against multidrug-resistant Pseudomonas aeruginosa
(MDRPA) causing ventilator-associated pneumonia (VAP) (Safarika A,
et al. ECCMID 2009; abstr. P1661). Validity of these results was further
investigated against a larger number of isolates.
Methods: Twenty-three MDRPA isolates from patients with VAP
were tested. All were genetically distinct as deﬁned after pulse ﬁeld
electrophoresis of their DNA. All were isolated at a density greater than
1x106/ml from tracheobronchial secretions. A log-phase inoculum of
1×106 cfu/ml of pathogens was exposed over time to 7.5, 11 and 25
microg/ml of LVF; this represents the range of concentrations achieved in
ELF. Isolates were also exposed to 16 microg/ml of meropenem (MER),
to 5 microg/ml of colistin (COL) and to their interactions with LVF.
The latter are concentrations equal to their mean serum levels. Time-
kill effect was deﬁned as any more than 3 log10 decrease of viable
cell counts. Synergy between antimicrobials was deﬁned as any more
than 2log10 decrease of bacterial growth compared with the most active
single agent.
Results: A time-kill effect was shown by 7.5, 11 and 25 microg/ml
concentrations of LVF against 13 (56.5%), 15 (65.2%) and 15 (65.2%)
isolates respectively; this was mainly observed at 4, 6 and 24 hours of
growth. A time-kill effect of MER was observed against ﬁve isolates
(21.7%) and of COL against seven isolates (30.4%). Synergy between
LVF and MER was found against 16 isolates (69.5%) notably at 6 hours
of growth; synergy was achieved at all studied concentrations of LVF.
Synergy between LVF and COL was found against all tested isolates
(100%) notably at 4, 6 and 24 hours of growth and at all studied
concentrations of LVF equal to 11 and 25 microg/ml.
Conclusions: LVF presents signiﬁcant in vitro time-kill effect against
MDRPA pathogens of VAP when applied at concentrations within the
range of those achieved in ELF. LVF may also enhance the weak time-
kill effect of COL so that a considerable synergy is produced. These
results render promising the management of VAP by MDRPA with the
administration of LVF at regimens delivering the studied concentrations.
O80 Staphylococcal resistance studies using susceptible organisms
supplemented with their resistant mutants: linezolid and
rifampin combinations simulated in an in vitro dynamic model
A. Firsov*, M. Smirnova, E. Strukova, Y. Portnoy, S. Zinner (Moscow,
RU; Cambridge, US)
Objective: Recently the clinically attainable ratio of the area under
concentration-time curve (AUC) of linezolid (LZD) to the MIC (120 h)
did not prevent S. aureus resistance in an in vitro model. To explore
if combinations of LZD with rifampin (RIF) are better able to restrict
S. aureus resistance, the selection of LZD- and RIF-resistant S. aureus
was studied by simulating single and combined treatments with LZD
and RIF at sub-therapeutic AUC/MICs.
Methods: A clinical isolate of S. aureus (8 log CFU/ml; MIC and MPC
of LZD 2 and 14mg/L, MIC and MPC of RIF 0.016 and 1024mg/L,
respectively) supplemented with its LZD-resistant mutant (2 log CFU/ml;
MIC of LZD 8mg/L) was exposed to twice-daily LZD and once-daily
RIF, alone and in combination, over 5 days. With both LZD and RIF, the
simulated AUC/MIC ratio was about half of clinically attainable values:
60 and 1850 h, respectively. Antibiotic effects on susceptible and resistant
sub-populations were expressed by areas under the bacterial or bacterial
mutant concentration-time curves (AUBC and AUBCm, respectively)
calculated from the beginning of the simulated treatment to 120 hours.
Results: The effects of LZD + RIF combinations on susceptible sub-
populations were respectively 1.4- and 1.6-fold greater than those of
LZD and RIF alone. With LZD and RIF given alone, mutants resistant
to 2× and 4×MIC of LZD and to 2×, 4×, 8× and 16×MIC of RIF
were intensively enriched, with resistant mutants completely replacing
susceptible organisms. Enrichment of LZD-resistant mutants did not
occur with the LZD + RIF combinations. Moreover, the combination
restricted ampliﬁcation of the RIF-resistant mutants for the entire
treatment period. The AUBCm’s for mutants resistant to 2×, 4×, 8× and
16×MIC of RIF were respectively 2.8, 3.7, 7.1 and 7.3 times smaller
with the combination than with RIF alone.
Conclusions: These ﬁndings suggest that combined treatment with LZD
and RIF is effective in preventing and/or inhibiting selection of LZD-and
RIF-resistant S. aureus in an in vitro model.
O81 Evaluation of ceftaroline activity versus daptomycin
(DAP) against DAP non-susceptible methicillin-resistant
Staphylococcus aureus strains in an in-vitro pharmacokinetic/
pharmacodynamic model
M. Steed, C. Vidaillac*, M. Rybak (Detroit, US)
Objectives: Investigate the potential role of CPT as a therapeutic option
for the treatment of DAP non-susceptible (DNS) MRSA infections. CPT
is the active form of the prodrug ceftaroline fosamil, a new parenteral,
broad-spectrum cephalosporin with activity against MRSA.
Methods: Four clinical DNS MRSA strains, R5717, R5563, R5996
(hVISA) and R5995 (VISA) were run in a two-compartment hollow
ﬁber in-vitro PK/PD model at a starting inoculum of 107 CFU/mL
for 96 hours. Simulated regimens were CPT 600mg q 12 h (free
Cmax=15.2mg/mL, T1/2=2.3 h), DAP 6mg/kg q 24 h (free Cmax
= 7.9mg/mL, T1/2=8 h), and DAP 10mg/kg q 24 h (free Cmax
= 15.2mg/mL, T1/2=8 h). Model PK were veriﬁed with bioassay.
Experiments were performed in duplicate to ensure reproducibility, and
differences in CFU/mL between 24 and 96 h was evaluated with a
Turkey’s Post-Hoc test. Bactericidal activity (99.9% kill) was deﬁned as
a 3-log10 CFU/mL decrease in colony count from the initial inoculum.
Development of resistance was evaluated between 24 and 96 hours by
plating samples on agar plates containing DAP or CPT at 3 times the
MIC.
Results: CPT MIC values were 0.25, 0.5, 0.5, and 0.5mg/mL and DAP
MICs were 2, 2, 4, and 4 mg/mL for R5717, R5563, R5996, and R5995,
respectively. Pharmacokinetic parameters were within 12% and 11% for
CPT and DAP, respectively. CPT displayed sustained bactericidal activity
[R5717 (−3.1 Log10 CFU/mL), R5563 (−2.5 Log10 CFU/mL), R5996
(−5.77 Log10 CFU/mL) and R5995 (−6.38 Log10 CFU/mL)] against
3 of the 4 strains. Re-growth occurred during the DAP 6mg/kg q 24 h
regimen for all 4 strains and during the DAP 10mg/kg q 24 h regimen for
3 of 4 strains. At 96 h, CPT 600mg q 12 h was signiﬁcantly better than
DAP 6mg/kg q 24 h against all 4 strains (p< 0.001) and DAP 10mg/kg
q 24 h against 3 strains (p< 0.01). Isolates with increased MIC values
were recovered for DAP (all 4 strains), but not for CPT.
Conclusion: CPT was the most effective regimen overall against the 4
isolates tested. This novel cephalosporin may provide a clinical option
to treat DNS MRSA infections.
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O82 Pharmakocinetcs of daptomycin in patients with
Gram-positive infections receiving different dosage regimens
M. Falcone*, M.I. Cassetta, A. Russo, A. Lappa, S. Fallani, L. Tritapepe,
D. Gabriella, V. Vullo, M. Venditti, A. Novelli (Rome, Florence, IT)
Background: Daptomycin is a concentration-dependent antibiotic
displaying bactericidal activity against Gram-positive bacteria. The
manufacturer recommends a 4−6-mg/kg dose administered every 24 hrs.
However, a higher dosage may be requested in some cases, and
daptomycin pharmacokinetics has not been extensively evaluated.
Aim: to evaluate pharmacokinetics of daptomycin in hospitalized
patients with severe Gram positive infections.
Methods: Blood collections were performed at 30 minutes, 1 h, 2 h, 4 h,
8 h, 12 h and 24 h following administration of the ﬁrst dose, up to 96
hours. Daptomycin was measured using an isocratic HPLC technique.
Results: Overall, 46 patient were included in the study, 24 with
bacteremia/endocarditis, 15 with complicated skin-soft tissue infection,
3 with prosthetic-joint infection, and 3 with chronic osteomyelitis.
The pharmacokinetics of daptomycin was examined in two groups
of patients, those receiving 4−6mg/kg (n = 30) and 8−10mg/kg
(n = 16), respectively. Three patients underwent continuous veno-venous
hemodialysis (CVVHD), four patients underwent continuous veno-
venous hemodiaﬁltration (CVVHDF) and one hemodialysis. Only one
patient treated with 8mg/kg had an increase of creatine kinase levels.
The mean area under the blood concentration-time curve (AUC) within
24 hours was signiﬁcantly lower in patients receiving 4−6mg/kg than
in patients receiving 8−10mg/kg (352.5 vs 539.3, p< 0.05). On the
same hand, patients receiving 4−6mg/kg had lower mean Cmax values
(47.4 vs 77.9, p< 0.05). Patients undergoing CVVHD and receiving
daptomycin every 48 hours had AUC and Cmax values similar to patients
with normal renal functiom; instead patients undergoing CVVHDF had
signiﬁcantly lower plasma levels, especially those using “high cut-off”
hemoﬁlters.
Conclusions: Increasing doses of daptomycin may enhance the AUC
and improve the pharmacokinetic proﬁle of this drug. An increased dose
seems necessary in critically ill patients undergoing CVVHDF and using
high cut-off hemoﬁlters.
O83 Clinical dose ﬁnding of sitaﬂoxacin (DU-6859a) =
pharmacokinetic/pharmacodynamic analysis in patients with
community-acquired respiratory tract infections
Y. Tanigawara*, S. Kohno (Tokyo, Nagasaki, JP)
Objectives: Pharmacokinetic and pharmacodynamic (PK/PD) analysis is
useful to select rational dosage regimens. We have conducted the PK/PD
analysis to ﬁnd the optimal dosage regimen of sitaﬂoxacin (STFX, DU-
6859a), a newly developed ﬂuoroquinolone, in patients with community-
acquired respiratory tract infections.
Methods: Serum STFX concentration data from six phase I studies
(75 subjects) and one phase III study (137 patients) were pooled
to conduct a population pharmacokinetic (PPK) analysis. The PPK
parameters were estimated by pooling data from 212 subjects, using
a nonlinear mixed-effect model, applying a one-compartment model
with ﬁrst-order absorption. Efﬁcacy data were obtained from the phase
III study of STFX orally administered 50mg or 100mg twice-daily
(BID) for 7 days for the treatment of community-acquired pneumonia or
acute exacerbation of chronic bronchitis. Individual PK parameters were
estimated by the Bayesian method and MIC was measured for each
organism. Furthermore, the PK/PD parameters for 100mg once-daily
(QD) dosage were simulated based on the obtained PPK parameters and
MIC values.
Results: MICs of STFX were measured for 91 organisms identiﬁed
from 74 adult patients. The microbiological cure rate (MCR) was
stratiﬁed by AUC/MIC and Cmax/MIC. AUC/MIC 81 or Cmax/MIC
 4.0 were associated with >95% of MCR against Streptococcus
pneumoniae. Estimated PK/PD parameters including simulation of
100mg QD implied that the efﬁcacy was not different between 50mg
BID and 100mg QD, and that mutant selection risk was low at either
dosage regimen. Because STFX has a high potency against Gram(+) and
Gram(−) bacteria, the twice daily regimen would be an effective option
in treating respiratory tract infections.
Conclusions: The present PK/PD analysis supports the 50mg BID
regimen as a proper dosage of STFX for the treatment of community-
acquired respiratory tract infections.
O84 Clinical dose ﬁnding of sitaﬂoxacin (DU-6859a): pharma-
cokinetic/pharmacodynamic analysis from two clinical trial
results for community-acquired respiratory tract infections
S. Kohno* (Nagasaki, JP)
Objectives: Sitaﬂoxacin (STFX, DU-6859a), a quinolone antibacterial
agent, has a potent activity. We had already examined the effect of STFX
50mg BID in RTI by the clinical efﬁcacy and the pharmacokinetics/
pharmacodynamics (PK/PD) analysis. Subsequently, PK/PD parameters
at 100mg QD were also simulated to compare with those of 50mg
BID regimen. From these results, we speculate that the efﬁcacy is
rarely different between 50mg BID and 100mg QD, furthermore the
mutant selection risk is low also in each regimen. To clarify the clinical
dosage based on the bacteriological efﬁcacy, PK/PD parameters against
Streptococcus pneumoniae (S. pneumoniae) and safety, the additional
PK/PD study was conducted.
Methods: In the additional PK/PD study, patients with RTI mainly
caused by S. pneumoniae were randomized (STFX 50mg BID:100mg
QD=1:2). Data from previous phase III study in patients with RTI
who were treated with STFX 50mg BID was pooled to merge with
this study data. Safety, bacteriological efﬁcacy, and PK/PD parameters
were evaluated. PK parameters were analyzed by the population
pharmacokinetics model which was reported by Tanigawara. MICs and
MPCs of STFX against each organism were tested to calculate PK/PD
parameters.
Results: Analytical subjects of safety were 264 patients (100mg QD:
98, 50mg BID: 166). Analytical subjects of efﬁcacy were limited to
patients caused by S. pneumoniae, and were 97 patients (100mg QD:
56, 50mg BID: 41). The eradication rate of S. pneumoniae was 98.2%
(55/56) in 100mg QD and 92.7% (38/41) in 50mg BID. The eradication
rate of multidrug-resistant S. pneumoniae was 97.7% (42/43) and 94.6%
(35/37) in each group. The table shows PK/PD parameters calculated
from relation between MIC, MPC of STFX against S. pneumoniae and
pharmacokinetics of STFX. In any case, the critical difference was not
admitted between both groups. The adverse drug reaction (ADR) rate
of 100mg QD and 50mg BID was 33.7% (33/98) and 40.4% (67/166),
respectively.
Conclusion: From standpoints of the bacteriological clinical efﬁcacy,
both 100mg QD and 50mg BID were good regimen for patients with RTI
whose causative bacteria was S. pneumoniae. Furthermore, the mutant
selection risk of each dosages was low. There was no clear difference
in the adverse event risk from the standpoint of safety between both
dosages. Therefore, both 100mg QD and 50mg BID were thought to be
a useful dosage regimen.
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O85 Outpatient and inpatient parenteral antibiotic therapy with
daptomycin in a large non-interventional study: reducing
total therapy costs
A. Gonzalez-Ruiz*, Z. Dailiana, P. Gargalianos-Kakolyris,
V.J. Gonza´lez-Ramallo, R.A. Seaton, V. Prisco, M. Heep, K. Bouylout,
Y. Yin, R.L. Chaves (Kent, UK; Larissa, Athens, GR; Madrid, ES;
Glasgow, UK; Salerno, IT; Basel, CH; East Hanover, US)
Objectives: Daptomycin (DAP) has several characteristics that support
OPAT, e.g. rapid bactericidal activity, rapid resolution of symptoms,
once-daily dosing and since 2009 drug administration via 2-min
injection. Here we compare the characteristics and outcomes of patients
(pts) who received DAP as OPAT and IPAT.
Methods: Investigators at 237 institutions collected retrospectively
anonymized demographic, antibiotic, microbiological and clinical data
from medical records using a standardized CRF in the non-interventional
European Cubicin Outcomes Registry and Experience in 3 consecutive
enrollment periods (Jan 2006-Jun 2010). In the 2nd and 3rd collection
periods some non-European sites were progressively included.
Results: A total of 3621 pts were enrolled in 15 countries, mostly from
Europe, 115 pts from Latin America, 27 pts from Russia and 59 pts from
India. 437 pts received DAP in OPAT (333 as OPAT following IPAT
[OPAT/IPAT] and 104 only OPAT). OPAT/IPAT was most commonly
used in Spain (n = 122), Italy (n = 86) and UK (n = 81); OPAT only in
Venezuela (n = 26), UK (n = 24) and Spain (n = 23). The use of OPAT
increased over the 3 collection periods from 2.6 to 4.5%. After regulatory
approval the 2-min injection was used in 12 of 58 IPAT/OPAT pts. The
median duration of DAP therapy for OPAT, OPAT/IPAT and IPAT was
14 (1−85), 10 (1–109) and 10 days (1–246) respectively. The most
commonly treated infections were cSSTI and osteomyelitis in OPAT,
cSSTI and endocarditis in OPAT/IPAT and cSSTI and bacteraemia in
IPAT. S. aureus (41 of 104) was the most frequent pathogen in OPAT
(MRSA rate 56%). Overall, success rates were high for all treated
infections with a trend to be higher in pts at least partially treated in
OPAT, except in cSSTI (Table 1). DAP doses used in OPAT or IPAT
were generally similar (mean 5.5mg/kg). AEs were reported in 19.2%
of pts on OPAT vs 13.7% on IPAT vs 14.4% on OPAT/IPAT with low
rates of discontinuation due to AEs in all settings.
Conclusion: Reducing hospitalization has signiﬁcant impact on overall
health care costs. It was previously observed that DAP was associated
with shorter duration therapy in cSSSI. Here we show that appropriately
selected pts receiving DAP once daily including 2-min injection may also
be successfully managed either entirely in the OPAT setting or following
initial hospitalization. DAP is an attractive and cost-effective therapeutic
option for complicated Gram-positive infections in the outpatient setting.
O86 Colistin minimum plasma concentration is an independent
risk factor for nephrotoxicity
L. Sorlı´*, S. Luque, S. Grau, N. Berenguer, H. Knobel, F. Alvarez-Lerma,
M. Montero, I. Rodriguez, C. Segura, J.P. Horcajada (Barcelona, ES)
Objectives: Data regarding the most efﬁcacious and less toxic schedule
of colistin are scarce.
The aim of this study was to determine the prevalence of colistimethate
sodium (CMS)-associated nephrotoxicity in patients with MDR-GBN
infections by using a standardised deﬁnition of acute renal failure
(RIFLE criteria), and to determine the potential risk factors for
nephrotoxicity.
Methods: Prospective review of patients who received intravenous
CMS for >72 hours from November 2010 to November 2011.
CMS doses ranged from 1−2 million U (80–160mg colistimethate)
every 8−12 hours. Collected data: demographic characteristics, Acute
Physiology and Chronic Health Evaluation II (APACHE II), Charlson
score, concomitant use of nephrotoxic, vasopressors and/or diuretics,
cumulative CMS dose (MU), and treatment duration. Blood samples
were collected on the third day of treatment (after steady-state
achieved), immediately before and 30 minutes after infusion in order
to asses minimum (Cmim) and maximal (Cmax) colistin concentration.
Glomerular ﬁltration rate (GFR) was calculated by the Cockcroft-Gault
formula at the beginning or treatment and monitored at the discretion
of the team. The RIFLE criteria were used to assess the presence of
nephrotoxicity at the end of treatment.
Plasma colistin concentrations were assayed using high-performance
liquid chromatography (HPLC).
In univariate analysis the differences between patients with and without
nephrotoxicity at the end of the treatment were assessed. In multivariate
analysis, risk factors for the presence of nephrotoxicity were identiﬁed
through a multiple regression analysis backwards, stepwise variable
selection.
Results: 36 patients were included. Baseline characteristics of are shown
in table 1. Fourteen (38.8%) had some degree of renal dysfunction.
Patients who developed nephrotoxicity were older, had a higher Charlson
score, were more likely treated with diuretic drugs, had a higher
cumulative doses of colistin, and had higher Cmax and Cmim values.
However, only Cmim (OR, 3,888; 95%CI, 1,383−10,935; p = 0,010) was
independently related with nephrotoxicity.
Conclusions:
1. Using the RIFLE criteria, 38.8% of patients developed nephrotoxicity.
2. Cmim is and independent risk factor for nephrotoxicity.
3. Colistin plasmatic levels could be useful to assess nephrotoxicity,
mainly by monitoring Cmin.
O87 Factors inﬂuencing pharmacokinetics of prophylactic
posaconazole oral solution in patients with acute myeloid
leukaemia or myelodysplastic syndrome
J. Vehreschild, C. Mu¨ller, F. Farowski, M.J. Vehreschild, O.A. Cornely*,
U. Fuhr, K.-A. Kreuzer, M. Hallek, V. Kohl (Cologne, DE)
Objectives: To estimate pharmacokinetic properties of posaconazole
in patients with acute myeloid leukemia (AML) or myelodysplastic
syndrome (MDS) undergoing chemotherapy in a clinical setting.
Methods: Posaconazole concentrations in patients with AML/MDS re-
ceiving prophylactic posaconazole were determined by high-performance
liquid chromatography. A population pharmacokinetic model with
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nonlinear mixed effect modeling was developed. The list of tested
covariates included age, weight, height, gender, posaconazole dose,
ethnicity, co-administration of antineoplastic chemotherapy, ranitidine
or pantoprazole, coincident fever, diarrhea, leukocyte counts and gGT
plasma activity.
Results: A total of 643 serum concentrations of posaconazole from
84 patients were obtained. A one-compartment model with ﬁrst order
absorption and elimination as the basic structural model appropriately
described the data, with an apparent clearance of 56.8 L/h (95%CI
52.8–60.8 L/h) and an apparent volume of distribution of 2,130 L
(95%CI 1646–2614 L). Signiﬁcant effects on apparent clearance were
found for presence of diarrhea and for co-medication with proton-
pump inhibitors (1.5-fold and 1.6-fold increase in CL/F, respectively),
weight (33.4 L larger apparent volume of distribution per kilogram),
and co-administration of chemotherapy (0.6-fold lower apparent volume
of distribution).
Conclusion: We developed a prediction basis for mean posaconazole
concentrations in AML/MDS patients. Patient weight, presence of
diarrhea and concomitant medication (chemotherapy and pantoprazole)
showed signiﬁcant effects on posaconazole exposure. Corresponding
adjustments of the starting dose according to presence of diarrhea
and to age appear justiﬁed before TDM results are available. Further
investigation of the interaction between different chemotherapeutic
regimens and posaconazole is warranted.
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O88 Development of bacteriophage cocktails for the management
of nosocomial and community-acquired methicillin-resistant
Staphylococcus aureus
S. Morales*, G. Mearns, C. Fernandes, B. Hudson, J. Iredell,
A. Smithyman (Sydney, AU)
Antimicrobial resistance is one of the greatest threats to human health.
The human and economic costs of treating infections caused by bacteria
such as nosocomial MRSA (EMRSA) continue to rise and have been
compounded by the spread of this pathogen into the community
(CA-MRSA). Of particular concern are the reports of development
of resistance to antibiotics recently developed such as linezolid and
daptomycin. This has prompted a search for novel classes of antibiotics
and also for radically different approaches to combat S. aureus infections.
One consequence of this is the recent revival of interest in phage therapy.
Phages are naturally occurring viruses that infect and kill bacteria with
high efﬁciency and speciﬁcity. Recent animal and human trials have
reconﬁrmed the potential of phage therapy as an effective alternative
and/or complementary option for the treatment of bacterial infections.
Objectives: To develop therapeutic phage combinations with a broad-
spectrum of activity against a reference collection consisting of 21 clones
of EMRSA and CA-MRSA of international importance (Table 1).
Methods: Lytic phages were isolated from environmental sources in
Australia and screened against the reference collection. Combinations
of these phages were then tested for their activity against 200 clinical
isolates in Australia and the UK.
Results: Fifty-eight lytic phages were isolated from environmental
sources. Nine of these phages showed a broad-spectrum range of
activity against the reference collection and were consequently selected
for further characterization. Combinations of these phages were then
developed and their activity tested against 200 clinical isolates in
Australia and the UK. The therapeutic phage combinations showed a
broad host range infecting over 95% of the isolates tested.
Conclusions: Therapeutic phages were combined and tested against
EMRSA and CA-MRSA clinical isolates from two geographical areas.
The phage combinations reacted with over 95% of the isolates tested.
The use of phage combinations extended their spectrum of activity
and minimised the emergence of phage resistant bacteria. Phage
combinations were shown to be endotoxin free, non-cytotoxic and free
of undesirable genes. This study showed that as the antibiotic resistance
crisis deepens and the number of treatment options narrows, the potential
of phages as therapeutic tools continues to be a viable option for the
treatment of infections caused by these difﬁcult pathogens.
O89 A novel silver colloid: assessment of antibacterial activity
R.A. Dixon*, M. Baron (Lincoln, UK)
Objectives: Silver in various forms has been employed in the last few
decades for the reduction of pathogen load particularly in Healthcare
Associated Infections. The purpose of this study was to determine the
preliminary antibacterial effects of a recently developed highly stable
novel silver colloid that exhibits exceptional fabrication characteristics
and has a narrow particle size distribution. Many previous studies on the
effects of silver nanoparticles against microbes have not addressed the
importance of the size of the nanoparticles in considering antibacterial
effects.
Methods: The antibacterial activities of the silver colloid AC 1 compared
to an appropriate silver control were assessed in ‘large volume’ MIC
determination both in broth and agar using conventional methodology
with a range of inocula. Plastic vessels were used throughout to prevent
silver interaction with glass. The activity of AC1 against a MRSA
reference strain was tested against a range of concentrations from 16
to 0.2mg/ml incorporated into the agar. The surface was inoculated with
appropriate numbers of MRSA. In addition, silver solution was applied
to ‘antibiotic’ discs sequentially with drying. Agar plates were inoculated
with MRSA and spread. Disks containing silver AC1, and controls were
placed on the surface and incubated at either 30 or 37C for 18h.
Results: The activity of AC1 against Gram-positive and negative
organisms was equivalent. The results were not consistent with previous
work in terms of either spectrum or degree of potency. Determinations
of AC1 in broth produced only moderate activity against ATCC strains
Escherichia coli or Staphylococcus aureus (MIC/MBC = 50/100mg/ml).
AC1 in agar test systems produced results remarkably different to
those in liquid broth. With lower inocula (105cfu/ml) agar MIC
equalled 10mg/ml − at least 5x more active when tested in agar rather
than liquid. The number of colonies however exposed to AC1 show
signiﬁcant reduction at concentrations of 5.5mg/ml and partial reduction
at 0.6mg/ml. The activity of AC1 against a single strain of MRSA was
conﬁrmed by bioassay producing a signiﬁcant zone of clearing.
Conclusion: A negatively charged silver phosphate nanoparticle (NP)
has been developed by a highly repeatable process that shows interesting
activity against a range of pathogen including MRSA.
O90 Effect of novel antibacterial GSK2251052 on mammalian
mitochondrial protein synthesis
P. Chan*, T. Cecconie, T. Mandal, D. Cooper, D. Holmes, P. DeMarsh
(Collegeville, US)
Objectives: GSK2251052 is the ﬁrst in a new oxaborole class of an-
tibiotics with robust Gram-negative coverage against drug-resistant En-
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terobacteriaceae and Pseudomonas aeruginosa. GSK2251052 uniquely
inhibits the editing active site of leucyl-tRNA synthetase (Leu-tRS),
an essential constituent of the bacterial protein synthesis machinery.
Some inhibitors of bacterial protein synthesis also target mitochondrial
translation due to structural similarity between some components and this
affect has been potentially linked to safety concerns with such drugs in
the clinic. Since human mitochondria also contain a Leu-tRS, this study
investigates the effect of GSK2251052 on mammalian mitochondrial
protein synthesis.
Methods: A medium-throughput, mitochondrial protein synthesis
inhibition assay was developed that measures levels of the mitochondrial
encoded protein cytochrome oxidase subunit III (Cox III). HEK293 cells
were treated with GSK2251052 for 96 h at 37ºC. Cells were lysed and
protein was immobilised on a MSD electrode microplate coated with Cox
III capture antibody, probed with Cox III speciﬁc antibodies and detected
by electro-chemiluminescence. As control, levels of the cytoplasmically
expressed outer membrane protein Tom 20 were measured.
Results: Chloramphenicol, tetracycline and linezolid are potent mito-
chondrial translation inhibitors with IC50s <4 uM in this study. In
contrast, azithromycin is negative in the assay with an IC50 of >100
uM. GSK2251052 gave an IC50 of >100 uM and hence does not have
an inhibitory effect on mitochondrial protein synthesis.
Conclusion: Unlike a number of bacterial protein synthesis inhibitors,
GSK2251052 does not inhibit mammalian mitochondrial protein
synthesis in vitro indicating that this clinical candidate has an excellent
selectivity proﬁle. This ﬁnding was further substantiated by the divergent
alignment of the editing domains of bacterial and human mitochondrial
Leu-tRSs.
O91 Carbohydrate-derived fulvic acid is a novel antifungal product
L. Sherry*, C. Murray, B. Jones, C. Williams, G. Ramage (Glasgow, UK)
Objectives: Carbohydrate derived fulvic acid (CHD-FA) is a heat stable
low molecular weight, water soluble, cationic, colloidal material with
proposed therapeutic properties. The aim of this study was to evaluate
the antifungal activity of CHD-FA against Candida albicans, and to
characterise its mode of action. It was also an aim to investigate the
immunomodulatory potential of CHD-FA.
Methods: A panel of C. albicans isolates (n = 50) derived from a range
of clinical specimens were grown planktonically and as bioﬁlms, and
the minimum inhibitory concentrations (MICs) determined. The role
of efﬂux pumps was also investigated using pump inhibitors. Scanning
electron microscopy was performed to examine ultrastructural changes
and different cell wall mutants were analysed to determine the possible
mode of action, which included cell wall inhibitor studies. Finally, we
investigated whether antifungal concentrations of CHD-FA were toxic to
oral epithelial cell lines, and whether it altered the expression of IL-6
and IL-8.
Results: CHD-FA was effective against planktonic (0.125% v/v) and
sessile (0.25% v/v) C. albicans, and was shown to be fungicidal.
Efﬂux activity was detected in C. albicans isolates, however, when
these efﬂux pumps where inhibited there was no reduction of inhibitory
concentration. Cell wall mutants displayed similar sensitivity proﬁles to
WT strains, and inhibition of hsp90 did not impact the sensitivity. CHD-
FA was not toxic to epithelial cells after a short incubation (2 min), and
when this compound was used on zymosan stimulated cells there was
apparent down-regulation of IL-6 and IL-8.
Conclusions: This study has shown that the natural antimicrobial CHD-
FA is non-toxic and has cidal activity against a range of C. albicans
clinical isolates. The ability to kill bioﬁlms is a beneﬁcial characteristic
not shown in conventional antifungal compounds. Therefore, CHD-FA
may offer a cheap and natural alternative to these agents. There is limited
scientiﬁc understanding of CHD-FA, however, given that no differences
were observed from cell wall and efﬂux studies, the likely mode of
action is the cell membrane. CHD-FA may offer potential in a number
of clinical applications, including within the oral cavity (mouthwashes),
skin and wounds, and the ITU (catheter lock). Further studies, both in
vitro and in vivo are required, but with an increasing incidence of fungal
infections then CHD-FA may be an attractive option.
O92 A novel chimeric lysin shows superiority to mupirocin for skin
decolonisation of antibiotic-resistant (MRSA) and sensitive
(MSSA) Staphylococcus aureus
M. Pastagia*, C. Euler, V. Fischetti (New York, US)
Objectives: Lysins are bacterial cell wall hydrolases generated during
the infection cycle of double-stranded DNA phage. When applied
exogenously, lysins (puriﬁed apart from phage) cleave essential bonds
in the cell wall peptidoglycan, resulting in immediate bacterial cell lysis
and death. ClyS (chimeric lysin for staphylococci) is a unique lysin
speciﬁc to staphylococcus, made recombinantly in our laboratory. ClyS
is bioengineered to contain a staphylococcus-speciﬁc catalytic domain
fused to a unique cell wall targeting domain. Our objective was to test the
ability of a topical formulation of ClyS to disinfect abraded skin infected
with methicillin susceptible (MSSA) or resistant S. aureus (MRSA) in
vivo.
Methods: ClyS solution is lyophilized and then incorporated into
commercially available Aquaphor ointment. We applied topical ClyS
to the skin of mice that were infected with S. aureus to determine
its in vivo efﬁcacy. Groups of mice were treated for one day with
either Aquaphor alone (placebo), topical ClyS, or commercially available
mupirocin ointment (comparator). For testing if there were differences
in colony counts among those groups, both ANOVA and Kruskal-wallis
were used. A P value of <0.01 was considered signiﬁcant. We also
tested the ability of staphylococci to develop in vitro resistance to
ClyS in comparison with mupirocin when exposed to sub-inhibitory
concentrations of the respective agent. Because antibodies towards ClyS
may affect enzyme function, we tested antibodies that developed in mice
after repeated ClyS exposure for effect on ClyS killing ability.
Figure 1. In vivo activity of ClyS ointment vs. placebo or mupirocin on tape-
stripped mice infected with S. aureus 8325-4 or MRSA MW2. Topical treatrnents
included Aquaphor® (control), 10% ClyS binding domain in Aquaphor® (placebo),
10% wt/wt ClyS in Aquaphor®, and 2% mupirocin. The median value of the data
for each group is shown as a horizontal bar; each sphere represents one mouse. No
statistical signiﬁcance was seen between untreated, control, and placebo groups.
Statistical signiﬁcance (p< 0.0001) was noted between untreated/control/placebo
and ClyS groups with a three log drop in bacteria recovered (CFUs). Statistical
difference (p= 0.001) was noted between ClyS and mupirocin treated groups, with
a one log drop difference between them. Figure is representative of experiments
using S. aureus strain 8325-4 or MRSA strain MW2.
Results: Topical ClyS eradicated a statistically signiﬁcantly greater
number of MSSA and MRSA when compared with mupirocin
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(p = 0.001), a 3 log as opposed to a 2 log reduction in our model
(Figure 1). ClyS also demonstrated decreased potential for development
of resistance by MRSA and MSSA organisms in vitro (no change in
minimum inhibitory concentration for ClyS as opposed to development
of low level resistance for mupirocin). Our results showed no inhibition
of ClyS activity at various antibody titers.
Conclusions: Topical ClyS: i) speciﬁcally targets staphylococci, ii) has
low probability for resistance, iii) does not lose activity in the presence
of antibodies, and iv) was found to be more effective than a comparator
drug (mupirocin). Our data substantiates topical ClyS as a plausible
therapeutic to be developed for human use.
O93 Completely novel protein synthesis inhibitors demonstrate
efﬁcacy in three mouse models of infection
A. Marra*, E. Bortolon, D. Molstad, Y. Wu, H. Jing, E.M. Duffy (New
Haven, US)
Objectives: Exemplars from three completely novel classes of protein
synthesis inhibitors with potent in vitro activity against a range of
bacterial pathogens and good ADME properties were evaluated for
efﬁcacy in mouse infection models of Escherichia coli peritonitis,
Klebsiella pneumoniae skin and soft tissue and Staphylococcus aureus
MRSA kidney abscess.
Methods: Murine peritonitis was initiated by injecting E. coli into the
peritoneal cavity; therapy was administered at 30 minutes, 3.5 and 6.5
hours post-infection and efﬁcacy was measured by monitoring colony-
forming units (cfu) burden in peritoneal wash ﬂuid samples and spleen
homogenates at 24 hours. Murine thigh infections were established in
neutropenic mice by injecting K. pneumoniae into both caudal thigh
muscles. Mice were dosed at 2 and 12 hr and the bacterial burden in thigh
tissues was determined 24 hours following bacterial challenge. Kidney
abscess infections were initiated via tail vein injection of MRSA and
therapy was administered at 4, 24 and 32 hours; kidneys were harvested
for bacterial quantitation at 48 hours post-infection. In some studies,
plasma and tissue concentrations of drugs were obtained at various time
points up to 6 hours post drug administration using an LC/MS/MS assay.
Results: Several novel compounds from the lead scaffold were
efﬁcacious in the E. coli peritonitis model, reducing bacterial loads to
the limit of detection by 24 hours. Exemplar novel compounds from a
second showed comparable efﬁcacy, and representative novel compounds
from a third showed static effects in this model. Many lead scaffold
compounds also demonstrated efﬁcacy in the K. pneumoniae skin and
soft tissue infection (SSTI) model, resulting in 1−1.5 log10 delta-cfu
reduction in bacterial burden and in the MRSA kidney abscess infection,
resulting in 2−2.5 log10 delta-cfu reduction. Furthermore, one of these
was efﬁcacious in all three mouse infection models. This compound has
good broad-spectrum activity, moderate PK and low protein binding.
Conclusions: Compounds from three completely novel classes of
antibiotics have demonstrated efﬁcacy in mouse infection models. A
number of these were efﬁcacious in two models, and bacterial burden
reduction in all three models was exhibited in at least one case. The
characteristics of this exemplar molecule suggest that a combination of
activity, PK properties and lower protein binding contribute to mouse
efﬁcacy.
O94 Efﬁcacy of the novel metallo-enzyme inhibitor VT-1129 in
combination with amphotericin B for cryptococcal meningitis
N.P. Wiederhold*, L.K. Najvar, W.J. Hoekstra, R.J. Schotzinger,
W.R. Moore, E. Garvey, R. Bocanegra, W. Kirkpatrick, T.F. Patterson
(San Antonio, Morrisville, US)
Objective: Cryptococcal meningitis is a signiﬁcant cause of morbidity
and mortality in immunocompromised patients. Combination therapy
involving amphotericin B is often initiated in patients against this
infection. VT-1129 is an investigational metalloenzyme inhibitor with
potent in vitro activity against Cryptococcus neoformans. Our objective
was to evaluate the in vivo efﬁcacy of VT-1129 in combination
with amphotericin B in an established murine model of cryptococcal
meningitis.
Methods: ICR mice received intracranial inoculation with C. neoformans
at 3.15–3.51 log cells/mouse. Treatment with VT-1129 at 5 or 10mg/kg
PO BID alone or in combination with a single intraperitoneal dose of
amphotericin B deoxycholate 3mg/kg began 1 day post-inoculation. In
survival studies (N = 10/group) treatment continued until day 10 and
mice were monitored off therapy until day 30. In fungal burden studies
(N = 10/group), treatment continued through day 7, brains were collected
on day 8, and fungal burden was assessed by colony-forming units
(CFU).
Results: The VT-1129 10mg/kg dose, both alone and in combination
with single-dose amphotericin B, signiﬁcantly improved the median
survival and percentage of animals surviving to the study endpoint
compared to untreated controls (Table). Median survival was also
prolonged with VT-1129 at 5mg/kg in combination with amphotericin B.
The improvements in survival were also associated with reductions in
fungal burden as the number of CFU/g of tissue in each group that
resulted in a survival beneﬁt was signiﬁcantly lower than that observed
within the brains of untreated mice. The combination of VT-1129 at
10mg/kg and amphotericin B resulted in a >4 log CFU/g reduction in
fungal burden.
Conclusions: The metalloenzyme inhibitor VT-1129 in combination
with single dose amphotericin B demonstrated potent efﬁcacy in this
murine model of cryptococcal meningitis. Both doses of VT-1129 when
combined with amphotericin B resulted in signiﬁcant improvements
in survival and reductions in tissue burden with the greatest beneﬁts
observed with the higher dose of this investigational agent. These
data demonstrate the potential utility of VT-1129 in the treatment of
cryptococcal meningitis.
O95 A phase 1 trial to evaluate the safety and pharmacokinetics
of single doses of intravenous solithromycin (CEM-101) in
healthy adult subjects
J. Schranz*, K. Clark, A. Marion, G. Ghibellini, P. Fernandes (Chapel
Hill, Omaha, Research Triangle Park, US)
Objectives: To determine the safety, pharmacokinetics (PK), dose
limiting toxicity and maximum tolerated dose of single escalating doses
of IV solithromycin. Solithromycin is the ﬁrst and only ﬂuoroketolide
with an oral (phase 2) and IV formulation (phase 1) in development for
the treatment of community acquired bacterial pneumonia (CABP) and
other infections.
Methods: This was a Phase 1 single-center, randomized, double-blind,
placebo-controlled, single IV dose-escalation study in healthy adults.
Each cohort consisted of 7 subjects, randomized 5:2 (CEM-101:placebo).
Subjects were given IV CEM-101 or vehicle placebo over 1.5 h and
remained in the Clinical Research Unit for 48 hours post-dose for
safety monitoring and PK assessments, returning on Day 6 for safety
assessment. Physical examinations, vital signs, ECGs, clinical laboratory
tests, and adverse events (AEs) were monitored. Dose escalation was
based on stringent safety criteria. PK was assessed pre-dose, during the
infusion and up to 48 hours post-dose.
Results: A total of 42 subjects (six cohorts of 7 subjects) were enrolled
in the single ascending dose portion of this ongoing study. 30 subjects
received CEM-101 doses of 25, 50, 100, 200, 400, and 800mg and
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10 received vehicle placebo. There were no serious AEs, clinically
signiﬁcant systemic adverse events, QT prolongation or clinically
signiﬁcant laboratory abnormalities. PK (Cmax and AUCinf) appeared
linear up to 200mg and slightly more than dose proportional at higher
doses. Clearance decreased with dose. Volume of distribution was large
and relatively constant over the dose range.
Conclusions: Solithromycin, the ﬁrst broad spectrum ﬂuoroketolide,
was systemically well tolerated and showed favorable PK in single
doses up to 800mg when given IV, achieving clinically relevant plasma
concentrations (~4 mcg/mL). IV exposure was 1.3−3 fold higher than
what was observed with equivalent oral doses. Multiple ascending doses
(7 days) are under investigation as well as determination of absolute
bioavailability. Due to favorable ﬁndings in this single dose escalation
study, further development is warranted.
O96 TP-2758 is a novel oral tetracycline targeting complicated
urinary tract infections and pyelonephritis
J. Sutcliffe*, Y. Deng, M. Ronn, X. Xiao (Watertown, US)
Background: The rising number of infections caused by multidrug-
resistant (MDR) bacteria is a serious public health threat globally. TP-
2758 is a novel, fully-synthetic tetracycline that is being developed to
speciﬁcally target MDR Gram-negative pathogens, including extended-
spectrum b-lactamase-producing (ESBL) and carbapenem-resistant
Enterobacteriaceae.
Methods: For UTI/pyelonephritis murine models, uropathogenic E. coli
EC200 or Klebsiella pneumoniae ESBL KP453 were inoculated IV
and allowed to colonize the kidney. Animals received oral (PO) or IV
treatment at 12 and 24 hours post-infection. 36 hours post-treatment
initiation, mice were euthanized, kidneys aseptically removed, weighed,
homogenized, serially diluted and plated on growth media. CFU/g kidney
was calculated and efﬁcacy was expressed as the change in CFUs from
infection controls. Pharmacokinetic experiments were performed in rat
and Cynomolgus monkey at IV and PO doses of 1mg/kg and 10mg/kg
respectively. Samples were taken up to 24 h post-dose and the plasma
concentration of the compound was quantiﬁed by LC/MS/MS.
Results: TP-2758 at 50mg/kg/dose PO produced a 1.49±0.66 log
reduction in kidney CFUs versus 1.44±0.42 log reduction for
meropenem (30mg/kg/dose, IV) when mice were challenged with
KP453; 20mg/kg/dose IV TP-2758 was superior to meropenem,
producing a 3.78±0.52 log reduction in CFUs. TP-2758 at 2mg/kg/dose
PO produced a 3.07±0.73 log reduction of E. coli EC200 versus
3.8±0.22 and 3.1±0.54 log reductions produced by levoﬂoxacin
(2mg/kg/dose PO) and meropenem (20mg/kg/dose IV), respectively. TP-
2758 IV (5mg/kg/dose) and levoﬂoxacin IV (2mg/kg/dose) produced
4.05±0.39 and 4.88±0.3 log reductions, respectively. The 1mg/kg IV
AUCinf, Cmax, and half-life in rat/monkey were 1046/5490 ng·h/mL,
551/1343 ng/mL, and 7.5/16.6 h. The 10mg/kg PO AUCinf, Cmax, and
half-life in rat/monkey were 963/16,333 ng·h/mL, 91/751 ng/mL, and
8.4/13.5 h. Oral bioavailability was 8.6% in rat and 30.4% in monkey
for TP-2758 compared to oral bioavailabilities of 14.8% and 6.7% for
tetracycline in the same respective species. Tetracycline has 60−80% oral
bioavailability in man.
Conclusion: TP-2758 showed promising oral bioavailability in 2 species
and oral protection equivalent to IV meropenem in UTI/pyelonephritis
mouse models. TP-2758 is being evaluated in further studies as a
unique IV/oral therapy for treatment of ESBL and carbapenem-resistant
Enterobacteriaceae.
O97 Investigation of potential mechanisms underlying transient
paraesthesia associated with PMX30063 administration in
human subjects
R. Scott*, J. Arezzo, B. Korczak (Radnor, Bronx, US)
Objectives: The most frequent adverse event noted in Phase 1 clinical
studies with the novel antibiotic PMX30063 consisted of peripheral
sensory effects deﬁned as paresthesia. Two potential causes may be direct
damage to peripheral neurons or disturbances in ion channel activity. To
investigate these possibilities, peripheral nerve electrophysiology studies
in rats and in vitro functional assays with cloned ion channels were
performed with PMX30063.
Methods: To investigate potential neurotoxicity, rats were administered
PMX30063 in the clinical formulation at 3 dosages (n = 7/group) once
daily by 1 hour IV infusion for 5 consecutive days. This dosing regimen
matched that used in the Phase 1 clinical studies and was designed to
achieve blood levels of compound in the rat that were associated with
a low (1mg/kg), moderate (3mg/kg) or frequent (10mg/kg) incidence
of paresthesia in human subjects. Electrophysiology measures were
assessed from sensory and motor neurons at baseline, Day 1, Day 5
and 30 days (recovery group). Nerve conduction velocity (NCV) and
compound amplitude were recorded from the caudal nerve, and onset
latency and peak amplitude of the compound muscle action potential
(CMAP) were recorded from the tibial nerve. To investigate effects
on ion channels, patch clamp assays were performed in the presence
(0.3, 1.0 or 10uM) or absence of PMX30063 using cell lines expressing
human sodium, potassium, acid-sensing or transient receptor potential
ion channels.
Results: Exposure to PMX30063 at 10mg/kg doses for 5 days is
associated with a slight (8%) slowing of caudal NCV and no signiﬁcant
change in CMAP following tibial nerve stimulation. Normal function
was regained in the 10mg/kg recovery group. No electrophysiology
changes were observed at Day 1 in any dose group. Several ion channels
were inhibited by PMX30063, reaching >80% inhibition at 10uM. At
1um, current inhibitions were 43.2% (ASIC1a), 56.3% (hNav1.7) and
45.8% (hKv1.6).
Conclusions: Following PMX30063 administration, no signiﬁcant
electrophysiological deﬁcits were observed in motor neurons and in
the high dose group after repeat dosing only small transient NCV
reductions were observed in mixed sensory and motor neurons that
were fully reversible. However, several different classes of ion channels
were inhibited in vitro at low concentrations. These results support
disturbances in channel function rather than direct neurotoxicity in the
paresthesia associated with PMX30063 treatment.
ESBLs from the environment to the clinic
O98 Does the change in the EUCAST ESBL expert rules help the
patient?
M. Hoeck, B. Wiedemann* for the EPICENTER Network
Objectives: ESBL producing E. coli strains often leave little therapeutic
options especially in intensive care units. The therapeutic options
seem further limited if the former EUCAST expert rule was used
to automaticly convert sensitivity to b lactams to intermediate and
intermediate to b lactams to resistant, if an ESBL was recorded
for the respective strain. The change for 2010 is: “Cephalosporin
breakpoints for Enterobacteriaceae will detect clinically important
resistance mechanisms (including ESBL). Some strains that produce
b-lactamases are susceptible or intermediate to 3rd or 4th generation
cephalosporins with these breakpoints and should be reported as found,
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i.e. the presence or absence of an ESBL does not in itself inﬂuence the
categorization of susceptibility.”
We analysed blood culture isolates in order to see if the change in the
EUCAST expert rule opens new therapeutic options.
Methods: The laboratory participates in the network using the automated
BD PHOENIX-systems measuring MICs. The BD EPICENTER Data-
Management-System is used for the evaluation of the data in the
laboratory and for the transfer of the data for joint analysis. For this
study we analysed the MICs of ESBL producing E. coli blood culture
isolates in a period from 2006 to 2010. The ESBL production was
checked with the associated BD-expert system, as the Phoenix shows
excellent performance for ESBL detection (Maurine A. Leverstein-van
Hall, et al.: J Clin Microbiol. 2002 October; 40(10): 3703). Copy strains
are excluded. Quality control assays are routinely performed.
Results: With the MICs of the ESBL producing strains to ceftazidime
(CAZ), cefotaxime (CTX), cefepime (FMC), and aztreonam (ATM) we
calculated the sensitivity, using the new EUCAST breakpoints. The table
displays that none of the 3rd and 4th generation cephalosporins and
azthreonam could be used as treatment in 37% of the cases. However
ceftazidime could be an alternative in 60% of all strains, aztreonam in
28%, cefotaxime in 20%, and cefepime in 17% (see table).
Conclusion: There is no doubt, that the knowledge of the underlying
mechanism is of great value for epidemiological and infection control
reasons. However in the every day routine laboratory, and in favour of
the patient the new breakpoins together with a reliable system for the
detection of ESBLs is beneﬁcial for the patient, as it opens treatment
alternatives and at the same time gives a warning for the infection
control.
O99 The adjusted attributable mortality of extended-spectrum
b-lactamase-producing Enterobacteriaceae bacteraemia: a
meta-analysis
W.C. Rottier*, H. Ammerlaan, M.J. Bonten (Utrecht, NL)
Objectives: Bacteraemia caused by Enterobacteriaceae (EB) producing
extended-spectrum b-lactamases (ESBL) has been associated with
attributable unadjusted mortality compared to episodes caused by non-
ESBL-producing EB. Yet, since such analyses depend on observational
data, adjustment for confounders, e.g. through multivariate analyses,
is necessary. The appropriateness of determinants included, though,
depends on the research question. For instance, inadequate empirical
therapy and severity of sepsis are in the causal pathway of outcome and
adjustment for these parameters can be considered “less appropriate”. We
performed a meta-analysis of adjusted data and determined the effects
of including “less appropriate” determinants in adjustment procedures.
Methods: Studies comparing mortality from bacteraemic infections
caused by ESBL-EB and non-ESBL-producing EB were systematically
identiﬁed in Pubmed. Unadjusted and adjusted odds ratios (ORs) were
pooled, and effects of adjustment procedures on adjusted ORs were
explored in subgroup analyses.
Results: Of the 139 articles retrieved, 32 (including 9658 patients)
allowed calculation of unadjusted ORs for mortality. The pooled
unadjusted OR was 2.35 (95% conﬁdence interval (CI) 1.90–2.91, I2
= 42%). The pooled adjusted OR for ESBL EB versus non-ESBL
EB bacteraemia (18 multivariate analyses, including 7 imputed ORs)
was 1.76 (95%CI 1.34–2.31, I2 = 50%). 14 analyses that adjusted for
underlying disease found a pooled OR of 1.66 (95%CI 1.22–2.24). 12
analyses adjusting for inadequate empirical therapy found a pooled OR
of 1.37 (95%CI 1.04–1.82). Increasing the number of “less appropriate”
adjustments was associated with decreasing ORs (Table). Within the
set of studies adjusting for underlying disease, two studies performed no
“less appropriate” adjustments, resulting in a pooled OR of 2.87 (95%CI
1.57–5.26), and ﬁve performed 1 “less appropriate” adjustment and the
pooled OR remained above 1 (1.90, 95%CI 1.20–3.02).
Conclusion: In this meta-analysis, ESBL EB bacteraemia is, compared
to non-ESBL EB bacteraemia, associated with a higher mortality
rate. Adjustment for underlying disease, without adjustment for “less
appropriate” variables (severity of sepsis, inadequate empirical therapy),
did not change this conclusion. Inadequate empirical therapy is an
intermediate in the causal pathway, and adjustment for this variable
reduces the association between ESBL production and mortality.
O100 Extended-spectrum b-lactamase-producing Escherichia coli
bloodstream infections upon hospital admission (ESBL-
EC/BSI-UHA): molecular epidemiology and virulence traits
S. Navon-Venezia*, D. Karfunkel, D. Frienkel-Krispin, T. Kotlovsky,
I. Chmelnitsky, Y. Carmeli on behalf of MOSAR and SATURN study
groups
Objectives: ESBL-EC/BSI-UHA are emerging worldwide. These
infections are major concern often associated with severe outcomes. We
studied the molecular epidemiology, the CTX-M genes, and the virulence
traits of ESBL-EC isolates causing BSI-UHA in our hospital.
Methods: 7-years retrospective data (2003–2009) on ESBL-EC/BSI-
UHA was analyzed. 41 representative isolates were subjected to
molecular and virulence analysis. Antibiotic susceptibilities were
determined by Vitek-2. Genotyping was performed using PFGE and
MLST. CTX-M genes, phylogroups and virulence genes were identiﬁed
by PCR. Virulence of EC strains (n = 20) was evaluated using the
Caenorhabditis elegans in-vivo model by nematode-killing assays.
Statistics of survival was performed using Log-rank test.
Results: Incidence rates of ESBL-EC/BSI-UHA steadily increased along
the years from 2.94, to 6, to 7.87 cases/10,000 admissions in 2003,
2007 and 2009, respectively. All isolates were MDR with co-resistance
to ciproﬂoxacin (93%), trimethoprim-sulfamethoxazole (85%) and/or
gentamicin (51%). Genotyping revealed for the ﬁrst time the emergence
of sequence type (ST) 131 in Israel, which gradually dominated to
become the most prevalent clone (from 25% to 85%), alongside 9
sporadic clones. Except a single isolate (ST2), all isolates belonged to the
virulent phylogroups B2 and D. All isolates were CTX-M-producers with
the following distribution: blaCTX-M-15, n = 22, (54%); blaCTX-M-14,
n = 8, (19.5%); A novel blaCTX-M-2 group-blaCTX-M-97, n = 7, (17%);
blaCTX-M-5, n = 1, (2%); blaCTX-M-27, n = 1, (2%). Additionally, 2
isolates produced two CTX-M genes (15 and 97 and 15 and 14).
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ST131 isolates, carrying various CTX-M genes, showed higher virulence
compared to non-ST131 isolates (an overall of 3.1 virulence genes
compared to 1.8, p< 0.05).
In C. elegans model the median survival was shorter after exposure to
ST131 isolates (n = 10) than after exposure to other ESBL-EC clones
(n = 10) (5.9±0.32 days vs. 7.3±1.13 days, p< 0.001). Exposure to EC
OP50 control strain did not cause mortality under these experiment
conditions.
Conclusions: ESBL-EC-ST131 has emerged as a major source of BSI-
UHA in our hospital. The increased incidence of ESBL-EC/BSI-UHA
during the 7 years studied is due to clonal expansion of ST131, carrying
either CTX-M-15 or CTX-M-14. ST131 isolates showed enhanced
virulence compared to other ESBL-EC clones both in-vitro and in-vivo,
demonstrating the major clinical and public health concern of this clone.
O101 Characterisation of extended-spectrum b-lactamase-
producing Escherichia coli from clinical patients, chicken
meat and domestic animals
Y. Ishii*, M. Eto, H. Esaki, T. Saga, S. Harada, A. Yoshizumi, K. Tateda,
M. Kuroda, S. Igimi, A. Rambach, K. Yamaguchi (Tokyo, JP; Paris, FR)
Objectives: Extended-spectrum b-lactamase (ESBL) producing Es-
cherichia coli are a serious problem worldwide. ESBL producing
organisms are isolated not only from hospitalized patients but also from
community settings. The aim of this study was to assess the frequency
and diversity of ESBL produced E. coli and compare them when isolated
from different human and animal sources.
Methods: In 2007, E. coli isolates from clinical parients and the stools
of healthy chickens were collected and screened for ESBLs according
to Clinical and Standards Laboratory Institute guidelines. In the case of
raw chicken meat, overnight broth culture was performed using in LB
broth followed by streaking on the selective CHROMagar ESBL medium.
ESBL typing was conﬁrmed by PCR analysis. Multilocus sequence
typing (MLST) was carried out following the scheme on the E. coli
MLST web site (http://www.mlst.net/).
Results: Fifty-six isolates from patients 12 from chicken meat and 11
from chicken stools were conﬁrmed to possess ESBL genes. All ESBL
genes belonged to the blaCTX-M group. Predominant ESBL genes from
patients, healthy chickens, and chicken meat were blaCTX-M-9 group
(69.6%), blaCTX-M-1 group (72.7%) and blaCTX-M-2 group (58.3%),
respectively. Interestingly, no blaCTX-M-9 group gene was found in
stools of healthy chickens. No blaCTX-M-8 group was detected. Thirty-
nine (69.6%) of E. coli isolated from patients were related with ST131,
the sequence associated with CTX-M b-lactamases genes. Approximately
72% of E. coli ST131 from patients (28/39 isolates) were blaCTX-M-9
positive. On the other hand, the frequency of E. coli ST131 related
isolates from healthy chickens and raw chicken meat were 27.2% (3
isolates) and 8.3% (1 isolate), respectively. Twelve isolates were not
categorized in novel STs from web site. blaCTX-M-1 group positive
E. coli ST117 was isolated from one patient and 3 stools of healthy
chicken.
Conclusions: ESBL encoding genes especially blaCTX-M were detected
form human patients, healthy chicken and raw chicken meets. The
characterization of the ESBL sequences shows no direct evidence for
transmission of ESBL producing E. coli between chickens and clinical
patients.
O102 Prevalence of ESBL-producing Enterobacteriaceae (ESBL-E)
in Raw Vegetables
E.A. Reuland*, N. al Naiemi, M.C. Rijnsburger, P.H. Savelkoul,
C.M. Vandenbroucke-Grauls (Amsterdam, Enschede, NL)
Introduction: Recent data show that ESBL-producing bacteria are found
in Dutch soil samples (Knapp et al., Environ. Sci. Technol. 2010), and
in food-producing animals such as broiler chickens and pork meat. We
wondered whether ESBL-E are also present in raw vegetables.
Objectives: The aim of this study was to evaluate the presence of
ESBL-E in raw vegetables in the region of Amsterdam.
Materials and Methods: Between October 14 and November 29,
2010, samples of 17 different types of vegetables were obtained from
the market, and from organic and conventional stores in the region of
Amsterdam. We focused on vegetables that grow on and in the ground.
Screening for ESBL-E was performed with a selective enrichment broth
and inoculation on a selective screening agar, containing cefotaxime
and ceftazidime. ESBL production was conﬁrmed with the double disc
synergy test with clavulanic acid. Species identiﬁcation and further
antibiotic susceptibility testing were performed with the Vitek-2 system
(bioMe´rieux). DNA-isolation was performed with the QIAamp DNA
mini kit (Qiagen). ESBL genes were characterized by microarray (Check-
KPC ESBL Check-Points).
Results: Out of 79 analyzed samples, four yielded ESBL-producing
Enterobacteriaceae (5%). ESBL-E were found in parsnip, bean sprouts
and radish; this means that three (17,6%) of the vegetables types were
contaminated with ESBL-E. Of the four positive samples, three were
from vegetables of organic origin. The ESBL-producing strains were
Enterobacter cloacae (in two samples), Citrobacter freundii (in one
sample) and Klebsiella pneumoniae (in one sample). Three strains were
positive in the microarray for CTX-M ESBL belonging to the CTX-M-1
family and one for an SHV ESBL. PCR and sequencing are pending.
Conclusion: Our results document the presence of ESBL-producing
Enterobacteriaceae in some raw vegetables obtained in Amsterdam, the
Netherlands, implying that raw vegetables may be a source of resistance
genes. The possible impact of our ﬁndings on human health highlights
the need to further evaluate the presence of ESBL-E in raw vegetables
and to explore whether colonization of the human gut from this source
does occur.
O103 Prevalence and characterisation of extended-spectrum-
b-lactamase producing Escherichia coli isolates in healthy
volunteers in Tunisia
R. Ben Sallem*, K. Ben Slama, A. Jouini, N. Klibi, V. Estepa, Y. Sa´enz,
A. Boudabous, C. Torres (Tunis, TN; Logron˜o, ES)
Objective: To analyse the prevalence of ESBL among faecal E. coli of
healthy humans and to characterize the recovered strains.
Method: 150 faecal samples of healthy volunteers were inoculated
in Levine Agar plates supplemented with cefotaxime (2mg/L), and
one E. coli per positive sample was further studied. ESBL genes and
their genetic environment were characterized by PCR and sequencing.
Detection of associated resistance genes, MLST and phylogroup typing
were performed by PCR and sequencing, and plasmid analysis by PBRT-
typing. Presence and characterization of integrons and virulence factors
were performed by PCR and sequencing.
Results: ESBL positive E. coli isolates were detected in 11 of 150 faecal
samples (7.3%) and they contained the following genes: blaCTX-M-1 (10
isolates) and blaTEM-52c (1). The ISEcp1 and orf477 sequences were
found upstream and downstream of blaCTX-M-1 gene, respectively, in all
10 isolates. Seven different sequence-types (STs) were identiﬁed among
CTX-M-1-producing isolates by MLST (number isolates/phylogroup):
ST58 (3/B1), ST57 (2/D), ST165 (1/A), ST155 (1/B1), ST10(1/A),
ST398(1/A), and ST48 (1/B1). The TEM-52-producing isolate was typed
as ST219 and phylogroup B2. Thirteen plasmid replicon types were
detected among the 11 ESBL-positive strains, and 9 of them carried
three or more replicon types. The plasmid IncI1 was detected in all
10 CTX-M-1-positive isolates but not in TEM-52-producing isolate.
Six ESBL isolates contained class 1 integrons with the gene cassettes:
dfrA17-aadA5 (5 isolates), and dfrA1-aadA1 (1). Five isolates showed
tetracycline resistance and they contained tet(A)±tet(B) genes. Virulence
genes detected were (number isolates): ﬁmA (10), aer (8), papG III,
papC, hly, cnf, and bfp (none).
Conclusion: A relatively high rate of healthy individuals showed faecal
carriage of ESBL-positive E. coli isolates, mostly of CTX-M-1 class. The
community could be a reservoir of these resistant isolates, representing
a problem in human health.
ESBLs from the environment to the clinic S23
O104 High faecal carriage rates of CTX-M ESBL-producing
Escherichia coli in the Birmingham area: implications of
global origin
A. Eustace, N. Wickramasinghe, L. Xu, T. Saluja, S. Shabir, P. Hawkey*
(Birmingham, UK)
Objectives: The primary objective is to determine the period prevalence
of blaCTX-M carrying Escherichia coli in the community population of
North/East Birmingham, and determine the distribution of blaCTX-M
genotypes according to global origin.
The secondary objective is to assess the prevalence of the global
pandemic clone 025b-ST131.
Methods: 727 GP and outpatient stool samples sent for investigation
were screened for ESBL producing E. coli using chromogenic agar and
a combination disc method. Multiplex PCR was used to screen for the
presence of blaCTX-M, and the individual blaCTX-M genotypes was
determined by dHPLC and full gene sequencing. The clonal relatedness
of all CTX-M-15 producing isolates was determined by PFGE analysis,
and 25 isolates sequence type were determined by MLST and PCR.
Isolates were assigned to either ‘European’, ‘Middle East/South Asian’
(MESA), or ‘Uncategorised’ groups using software to determine global
origin based on patient name.
Results: Prevalence of blaCTX-M carriage in the sample population was
11.3%. There was a signiﬁcant difference (p< 0.0002) between carriage
in the European (8.1%) and the MESA group (22.4%). There was also
a signiﬁcant difference (p< 0.0002) in the carriage of blaCTX-M-15
between the two populations. 025b-ST131 accounted for 14 (23.7%)
of 59 CTX-M-15 producing E. coli isolates. By PFGE the 025b-ST131
isolates constituted one large cluster at the 65% similarity level grouping
with the local epidemic strain A. A high diversity of proﬁles was
observed with 41/59 samples displaying unique PFGE proﬁles at 85%
similarity level.
Conclusions: Based on the high community carriage rate and the
signiﬁcant difference in carriage between the groups, it is suggested
that antimicrobial therapy for Gram-negative sepsis presenting from
the community should take ESBL-producing organisms into account,
especially in community patients originating from the Middle East/Asian
sub-continent. The pattern of spread of blaCTX-M-15 is a cause for
concern and highlights the potential threat that this may be replicated in
the future by broader b-lactamases such as NDM-1.
O105 Tracking the presence of class 1 integrons in Gram-negative
bacteria collected from surfaces and biological samples in
Hospital Infante D. Pedro, Aveiro, central Portugal
C. Santos, C. Lima, E. Ramalheira, T. Caetano, S. Mendo* (Aveiro, PT)
Objectives: The use and misuse of antibiotics selects for multidrug
resistant strains. Within the hospital bacteria can colonize the
surrounding environment being able to ﬁnd their way into patients.
The aim of the present work was to evaluate the prevalence of class
1 integrons in Gram-negative bacteria collected from surfaces of female
ward’s furniture and track their dissemination to inpatients within the
period of their hospitalization in the Hospital Infante D. Pedro, Aveiro.
Methods: In a female ward, sterile swabs were rubbed in inanimate
surfaces, placed in rich medium (TSB), overnight at 37ºC. Serial
dilutions were plated in MacConkey agar. In the same period, bacteria
were isolated from biological samples (sputum, blood, urine) from
inpatients hospitalized in the same ward. The clonal relationship of the
isolates was evaluated by rep-PCR and analysed with the GelComparII
5.0 (Applied Maths, Kortrijk, Belgium). Identiﬁcation and antibiotic
susceptibilities were determined using the automatic VITEK2 system
and Advanced Expert System (VITEK2 AES) (BioMe´rieux, Marcy
L’Etoile, France). Identiﬁcation to the species level was conﬁrmed by
16S ampliﬁcation. Presence and characterization of class 1 integrons
and b-lactamases enzymes were performed by PCR. Nucleotide and
deduced aminoacid sequences were analyzed with Blast and ClustalW
programs. PFGE of S1 digested total DNA followed by Southern blotting
hybridization using intI1 DIG labelled probe was performed to locate the
class 1 integrons.
Results: New class 1 integrons, never described before in Portugal,
were identiﬁed. The same gene arrays were found in biological samples
and also in inanimate surfaces. The most prevalent species found were
E. coli, C. freundii, K. pneumoniae, P. aeruginosa and E. cloacae.
These isolates were multidrug resistant (b-lactams, aminoglycosides,
trimethoprim/sulphamethoxazole and quinolones). S1 digested genomic
DNA and PFGE analysis revealed the presence of plasmids in some
isolates. Hybridization with intI1 DIG labelled probe was unsuccessful,
thus integron location was not determined yet. b-lactamases enzymes
(TEM, SHV, CTX-M, OXA and VIM) are present.
Conclusion: Dissemination of resistance determinants by horizontal
gene transfer is facilitated between bacteria within the hospital
environment and can therefore infect the inpatients. These results are
worrisome, since all the isolates studied are multidrug resistant.
O106 Clonal group 025b-ST131 accounts for more than 90% of
clinical isolates of CTX-M producing E. coli from residents
of 26 nursing homes in one region
C. Ludden, F. Boyle, B. Hanahoe, M. Lyons, M. Cormican*, D. Morris
(Galway, IE)
Objectives: The association of CTX-M-15 with the O25b-ST131 clonal
group of E. coli has contributed to its dispersion worldwide. The
objective of this project was to examine the prevalence of this clonal
group among CTX-M producing E. coli isolated from nursing home
residents in one region of Ireland.
Methods: Forty eight isolates of CTX-M (CTX-M group 1 (n = 43;
CTX-M group 9 (n = 5)) producing E. coli were collected from routine
clinical specimens submitted from residents of 26 nursing homes in one
region of Ireland between January 1st and June 30th 2010. PCR was
performed on all 48 isolates using primers speciﬁc to the pabB (region
speciﬁc to the 025b-ST131 clone) and trpA genes (to conﬁrm quality and
ampliﬁcation of DNA) as previously described (Clermont et al., 2009,
64:274−77). Pulsed ﬁeld gel electrophoresis (PFGE) was performed with
XbaI by the Pulse-Net protocol.
Results: An amplicon speciﬁc to the trpA gene was identiﬁed in all
isolates, and an amplicon speciﬁc to the pabB gene was identiﬁed in
46 (96%) isolates. By PFGE analysis 39 individual pulsed ﬁeld proﬁles
(PFPs) and 6 major clusters (A-F) were identiﬁed among the 48 isolates
examined based on a similarity of >85%. With the exception of 2 isolates
(both cluster F isolated from residents of the same nursing home) all
PFPs were closely related with a similarity of >71%. These 2 isolates
were negative for the region of pabB speciﬁc to the 025b-ST131 clone.
Conclusion: This data provides evidence that the 025b-ST131 clone
of E. coli is widely disseminated in nursing homes in one region of
Ireland and that this clonal group accounts for the vast majority (96%) of
CTX-M E. coli clinical isolates from nursing homes. PFGE discriminates
between members of the 025b-ST131 and can therefore be useful for sub-
typing within the clonal group for epidemiological purposes. Our data
suggest that members of the 025b-ST131 clonal group cluster as >70%
similar by PFGE.
O107 Klebsiella pneumoniae sequence types originally associated
with speciﬁc ESBLs might act as substrates for recently
emerged metallo-b-lactamases or KPC enzymes
A. Valverde*, P. Ruiz-Garbajosa, T. Curiao, M. Tato, D. Gijo´n,
F. Baquero, T.M. Coque, R. Canto´n (Madrid, ES)
Background: Klebsiella pneumoniae (Kp) represent an important
reservoir of b-lactamases both in the hospital and in the community
settings. They have been associated with several nosocomial outbreaks
and global dissemination of extended-spectrum-b-lactamases (ESBLs),
metallo-b-lactamases (MBLs) or KPC enzymes. Population structure
studies in this specie using an MLST typing scheme are increasingly
being reported. This was further analyzed in a collection of different
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b-lactamase producing Kp recovered in our institution from 1989 to
2010.
Methods: 125 Kp clinical (101) and surveillance (24) isolates with
different ESBLs (19 SHV-12, 34 TEM-4, 23 CTX-M-10 and 13 CTX-
M-15), MBLs (22 VIM-1) and KPC (2 KPC-2 and 12 KPC-3) and
clustered in 46 PFGE-XbaI patterns were further selected for MLST
typing. Allele sequences and sequence types (STs) were assigned at
www.pasteur.fr/recherche/genopole/PF8/mlst/.
Results: 80 Kp-ESBL representing 38 PFGE patterns were classiﬁed in
26 STs. ST37 (11 TEM-4), ST385 (11 SHV-12) and ST16 (9 CTX-M-15)
grouped the highest number of isolates. Three ST clustered isolates
with different ESBLs: ST13 (1990–2005; CTX-M-10, CTX-M-15 and
TEM-4); ST14 (1995–2004; SHV-12, TEM-4); ST37 (2001–2005 SHV-
12, TEM-4). The rest of STs were linked to single ESBL-types. Twenty-
two VIM-1 producers were clustered in 3 pulsotypes corresponding to
3 STs, 18 of them belonging to ST39 which were responsible of a
nosocomial outbreak whereas the remaining isolates were grouped into
ST163 and ST253 associated with CC23. KPC isolates were resolved in
3 PFGE types classiﬁed in 3 ST (12 ST384 responsible of an outbreak of
KPC-3 producing isolates and one each ST388 and ST20 with KPC-2).
Interestingly, ST20, ST388 and ST39, originally associated with CTX-
M-10 and SHV-12, were recently described among isolates producing
KPC-2, KPC-3+CTX-M-10 and VIM-1+SHV-12, respectively.
Conclusions: ESBL, MBL and KPC enzymes are expressed in our
institution among different K. pneumoniae MLST genetic lineages.
Nevertheless, some ST originally associated with speciﬁc ESBL types
could act as substrates for VIM-1, KPC-2 and KPC-3 enzymes that have
recently emerged in our institution. This demonstrated the importance
of these clones in the capture and maintenance of different b-lactamase
determinants.
Pneumococcal vaccination with focus on
NTHi
S112 Epidemiology and burden of disease due to S. pneumoniae
and NTHi
R. Dagan* (Beer Sheva, IL)
Acute respiratory tract infections (RTIs) comprise a wide spectrum
of disease, including sinusitis, bronchitis, pneumonia and otitis media
(OM), and confer a large burden on society. Streptococcus pneumoniae
and non-typeable Haemophilus inﬂuenzae (NTHi) are major causative
pathogens in RTIs, with particular dominance in acute OM (AOM).
AOM caused by S. pneumoniae is somewhat more severe and can be
distinguished by a higher body temperature, more inﬂamed ear drum
and an increased inﬂammatory and white blood cell response.1 NTHi
tends to be more commonly associated with bilateral, recurrent and non-
responsive AOM.2 However the clinical picture is too indistinct to permit
a differential diagnosis in the clinical setting.
It has long been thought that both S. pneumoniae and NTHi are involved
in similar ways in AOM. However, new evidence is emerging on various
stages of AOM (i.e. simple AOM, recurrent AOM, non-responsive AOM)
and its bacteriology, much of which has been derived from prospective
studies on AOM and vaccine studies. In a study of over 5000 cases
of bacteriologically proven cases of pneumococcal AOM in Southern
Israel, 40% were in fact mixed pneumococcal-NTHi infections (M-
AOM) and only 60% were single-pathogen pneumococcal AOM (S-
AOM). Further analysis demonstrated that M-AOM was associated with
crowded populations, recurrent and non-responsive cases, older age and
bilaterality, consistent with a more prolonged or complicated course.
Moreover, pneumococcal serotypes appeared to differ between S-AOM
and M-AOM. These ﬁndings suggest that some virulent pneumococcal
strains cause more S-AOM than M-AOM cases, and that in M-AOM
somewhat less virulent pneumococcal strains are found in conjunction
with NTHi.
Mixed infections are more frequently found in more complex (i.e.
recurrent and non-responsive) OM. One reason for this could be the
presence of bioﬁlm, which is often polymicrobial and renders bacteria
non-responsive to treatment. Recent data in a chinchilla model of AOM
suggesting a passive protective effect of NTHi towards S. pneumoniae
due to bioﬁlm and b-lactamase production support the intractable nature
of such dual infections.3 Observations made in AOM might provide
insights on how these pathogens behave and interact in RTIs in general.
Reference(s)
[1] Leibovitz E, Satran R, Piglansky L et al. Can acute otitis media
caused by Haemophilus inﬂuenzae be distinguished from that caused
by Streptococcus pneumoniae? Pediatr Infect Dis J 2003; 22:
509−15.
[2] Barkai G, Leibovitz E, Givon-Lavi N, Dagan R. Potential
contribution by nontypable Haemophilus inﬂuenzae in protracted and
recurrent acute otitis media. Pediatr Infect Dis J 2009; 28: 466−71.
[3] Weimer KE, Juneau RA, Murrah KA et al. Divergent mechanisms
for passive pneumococcal resistance to b-lactam antibiotics in the
presence of Haemophilus inﬂuenzae. J Infect Dis 2011; 203: 549−55.
S113 Current management and treatment guidelines: their
implications and the status of antibiotic resistance in Europe
J. van Eldere* (Leuven, BE)
Antimicrobial resistance in Streptococcus pneumoniae has changed
over time and is the result of a complex interplay between factors.
Important factors to consider are antibiotic use, population density,
spread of resistant clones and, more recently, the effects of pneumococcal
conjugate vaccination. Many studies have examined the links between
these factors, the use of speciﬁc antibiotics and resistance to related and
unrelated antibiotic classes. The insights generated by these studies have
affected treatment guidelines for respiratory infections.
As a community-acquired respiratory pathogen, non-typeable Haemo-
philus inﬂuenzae (NTHi) is second in importance to S. pneumoniae.
Particularly in Japan and neighbouring regions, b-lactam-resistant NTHi
strains have rapidly attained high levels of prevalence,1 leading to
antibiotic treatment challenges for infection, such as recurrent or chronic
otitis media. Unlike S. pneumoniae, these highly b-lactam-resistant
NTHi will not respond to increased doses of aminopenicillins or oral
cephalosporins. The observations in Japan raise the concern of spread
of highly resistant and epidemic NTHi clones. Data from some European
countries indeed suggest a similar development.2,3 However, regular
NTHi surveillance is lacking in many countries, and there are conﬂicting
data on which antibiotics are driving this increase in resistance. Should
the above trends in accelerated resistance be conﬁrmed in Europe, this
would profoundly affect current treatment guidelines for respiratory
infections.
Reference(s)
[1] Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in
Haemophilus inﬂuenzae. Clin Microbiol Rev 2007; 20: 368−89.
[2] Dabernat H, Seguy M, Faucon G, Delmas C. Epidemiology of
Haemophilus inﬂuenzae strains collected in 2004 in France and in
vitro assessment of their susceptibility to antibiotics. Med Mal Infect
2007; 37: 320−4.
[3] Garcı´a-Cobos S, Campos J, La´zaro E et al. Ampicillin-resistant
non-b-lactamase-producing Haemophilus inﬂuenzae in Spain: recent
emergence of clonal isolates with increased resistance to cefotaxime
and ceﬁxime. Antimicrob Agents Chemother 2007; 51: 2564−73.
S114 Potential role of vaccination in decreasing antibiotic use
P. Marchisio* (Milan, IT)
Respiratory tract infections (RTIs) are the most commonly encountered
diseases in infants and children. Streptococcus pneumoniae is a major
bacterial pathogen, being the main cause of, among others, acute
otitis media (AOM) and community-acquired pneumonia (CAP). These
diseases, in particular AOM, are the main drivers for antibiotic
prescriptions in young children, both in Europe and in the USA.
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In clinical efﬁcacy studies, different pneumococcal conjugate vaccine
(PCV) formulations have demonstrated beneﬁt against different RTIs.
Since the introduction of the heptavalent PCV (PCV7) in the USA
in 2000, signiﬁcant reductions in the rates of RTI visits (in particular
AOM), pneumonia admissions and RTI-related antibiotic prescriptions
have been reported.1,2 In addition, PCV7 has been associated with
changes in the pathogenesis of RTIs, with proportionate increases in the
importance of non-vaccine serotypes as well as other microorganisms,
in particular non-typeable Haemophilus inﬂuenzae. Similar trends have
been observed in Italy, where PCV7 has also been found to be effective
in the prevention of AOM and CAP and in reducing the number of
antibiotic prescriptions.3 The potential beneﬁts of vaccination could be
taken into account in clinical guidelines for the management of RTIs,
in terms of lessening the indiscriminate use of antibiotics and lessening
selective pressure for resistance.4 Similar to other European countries,
various attempts have been made in Italy to deﬁne the most appropriate
ways to manage RTIs. Recently this gap was ﬁlled by the Italian
Society of Pediatrics, which coordinated the preparation of the national
Italian Multidisciplinary guideline for AOM;5 a similar guideline for
CAP is currently underway. These guidelines are based on the broad
participation of representatives of different specialties (paediatricians,
otolaryngologists, pharmacologists, allergologists, microbiologists, etc.)
and are aimed at translating the newly acquired knowledge on RTIs,
antibiotic resistance and the consequences of old and new pneumococcal
vaccines into precise recommendations for clinical practice, also taking
into account the peculiarities of microbiological data in the Italian
setting.
Reference(s)
[1] Grijalva CG, Nuorti JP, Arbogast PG et al. Decline in pneumonia
admissions after routine childhood immunisation with pneumococcal
conjugate vaccine in the USA: a time-series analysis. Lancet 2007;
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[3] Esposito S, Lizioli A, Lastrico A et al. Impact on respiratory
tract infections of heptavalent pneumococcal conjugate vaccine
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[4] Vergison A, Dagan R, Arguedas A et al. Otitis media and its
consequences: beyond the earache. Lancet Infect Dis 2010; 10: 195–
203.
[5] Marchisio P, Bellussi L, Di Mauro G et al. Acute otitis media:
From diagnosis to prevention. Summary of the Italian guideline.
Int J Pediatr Otorhinolaryngol 2010; 74: 1209−16.
S115 The need for improved surveillance of invasive bacterial
disease
M. Slack* (Oxford, UK)
Surveillance of invasive bacterial diseases (IBD) caused by Neisseria
meningitidis, Haemophilus inﬂuenzae and Streptococcus pneumoniae
is important to monitor epidemiological trends, circulating strains
and antimicrobial resistance. Following the widespread introduction of
conjugate vaccines for H. inﬂuenzae type b (Hib), N. meningitidis
serogroup C and multiple-valency pneumococcal conjugate vaccines
(PCVs), there has been a dramatic decrease in the occurrence of
diseases caused by vaccine-preventable strains.1,2 However, monitoring
of IBD caused by these organisms to assess the impact of vaccination
programmes, detect vaccine failures and to assess any geographical
or temporal variations remains a necessity. It is also important
to monitor circulating strains to investigate evidence of disease
replacement by non-vaccine-preventable strains, including non-vaccine
serotypes of pneumococcus, non-b capsulated H. inﬂuenzae, non-
typeable H. inﬂuenzae (NTHi) and non-Group C meningococcus, which
in many countries now constitute the majority of invasive infections
caused by these three organisms. For example, in the post-Hib era in
the UK, NTHi emerged as a leading cause of remaining H. inﬂuenzae
invasive disease.3
The EU-IBIS surveillance network (funded by EU DG SANCO)
collected data on invasive meningococcal and H. inﬂuenzae disease
between 1999 and 2007. From 2008, laboratory surveillance and external
quality assurance for meningococci, H. inﬂuenzae and pneumococci has
been organised by IBD-labnet (funded by ECDC). The data generated
by these networks indicate that IBD surveillance varies widely between
countries in terms of completeness, the age of the population surveyed,
the clinical presentations included, the level of identiﬁcation of isolates
and the geographical area covered. In addition, surveillance systems in
some countries have changed over time; comparisons between and within
countries should therefore be viewed with caution.
There is a need for continued large scale clinico-epidemiological
surveillance to collect comparable data on IBD, particularly those that are
potentially vaccine-preventable. Standardised questionnaires examining
clinical presentations, underlying risk factors, clinical management and
attributable death would contribute to a fuller understanding of IBD
caused by these pathogens.
Reference(s)
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Genetics and epidemiology of mobile
resistance: mobilome and resistome
S124 Transposable elements in mobilisation and spread of
resistance genes in Gram-negatives
T.R. Walsh* (Cardiff, UK)
At a time when the clinical fraternity is lamenting the lack of novel,
even new, worthy antimicrobials in the Pharmaceutical pipeline, MDR
bacteria are now consistently reported in most countries − a situation
which 15 years ago would have been unimaginable. Human travel and
globalisation aside, the relentless evolving of bacteria to MDR, and
some pan-drug resistance, status is a direct result of the bacteria’s
ability to mobilise and ultimately share DNA, a phenomenon called
horizontal gene transfer which occurs considerably more frequently in
Gram-negative bacteria. Intrinsic to this DNA plasticity are transposable
elements; mobile sections of DNA capable of moving themselves and
adjacent DNA which in this case involves antibiotic resistance genes.
The emergence of MDR in the early clinical isolates was due to the fact
that genetic engineering tools and resistance mechanisms were already
present at the beginning of the antibiotic era of the 1950’s and 1960’s.
In the 1970’s MDR was determined in many cases to be associated with
transmissible plasmids and transposons, and in 1989 the class 1 integron
was ﬁrst described. The resistance genes carried by these elements have
also evolved in response to increasingly broader-spectrum antibiotics
e.g. TEM-1 in the 1960’s to NDM-1 in 2010. However, even before
the introduction of sulpha drugs and penicillin, the use of mercury
in industry, agriculture and medicine probably aided and abetted the
establishment of mercury resistance transposons e.g. Tn21 that are now
prevalent and mobilise MDR regions.
We now appreciate the evolvement of class 1 (including 2 and 3)
integrons in MDR phenotypes but have also recently witnessed the
contribution of their ancestor Tn5050 which has made a renaissance
and has shown to be active as a transposon. Coupled to one end of
some of the classic class 1 integrons are Tn21 transposons allowing
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inter-plasmid/chromosome movement. Five years ago, ISCR elements
were but an academic curiosity but have now been shown to be
instrumental in moving huge sections of bacterial DNA carrying many
antibiotic resistance genes and pathogenicity factors. ICEs can also move
DNA using one-ended transposition. This presentation will review the
deﬁnition and classiﬁcation of transposons and provide recent examples
of antibiotic resistance gene transfer which are the most clinically
relevant.
New aspects of antimicrobial treatment of
anaerobic infections
S127 Antimicrobial resistance in Clostridium difﬁcile
P. Mastrantonio* (Rome, IT)
Clostridium difﬁcile has been identiﬁed as one of the major causative
agents of antibiotic-associated diarrhoea. The antibiotic susceptibility
of C. difﬁcile strains, including epidemic clones, is changing. Most of
the prevalent types responsible for disease in humans were resistant to
clindamycin and/or erythromycin due to an ermB gene encoding for
an rRNA methyltransferase, whereas, currently, we are observing an
increase in the number of resistant ermB-negative C. difﬁcile isolates,
including the epidemic strain C. difﬁcile BI/NAP1/027. Resistance to
tetracycline has also been observed in both historic and recent isolates.
Tetracycline resistance is commonly conferred by a tet(M) gene that
encodes for a ribosomal protection protein. This gene is usually carried
by a Tn5397 transposon, but recent strains can harbour elements
belonging to the Tn916 family, which are widely dispersed in Gram-
positive and negative bacteria. Moreover, C. difﬁcile clinical isolates
resistant to ﬂuoroquinolones have recently appeared and their number is
on the rise too. In particular, resistance rate to moxiﬂoxacin has increased
dramatically over the last years due to amino acid substitutions in the
DNA gyrase subunits GyrA or GyrB. The current standard treatment
for C. difﬁcile infection is oral metronidazole or vancomycin, the latter
as the antibiotic of choice for severe cases. Few C. difﬁcile strains
resistant to metronidazole have been described in the world, but recently
an increase in minimum inhibitory concentrations and heteroresistance
have been observed. The exact mechanism of reduced susceptibility to
metronidazole remains to be determined since this pathogen does not
show nitroimidazole genes, commonly associated with this resistance
in other bacteria. Antibiotic resistance is important in infection, as it
would provide C. difﬁcile a competitive growth advantage in the gut of
patients after antibiotic treatment. A comprehensive picture of different
phenotypic and molecular characteristics of the antibiotic resistance in
a very large sample of clinical isolates collected during an European
survey of C. difﬁcile infection will be presented.
S128 Bacteroides, Prevotella and Porphyromonas are becoming
more resistant to antimicrobial agents
E. Nagy* on behalf of the ESGAI
The most frequent anaerobic pathogens are the members of the
Bacteroides, Prevotella and Porphyromonas genus. Among Bac-
teroides strains, chromosomally mediated b-lactamase production
and tetracyclin resistance are most prevalent world-wide. Resistance
to b-lactam/b-lactamase inhibitor combinations has been increasing
throughout the years both in the US and in Europe. The same is
true for cefoxitin, and heteroresistance can be observed among isolates.
The resistance to clindamycin is mediated by a macrolide-lincomycin-
streprogramin mechanism; its frequency differs from country to country
in Europe. The occurrence and spread of resistance to imipenem
and metronidazole among Bacteroides strains, and their expression
mechanisms, merit special clinical attention. The presence of the cﬁA
gene responsible for carbapenem resistance is much more prevalent
than the expression of high-level imipenem resistance. Nim genes are
responsible for the metronidazole resistance. High-level resistance can
easily be induced in nim-positive strains by culturing in the presence of
a subinhibitory concentration of metronidazole. Moxiﬂoxacin resistance
has proven to be increasing in all countries. The lowest rate of resistance
was observed in the case of tigecycline in Europe.
Prevotella and Porphyromonas strains are usually considered more
susceptible to anti-anaerobic drugs than Bacteroides, though surveillance
data on the susceptibility of these organisms are rather limited.
About 50% of Prevotella species are resistant to ampicillin, due
to different b-lactamases, including those coded by the cfxA gene.
The resistance of Porphyromonas to ampicillin is much lower
(5−10%). b-lactam/b-lactamase inhibitor combinations, carbapenems and
metronidazole are uniformly active against most isolates of both genera,
but some Prevotella isolates harbor nim genes and demonstrate high level
of resistance to metronidazole. Clindamycin resistance among Prevotella
and Porphyromonas isolates is rare. The spread of tetracycline resistance
can be discerned in both genera, mostly due to the presence of the tetQ
gene. Tigecycline, which can overcome resistance mechanisms against
tetracycline, is highly active and the same is true for moxiﬂoxacin. To
assess the real importance of the development of resistance in Prevotella
and Porphyromonas is difﬁcult, due to the lack of regular antibiotic
sensitivity testing in routine laboratories and to the infrequency of
surveillances.
Q fever: a major threat in Europe
S130 Q fever in the Netherlands: epidemiology of the largest
ongoing European outbreak
W. van der Hoek* (Bilthoven, NL)
Objectives: Since 2007 the Netherlands is facing an epidemic of Q fever
with a size that is unprecedented in the world. Q fever has become a
major public health problem with political implications and has led to
drastic veterinary measures, including the large-scale culling of pregnant
goats on infected farms. The presentation will give the latest ﬁgures from
the surveillance of Q fever and results from ongoing studies, primarily
those focusing on risk factors for human disease.
Methods:Monitoring of the epidemic is based on mandatory notiﬁcation
of acute Q fever (fever, or pneumonia, or hepatitis with laboratory
conﬁrmation). To ﬁll the remaining knowledge gaps there is an extensive
ongoing research agenda, including at least 18 PhD projects, covering
such ﬁelds as host-pathogen characteristics, transmission and risk factors,
and chronic Q fever.
Results: Epidemiological studies show that living close (<2km) to a
large dairy goat farm where an abortion wave due to Coxiella burnetii
has occurred, is the most important risk factor for human Q fever.
Seroprevalence among the general population has increased from 2.4%
before the ﬁrst outbreak to around 12% in the high incidence area in
2009. The number of notiﬁed acute Q fever patients went down from
2354 in 2009 to 508 in 2010. Because several veterinary measures were
implemented at the same time, it is difﬁcult to establish the relative
contribution of vaccination, culling, and hygiene measures to this decline
in incidence.
Conclusion: Despite the veterinary measures that were implemented,
and the reduced incidence of acute Q fever in 2010, Q fever is not
expected to disappear from the Netherlands, because of the long-term
survival of C. burnetii in the environment and the occurrence of the
bacterium in other animals than goats. A major challenge ahead is
early detection and treatment of patients who are at risk for chronic
Q fever, and developing effective treatment strategies for patients with
other sequels of acute Q fever.
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S131 Q fever in animals: epidemiology, diseases in animals and
zoonotic risk
A. Rodolakis* on behalf of the ESCMID Study Group for Coxiella,
Anaplasma, Rickettsia and Bartonella (ESCAR)
Coxiella burnetii, infects a wide range of wild and domestic animals
including mammals, marsupials, birds, reptile and arthropods all around
the world. Lice, mites and parasitic ﬂies are also infected.
There is consensus among public health and veterinary professionals
that most of the human Q fever outbreaks are linked to small ruminants,
however, other species in the vicinity of livestock (dogs of herds, rodents,
migratory birds, ticks, . . . ), could play a role as secondary reservoirs.
In ruminants infection is mostly asymptomatic but, especially in small
ruminants, C burnetii can induce abortions, stillbirth or premature
delivery. High rates of abortion have been observed only in goats. In
cattle, abortions are sporadic and metritis and infertility are frequently
the main clinical signs.
Infected ruminants shed C burnetii in huge quantities into parturition
products, during abortion and normal delivery, and smaller numbers in
faeces, urine, vaginal mucus, or milk. This shedding may persist over
several months particularly in milk. However vaginal and faecal bacterial
discharges have the major impact on environmental contamination.
The transmission of infection is mostly associated with abortion of sheep
and goats. The infection is mainly due to inhalation of aerosolized
bacteria or contaminated dust resulting from contaminated manure and
desiccation of infected placenta and body ﬂuids. Farmers, veterinarians
and slaughterhouse workers may be infected through occupational
exposure, but direct contact with animals is not required, handling
contaminated wool, manure, or clothes contaminated with faeces are
sufﬁcient to become infected. Transhumance of infected ﬂocks and
increased urbanisation in rural areas are hypothesised as contributing
factors to human outbreaks. In addition the environmental survival of C
burnetii allows it to be transported by wind far away from the original
source. C burnetii DNA was detected in the soil of farms but also in
urban areas, brough by wind or birds.
Dogs and cats infected by aerosol inhalation, by tick bite or by feeding
on infected placentas shed C burnetii in urine, milk and birth products.
Ticks are considered to be a reservoir and vector of C burnetii in several
countries. They transmit the agent via bite or feces to birds, rodents or
ruminants. Infected domestic poultry can transmit Q fever to humans
through aerosolized fomites.
Vaccination of ruminants is currently the best way to prevent human Q
fever.
S132 Q fever: Prevention and treatment issues during an outbreak
A.M. Horrevorts*, M.H. Nabuurs-Franssen (Nijmegen, NL)
Since 2007, the Netherlands has experienced the largest Q fever outbreak
ever. From 2007 till today more than 4000 patients have been reported.
Q fever is a zoonosis caused by Coxiella burnetii that occurs worldwide.
The most common animal reservoirs are goats, sheep and cattle. These
animals, when infected, shed the bacteria in urine, feces, milk and
birth products. C. burnetii is a highly infectious bacterium. Humans
are infected by inhalation of contaminated aerosols or ingestion of
contaminated milk or milk products. Diagnosis is based on serological
tests and PCR’s. Infection may lead to asymptomatic seroconversion
(60%), acute disease (40%) or chronic infection (1−2% in NL). In the
Dutch outbreak, an association with intense goat farming was suggested.
One MLVA type of C. burnetii prevails on Q fever-positive dairy goat
and diary sheep farms, indicating clonal spread. The outbreak prompted
preventive regulations: Hygiene measures were instituted on farms, a
ban of the spread of manure was issued, vaccination of goats was
ordered, testing for C. burnetii in bulk milk was started, breeding on
infected farms was prohibited and ﬁnally all pregnant goats and sheep
on infected farms were culled. The decreasing numbers of human cases
in 2010 might indicate that these measures have been effective. Special
attention was paid to infected pregnant women concerning treatment
during pregnancy and hygiene measures during birth. A retrospective
study showed so far no signiﬁcant correlation of seropositivity for Q
fever during early pregnancy and adverse pregnancy outcome. In the
Netherlands blood donations are not regularly tested for the presence of
C. burnetii and/or antibodies against the bacteria. A prevalence study is
ongoing.
A vaccine against C. burnetii has been manufactured. In the Netherlands,
vaccination is now available for patients with underlying cardiac and
vascular diseases without immunity against C. burnetii.
Acute Q fever is frequently self-limiting. When treatment is needed
in acute Q fever, doxycycline is still the drug of choice as is co-
trimoxazole in children and pregnant women. The newer quinolones
such as moxiﬂoxacin have also been shown to be effective against
C. burnetii. Treatment of chronic Q fever is difﬁcult, prolonged, requires
monitoring of serum levels of the drugs used, and in special cases
surgical intervention.
S133 Coxiella burnetii: lessons from genomics
D. Raoult* (Marseille, FR)
Coxiella burnetii is an intracellular bacterium causing Q fever. The
genomic sequence carried out of Coxiella burnetii could make it possible
to obtain signiﬁcant advances. Firstly, the techniques of molecular
genotyping, based on the sequence, allow deﬁning the microbial groups
showing that if all species must be associated with chronic infections,
only a selected group of species appear to be causing acute Q fever.
This chromosomal genotyping is coherent with the genotyping plasmid.
In addition, the availability of the genome made it possible to do
genomotyping which ﬁnds the same classiﬁcation. This genotyping made
it possible to identify Coxiella burnetii on the strain level and this type
of genotyping was set up in order to show the clonality of the epidemic
currently prevailing in the Netherlands. On the epidemiologic level, the
genomotyping made it possible to highlight that a group of bacteria was
speciﬁcally related to the ticks, and which found in this group all the
bacteria found in the hard ticks, but also isolates obtained in animals or
humans. It appears, based on this work, that the role of the ticks in the
epidemiology of Coxiella burnetii was underestimated. Lastly, the study
of the genome made it possible to do exhaustive proteomic studies and
to deﬁne the best conditions allowing in vitro culture. This work made
it possible to determine that Coxiella burnetii was microaerophilic, and
that its medium had to be supplemented, which brought to the realization
of axenic mediums now allowing the easier culture of Coxiella burnetii.
Opportunistic infections in solid organ
transplant recipients
S134 Human cytomegalorvirus infection in transplant recipients
P. Grossi* (Varese, IT)
Human cytomegalovirus (CMV) was the ﬁrst “opportunistic” virus de-
scribed in renal transplant recipients under azathioprine and prednisone.
It has been the most frequent cause of infectious complications after solid
organ transplantation with all subsequent immunosuppressive regimens.
In seronegative recipients, latently infected allografts and leukocyte
containing blood products are documented means of virus transmission.
Among pre-transplant CMV seropositive transplant recipients, CMV
infection may occur after reactivation of latent infection or after
reinfection. Active CMV infection occurs during the ﬁrst three months
after transplantation and may be accompanied by a broad spectrum of
disease manifestations. The primary infection is usually more severe
than reactivation or superinfection. Antiviral prophylaxis and pre-
emptive therapy are similarly effective in preventing CMV disease after
transplantation. However, current guidelines prefer antiviral prophylaxis
over pre-emptive therapy in preventing CMV disease in high-risk SOT
recipients. Antiviral prophylaxis is preferred due to the potential beneﬁt
of reducing not only the incidence of CMV disease, but also the indirect
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effects of CMV on allograft and patient survival. The major drawback
of antiviral prophylaxis is delayed-onset CMV disease which has been
signiﬁcantly associated with allograft loss and mortality. Pre-emptive
therapy consists of weekly laboratory monitoring to detect CMV in
the blood using quantitative PCR, prior to the onset of symptoms.
Once CMV is detected, pre-emptive therapy is initiated to prevent
the progression of asymptomatic infection to clinical disease. The
potential advantage of pre-emptive therapy is the exposure of the host’s
immune system to CMV, thereby allowing earlier CMV-speciﬁc T-cell
reconstitution, which could potentially explain the very low rates of
late-onset CMV disease with this approach. The success of pre-emptive
therapy is highly dependent on the consistency of collecting weekly
specimens and the predictive value of the assay used. Undetectable
viraemia should be achieved prior to discontinuation of therapy in order
to reduce the risk of virological relapse.
In conclusion, the current availability of powerful antiviral agents, given
as prophylaxis or pre-emptive treatment, has dramatically reduced the
rate of CMV disease after solid organ transplantation. However, there is
a lack of consensus on the best strategy to be used.
Can we decrease hospital-acquired infections
in “real” life?
O138 Understafﬁng, overcrowding, inappropriate nurse-to-
ventilated patient ratio and nosocomial infections − which
parameter reﬂects deﬁcits best?
F. Schwab, P. Gastmeier, C. Geffers, E. Meyer* (Berlin, DE)
Objective: We investigated the impact of nurse to patient ratio, nurse
to ventilated patient ratio and bed occupancy on nosocomial blood
stream infections (BSI) and pneumonia in 182 intensive care units. In
stressed and high-throughput systems, periodic overcrowding (high bed
occupancy) and understafﬁng (low nurse to patient ratio) are widely
described risk factors in infection control. We compared the impact of
these well known parameters with a new parameter (nurse to ventilated
patient ratio).
Methods: ICUs reported data on device use and nosocomial device-
associated infections to KISS which is the German hospital surveillance
system for nosocomial infections and we analyzed data from the year
2007. Information of the number of health care workers on the ward per
24 hours in 2007 and structure parameters (type and size of ICU and
hospital) was obtained by questionnaires. We categorized the parameters
by (a) the quartiles in each ICU and by (b) the quartiles in all ICUs and
analysed association of the number of nosocomial infections per month
by generalized linear regression models based on Poisson distribution.
Results: 182 ICUs provided data on all parameters. Of these KISS-ICUs
1,921 months (10.6 month per ICU) were analysed including 159,400
patients with 563,177 patient days, 1313 pneumonia cases (of them 1064
were ventilator associated) and 513 BSI cases (491of them were central
venous catheter associated). Less nosocomial infections were associated
with more nurses per ventilated patient. Interestingly, the nurse-patient
ratio did not reveal to be a signiﬁcant parameter with respect to the
occurrence of nosocomial blood stream infections and pneumonia and
a high bed occupation (above the 75% percentile of all ICUs) was
associated with less nosocomial infections.
Conclusion: The estimation of thresholds (of parameters) above which
the infection risk increases would be the paramount importance for
administrators and policy makers. Formal economical evaluation is
needed, which will probably demonstrate that the beneﬁt resulting from
cutting down on nursing resources is by far outweighed by the cost of
nosocomial infections attributed to staff shortages.
O139 Selection of qacA carriage in MRSA clonal complex 22
but not 30 during a successful infection control programme
incorporating chlorhexidine-based decolonisation
R. Batra, E. Halligan, P. Cliff, J. Otter, J. Edgeworth* (London, UK)
Objectives: A chlorhexidine (CHX) based methicillin-resistant Staphy-
lococcus aureus (MRSA) decolonisation policy was introduced into our
intensive care unit (ICU) in 2004. This led to a 70% reduction in
transmission of endemic MRSA (predominantly clonal complex (CC)30
and CC22), which had low carriage rates of the antiseptic resistance
gene qacA (<10%), but no effect on an outbreak strain (sequence type
(ST)239-TW) carrying qacA (Batra R et al. Clin Infect Dis 2010;50:210–
217). Around the same time a hospital-wide heightened infection control
programme incorporating CHX decolonisation policy for MRSA carriers
was introduced which led to a 90% reduction in MRSA bacteremias. The
aim of this study was to assess whether qacA selection has occured
in dominant UK MRSA clones following implementation of CHX
decolonisation policies.
Methods: ICU MRSA acquisition isolates during one year before and
one year after introduction of the CHX policy and 399 consecutive
hospital-wide CC22 and CC30 MRSA bloodstream isolates obtained
between 2001 and 2009 were analysed. Discriminatory qacA and qacB
genotyping was performed using a single nucleotide polymorphism
genotype assay. Clones were deﬁned using Based Upon Repeat Pattern
clustering of spa type and staphylococcal cassette chromosome mec
allotype or restriction modiﬁcation typing.
Results: qacA carriage by ICU-acquired CC22 and CC30 isolates
increased in CC22 but not CC30 following implementation of the CHX
policy (1/14 before and 3/4 after (p = 0.028) v. 1/20 before and 1/9 after
(p> 0.05), respectively). qacA carriage by bloodstream CC22 and CC30
isolates in 2001 and 2002 was low (5−10%), but from 2003 there was
a signiﬁcantly increased carriage of qacA in CC22 (range 24−37% per
annum OR 1.25 95%CI 1.07–1.45; p = 0.003), but not CC30 (<10%),
associated temporally with the decline in MRSA bloodstream infection
rates. From being the dominant cause of bloodstream infection CC30
declined more rapidly than CC22, a phenomenon observed nationally.
Conclusions: These observations provide the ﬁrst evidence of qacA
selection in response to intensive CHX use in some but not other MRSA
clones. Selection for qacA in CC22 but not CC30 may help explain
changing national epidemiology and provides further evidence that CHX
use has been an important component of MRSA control programmes.
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The emergence of qacA positive strains is a potential concern for
effectiveness of MRSA decolonisation policies.
O140 First global survey on hand-hygiene compliance before
patient contact − Results from 47 countries
B. Allegranzi*, H. Sax, F. Eggimann, L. Pievaroli, H. Attar, N. Colaizzi,
C. Kilpatrick, D. Pittet (Geneva, CH)
Objectives: The WHO SAVE LIVES: Clean Your Hands (SLCYH) is a
global campaign launched by the Clean Care is Safer Care programme;
it supports sustained hand hygiene (HH) improvement worldwide by
promoting registrations of healthcare facilities in this global movement
and providing guidance and tools. Global call for action is renewed every
year through the participation in the 5 May initiative, a day focused on
HH in health care worldwide.
Methods: In March 2010 all SLCYH registered facilities were invited to
participate in a global survey on or around 5 May 2010 by observing HH
compliance with the indication “Before touching a patient” (Moment 1;
J Hosp Infect 2007;67:9−21) for one or few days and to submit their data
to WHO. A simple, validated form and instructions for observation were
made available and facilities were recommended to collect approximately
50 opportunities in the selected wards/departments. Electronic data
submission and a system for enquiries via email were made available
by WHO. Data revision and analysis were performed by WHO while
keeping facilities’ identity conﬁdential.
Results: Overall, 327 healthcare facilities from 47 countries submitted
data collected in 1527 wards. A total of 76,803 HH opportunities were
included in the analysis. The overall mean HH Moment 1 compliance
was 51.4+0.07% (weighted mean adjusted by number of opportunities
per facility). HH actions were performed by handrubbing in 60.7% of
cases, by handwashing in 37.6% and using both methods in 1.7%. HH
Moment 1 compliance was highest in European countries (64%, 22278
opportunities) and lowest in the Americas’ (26%, 23183 opportunities).
Compliance by department and professional category are reported in
Table.
Conclusion: The high number of participating facilities and of reported
opportunities allow the ﬁrst estimation of HH compliance before patient
contact around the world. Healthcare workers miss HH actions when this
indication applies almost once in every two opportunities. Nurses show
better compliance than doctors. HH practices require urgent improvement
in some areas of the world. This survey helps catalyse attention on a
frequently neglected HH indication aiming to protect the patient from
microbial transmission through healthcare workers’ hands.
O141 A comparison of the microbiological efﬁcacy of hydrogen
peroxide vapour and ultraviolet light processes for room
decontamination
N.L. Havill*, J. Boyce (New Haven, US)
Objectives: Since standard methods of cleaning surfaces in hospitalised
patients’ rooms are often suboptimal, several novel technologies have
been used to decontaminate more reliably patients’ rooms after discharge.
We compared the microbiological efﬁcacy of an ultraviolet light (UVC)
process with a hydrogen peroxide vapour (HPV) micro condensation
process for decontaminating patient rooms.
Methods: Fifteen patient rooms were selected for the study to represent
a range of shapes and sizes (from 46m3 to 86m3). Each room was
decontaminated once using HPV and once using UVC, separated by at
least 2 months (range 11−70 weeks). Five standardised high touch sites
were sampled using D/E neutralizing contact agar plates both before
and after the automated decontamination process. Aerobic colony counts
were determined for each site. In addition, stainless steel carrier discs
inoculated with approximately 106 Clostridium difﬁcile (CD) spores and
commercially available biological indicators (BIs) containing 104 and
106 CFUs of Geobacillus stearothermophilus were placed in 5 sites
in the patient rooms before decontamination. After decontamination,
a modiﬁed ASTM 2197 method was performed to determine the log
reduction of the CD spores on the carrier discs. All BIs were placed in
Trypticase Soy Broth and incubated at 60 C for 5 days and results were
recorded as growth or no growth.
Results: Of 75 sites sampled, 70 yielded aerobic growth in rooms before
HPV decontamination and 93% (65/70) of the samples were negative
after HPV. 68 sites yielded aerobic growth before UVC and 52% (35/68)
were negative after UVC decontamination (P 0.0001). The percentage
of the ﬁve sites negative after decontamination ranged from 87–100%
for HPV and 9−87% for UVC (ﬁgure). Shadowed areas were less likely
to be decontaminated by UVC. HPV yielded a 6 log reduction for all of
the carrier discs compared to a median of a 2 log reduction after UVC.
After HPV, none of the 104 BIs grew and 71% grew after UVC with
a range of 47−92% for the 5 sites (p< 0.0001). For the 106 BIs, none
grew after HPV and all grew after UVC (p< 0.0001).
Conclusion: Both HPV and UVC signiﬁcantly reduced the bacterial
contamination in patient rooms. HPV is more effective than UVC for
the eradication of bacteria, including CD spores. The number of spores
on the carrier discs and BIs is greater than that present on surfaces
in patient rooms, presenting a difﬁcult challenge for decontamination
processes.
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O142 State-wide admission prevalence screening in Saarland,
Germany (MRSAarNetz)
C. Petit, B. Biechele* (Homburg, DE)
Objective: The Federal State of Saarland is located in southwest
Germany, and comprises of 24 hospitals, including one University
hospital and one additional tertiary care hospital. ~250.000 admissions
are registered annually. While methicillin-resistant S. aureus (MRSA)
rates are available for some institutions (typically expressed as
MRSA/MSSA clinical isolate ratio), overall data on MRSA prevalence
are lacking. In order to assess the burden of colonization and disease for
MRSA in the context of a regional MRSA network (www.mrsaar.net), a
State-wide admission prevalence screening (APS) was conducted.
Methods: APS was performed during October-November, 2010, in all
Saarland hospitals. For screening, combined throat and nasal swabs were
taken from patients immediately upon admission using a novel swab
(ESwab, Copan, Italy) system for enhanced pathogen recovery. Samples
were processed by a novel, fully automated, roboter driven specimen
processor (WASP, Copan, Italy) and plated on selective biplate media
for MRSA and methicillin sensitive S. aureus (MSSA). All analyses
were performed in the State Hygiene laboratory at the University of
Saarland Hospital.
Results: Of 20,007 specimen tested, 405 (392 throat/nose swabs, 13
wound swabs) were positive (prevalence, 2.0%; 11.7% of total S. aureus);
prevalence varied between institutions (0−8,6%). These ﬁgures are
higher than those previously determined in other German APS programs
(Euregio MRSA-net 1.6%, Siegen 1.4%), and they also differ from those
previously reported from other central European regions or institutions.
spa type 003 (ST225) was most frequent among MRSA followed by spa
type 504 (previously rarely reported). A detailed risk assessment was
documented (analysis pending).
Conclusion: The conduct of a large regional APS study allowed
for comparative determination of MRSA colonization/infection upon
admission in an entire Federal State. These results are important to
estimate the burden of MRSA cost and disease for the hospitals, for
designing a cost-effective continuous screening program for the region,
and for developing a rational approach to combat the circle of MRSA
introduction from the community and care facilities into hospitals and
back into the community. As a side effect, a general enhanced attention
of general public, institution administrators, and policy makers towards
the quality goals of MRSAarNetz was observed.
O143 Long-term maintenance of very low incidence of nosocomial
multidrug-resistant pathogens in a tertiary hospital in Spain
J. Rodrı´guez-Ban˜o*, L. Garcı´a, L. Lo´pez-Cerero, C. Lupio´n, M. Alex,
C. Gonza´lez, M. del Toro, J. Lo´pez-Me´ndez, E. Ramı´rez, M. Muniain,
A. Pascual (Seville, ES)
Objectives: Most reports on control of multidrug-resistant organisms
(MDRO) refer to single organisms or units. In Spain, high incidence of
MDRO are usually reported. We report the long term results of a very
active MDRO control program in a teaching hospital.
Methods: Both an infection control program for MDRO and an antibiotic
use program were implemented in 1997 in a 950-bed hospital in Spain,
including periodic continuous educational activities, use of alcohol-
based handrubs, protocolised environmental cleaning, targeted active
surveillance of colonisation with MDRO, contact precautions, hygiene of
colonised patients with clorhexidine, and audits plus active consultancy
for antibiotic use. We previously published our successful results in
the control of methicillin-resistant Staphylococcus aureus (MRSA)
and Acinetobacter baumannii (AB) until 2002. The yearly incidence
(new cases per 1,000 patient-days) from 2002 to 2009 for MRSA,
AB, carbapenem-resistant Pseudomonas aeruginosa (CRPA), extended-
spectrum b-lactamase-producing Klebsiella pneumoniae (ESBLKP) and
Escherichia coli (ESBLEC), carbapenemase-producing enterobacteria
(CPE) and vancomycin-resistant enterococci (VRE), and antibiotic
consumption are reported. Data were compared by Poisson regression.
Results: The incidence of colonization/infection caused by MRSA
decreased from 0.13 cases per 1,000 patient-days in 2002 (38 cases)
to 0.09 in 2009 (26 cases); and that of AB, from 0.17 (50 cases) to 0.01
(4 cases) (p< 0.01 for both comparison). The rates of ESBLKP, and
CRPA were very low during the whole study period and without trends,
ranging from 0.01 to 0.06 (2 to 17 cases per year), and 0.02 to 0.07 (6 to
22 cases per year), respectively. As regards ESBLEC, the rate increased
from 0.12 to 0.35 (37 to 105 cases per year), although neither the cases
were clustered nor the isolates were clonally related; many cases were
colonised at admission. No cases of VRE, CPE or outbreaks caused by
other MDRO were detected despite active search. No signiﬁcant trends
were noted in antibiotic consumption, which ranged from 46 to 49 DDDs
per 100 patient-days.
Conclusions: In an area where average rates for MDRO are usually
moderate to high, a very low incidence of these pathogens was
maintained in our hospital from 2002 throughout 2009, in association
with very active speciﬁc infection control and antibiotic use programs.
Speciﬁc efforts to prevent infection in colonised patients with ESBLEC
are needed.
O144 What is the optimal period for measuring hand-hygiene
compliance? Are longer periods any better than 20-minute
periods?
S. Stone*, C. Fuller, S. Michie, A. Charlett (London, UK)
Objective: Direct observation of hand hygiene is considered the gold
standard for measurement of hand hygiene compliance. Most studies or
audits use 20−30 minute periods of observation. Recent WHO guidance
recommends this. However, it is not clear whether such short periods
provide a representative, unbiased sample of hand hygiene behaviour.
The aim of this study was to examine whether compliance over 20
minutes differed signiﬁcantly from that recorded over one or four hours.
Methods: Using a robustly standardised measure (the Hand Hygiene
Observation Tool). Hand hygiene observations were covertly collected, in
consecutive 20-minute segments, over 53 “4 hour” observation periods,
comprising 3989 hand hygiene moments, during the morning and early
afternoon, on 13 Intensive Care Units (ICUs) and 36 Acute Care of the
Elderly (ACE) wards in 13 hospitals, A mixed effects logistic regression
model analysed compliance with hospital & ward as random effects, and
with type of ward (ICU or ACE) & sequential 20-minute or 1-hourly
observation periods as ﬁxed effects.
Results: Overall compliance was 75%, being lowest in the 1st 20-minute
period (69%) and in the 1st hour (71%). Analysis of sequential 20 minute
observation periods showed the estimated odds ratios for compliance rose
signiﬁcantly in the 2nd 20-minutes (1.42, 1.02–1.96; p = 0.04), remaining
stable thereafter (Table). For sequential hour periods, the estimated odds
ratios for compliance rose signiﬁcantly (1.32, 1.08–1.61; p = 0.007) in
the 2nd hour, remaining stable thereafter. Type of ward had no signiﬁcant
effect.
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Conclusions: Compliance rose by a small but signiﬁcant amount in
the 2nd 20 minute period of observation, but remained stable thereafter.
Possible explanations are a delayed but small reactivity to being observed
(Hawthorn effect), improving health care worker performance as the
shift progresses, or observer fatigue, especially in the latter stages
of observation. This study supports the WHO recommendation of a
20-minute observation period. Frequent measurements are required to
establish time trends & changes. In both clinical audit & research
settings, 20-minute observation periods appear able to provide a
relatively unbiased sample, provided the number of hand hygiene
moments reaches observation tools’ established reliability criteria.
Researchers should state & explain the period & frequency of
observations in both grant applications & publications.
O145 Control measures for preventing the spread of vancomycin-
resistant enterococci in hospitals: where is the evidence?
M.A. Cataldo*, G. De Angelis, C. De Waure, S. Venturiello, G. La
Torre, R. Cauda, Y. Carmeli, E. Tacconelli (Rome, IT; Tel Aviv, IL)
Objectives: A systematic review was performed to determine the efﬁ-
cacy of control measures (CM) for preventing the spread of vancomycin-
resistant enterococci (VRE) in hospitalised patients. Secondary outcomes
were: crude mortality, length of hospital stay, costs and CM’s adverse
effects.
Methods: Cochrane Wounds Group Specialised Register, The Cochrane
Central Register of Controlled Trials, MEDLINE, EMBASE, and
CINAHL were searched (1980-May 2010) for randomized clinical trials
(RCTs), non-randomized controlled clinical trials (CCTs), interrupted
time-series (ITS) and controlled before and after studies (CBA)
that prospectively compared wards/hospitals applying two different
intervention policies or wards/hospitals where intervention policies were
used to hospitals/wards where those policies were not used. In the
absence of clinical and statistical heterogeneity (signiﬁcant if I2> 50%)
a ﬁxed-effect model was used to estimate the pooled relative risk (RR).
The methodological quality of included studies was assessed according
to the criteria developed by the EPOC group.
Results: Three CCTs and 5 ITS were included. The overall quality
of the studies was low. Intervention was represented by physical
barriers by health care workers (HCWs) to transmission (3 studies),
environmental cleaning (2), hand-washing measures (2), and antibiotic
formulary interventions (2). Implementation of hand hygiene measures
was associated with a 47% decrease in the VRE acquisition rate (RR
0.53, 95%CI 0.39–0.73). Physical barriers by HCWs and environmental
cleaning did not signiﬁcantly reduce the VRE acquisition rate (RR
0.97, 95%CI 0.58–1.62 and 0.66, 95%CI 0.32–1.38, respectively).
Slight heterogeneity was detected only among studies analysing the
effectiveness of physical barriers (I2=45%). The effectiveness of
antibiotic formulary was not assessed through a statistical approach since
the heterogeneity of the outcomes. Implementation of CMs did not result
in a signiﬁcant reduction of length of stay. None of the studies analysed
costs or adverse effects. One reported on crude mortality.
Conclusions: Surprisingly, review of the literature did not show any
RCT on the efﬁcacy of CM for preventing the acquisition of VRE. Our
study seems to suggest a signiﬁcant effect of hand-hygiene measures on
VRE acquisition. However, the level of the evidence is still very poor
due to study designs, insufﬁcient study quality and lack of data to show
the effect of a single intervention.
O146 Low environmental contamination of rooms in ESBL-positive
patients
R.J. Piso*, E. Grui, U. Schibli, M. Bu¨hlmann, S. Bassetti (Olten, Aarau,
CH)
Objectives: The steep rise of patients colonized with ESBL-producing
enterobacteriacea creates a challenge in developing adequate trans-
mission precautions. In many institutions, the rate of ESBL exceeds
the rate for MRSA positive patients. The isolation policies for ESBL
positive patients are less standardized and differ between institutions.
We wanted to know if the rooms of ESBL-positive hospitalized patients
are contaminated with ESBL producing bacteria.
Methods: Patients positive for ESBL and hospitalized for more than 48
hours in one room were selected. In all these patients, rectal, inguina,
urine, throat and wounds were screened for ESBL. Additional swabs
of the bed (frame, bed cradle), patient telephone, sink and toilet seat
were taken and cultured for ESBL. Room cleaning was performed
according to routine protocol. Contamination rate of the patient rooms
were calculated.
Results: From June 2009 until December 2010, twenty patients were
included. ESBL was found in 17/20 inguinal, in 18/20 rectal, in 13/20
in urine, in 3/20 in wounds and 3/20 in the throat. ESBL was found
in 4 (2 patients), 3 (9 patients), 2 (4 patients) and 1 (2 patients)
screened sites. Only in 2/20 patients, ESBL was found on surfaces of the
environment. In one patient, the sink was positive, and in one patient, the
telephone and the toilet seat were positive. These two patients had both 3
colonized sites (urine, rectal, inguina). No relationship between positive
environment and colonisation load could be observed. The contamination
of environment was calculated 10% (95%CI 0−23%) for rooms and
3.75% (95%CI 0−7.9%) for screened locations.
Conclusion: Compared to data for MRSA and VRE published in
literature, we found a low contamination rate of environmental surfaces
in hospitalized ESBL positive patients. Main route of transmission may
not be indirect via contaminated surfaces. This might inﬂuence isolation
policy.
O147 Model-based cost-effectiveness evaluation of methicillin-
resistant Staphylococcus aureus screening and control in
general medical hospital wards
J.V. Robotham*, N. Graves, B. Cookson, J. Wilson, A.G. Barnett,
C. Worby, B.S. Cooper (London, UK; Brisbane, AU; Bangkok, TH)
Objectives: To use dynamic transmission models to assess the cost-
effectiveness of methicillin-resistant Staphylococcus aureus (MRSA)
screening and infection control strategies in general medical (GM) wards.
Methods: A dynamic model of MRSA transmission in GM hospital
wards was developed. Model parameters were derived from literature
review, data analyses and expert opinion. Twenty-ﬁve intervention
combinations were evaluated, involving screening all vs. high risk
patients, and using conventional culture, chromogenic agars or rapid
(PCR) technologies. Screening was combined with isolation (contact
precautions, side rooms, isolation wards or cohorting) or decolonisation
(nasal ointments and/or body-washes). Incremental costs and health
beneﬁts (measured in quality adjusted life years, QALYs) were evaluated
under different assumptions about MRSA prevalence, proportion of high
risk patients and ward size. Probabilistic sensitivity analyses (PSA) were
conducted, incorporating full uncertainty in model parameters.
Results: All isolation strategies led to only small reductions in MRSA
infection rates (less than 5%) and had cost/QALY values much higher
than the usual National Health Service willingness to pay threshold
(£30,000 [€35,500] per QALY). This was reﬂected in the PSA, which
showed the baseline ‘do nothing’ approach to be preferred. For a slightly
higher willingness to pay, a strategy of pre-emptive isolation of high risk
patients (without screening) was cost-effective. Decolonisation strategies,
though able to reduce MRSA infection rates by nearly 50%, were not
cost-effective (at the most likely parameter values). Accounting for full
parameter uncertainty, the strategy of decolonising only those identiﬁed
via clinical culture gave both the highest expected net monetary beneﬁt
and had the highest probability of being cost-effective.
Conclusion: The potential for screening and control strategies to be cost-
effective in GM wards is much more limited than in critical care settings.
Full PSA showed that within the usual willingness to pay threshold,
neither screening with isolation nor decolonisation were cost-effective.
This reﬂects the fact fewer infections in GM wards are due to cross-
transmission and, because infection and mortality rates are much lower,
interventions that depend on expensive screening are much less likely
to be cost-effective. However, our results are likely to underestimate
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intervention beneﬁt as they ignore QALY loss due to MRSA following
ward discharge and long-term effects.
What is changing in the invasive mycosis
ﬁeld?
O148 Six-year prospective candidemia survey from the fungal
infection network of Switzerland (FUNGINOS) − Candida
species distribution and antifungal susceptibility according
to recent EUCAST and old vs. new CLSI clinical breakpoints
C.E. Orasch*, O. Marchetti, C. Durussel, C. Guyaz, M. Ochsner,
J. Bille and the Microbiological and Clinical FUNGINOS Investigators
Objective: Changing Candida spp. distribution and emerging cross-
resistance to azoles and multiresistance to azoles and echinocandins
is increasingly reported in Europe and North America. To analyse the
species distribution of Candida blood isolates prospectively collected
during 2004−9 from 27 hospitals (7 university, 20 afﬁliated) of the
FUNGINOS network and to compare the antifungal susceptibility
according to the clinical breakpoints (bp) deﬁned by EUCAST in Europe
and CLSI in North America.
Methods: Candida isolates were identiﬁed in the FUNGINOS mycology
reference lab and tested for susceptiblity to ﬂuconazole (F), voriconazole
(V) and caspofungin (C) by microtitre broth dilution method with the
Sensititre® YeastOne™ test panel. Clinical bp were: (i) EUCAST 2010/
CLSI 2008 = old for F and V, (ii) CLSI 2011 = new for F, V, C.
Results: 1090 Candida blood isolates were tested: 675 (61.9%)
C. albicans, 191 (17.5%) C. glabrata, 64 (5.9%) C. tropicalis, 59 (5.4%)
C. parapsilosis, 33 (3%) C. dubliniensis, 22 (2%) C. krusei and 46 (4.2%)
rare Candida spp. No change in Candida species distribution occurred
during 2004−9. The table shows the percentages of susceptibility and
numbers of non-susceptible isolates for each Candida species according
to the different bp (mg/ml).
Eight isolates (4 C. tropicalis, 3 C. albicans, 1 C. parapsilosis) showed
a cross-resistance to azoles (F and V) according to EUCAST bp vs.
2 isolates (C. albicans) according to old and new CLSI bp. One
C. tropicalis isolate was tested multi-resistant according to EUCAST
bp (MIC F: 2mg/ml, V: 0.25mg/ml, C: 16mg/ml) vs. none according to
old and new CLSI bp.
Conclusions: In Switzerland the majority of Candida blood isolates were
C. albicans (61.9%), followed by C. glabrata (17.5%). C. albicans was
susceptible to all antifungals independently of the applied bp, whereas the
proportion of ﬂuconazole-susceptible C. tropicalis and C. parapsilosis
was lower with the EUCAST and new CLSI vs. the old CLSI bp.
Applying the EUCAST bp for voriconazole lowered the proportion
of susceptible C. tropicalis and C. parapsilosis isolates vs. old and
new CLSI bp. As expected, all Candida isolates were susceptible to
caspofungin, except in C. krusei and C. parapsilosis. Only 4 isolates were
cross-resistant to azoles and 1 C. tropicalis was multiresistant to azoles
and caspofungin. The impact of recent EUCAST and CLSI breakpoints
for predicting clinical response to therapy remains to be investigated.
O149 Epidemiology of ﬁlamentous fungi in cystic ﬁbrosis patients
in the Netherlands
P. Terpstra*, M.v. Westreenen, P. Croughs, P. Verweij, R. Brimicombe,
J. Yntema, C.H. Klaassen, P. Merkus, J. Meis (Nijmegen, Rotterdam,
Maastricht, The Hague, NL)
Objectives: The clinical signiﬁcance of fungal infections in Cystic
Fibrosis (CF) are poorly understood. Infections with viruses and bacteria
are the main cause of deterioration of lung function in these patients.
However there is also evidence of an increasing prevalence of fungi
in sputum but the reported results vary widely between countries and
centers (9−56%). Very little is known about the epidemiology, genotypes
and resistance patterns of ﬁlamentous fungi in Dutch patients with CF.
Here we describe the ﬁrst results of a recently initiated large prospective
study of fungal colonization in CF patients in the Netherlands.
Methods: Standardized routine sputum samples were collected in four
CF centers. All samples were cultured on mould-selective plates and
incubated at two temperatures. All non-Candida fungi were collected
and stored centrally. After initial morphologic identiﬁcation, molecular
conﬁrmation was sought using AFLP and ITS + D1/D2 sequencing. All
Aspergillus fumigatus isolates were additionally analyzed for presence
of the most common mutations in the CYP51 gene.
Results: A total of 484 ﬁlamentous fungi were isolated from 231
patients in the period May 2010–November 2010. The main species
found was A. fumigatus (58%). In addition, a variety of other Aspergillus
species were found: A. ﬂavus, A. terreus, A. sydowii, A. protuberans
and A. versicolor. Next to these Aspergillus spp., Penicillium spp.
(12%) and Scedosporium spp. (5%) were the most common fungi.
Exophiala dermatitidis, an already known potential pathogen in CF,
was isolated 10 times (2.1%). Interestingly we also report the ﬁrst
isolations of Geosmithia argillacea in Dutch CF patients. At least 10% of
the samples showed a discrepancy between morphologic and molecular
identiﬁcation. A total of 5.0% of the tested A. fumigatus appeared to
contain the TR/L98H mutation while no other mutations (G54, G138,
M220) responsible for azole resistance where found.
Conclusion: These results suggest that the Dutch epidemiology of
ﬁlamentous fungi in CF patients is comparable to our neighboring
countries. The main fungus was A. fumigatus, but also other fungal
species such as Scedosporium spp. and Exophiala spp. were identiﬁed
including the newly described species Geosmithia argillacea. In addition
5% of A. fumigatus isolates appeared to harbour mutations reported to
confer azole resistance. These are the ﬁrst epidemiological data of azole
resistance in A. fumigatus from CF patients.
O150 Improved clinical diagnosis of invasive Candida infections
in patients undergoing cardiac surgery
C. Kratzer*, S. Tobudic, A. Lassnigg, A. Schiferer, H. Fischer,
W. Graninger, N. Kreischitz, B. Steinlechner, E. Presterl (Vienna, AT)
Objectives: The high mortality of invasive Candida infections in the
intensive care unit (ICU) and the absence of rapid diagnostics require
identiﬁcation of risk indicators, Candida colonization and Candida
presence for early diagnosis. To investigate these characteristics in
long-term intensive care patients after cardiac surgery, a prospective
observational study was performed at the University Hospital of Vienna.
Methods: One hundred sixty-nine consecutive cardiac surgery patients
with prolonged ICU stay of at least 7 days were prospectively enrolled
in a two-year period. Preoperative, perioperative and postoperative data
were assessed. Candida colonization and Candida score (CS) were
evaluated twice weekly. Variables associated with both proven and
possible invasive candidiasis (P< 0.05) in the univariate analysis were
considered to be candidates for building multivariate models using
stepwise logistic regression analysis.
Results: Ten patients (5.9%) developed proven, 71 patients (42%)
developed possible invasive candidiasis. Multi-site Candida colonization
and a CS 3 preceded proven infection in 9/10 and 10/10 patients. In
59 patients with both multi-site colonization and a CS 3, the score
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was positive 7.1 days (arithmetical average) earlier than the colonization
index. Redo surgeries 2, multi-site Candida colonization, persistent
fever, bacteremia, and increasing or persistently high sequential organ
failure assessment (SOFA) score >7 were signiﬁcantly associated with
both proven and possible invasive candidiasis by univariate analysis
(P< 0.05). Only increasing or persistently high SOFA score >7 (adjusted
odds ratio 6.2, P = 0.018) and bacteremia (adjusted odds ratio 4.6,
P = 0.043) were independent risk factors for proven infection using
stepwise logistic regression analysis.
Conclusions: Long-term ICU patients after cardiac surgery are at
high risk for invasive Candida infections in the presence of preceding
bacteremia and a persistently high or increasing SOFA score. Severe
Candida colonization and a CS 3 are of value in identiﬁcation of
cardiac surgery patients with present or future invasive candidiasis.
O151 Analysis of aetiology of invasive fungal infections using a
panfungal PCR-based method in tissue biopsies with proven
infection
M. Cuenca-Estrella*, M.J. Buitrago, L. Bernal-Martinez,
A. Gomez-Lopez, J.L. Rodriguez-Tudela (Majadahonda, ES)
Objectives: The etiological cause of many IFIs is never revealed. PCR-
based methods can detect speciﬁc DNA of fungal species in tissue
biopsies, in order to know the prevalence of fungal species. Those data
will help us to choose the most efﬁcient therapeutic alternative for ﬁrst
line therapies of IFI.
Methods: A total of 116 parafﬁned and fresh tissue biopsies were sent
to Spanish Reference Mycology Laboratory between 2006 and 2010
from 36 different hospitals. Biopsies came from 93 patients suffering
from proven infection as microscopical examination of tissues showed
invasion by fungal structures. Cultures were negative for all samples. A
total of 36 (30%) biopsies came from lungs, 23 (19%) were subcutaneous
or skin biopsies, 19 (16%) from gastrointestinal tract, 10 brain biopsies,
9 from nasal sinus, 7 from liver, and 18 from other tissues. Procedures of
DNA extraction and ampliﬁcation followed routine methods. The tissue
samples were analyzed using a panfungal Real-Time PCR-based assay.
It was designed to amplify the ITS regions 1 and 2 from fungal rDNA
gene complex. Ampliﬁed DNA was identiﬁed by sequencing. Controls
were used in each set of experiments which were done in duplicate.
Results: A total of 80% of biopsies were positive by the PCR-based
technique (93/116). When data were analyzed by patient, fungal DNA
was detected and identiﬁed in 77 out of 93 patients (83%). Results
by patients of species identiﬁcation were: 37/77 (48%) Aspergillus
fumigatus, 4 (5%) Aspergillus ﬂavus, 7 (9%) Zygomycetes, 7 (9%) other
phaeohyphomycosis with 3 scedosporiosis, 6 (7.7%) hyalohyphomycosis
with 3 fusariosis, and 6 (7.7%) Candida. A total of 10 (13%) cases of
histoplasmosis were detected as well. Other 4 cases were mixed infection.
By samples, main data were: Aspergillus DNA was detected in 76% of
positive lung biopsies and 43% of brain tissues, and Candida DNA in
50% of gastrointestinal biopsies.
Conclusion: (i) PCR-based methods can be used for species identiﬁ-
cation in tissue biopsies as a complementary technique of cultures. (ii)
Emerging fungal pathogens could be underestimated as microbiological
conventional methods have a limited accuracy for species detection and
identiﬁcation. (iii) Further studies are warranted.
O152 Comparison of a commercial Aspergillus real-time PCR assay
with galactomannan testing of BAL ﬂuid for the diagnosis of
invasive pulmonary aspergillosis in lung transplant recipients
M. Luong, C. Clancy*, M. Wissel, K. Grantham, S. Kleiboeker,
E. Kwak, F. Silveira, Y. Toyoda, R. Shields, S. Reddy, T. Walsh,
M. Nguyen (Pittsburgh, Kansas City, New York, US)
Background: Early diagnosis and treatment of invasive pulmonary
aspergillosis (IPA) improves outcome.
Methods: We compared commercially-available Aspergillus real-time
PCR and Platelia galactomannan (GM) assays performed on 150 BAL
samples from lung transplant recipients (16 proven/probable IPA, 26
Aspergillus colonization, 11 non-Aspergillus mould colonization and 97
negative controls).
Results: Sensitivity and speciﬁcity of pan-Aspergillus PCR (optimal
Cq 35.0 by ROC analysis) and GM (0.5) for diagnosing IPA
were 100% (95%CI: 79–100%) and 88% (79−92%), and 93% (68–
100%) and 89% (82−93%), respectively. Corresponding positive and
negative predictive values were 50% (30−65%) and 100% (77–100%),
and 48% (29−67%) and 99% (95–100%), respectively. Sensitivity and
speciﬁcity of A. fumigatus-speciﬁc PCR were 69% (41−89%) and 96%
(92−99%). Most false-positive PCR and GM were in samples from
patients colonized by Aspergillus and negative controls, respectively.
A. fumigatus-speciﬁc PCR had sensitivity and speciﬁcity of 69% (11/16)
(41−89%) and 96% (129/134) (92−99%), respectively, for diagnosing
IPA due to this species. A. terreus-speciﬁc real-time PCR was positive
for the one patient with IPA due to this species; speciﬁcity was 99%
(133/134).
Conclusions: A recently developed, commercial Aspergillus PCR assay
and GM testing of BAL ﬂuid may facilitate diagnosis of IPA after lung
transplantation. Both tests offer the potential advantage over culture-
based diagnostic methods of rapid turn-around, which may facilitate
more timely initiation of antifungal therapy. In distinguishing between
clinically important species, PCR may afford a further advantage over
indirect markers like GM.
O153 A phase IV, open-label study evaluating efﬁcacy and safety
of intravenous anidulafungin followed by oral azole for the
treatment of candidaemia/invasive candidiasis in US/Korean
patients
J. Vazquez*, A. Reboli, P. Pappas, T.F. Patterson, J. Reinhardt,
P. Chin-Hong, E. Tobin, D. Kett, P. Biswas, R. Swanson (Detroit,
Camden, Birmingham, San Antonio, Newark, San Francisco, New
York, Miami, US)
Objectives: To evaluate the efﬁcacy and safety of a Rapid Switch
Regimen (RSR; short course of intravenous [IV] anidulafungin [ANID],
followed by an optional switch to oral azole therapy with either
ﬂuconazole [FLU] or voriconazole [VORI]), for the treatment of
candidaemia/invasive candidiasis (C/IC).
Methods: A Phase IV, open-label, multicentre, non-comparative study.
Patients received 200mg IV ANID (loading dose) followed by
100mg/day thereafter. After 5 days, patients meeting criteria could be
switched to oral azole therapy (FLU 400mg/day or VORI 200mg BID).
The primary endpoint was global response (clinical + microbiological
response) at the end of all treatment (EOT) in the modiﬁed intent-to-treat
(MITT) population (at least one dose of ANID + positive Candida within
96 h of study entry). Secondary endpoints, assessed by the investigator
included: global response at end of IV treatment (EOIV), 2 weeks post
treatment and end of study (EOS; 6 weeks post-therapy). Global response
was also determined at EOT in predeﬁned patient subsets. Safety and
tolerability were evaluated by adverse event (AE) monitoring and clinical
and laboratory assessments.
Results: 294 patients were enrolled (270 in US, 24 in Korea): 53.5%
male, mean (SD) age 55.4 (16.7) years, and mean APACHE-II score 14.1.
Ten patients were neutropenic when enrolled. C. albicans (42%) was
the most common baseline pathogen isolated. The mean (SD) duration
of ANID treatment was 8.6 (5.8) days; 44.3% of patients received
ANID with no switch to oral azole therapy. 105 patients switched to
FLU (mean [SD] duration 9.3 [5.6] days) and 54 patients switched to
VORI (mean [SD] duration 11 [7.8] days). Mean (SD) duration of total
antifungal therapy (IV + oral) was 14.1 (8.2) days. Global response rate
at EOT in the MITT population was 83.7% (95%CI: 78.7, 88.8). Global
response rates in patient subsets are shown in the table. EOT global
response in neutropenic patients was 42.9% (3/7). 33 patients (11.7%)
developed treatment-related AEs, with nausea and vomiting being the
most frequently reported (4 cases during ANID treatment and 4 during
oral azole therapy). AEs were mostly mild or moderate in severity.
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Conclusions: An RSR was shown to be effective in the treatment of
C/IC, with a comparable safety proﬁle to previous studies. RSR has
shown to be a tolerable and effective treatment in different subgroups.
RSR should ease the burden of long-term parenteral therapy to manage
these infections.
O154 Survey of antifungal combination therapy for treatment of
proven or probable invasive fungal diseases in Italian haema-
tological centres. The Seifem-Combo Study (NCT 00906633)
A. Candoni*, M. Caira, S. Cesaro, A. Busca, M. Giacchino, R. Fanci,
G. Specchia, A. Nosari, A. Bonini, C. Cattaneo, L. Melillo, P. Musto,
M. Ofﬁdani, J. Peccatori, N. Vianelli, G. Milone, R. Scime`, A. Venditti,
L. Pagano on behalf of SEIFEM Group (Sorveglianza Epidemiologica
Infezioni Fungine Nelle Emopatie Maligne), Italy
Background: This prospective observational Clinical Trial (NCT
00906633) evaluated the feasibility, efﬁcacy and toxicity of Antifungal
Combination Therapy (Combo) as treatment of proven or probable
Invasive Fungal Diseases (IFDs) in Hematological patients (pts).
Materials and Methods: Between Jan 2005 and Dec 2009, 84 cases of
Combo were reported from 20 Hematological Centers in Italy. Median
age of pts was 34 yrs (range 1−73) and 37% had less than 18 yrs.
Acute Leukemia was the most common underlying hematologic disease
(68/84; 81%). The status of hematologic disease was: onset 21/84 (25%),
remission 18/84 (21%), refractory/relapse 45/84 (54%). The main site
of fungal infection was lung with or without other sites. The etiological
agents were: Aspergillus sp 68 cases (81%), Candida sp 6 cases (8%),
Zygomycetes 4 cases (5%), Fusarium sp 4 cases (5%)and others (2
cases).
Results: The most used Combo were: Caspofungin + Voriconazole 35/84
(42%), Caspofungin+Liposomal Amphotericin B (L-AmB) 20/84 (24%),
and L-AmB+Voriconazole 15/84 (18%). The median duration of Combo
was 19 days (range 3–180). The Overall Response Rate (ORR) was 73%
(61/84 responders) without signiﬁcant differences between the Combo
regimens. The most important factor that signiﬁcantly inﬂuenced the
response rate (in univariate and multivariate analysis) was PMN recovery
during Combo (P< 0,0001). Only one patient discontinued therapy
(voriconazole related neurotoxicity) and 22% experienced mild and
reversible adverse events (hypokalemia, ALT/AST increase, creatinine
increase) without differences between pediatric and adult pts. The IFI
attributable mortality rate was only 17%.
Conclusion: This is the ﬁrst multicenter, prospective, observational study
exploring feasibility, efﬁcacy and toxicity of Antifungal Combination
Therapy (Combo) as treatment of proven or probable Invasive Fungal
Diseases (IFDs) in Hematological patients (pts). The results of this
study indicate that: 1) Combo was well tolerated in both children and
adults hematologic pts. 2) The Overall Response Rate was 73% and the
mortality IFDs related was only 17%. 3) The most used Combo regimens
were Caspofungin+Voriconazole (ORR 80%) and Caspofungin+L-AmB
(ORR 70%). 4) In univariate and multivariate analysis PMN recovery
during Combo predicts a better outcome.
O155 Mortality due to invasive fungal infections is low in lung
transplant recipients receiving voriconazole prophylaxis
C. Clancy*, U. Celik, A. Vadnerkar, M. Nguyen (Pittsburgh, US)
Background: Invasive fungal infections (IFIs) are major complications
and causes of mortality in lung transplantation (LTX). The role of
voriconazole prophylaxis (VOR px) in LTX pts (pts) is controversial.
Methods: We reviewed 154 consecutive pts who underwent LTX or
heart-LTX from 1/05−9/06. All pts received alemtuzumab induction and
VOR px 3 mos.
Results: 49 received single, 94 double and 11 heart-LTX. 54% of
pts had >1 episode of respiratory mould colonization, and 21% had
respiratory IFI (16 episodes proven, 14 probable, 5 possible). The
mean (median) time from LTX to IFI was 13 (12) mos. 66% of
IFIs involved lung parenchyma, 26% anastomotic sites and 9% pleura.
Parenchymal IFIs and empyemas were more likely to occur as late onset
(>6 mos), and anastomotic infections as early onset (6 mos) (p = 0.02).
Parenchymal infections were by Aspergillus (48%), Mucor (13%), other
moulds (13%), Cryptococcus (13%) and unidentiﬁed moulds (13%). 74%
occurred >6 mos and 63% >12 mos after LTX; 24% of late IFI occurred
during VOR px (A. fumigatus, A. niger, Mucor, Penicillium, 1 each).
All 6 early onset parenchymal IFI occurred during VOR prophylaxis (2
Cryptococcus, 1 Mucor, 1 Scedosporium, 2 unidentiﬁed). The overall
mortality was 8% for pts with parenchymal IFI. 1 died from ruptured
Scedosporium mycotic aortic aneurysm, and 1 from lung and facial IFI
due to Mucor. Anastomotic site IFI were due to yeasts (67%, Candida
spp. and S. cerevisiae), A. fumigatus, Penicillium and Cladosporium
(11% each). 78% occurred early during VOR px. Late infections by
A. fumigatus and C. albicans (1 each) occurred after discontinuation
of VOR. Empyemas were caused by C. glabrata and Histoplasma late
(off VOR), and C. parapsilosis early (on VOR). None of the pts with
anastomotic infections or empyema died.
Conclusions: Despite routine VOR px for 3 mos post-LTX, the
incidence of IFI remained high. VOR px was associated with delay in
onset of parenchymal IFI to >1 year post-LTX, and low incidence of
Aspergillus, an observation that raises the question if VOR selected for
emergence of antifungal-resistant moulds like Mucor and Scedosporium.
VOR px did not change the epidemiology of anastomotic site IFI.
Mortality among pts with IFIs, in particular parenchymal infections,
was much lower than previously reported. By delaying serious IFIs
to periods of reduced immunosuppression, VOR px might facilitate
improved survival.
O156 Impact of posaconazole prophylaxis on fungal colonisation
and invasive fungal infections: a prospective study
A. Scemla*, M. Lafaurie, C. Lacroix, E. Raffoux, P. Ribaud,
S. Touratier, J.-M. Molina (Paris, FR)
Background: The use of posaconazole (PZC) prophylaxis in patients
with haematological conditions has increased in our hospital. Emergence
of resistant azole isolates and invasive fungal infection (IFI) has not been
extensively studied.
Methods: Prospective monocentric study. Patients receiving PZC
prophylaxis for graft versus host disease (GVHD) after hematopoietic
stem cell transplantation (HSCT) or chemotherapy for Acute Myeloid
Leukemia (AML) were enrolled. Serial mouth swabs and stool
samples were obtained for fungal identiﬁcation: before initiation of
PZC (baseline), during treatment and up to 3 months after PZC
discontinuation. Clinical data with a focus on IFI and plasma PCZ
concentrations were also collected during the study period.
Results: From october 2009 to november 2010, 56 patients were
included, 32 for AML and 24 for GVHD. There were 37 men and 19
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women, with a mean age of 52 years. Median PZC duration was 35
days (9–120 days). Patients could be colonized with multiple isolates.
Ten out of 49 patients (20%) were colonized at baseline with a positive
mouth or stool culture (C. albicans n = 7, C. glabrata n = 4, C. kefyr
n = 1, Geotrichum sp n = 1), 20/49 (41%) colonized during prophylaxis
(C. albicans n = 11, C. glabrata n = 9, Saccharomyces n = 4, C. Kefyr,
C. norvegensis, C. guilliermondii, C. tropicalis, Geotrichum sp, n = 1
each) and 4/23 (17%) colonized three months after PZC discontinuation
(C. glabrata n = 2, C. albicans, C. tropicalis and C. kefyr, n = 1 each).
An IFI was diagnosed in 4 patients under PZC prophylaxis (7%): invasive
aspergillosis (n = 2), disseminated zygomycosis (n = 1), fusariosis (n = 1).
Median through plasma PZC concentration was 0,27mg/l (0,1−0,55) in 3
of these 4 patients while it was 0,53mg/l (0,1−1,15, p = 0,9) for patients
without IFI. Four other patients developed an IFI a mean of 26 days
after PZC discontinuation: invasive aspergillosis (n = 2), disseminated
zygomycosis (n = 1) and C. parapsilosis candidemia (n = 1). Among
patients with IFI, 6 out of 8 had a fungal colonization. Six patients (11%)
died during the study period. The death was related to the IFI in 3 cases.
Conclusion: Fungal colonization is frequent in patients receiving PZC
prophylaxis, particularly due to C. albicans and C. glabrata. The
observed high rate of breakthrough IFI among PZC recipients requires
further evaluation.
O157 Stewardship in antifungals. How much do prescribing
physicians know?
M. Valerio*, P. Mun˜oz, E. Zamora, M. Salcedo, E. Verde,
A. Bustinza, J. Peral, J. Gayoso, C. Menarguez, J. Hortal, I. Ma´rquez,
L. Ferna´ndez-Quero, B. Pinilla, E. Vilalta, E. Bouza on behalf of
the COMIC (Collaboration in Mycoses) Study Group
Background: The use of antifungal agents and their cost has rocketed
in most hospitals. Implementation of antifungal stewardship requires
training of prescribers and the use of restrictive policies. Assessing the
knowledge of those who prescribe antifungal agents is a key ﬁrst step to
guide the design and implementation of training strategies for providers.
Objective: To assess prescribing physician’s knowledge and compliance
with current guidelines in the diagnosis and therapy of invasive fungal
infection (IFI).
Methods: Attending physicians and residents that prescribe antifungals
in our institution were invited to complete a 20-question test that was
scored from 0 to 10. Questions assessed different aspects of management
of invasive candidiasis and invasive aspergillosis (IA).
Results: Overall, 60.8% (200/329) of the physicians, belonging to the
following departments (medical 59.5%, pediatric 19%, ICUS 16.5% and
surgical 5%) completed the survey. Their mean age (±SD) was 34.9±9.8
and the mean number of years of medical practice was 10.7±10.3.
Mean score was 5.14±1.72. Scores differed among departments:
medical: 5.39±1.7, ICUs: 5.27±1.64, pediatrics: 4.6±1.74 and surgical:
3.95±1.28. Attending physicians scored better than residents (5.5±1.6
vs 4.6±1.6, p=NS).
Regarding candidemia, only 54.7% of the physicians distinguished
colonization from infection and 17.5% were aware of current rates of
ﬂuconazole resistance. Only 32.6% knew the indications for antifungal
prophylaxis and 23.1% when to begin empiric therapy. However, most
physicians knew which antifungals were recommended as empirical
therapy (73.3%). Indications of amphotericin B, azoles or candins were
answered correctly by 57.3%, 26.1% and 41.2%, respectively.
Regarding IA, 67.3% of the physicians could distinguish colonization
from infection and only 34.6% were familiar with galactomannan
use. Radiological features of IA were well recognized by 63.8%, but
only 31.1% knew the ﬁrst line therapy for IA and 36.1% knew the
recommended length of therapy. The clinical beneﬁt of measuring
antifungal seric levels was acknowledged by 66.8%.
Conclusion: A simple test enabled us to assess the knowledge of pre-
scribing physicians in important aspects of IFI diagnosis, prophylaxis and
antifungal therapy. The results of the study have revealed the inadequate
knowledge of prescribers in this area of their practice and serve as a
guide to design a tailored training program for management of IFI.
The Big Question – are we staying ahead of
resistance in the hospital setting?
S158-S162 The Big Question − are we staying ahead of resistance
in the hospital setting?
T. Welte, M. Sa´nchez Garcı´a, J. Picazo, M. Bassetti, J. Garau
(Hannover, DE; Madrid, ES; Genua, IT; Barcelona, ES)
Serious infection is a common reason for patient admission into critical
care and frequently arises as a complication during a patient’s stay in the
intensive care unit (ICU). Within the hospital environment, staphylococci
are the most prevalent Gram-positive pathogens, with Staphylococcus
aureus being a leading cause of infections in the ICU. Currently, the
prevalence of infections with methicillin-resistant Staphylococcus aureus
(MRSA) is unacceptably high in many parts of Europe, although changes
in infection control strategies have reduced incidences in some countries.
To optimise clinical outcomes in patients with serious infections, it is
necessary to initiate appropriate antibacterial therapy, using antibacterial
agents with efﬁcacy against all key pathogens including multidrug-
resistant strains, administered at correct doses and via correct routes.
Strains of S. aureus that exhibit reduced glycopeptide susceptibility,
such as vancomycin intermediate S. aureus (VISA) and heterogeneous
VISA, increase the risk of poor clinical outcomes. In cases of Gram-
positive infections that are non-susceptible to established antibacterials,
the implications for patient care are signiﬁcant due to the increased
risks of treatment failure, increased duration of hospitalisation, increased
mortality, and increased costs. In addition, there are worrying signs that
resistance to newer anti-staphylococcal agents is emerging among MRSA
and other staphylococci. Optimising antibiotic use is therefore important,
and can be achieved through effective multidisciplinary cooperation
between clinicians, infectious disease specialists, hospital pharmacists
and medical microbiologists. Increasing attention has also been paid to
antimicrobial stewardship and antibacterial heterogeneity as strategies
for optimising outcomes for patients, minimising the risks of toxicity,
and the emergence of resistance. Inherent within this strategy is an even
greater need for a wider choice of anti-Gram-positive agents of different
classes or mechanisms of action to reduce selective pressure and the
risk of resistance development. To enable this and to provide physician
reassurance and optimal outcomes in seriously-ill patients, novel and
potent antibacterial agents are needed. Potential future options for the
treatment of serious Gram-positive infections in severely ill patients may
be found in new antibacterial classes, such as the lipoglycopeptides.
New challenges for the infectious disease
laboratory
S163 Gram negative resistance: new b-lactamases and testing
methods for detection
D.W. Wareham* (London, UK)
Resistance to antimicrobials is one of the most serious challenges
facing modern healthcare. The situation is most acute with respect to
Gram-negative infections, with extended-spectrum b-lactamase and car-
bapenemase (NDM-1) producing Enterobacteriaceae and Acinetobacter
baumannii strains being particularly problematic. Accurate and timely
detection and identiﬁcation of multi-drug resistant isolates is a key role
of the clinical laboratory. In this session the options currently available
to diagnostic laboratories (phenotypic, molecular, automated) will be
reviewed and their ability to inﬂuence treatment and infection control
interventions discussed.
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S164 New advances in virological monitoring of herpes viruses in
solid organ transplantation
T. Lazzarotto* (Bologna, IT)
The risk of infection in the transplant recipient is a continuous function
of the interplay between the net state of immunosuppression and
the epidemiologic exposures of the donor and transplant recipient.
Traditionally, herpes viruses were considered the most important viral
pathogen in terms of their ability to cause clinical illness after
transplantation. The prevention of post-transplantation cytomegalovirus
and other herpesvirus infections/diseases and the availability of oral
antiviral agents have revolutionized post-transplantation care.
The vast majority of infections due to herpes virus simplex 1 and 2
(HSV1−2) and varicella zoster virus after solid organ transplantation
(SOT) represent reactivation of latent virus. The ﬁrst month after
transplantation represents the period at highest risk of HSV1−2
reactivation. There is no speciﬁc indication for the surveillance of these
viruses because the antiviral prophylaxis with acyclovir/valacyclovir has
markedly reduced its incidence after transplantation.
During the intermediate post-transplantation period most opportunistic
viral infections occur and viruses such as cytomegalovirus (CMV),
Epstein Barr virus (EBV) and human herpesvirus 6 (HHV6) are
commonly observed. Virological tests are the best means of establishing
a diagnosis of the infection and monitoring the virus infection in SOT. In
cases of disseminated virus infection, blood is the specimen of choice.
Local organ samples (secretions or tissue biopsy specimens) are the
best specimens to use in cases of organ syndromes, either separate
from or associated with systemic infection. The test method of choice
is quantitative measurement of viral DNA in the different pathological
materials and real-time PCR assays are now the most commonly used
diagnostic method.
Standardized protocols and methods for virological monitoring are
mandatory for the correct surveillance of CMV and EBV infection in
transplant patients receiving pre-emptive therapy. Multicenter studies
conducted to examine the intra- and inter-laboratory variability in
qualitative and quantitative CMV and EBV DNA assays indicated that
virus DNAemia may be reliably quantiﬁed using a variety of commercial
and in-house molecular protocols.
In the future, the best approach to monitoring transplant patients for
CMV and EBV infections is to perform a careful virological and
immunological follow-up in all patients.
S165 HBsAg mutants in routine diagnostic: impact and
consequence
J. Verheyen* (Cologne, DE)
Worldwide about 350 million people are chronically infected with
HBV and are at risk of developing liver cirrhosis and hepatocellular
carcinoma. The detection of HBsAg in the serum of patients is a
corner stone in the diagnosis of HBV. Additionally antibodies against
the viral HBsAg are associated with immunity towards viral infection
either induced by exposure to HBV or by HBV vaccination. In recent
years numerous cases of vaccination failure of newborns born to
chronically HBV infected mothers have been reported. Most often
mutations in the HBsAg of HBV lead to this immunoescape and
could also hamper the detection of HBsAg by diagnostic screening
assays. Diagnostic escape can cause severe complications, since the HBV
diagnosis might be delayed and/or the risk of HBV transmission might
be overseen (like the risk of mother to child transmission at birth or
during surgery). Therefore it is mandatory for diagnostic assays used
for HBsAg screening not only to be highly speciﬁc and sensitive but
also to tolerate HBsAg variability of clinical isolates. Even though the
frequency of HBsAg mutants causing vaccination and/or immunoescape
is still a matter of debate, there is evidence that these mutations
are not only selected in patients failing HBV vaccination. The same
HBsAg mutantions are frequently observed in patients receiving aHBs
antibody immunoglobulin therapy after liver transplantion. Due to the
overlapping reading frame of the HBsAg and viral polymerase mutations
selected by antiviral treatment with nucleot(s)ide analoga can also lead to
changes in the HBsAg sequence. Moreover it was shown that mutations
previously associated with immunoescape in the HBsAg might also
be compensatory in the polymerase reading frame of drug resistant
HBV isolates. Newer antiviral treatment regimens for HBV currently
provide the opportunity of sustained viral suppression in the majority
of HBV infected patients without the selection of drug resistance.
However, worldwide efﬁcient antiviral treatment of HBV is limited by
HIV coinfection, the accessibility of the newer drugs and higher costs.
HBsAg screening assays have to take care of the probably increasing
sequence variability of clinical HBV isolates selected by the antiviral
therapy and the immune system.
Prospects for the control of neglected
tropical diseases
K176 Prospects for the control of neglected tropical diseases
D. Molyneux* (Liverpool, UK)
Over recent years the proﬁle of the Neglected Tropical Diseases (NTDs)
has been increased through as series of high impact publications
which have highlighted the problems of these diseases in the context
of the Millennium Development Goals and as major contributors to
poverty − indeed it will be argued that the prevalence of NTDs are
the best indicators of the poverty status of populations. The NTDs,
some 17 of which are included in the ﬁrst WHO Global Report of
2010 “Working to overcome the global impact of neglected tropical
diseases” (www.who.int/topics/tropical_diseases/en/) are categorised as
“other diseases” within MDG 6, a derisory status, given that some current
estimates of the Burden of these diseases outweighs those of malaria or
TB whilst the numbers of deaths attributed to NTDs is also greater than
the estimated mortality attributed to maternal mortality. The recognition
that these infections, which are mainly parasitic, and affect more than
one billion people with more than two billion at risk, can and have been
cost effectively controlled has
a. increased advocacy for their control through higher prioritisation by
policy makers
b. maintained the availability of long term quality drug donations from
major pharmaceutical companies
c. ensured increased resources are committed to research on those
disease where tools remain inadequate and
d. recognised the cost effectiveness of the interventions allied to robust
monitoring and evaluation methodologies.
These factors amongst others are driving the increased commitment
from bilateral donors, Foundations, Non Governmental Development
Organisations (NGDOs), civil society and most importantly national
health authorities to commit more resources to their control or
elimination. In addition, there is a real prospect that Guinea worm
disease will be eradicated as it only remains endemic in 5 countries
in Africa. NTDs are “low hanging fruit” in terms of our capacity to
make a rapid impact on the health of the poorest populations with
the tools currently available and the proven reach of some programmes
which in the case of preventive chemotherapy for helminth infections −
lymphatic ﬁlariasis, onchocerciasis, schistosomiasis and soil transmitted
helminthiasises − through various delivery methods reached some 680
million people in 2009 alone. The annual per person delivery costs
being often much less than US$0.50 and in some settings as low as
US$0.02. NTDs are diseases, which have been largely ignored whilst
the international focus has remained on HIV, TB and malaria, yet
they are diseases most prevalent amongst the poorest sectors of the
most vulnerable populations. Any attempt at poverty alleviation must
include addressing NTDs if development targets are to be met. The
address will focus on recent developments and progress towards the goals
set by various World Health Assembly Resolutions in controlling and
eliminating NTDs whilst highlighting the challenges posed by the need
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for diverse interventions against biologically very different organisms in
the different health system and geographic settings.
Amoeba as genitor of new pathogenic
microorganisms
K177 Amoeba as genitor of new pathogenic microorganisms
D. Raoult* (Marseille, FR)
The amoebas are phagocytic protists that live in water, on the ground
and in the mucous membranes of animals. These protists have the
capacity to phagocytise all particles of size higher or equal to 100
nanometers. Phagocytosis is not speciﬁc but depends on size. Once
inside the phagocytes, some micro-organisms acquired the capacity to
resist to the intracellular destruction. The protists feed microorganisms,
and some microorganisms worked out mechanisms which allowed
them, while resisting to the phagocytic protists, to resist to the
macrophages later on or to even become potentially disease-causing
agents. Inside these phagocytic protists, a microbial community is seen
which comprise bacteria, but also giant viruses and eukaryotes, of which
fungi. This community life (sympatry) allows exchanging of genes.
In fact, genomes of micro-organisms that live in the amoebas are the
largest of the intracellular microorganisms and in contrast with other
intracellular microorganisms, have chimerical genomes composed of
genes from various inhabitants from the amoeba. The amoebas make it
possible to create new repertoires and to generate new microorganisms
likely to resist the phagocytic action. The ﬁrst example of bacteria,
selected in the amoebas, becoming pathogenic to humans is Legionella
pneumophila, but the majority of the giant viruses, of which, Mimivirus
and Marseillevirus and of many pathogenic microorganisms including
mycobacteries, seem to have followed in the same way.
Pro vs Con: guideline vs. clinical practice-
driven strategies in treating severe infectious
diseases
S184 Nothing can replace clinical judgement
B.E. de Pauw* (Nijmegen, NL)
It has become customary to issue guidelines for the management
of life-threatening diseases such as invasive fungal infections. These
guidelines are supposed to offer the clinician easy access to the
overwhelming amount of sometimes confusing data assuming that the
assorted information will help to select the most suitable treatment for
the seriously ill patient. Moreover, patients and authorities alike demand
clear regulations to provide insight in the medical procedures and an
objective benchmark for quality control, repectively. It is obvious that
administrative people and clinician appreciate treatment guidelines in a
different way. The individual patient occupies the central position in the
vision of the clinician, while administrators see a group of patients with
a similar disease who require a particular therapy.
Guidelines for its treatment have been published in English by
working parties from various countries and as all committees had
the same data set at their disposal, great congruency amongst the
various documents could be expected. The differences, however, are
considerable. Most discrepancies are related to a different interpretation
of the clinical trials. However, the value of clinical trials for this purpose
is largely overestimated, especially by unexperienced practitioners and
regulatory authories. Stringent inclusion and exclusion criteria will
prohibit enrollment of children, pregnant women, certain concurrent
drugs and serious concomitant diseases. In daily practice there are no
such exclusion criteria, which renders study populations often more
suitable for the statistian than for the clinician. In addition, empirical
trials and salvage studies, which are rather strategic than drug-efﬁcacy
studies are of no value at all. Therefore the published guidelines for the
treatment of invasive fungal disease have to be taken into consideration
but applied with prudence. They are provided for groups but there
are frequently good reasons to deviate from the recommendations in
individual cases.
Bioﬁlm: from pathogenesis to preventive
measures
O187 Modelling of controlled bioﬁlm infection using rats with
totally implantable port access intravenous catheter
A. Chauhan*, D. Lebeaux, I. Kriegel, B. Decante, J.-M. Ghigo,
C. Beloin (Paris, Le Plessis-Robinson, FR)
Objectives: Safe and easy-to-use port-access intravenous catheters
(PAVCs) are integral part of daily clinical practices that may be subjected
to major complications such as thrombosis and bioﬁlm infections. The
main objective of our study is to develop and validate an IN VIVO rat
model of controlled bioﬁlm infection in PAVCs that will allow the real
time monitoring of the bioﬁlm establishment and its consequences.
Methods: The PAVC was implanted into the jugular vein by a procedure
close to the one used for implantation in patients with the aim to monitor,
on a real time basis, bioﬁlm formation within the PAVCs and possible
associated infection using bioluminescence. PAVCs were inoculated with
controlled dose of bacteria (luminescent variants of bioﬁlm-forming
pathogens ESCHERICHIA COLI, STAPHYLOCOCCUS AUREUS and
PSEUDOMONAS AERUGINOSA) and monitored over a period of time
for bioﬁlm development in both the chamber and along the catheter,
using Xenogen IVIS-100.
Results: Immunocompetent rats were able to clear the bacterial load
from the blood within 8 days restricting the infection to PAV catheters
and in addition, no bacteria were detected in the surrounding organs as
determined by colony count method. Defects in the host immune system
commonly promote microbial infection. Inﬂuence of animal immune
system on bioﬁlm development on PAV catheter was analysed and our
results showed that immunocompromised rats were highly susceptible to
the PAV catheter bioﬁlm related infection leading to bacteremia and
metastatic infectious disease that ultimately led to the death of the
animal.
Conclusions: We were able to reproducibly establish and non-invasively
monitor bioﬁlm development in PAV catheterised rats by three different
clinically relevant pathogens allowing us to monitor the progression
of the colonisation process along the catheter as well as detection of
the associated infection in the blood stream and in the organs. With
the application of our in vivo model of PAVC bioﬁlm infection to
immuno-suppressed animals we clearly demonstrated that the immune
system of the rats is essential to restrict bioﬁlm infection to the device
itself. This model will allow evaluating antibacterial strategies as well
as anti-adhesive and anti-thrombotic catheter coatings to prevent bioﬁlm
infections. Moreover, this controlled model of catheter infection opens
the way for studies evaluating the inﬂuence of host immune factors on
the bioﬁlm-associated infections.
O188 Multidrug-resistance efﬂux pumps are required for bioﬁlm
formation of Salmonella enterica serovar typhimurium
S. Baugh*, M.A. Webber (Birmingham, UK)
Objectives: Multidrug resistant (MDR) efﬂux pumps export a wide
variety of substrates including antibiotics, detergents and dyes. As well
as this export of a broad spectrum of substrates we show here that MDR
pumps have a role in the formation of bioﬁlms. Inactivation of a range
of MDR pumps impacts on the ability of Salmonella to form a bioﬁlm.
We have investigated the mechanisms by which efﬂux pumps contribute
to bioﬁlm formation using the well characterised RND pump, AcrAB-
TolC in Salmonella enterica serovar Typhimurium as a model. This study
investigated three hypotheses; AcrAB-TolC exports a factor required for
bioﬁlm formation, mutants lacking components of AcrAB-TolC have
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altered membrane integrity, loss of AcrAB-TolC alters expression of
bioﬁlm related genes.
Methods: The amount of bioﬁlm produced by wildtype and mutants
was quantiﬁed under various conditions. Assays used to investigate
export of a ’bioﬁlm factor’ were; transwell bioﬁlm assays, co-incubation
bioﬁlm assays and bioﬁlm assays with addition of exogenous efﬂux pump
inhibitor (EPI). Settle assays, hydrophobicity tests and LPS analysis were
used to investigate differences to the cell surface membrane resulting
from the loss of AcrAB-TolC. Expression of matrix components was
also investigated in all strains.
Results: AcrB and TolC mutants both formed much less bioﬁlm than
wildtype in the simple ‘crystal violet’ bioﬁlm model and mutants formed
no bioﬁlm in the more complex ‘bioﬁlm mat’ model in comparison
to wildtype forming an established bioﬁlm mat on the surface of
the liquid. Transwell and co-incubation assays showed no rescue of
mutant bioﬁlms when cultured with wildtype. Addition of exogenous EPI
reduced bioﬁlm formation of wildtype Salmonella in a dose dependent
manner. Aggregation and hydrophobicity assays all showed no signiﬁcant
difference in the mutants’ ability to aggregate compared to wildtype and
LPS analysis uncovered no differences between mutant and wildtype LPS
composition. Mutants lacking AcrB or TolC did however not express
speciﬁc components of the bioﬁlm matrix.
Conclusion: An intact, functional AcrAB-TolC efﬂux system is crucial
for Salmonella to form a complex bioﬁlm, inhibition of this system
blocks bioﬁlm formation, representing a therapeutically useful avenue for
EPI development. The role of AcrAB-TolC in bioﬁlm formation appears
to be related to regulation of matrix formation, a model is proposed to
explain this regulatory circuit.
O189 Lysogenic phages promote pneumococcal bioﬁlm
development
M. Carrolo, M.J. Frias, F.R. Pinto, J. Melo-Cristino, M. Ramirez*
(Lisbon, PT)
Objectives: Streptococcus pneumoniae recovered from human infections
have a high prevalence of lysogeny. As pneumococcal bioﬁlms have been
implicated both in colonization and infection, we decided to investigate
the impact of lysogeny in pneumococcal bioﬁlms. Since extracellular
DNA (eDNA) is a major factor in the bioﬁlm matrix, we reasoned
that prophage spontaneous activation with the consequent bacterial lysis
could provide a source of eDNA, enhancing pneumococcal bioﬁlm
development.
Methods: We monitored bioﬁlm development of the pneumococcal
isogenic strains R36A and R36AP, which differ only in the presence
of a prophage (R36AP is lysogenic for phage SV1). Bioﬁlm growth
was followed by biomass quantiﬁcation, viable cell counts and confocal
laser scanning microscopy (CLSM). Phages released during bioﬁlm
formation were measured by the total number of PFUs at speciﬁc time
points. The impact of phage-mediated lytic events within the bioﬁlm
structure was determined by comparing bioﬁlm development of the
lysogenic strain R36AP to that of the mutants for the phage lysin Svl
(R36APdeltasvl), bacterial autolysin LytA (R36APdeltalytA) or both
lysins (R36APdeltalytAdeltasvl). To further explore the potential role
of eDNA on bioﬁlm development, we determined the effect of the
addition of external DNA and DNase I and measured the amount of
eDNA released within bioﬁlms by real-time PCR.
Results: Phage-infected bacteria are more prone to form bioﬁlms,
yielding structures with higher biomass and cell viability and with CLSM
showing denser bioﬁlms for the lysogenic strain R36AP. Phages were
detected throughout bioﬁlm growth, indicating that spontaneous phage
induction is occurring continuously. Treatment with DNase I resulted in
sparser and thinner bioﬁlms while supplementation with DNA resulted
in a more densely packed structure. Moreover, the addition of DNA
overcomes the impairments created by the ablation of either the phage
or bacterial lysins. The quantiﬁcation of eDNA within pneumococcal
bioﬁlms also supports that phage-mediated lytic events are an important
source of this matrix component.
Conclusion: Our data indicates that limited phage-mediated host lysis
constitutes an important source of eDNA in S. pneumoniae bioﬁlms
favoring bioﬁlm formation by lysogenic strains.
O190 HWP1 gene polymorphism in Candida albicans isolates from
bloodstream infections: a possible role in bioﬁlm formation?
E. Borghi*, C. Biassoni, L. Cappelletti, R. Sciota, D. Cirasola,
L. Vizzini, C.F. Orsi, G. Morace (Milan, IT)
Objectives: Speciﬁc signaling pathways regulate Candida albicans
bioﬁlm formation, involving several gene families. A novel allele of
HWP1 (Hyphal Wall Protein 1), a protein required for hyphal growth,
has recently been associated to a less adherence capability. The aim of
this work was to assess the bioﬁlm formation ability of 142 C. albicans
BSI isolates, the natural occurrence of the HWP1 polymorphism in this
population, and its signiﬁcance in bioﬁlm formation.
Methods: Bioﬁlm forming ability was assessed in a 96-wells microtitre
plate system through quantiﬁcation by crystal violet (CV) staining and by
XTT reduction assay. The polymorphism of HWP1 locus was determined
by PCR, and a semi-quantitative RT-PCR was used to discriminate
HWP1 alleles expression in heterozygous strains. For gene expression
experiments, Candida bioﬁlms were formed on polystyrene ﬂasks, and
harvested at 4, 8 and 24 hours post bioﬁlm induction. The relative
quantiﬁcations of HWP1 and ECE1 (Extent of Cell Elongation 1b) gene
expressions were made by real-time PCR in a selected group of 12
isolates (6 producers and 6 non-producers).
Results: The propensity to form bioﬁlm was shown in 65/142
C. albicans isolates, 60 of them being HWP1 wild type (HH)
homozygous strains. The heterozygous presence of HWP1 (Hh)
was observed in 5 bioﬁlm producers and in 6 non-producers. The
homozygous type HWP1−2 (hh) was seen only in one bioﬁlm non-
producer isolate. Only one Hh strain, bioﬁlm producer, showed a
preferential expression of the H allele during the early stages of bioﬁlm
production. In the initial adhesion stage (4 h) we observed a differential
gene expression in bioﬁlm producers, either HH or Hh strains, for both
the studied genes (Figure), although Hh strains showed a poor presence
of hyphae in their bioﬁlms.
Conclusions: The frequency of the HWP1−2 allelic variant in our
Candida population was low, including the heterozygous strains. This
aspect could reﬂect the particular setting of our isolates, all from BSI,
and the pathogenic importance of HWP1 in invasion. Clinical strains of
C. albicans vary signiﬁcantly in their ability to form bioﬁlm. HWP1
seems to play a role in bioﬁlm production, but other genes must
cooperate in the bioﬁlm formation such as ECE1. Our results conﬁrm
the complexity of molecular mechanisms underlying bioﬁlm production,
and the need to investigate its possible pathogenic role in vivo, where
other factors as the immune system interact.
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O191 Characterisation of accumulation-associated protein
interaction partners involved in Staphylococcus epidermidis
bioﬁlm formation
M. Michel, C. Burdelski, R. Decker, G. Franke, M. Christner,
H. Rohde* (Hamburg, DE)
Staphylococcus epidermidis is a leading cause of implant-associated
infections. Surface colonization crucially depends on bioﬁlm formation,
representing the key virulence mechanism of S. epidermidis. The 220
kDa accumulation associated protein (Aap) mediates intercellular adhe-
sion and bioﬁlm formation after proteolytic processing and exposure of
repetitive domain B. In order to function as an intercellular adhesin, Aap
domain B must interact with surface structures on neighbouring cells.
Therefore, the aim of this study was to identify Aap domain B ligands
involved in intercellular adhesion. To this end we used recombinant Aap
domain B to afﬁnity purify binding partners from crude preparations
of S. epidermidis surface proteins. Amongst other candidates mass
spectrometry identiﬁed a protein with so far unknown function which
we refer to as the Aap associated Staphylococcus epidermidis adhesin
(AaStrA). AaStrA is a 20 kDa protein which possesses an N-terminal
export motive, but lacks homologies to other proteins with known
function. Analysis of interactions using recombinant proteins in solid
phase ELISA and ligand blotting experiments validated speciﬁcity of
Aap domain B–AaStrA interactions. In addition, independent t from
Aap, AaStrA bound to the staphylococcal cell surface, induced bacterial
aggregation and bioﬁlm formation. These data suggest that AaStrA itself
is a bona ﬁde intercellular adhesin. aastra is widespread in clinical
signiﬁcant S. epidermidis isolates from catheter-related blood stream and
prosthetic joint infections. Moreover, AaStrA-speciﬁc antibodies were
detected in sera from patients with infections related to aastra-positive
S. epidermidis isolates, indicating that AaStrA is produced in vivo.
In conclusion we here identiﬁed a novel cell surface protein involved
in S. epidermidis bioﬁlm formation contributing to implant associated
infections, giving noel evidence that protein dependent bioﬁlm formation
results from speciﬁc protein–protein interactions.
Antimicrobial activity of different antibiotics
alone or in combination against MDR
Gram-negative goals
O192 The effect of NaCl on carbapenem susceptibility in
Acinetobacter baumannii
E. Zander*, H. Seifert, P.G. Higgins (Cologne, DE)
Objectives: Carbapenem-resistance in Acinetobacter baumannii is
mediated most frequently through carbapenem-hydrolysing oxacillinases
(OXA). NaCl is reported to completely inhibit the action of most OXA
and this has led some researchers to screen for OXA by performing
carbapenem-MICs in the presence of 200 mM NaCl. However, data
on the effectiveness of this is contradictory, and observed effects may
be a combination of strain-related characteristics as well as OXA-
inhibition. The aim of this study was to investigate the effect of NaCl on
carbapenem-susceptibility with deﬁned OXAs expressed in A. baumannii
ATCC 19606 and ATCC 17978.
Methods: The genes encoding OXA-58 and OXA-164 were cloned into
shuttle-plasmid pWH1266 and transformed into ATCC 19606 and ATCC
17978. Clinical plasmids carrying genes encoding OXA-23, OXA-40 and
OXA-143 were isolated and transformed in ATCC 19606 and 17978
strains. Transformants (TFs) were selected on Mueller-Hinton Agar
(MH) plates with ticarcillin [100mg/ml]. Plasmid transfer was conﬁrmed
by PCR. Susceptibility of TFs and parent ATCC strains against imipenem
(IPM) and meropenem (MEM) was determined by Etest using MH plates
with and without 200 mM NaCl.
Results: The IPM and MEM MIC values (mg/ml) of the wild-
type (wt) and OXA-transformants tested with and without NaCl are
shown in the table. OXA-23 did not transfer into ATCC 19606.
MICs appear to be strain-dependant; OXA-58/164 transformed ATCC
19606 recorded higher MICs than OXA-58/164 transformed ATCC
17978. Untransformed strains showed a small increase in carbapenem-
susceptibility when tested in the presence of NaCl. While MICs of some
TFs were reduced when tested in the presence of NaCl, this also appears
to be strain-dependant; ATCC 19606 (OXA-164/40) exhibited greater
susceptibility than ATCC 17978 (OXA-164/40) when tested with NaCl.
OXA-58 TFs were unaffected.
Conclusions: Because carbapenem-MICs of TFs in the presence of NaCl
did not reach the susceptibility of untransformed parent strains, the effect
of NaCl is probably not due to complete OXA-inhibition. These data also
suggest that the effect of NaCl on carbapenem-susceptibility may be
dependent upon a combination of strain and OXA-type. We therefore do
not recommend performing MICs in the presence of NaCl for screening
for the presence of OXA in A. baumannii.
O193 In vitro activity of doripenem in combination with polymyxin
against multidrug-resistant Acinetobacter baumannii
J. Teo*, T. Lim, W. Lee, S. Sasikala, D.Q. Chia, L.Y. Hsu, T.T. Tan,
A.L. Kwa (Singapore, SG)
Objective: The prevalence of pandrug resistant (PDR) Acinetobacter
baumannii (AB), sensitive to polymyxins only is increasing in Singapore;
leaving few therapeutic options available. Polymyxin B (P) monotherapy
is a viable option, but heteroresistance has become a major problem.
Combination therapy may be the only therapeutic option until new
antimicrobial agents become available. We evaluate the in-vitro activity
of doripenem (D), a new carbapenem in combination with P against
PDR AB.
Methods: Multidrug-resistant (MDR) AB isolates from all public
hospitals in Singapore were collected from 2006−07. Clonal relatedness
was determined by multiplex PCR strain typing; with cluster analysis
of banding data performed using the unweighted pair group method
with arithmetic mean. MICs were determined according to CLSI
broth-dilution method. Time-kill studies (TKS) were conducted with
approximately 105 CFU/ml at baseline with maximally clinical
achievable concentrations of D (13mg/L, corresponding to 1g every 8h
over 4h) and P (2mg/L, corresponding to at least 1MU q12h), alone and
in combination against PDR AB.
Results: Among 361 non-repeat MDR AB isolates screened, 31 PDR
AB isolates found were mostly susceptible to P (MIC 1 to 64mg/L) and
resistant to all antibiotic classes, including D (MIC >64mg/L). Molecular
typing data demonstrated limited clonal clustering of the 31 isolates. In
TKS, regrowth occurred in all isolates at 24h with D alone,. With P
alone, regrowth occurred in 24/31 isolates and bactericidal activity (3
log decrease from baseline inocula) were achieved with 7/31 isolates
at 24h. This showed that heteroresistance was present in most of our
PDR AB isolates. For D+P, it was synergistic (>2 log decrease when
compared to its most active antibiotic) in 11/31 isolates (bactericidal in
9 isolates), bacteriostatic (<1 log difference when compared to baseline
inocula) in 10/31 isolates, additive in 3/31 isolates and undetermined in
7/31 isolates (P alone is bactericidal) at 24h.
Conclusion: D+P may be a potential antibiotic combination as pre-
emptive therapy for PDR AB infections even though PDR AB may
remain susceptible to P. The in-vivo relevance of our results warrants
further investigations.
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O194 Antimicrobial activity of telavancin combined with low-dose
colistin versus multidrug-resistant strains of Acinetobacter
baumannii
M. Hornsey*, N. Gordon, L. Phee, C. Longshaw, D. Wareham (London,
Staines, UK)
Objectives: Antimicrobial treatment of MDRAB infections remains an
important therapeutic challenge. With strains now resistant to tigecycline
and colistin, clinicians are increasingly forced to use unorthodox
antimicrobial combinations in the hope that they may elude the myriad
of resistance mechanisms present in MDRAB. We recently described
synergy when the glycopeptide vancomycin was combined with low
doses of colistin due to its ability to permeabilise the MDRAB outer
membrane. In this study we assessed the activity of telavancin (TLV)
when combined with colistin 0.5mg/L (COL) versus a well characterised
collection of MDRAB.
Methods: Forty-two MDRAB isolates were studied, including 5
belonging to the UK epidemic lineages known as ‘SouthEast, OXA-
23 clone 1, 2, T and Burn’. The remaining isolates were identiﬁed
as A. baumannii by API 20NE and conﬁrmed by species speciﬁc
PCR (blaOXA-51-like). Susceptibility to b-lactams, quinolones and
aminoglycosides was performed using the BSAC disc diffusion method
and MICs determined by Etest (tigecycline) or agar dilution (COL).
The MIC of TLV was determined by Etest (0.002−32mg/L range) using
isosensitest agar supplemented with and without COL at a ﬁxed sub-
inhibitory concentration of 0.5mg/L.
Results: 42 isolates were studied, all of which were resistant to
b-lactams, quinolones and aminoglycosides, 4 were also resistant to
tigecycline (MIC >2) and 1 resistant to COL (MIC >256mg/L).
Although the MIC of TLV was >32 for every isolate tested, this was
reduced in the presence of COL in 34/42 (80%) isolates. The mean
fold reduction in TLV MIC was 4.5 dilutions. For 27 isolates, the
TLV+COL MIC was less than the BSAC breakpoint for susceptibility
to glycopeptides (2mg/L), and for 11 isolates, it was below the FDA
TLV Staphylococcus aureus breakpoint of 1mg/L, including 3 of the
tigecycline resistant strains (Figure 1).
Conclusion: Potent synergy was observed when COL was combined
with TLV versus the majority of MDRAB tested in-vitro. This effect
was observed with relatively low concentrations of COL, an important
consideration when considering potential toxicity. With little prospect of
new agents becoming available for the treatment of MDRAB in the near
future, further work to assess the relevance of the interactions observed
is warranted.
O195 Activity of polymyxin B and rifampin against Acinetobacter
baumannii in suspension and bioﬁlm
C. Speil, R. Rzepka, N. Khardori* (Springﬁeld, US)
Objectives: Multidrug resistant (MDR) A. baumannii is a major noso-
comial pathogen. Polymyxins are predictably active against carbapenem
resistant isolates, with dose related nephrotoxicity. Bacterial adherence
and bioﬁlm production is associated with antibiotic resistance. Rifampin
is able to penetrate into bacterial bioﬁlms. We studied polymixin B
and rifampin combination for synergy against carbapenem-resistant
A. baumannii isolates in suspension and bioﬁlm, thus potentially
allowing polymixin B dose reduction, decreasing nephrotoxicity.
Methods: A total of 21 MDR A. baumannii isolates, from an institutional
outbreak were typed by pulse ﬁeld gel electrophoresis (PFGE), showing 5
clonally distinct types. All 21 isolates were tested for bioﬁlm production
by modiﬁed microtiter assay. The strongest bioﬁlm producers of each
clonal type were selected for susceptibility testing. MIC’s for imipenem,
polymyxin B and rifampin were determined by broth microdilution
assay. Combination of polymixin B at 0.015−8 mcg/ml and rifampin
at 0.125−16 mcg/ml was tested for synergy by checkerboard method.
Fractional Inhibitory Concentration Index (FICI) was calculated, synergy
being deﬁned as FICI 0.5, indifference as >0.5 to 4 and antagonism
as >4. The same isolates were then tested in a bioﬁlm model. Bioﬁlm
sampling was done and the MBC’s for polymyxin B and rifampin were
determined. MBC’s were also determined for the antibiotic combination
in suspension and bioﬁlm.
Results: Three strains were strong and 2 were weak bioﬁlm producers.
All were resistant to imipenem and susceptible to polymixin B (MIC 1
mcg/ml). MIC’s for rifampin were 4−16 mcg/ml. Polymixin B MBC’s in
suspension were 1 mcg/ml for 4 isolates but higher (MBC 8) for all
isolates in bioﬁlm. The combination of polymixin B and rifampin showed
synergy (FICI 0.5)against all isolates at polymyxin B concentrations
0.125 mcg/ml and rifampin concentrations 1 mcg/ml. Polymixin B
combined with rifampin at 0.25 and 2 mcg/ml showed at least a 2 fold
decrease in MBC’s for 4 isolates in suspension but not in bioﬁlm.
Conclusions: Polymyxin B and rifampin are synergistic against bacteria
in suspension but not bacterial bioﬁlms, which signiﬁcantly increases
antibiotic resistance even in “weak” bioﬁlm producers. Polymyxin B
dose reduction may not be feasible in bioﬁlm-associated infections.
O196 The in vitro antimicrobial effect of colistin alone and in
combination, against clinical isolates of multidrug-resistant
Pseudomonas aeruginosa
F.M. Zali*, L. Thabet, C. Andre´, V. Dubois, F. Me´graud, C. Quentin
(Bordeaux, FR; Tunis, TN)
Introduction: The global emergence of “pan resistant” clinical strains
of Pseudomonas. aeruginosa has led to the increasing use of colistin
(CS) in the treatment of infections due to these isolates.
Objectives: The aim of this study was to ascertain the in vitro effect of
CS alone and in combination on MDR clinical strains of P. aeruginosa.
Methods: 30 clinical strains of P. aeruginosa genetically characterized
for their b-lactam resistance were collected. All strains harbored multiple
resistance determinants (ESBLs, AmpCs, carbapenemases, loss of porins
and efﬂux mechanisms). The MICs and the in vitro synergistic effect of
colistin and 7 other antibiotics [ceftazidime (CAZ), aztreonam (ATM),
meropenem (MEM), doripenem (DOR), amikacin (AKN), levoﬂoxacin
(LEV), rifampicin (RIF)] were determined by the checkerboard method.
For 10 strains these associations were also evaluated by the E-test
diffusion method. The bactericidal effect of the most frequently
synergistic combination (RIF-CS) was assessed by killing curves.
Results: All strains were susceptible to CS (MIC = 1−2mg/l),
but presented different levels of resistance to the other antibiotics
tested: MICs (mg/l): CAZ, 1−>64, ATM: 4−>64, MEM, 0,2−>64;
DOR, 0,1−64; AKN, 4−>64; LEV, 0,2−>64; RIF, 8−>64. The MICs
determined by E-test were in concordance. The SigmaFIC analysis
showed that the combination of CS to b-lactams was primarily additive
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(CS-CAZ, n = 22; CS-ATM, n = 25; CS-MEM, n = 16; CS-DOR, n = 23),
regardless of the mechanism of resistance present in the strain. The
combination of CS to AKN or LEV was additive or indifferent (n = 21
and 25, respectively) whilst CS-RIF was additive or synergistic (n = 28).
By killing curves, preliminary results with two strains showed that the
combination CS-RIF was more synergistic when CS was used at sub-
inhibitory concentrations (0.5mg/L) than when used at the breakpoint
concentration (2mg/l).
Conclusion: Colistin improved readily the in vitro activity of the
antibiotics tested on all MDR clinical strains of P aeruginosa. No
antagonism was observed. The most synergistic combination was
CS-RIF. This combination of antibiotics could represent a valuable
therapeutic option for the treatment of patients infected by MDR
P. aeruginosa.
Excellence Award
K197 Vaccines, medicine and public health in the XXI century
R. Rappuoli* (Siena, IT)
During the 20th century, vaccines have eliminated most of the
childhood diseases with the major exceptions of the diseases caused
by meningococcus and respiratory syncytial virus (RSV). What is the
role of vaccination in the 21st century? The ﬁrst target will be to develop
vaccines for meningococcal meningitis, which is perhaps the last disease
that in a few hours can attack and kill healthy children and young
people, and RSV that affects virtually every single child in the ﬁrst few
months of life. Fortunately, thanks to several revolutionary technologies
developed during the last 30 years, including conjugation, genomics and
new adjuvants, we are in the ﬁnal stages to conquer meningococcal
meningitis and new approaches are being tested for RSV. The second
and perhaps most important target of vaccination in the 21st century
will be to take care of the global health problems of this century. These
include taking care of the aging population, with new vaccines targeting
the diseases typical of the elderly with an aging immune system, to
control emerging antibiotic resistance, to preventing cancer, taking care
of the diseases present only in countries affected by poverty, and taking
care of emerging diseases such as pandemic inﬂuenza. Overall, vaccines
in the 21st century will have an increased safety, and will be used as an
insurance to ensure health across all ages, for the entire life.
Are probiotics growth promoters in humans?
S204 Are probiotics growth promoters in humans? − No
Y. Sanz* (Valencia, ES)
It has been hypothesized that the intestinal microbiota could be causally
related to obesity and associated metabolic disorders and, therefore,
its intentional manipulation could be a therapeutic target. Evidence of
the role microbiota plays in obesity is primarily based on comparisons
between germ-free and conventional mice showing that germ-free mice
have 40% less body fat, and that conventionalization with the caecum
microbiota causes a 60% increase in body fat and insulin resistance.
Observational studies comparing the gut microbiota of obese and lean
subjects have led to establish associations between obesity and speciﬁc
phyla and bacterial groups. Although, there is not full consensus, several
studies have associated obesity with reduced proportions of Bacteroidetes
and increased Firmicutes, and weight loss in obese human subjects
with increases in Bacteroidetes or Bacteroides subgroups. Observational
studies on the relationships between bacteria used as probiotics for
humans (Lactobacillus and Biﬁdobacterium) and obesity have, however,
yielded conﬂicting results or no associations. In addition, the use of
probiotics as growth promoters in farm animals has led part of the
scientiﬁc community to attribute to these bacteria an obesogenic role.
Nevertheless, the effect of probiotics on animal weight-gain can be
secondary to suppression of infections and no primary role in obesity has
been proven; this is supported by the fact that probiotic administration
is not accompanied by increases in body fat, which would be expected
from an obesity promoter. Moreover, most interventions conducted in
infants and children indicate that probiotics do not inﬂuence growth,
except for a few cases of undernourished children or those suffering
infections. Conversely, other scientists are exploring the possibility that
probiotic bacteria help in the management of obesity and associated
disorders by regulating the host’s metabolic and immune functions.
So far evidence from human studies is limited but in obese animal
models speciﬁc Lactobacillus and Biﬁdobacterium strains and prebiotics
have exerted protective roles, for instance reducing lipid absorption,
liver steatosis, adipocyte size, intestinal permeability and inﬂammatory
markers associated with insulin resistance. Although, the possible anti-
obesogenic role of probiotics has yet to be proven by conducting
appropriated human intervention studies, there is no evidence that
probiotics constitute growth promotes and contribute to the obesity
epidemic in humans. Most likely the answer to the question whether
probiotics have a positive or negative impact on obesity cannot be
addressed by a simplistic answer but would depend on the complex
interplay between speciﬁc strains, the host status and the diet.
S205 Are probiotics growth promoters in humans? − Yes
D. Raoult* (Marseille, FR)
Several bacteria, of which much was used for the fermentation of
milk, are used in humans as probiotics, such as various species of
Lactobacillus, Biﬁdobacterium, or Lactococcus. Some are used as growth
promotor factors in farm animals, such as species of Lactobacillus,
Lactococcus, Enterococcus, and Biﬁdobacterium. Until a recent past, no
comparative study between those which were used in the farm industry
as growth promotors, to obtain weight gain in farm animals (pigs,
calves, chickens) and those used on humans for health beneﬁt, had been
compared. We undertook an exhaustive study, species by species, of
the role of these bacteria, by comparing the work completed in the farm
animals, in the experimental models (mouse and rats) and the preliminary
studies carried out in humans. The probiotics were tested in children, and
the quantiﬁcation of Lactobacillus in obese, compared with lean subjects
were tested. The whole of these studies shows that a certain number of
species seems protective against obesity, and other species marketed for
human consumption seem signiﬁcantly associated to weight gain in all
the studies that were carried out.
Molecular bacteriology: insight in the
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O210 The contribution of bacterial virulence to the clinical course
of Staphylococcus aureus bloodstream infection
S. McNicholas*, A. FeTalento, J. O’Gorman, M. Hannon, M. Lynch,
A. Shore, D. Coleman, H. Humphreys, D. Fitzgerald-Hughes (Dublin, IE)
Objectives: Bloodstream infections (BSI) caused by S. aureus occur
in many different patient groups with a variety of outcomes. The
contributing factors to these outcomes are unclear. We prospectively
determined the genotypes and virulence characteristics of 58 S. aureus
isolates recovered from patients with methicillin-resistant S. aureus
(MRSA) and methicillin-susceptible S. aureus (MSSA) BSI.
Methods: Demographic information and clinical details were recorded.
Isolates were characterised by spa-typing and using a DNA microarray
(Alere Technologies, Germany) which detects 185 S. aureus genes
(and allelic variants) including strain afﬁliation and virulence-associated
genes.
Results: Almost a third (32.8%) of patients were renal and in half of all
the patients an infected intravenous catheter was the source. Over 20% of
patients developed a complicated infection (e.g. infective endocarditis).
Thirty different spa-types were represented among the 58 isolates tested.
All MRSA isolates (n = 13) belonged to accessory gene regulator (agr)
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type I, capsule type 5 and the ST22-MRSA-IV clone. The MSSA isolates
(n = 45) belonged to a variety of agr types, capsule type 5 or 8 and
a number of clonal complexes (12 in total). All isolates were lukPV
negative. The enterotoxin gene cluster (egc) (seg, sei, sem, sen, seo
and seu) and the staphylococcal enterotoxin genes sec, sel, were more
prevalent in MRSA than MSSA (p< 0.05). There was no signiﬁcant
difference in the prevalence of virulence genes, such as toxic shock
syndrome and enterotoxin genes or in clonal complexes between isolates
from complicated (n = 12) and uncomplicated clinical infection (n = 46).
Conclusion: The clinical course of infection appeared independent
of the clonal complex. Carriage of virulence genes, particularly the
pathogenicity islands, appears to be clonal. The virulence potential of
the infecting organism, in terms of carriage of virulence genes, does
not appear to be a signiﬁcant factor in clinical outcome. However, the
increased prevalence of egc and sec/sel among the ST22-MRSA-IV
clone, the predominant clone in Irish hospitals, may be a marker for
increased pathogenic potential compared to MSSA clones.
O211 Correlation between bacterial DNA load and severity of
disease in S. aureus bacteraemia
W. Rozemeijer*, A.E. Nieman, R.P.H. Peters, J. Kluytmans,
P.H. Savelkoul, R.P. Schade (Amsterdam, NL; Tzaneen, ZA)
Objectives: Bloodstream infection with Staphylococcus aureus is a
serious infection that requires rapid and adequate treatment. Little is
known about the bacterial DNA load (BDL) of S. aureus in different
types of infection, ranging from less severe uncomplicated phlebitis to
severe life threatening endocarditis. Previous studies have shown that
level of BDL in infections with other pathogens corresponds to severity
of disease, but this has not yet been shown for S. aureus. We determined
the BDL in blood of patients with S. aureus infection and concurrent
bacteraemia.
Methods: A cohort of 32 consecutive patients with culture proven
S. aureus bacteraemia was categorized into superﬁcial tissue infections
(postoperative wound infections and phlebitis), deep tissue infections
(osteomyelitis and arthritis) or endocarditis. Temporarily stored whole
blood samples, which had been drawn at the time of the blood culture,
were collected. Quantiﬁcation of S. aureus speciﬁc DNA was performed
by real time PCR on DNA extracted from 200ul of blood.
Results: Of 32 patients, 18 patients had a soft tissue infection, 10 a
deep tissue infection and 4 endocarditis. The S. aureus speciﬁc BDL was
above the detection limit in 19 patients (59%). All endocarditis patients
had a positive PCR while there was no signiﬁcant difference between the
percentages of positives in the other 2 groups. The median BDL in the
endocarditis group was 422 cfu/ml (range 92–759), clearly higher than
the median BDL of deep tissue infections and superﬁcial tissue infections
being 12 cfu/ml (range 3−34) and 4 cfu/ml (range 2−74) respectively.
Conclusion: In patients with S. aureus bacteraemia, the BDL is
higher in patients with a severe infection (endocarditis) compared to
patients with other causes of S. aureus bacteraemia. Measurement of
the BDL could potentially help clinicians recognise patients at risk
of having endocarditis. In patients with superﬁcial and deep tissue
infections around 50 percent is detected by our PCR and height of BDL
does not differ between these groups. This suggests these infections
are characterized by lower amount of DNA in the blood stream or
intermittent circulation of bacteria.
O212 The distribution of enterotoxin and immune evasion
cluster genes among Staphylococcus aureus isolates causing
bloodstream infection
S. McNicholas, A. FeTalento, J. O’Gorman, M. Hannon, M. Lynch,
A. Shore, D. Coleman, H. Humphreys, D. Fitzgerald-Hughes* (Dublin,
IE)
Objective: Bloodstream infections (BSI) caused by S. aureus often
have unpredictable outcomes. Enterotoxin genes and the newly identiﬁed
immune evasion cluster genes (IEC) (sea, sak, chp and scn) are thought
to contribute to the severity of S. aureus infection. We determined the
distribution of enterotoxin and IEC genes across 12 clonal complexes
(CC) of both methicillin-resistant S. aureus (MRSA) (n = 13) and
methicillin-susceptible S. aureus (MSSA) (n = 45) isolates recovered
prospectively from patients with BSI.
Methods: S. aureus isolates causing BSI over a two year period, (2008–
2010) were collected. A DNA microarray (Alere Technologies, Germany)
which detects 185 S. aureus genes (and allelic variants) was used for
molecular characterisation and strain afﬁliation of the isolates.
Results: The enterotoxin gene cluster (egc) (seg, sei, sem, sen, seo and
seu) was associated with CC5, CC9, CC22, CC25, CC30, CC45 and
CC121, the staphylococcal enterotoxin genes sec/sel were associated
with CC22 and CC45. Sek/seq was found in CC1 and CC8, while
sed/sej/ser was found in CC8. While sec/sel, sed/sej/ser and sek/seq were
associated with only some isolates within a given clonal complex, egc
was common to all isolates within each CC when it was present. CC15
and CC398 carried no enterotoxin genes. Both egc and sec/sel, were more
prevalent in MRSA than MSSA (p< 0.05) due to the preponderance of
CC22 in MRSA. The IEC genes were found in all CCs examined. The
majority of isolates belonged to IEC type B (35, 60%) with IEC types
A and E also represented in a signiﬁcant number of isolates (11, 18.9%
and 8, 13.7% respectively). Only 3% of isolates (2/58) harboured IEC
types D or E. All isolates within a given CC belonged to the same IEC
type, with the exception of CC30 and CC8 which showed variation in
IEC type. CC30 isolates harboured IEC types A (5/9), B (3/9) and C
(1/9), while CC8 isolates harboured IEC types B (2/3) and E (1/3). All
MRSA isolates belonged to IEC type B, while all IEC types were seen
among the MSSA isolates with type B being the most prevalent.
Conclusion: The presence of egc in seven clonal complexes suggests
that both vertical and horizontal transmission of this genomic island has
occurred. The prevalence of egc and sec/sel among MRSA isolates is
probably due to the prevalence of the ST22-MRSA-IV clone.
O213 Invasive infections caused by a novel species within the
Streptococcus mitis group
A. Zbinden*, N.J. Mu¨ller, P.E. Tarr, P.M. Keller, G.V. Bloemberg
(Zurich, Basel, CH)
Objectives: Twelve clinical cases were observed with infections caused
by a novel streptococcal species within the Streptococcus mitis group.
The corresponding ATCC 15914 strain was previously assigned to
Streptococcus mitis, but molecular and phenotypic analyses showed a
clear distinction from the established species within the S. mitis group.
Methods: Microbiological and clinical data were analysed retrospec-
tively. 16S rRNA gene sequencing and subsequent homology analyses
in the GenBank database was performed for the clinical streptococcal
isolates (n = 16) and the strain ATCC 15914. Additionally, a 313 bp
fragment of the recA gene was ampliﬁed with a speciﬁc set of recA
primers for sequence analysis. Biochemical data of the strain ATCC
15914 were obtained by API Strept 20 (bioMe´rieux, Marcy-l’Etoile,
France). For differentiation within the S. mitis group, type strains
of the most closely related species were analysed, i.e. Streptococcus
infantis, S. mitis, Streptococcus oralis, Streptococcus pneumoniae and
Streptococcus pseudopneumoniae.
Results: The isolates (n = 16) were obtained from different body
sites, e.g. blood, aortic/mitral valve, cerebrospinal ﬂuid, from 12
patients with invasive infections such as sepsis, endocarditis and
meningitis. Partial 16S rRNA gene sequences of the 16 clinical
isolates and the strain ATCC 15914 showed sequence homologies of
>99.5%. Phylogenetic analyses revealed a clear differentiation from
the closest related species within the S. mitis group. 16S rRNA
gene sequence similarities of the ATCC strain 15914 were 98.3%
with S. infantis (AY485603) and S. oralis (AY485602), 98.0% with
S. mitis (AY485601), 97.8% with S. pneumoniae (AY485600) and 97.9%
with S. pseudopneumoniae (AY612844), respectively. recA sequence
similarities of the ATCC strain 15914 were 94.2% (S. oralis), 91.7%
(S. mitis), 91.4% (S. pseudopneumoniae), 90.7% (S. pneumoniae) and
90.1% (S. infantis), respectively.
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Biochemical characteristics conﬁrmed the accurate differentiation of the
strain ATCC 15914 from S. mitis and its closest related species within
the S. mitis group.
Conclusion: We propose an emended description of the ATCC strain
15914, which was formerly assigned as S. mitis. We found a clear
distinction within the S. mitis group based on 16S rRNA gene, recA
and biochemical characteristics. The pathogenic potential of this strain
was demonstrated in 12 clinical cases with severe infectious diseases.
O214 Fitness cost of widely disseminated conjugative plasmids
carrying Tn1546-vanA among Enterococcus faecium and
Enterococcus faecalis
A.P. Tedim*, A.R. Freitas, F. Baquero, T.M. Coque (Madrid, ES;
Oporto, PT)
Objectives: Tn1546-vanA is located in conjugative plasmids containing
replication proteins of RepA_N family in Enterococcus faecium (Efm,
Inc18, pRUM, pLG1) and Enterococcus faecalis (Efc, pheromone
responsive plasmids). Little is known about the ﬁtness cost of either
Tn1546 or Tn1546-plasmids in enterococci. The aim of this study was
to address these issues by analyzing representative plasmids encoding
vancomycin resistance in Efm and Efc.
Methods: We studied Tn1546-plasmids from Efm (n = 6, Inc18, pRUM,
pHTB and pLG1 derivatives) and Efc (n = 2, pAD1-like). They are
mosaic plasmids of Efm (2 megaplasmids of 150 and 240kb, 1 rep-
pRUM/relpEF1 of 90kb; 1 repInc18/reppRE25/reppRUM/relpEF1/w-e-z
of 50kb; 1 repInc18/reppRE25/reppRUM/relpEF1/axe-txe of 40kb and 1
repInc18/reppHTB/relpHTB of 85kb) and Efc (75kb repInc18/relpAD1;
110kb reppRE25/reppAD1/par). Plasmids were introduced in plasmid
free strains of Efm (ST515-GE-1, ST172-BM4105) and Efc (ST8-
JH2−2) by conjugation. Growth curves were performed as described by
Foucault et al. using isogenic plasmid-free strains as controls. Relative
growth rates (RGR) in presence/absence of vancomycin were used to
determine ﬁtness cost.
Results: Efm plasmids did not show signiﬁcant ﬁtness cost in either
Efm bacterial background tested in absence of vancomycin (RGR±1).
However, experiments induced with vancomycin revealed cost for the
expression of Tn1546 on particular plasmids and host backgrounds.
While the carriage of Tn1546 had a relatively low ﬁtness cost for Efm-
BM4105 (ST172) (<6%), this value varied in Efm-GE-1 (ST515) from
14−17% for plasmids carrying modules of pRUM (rep, TA), Inc18 (repI,
repII) and pEF1 (rel) to >57% for plasmids carrying modules of pRUM
(rep), Inc18 (repI, repII, PSK) and pHTB (rep, rel). Efc Tn1546-plasmids
frequently suffered reorganizations during conjugation. They conferred
a relatively high ﬁtness cost for the host in the absence of vancomycin
(13%-22%). However, the expression of Tn1546 had a low cost for the
host (<7%).
Conclusions: The low ﬁtness cost of Tn1546-carrying plasmids in
Efm, in the absence of selective pressure, might determine the wide
dissemination of vancomycin resistance in this species. The instability
of Efc Tn1546-carrying plasmids as well as the relatively high cost of
these plasmids might determine their loss in the absence of selective
pressure and there for, up to some extent, explain the low prevalence of
vancomycin resistance among Efc.
Genetics of NDM-1
O215 Complete DNA sequence of blaNDM-1 gene cassette
integrated into the chromosome of Acinetobacter baumannii
Y. Pfeifer, E. Zander, S. Go¨ttig, K.P. Hunfeld, H. Seifert, P.G. Higgins*
(Wernigerode, Cologne, Frankfurt, DE)
Objectives: New Delhi metallo-b-lactamase 1 (NDM-1), ﬁrst reported
in a Klebsiella pneumoniae isolate in Sweden, has now been detected
in other Enterobacteriaceae species from Europe, Kenya, Australia and
India. More recently it has been detected in Acinetobacter baumannii.
The genetic location of NDM-1 is assumed to be a plasmid but there
are reports of non-transferability which suggests that in some cases it
is chromosomal. In the present study we have investigated the genetic
location of blaNDM-1 detected in A. baumannii isolated from a patient
in Frankfurt in 2007.
Methods: Transfer of blaNDM-1 was tested by conjugation into
Escherichia coli J53 and transformation with plasmid DNA into
A. baumannii. Whole genomic DNA was isolated and shotgun-cloned
into E. coli NEB 5-a and selected with ticarcillin. Plasmid-inserts of
transformants were ampliﬁed by PCR and sequenced by primer walking.
Results: Transformation of A. baumannii with native plasmid, and
conjugation into E. coli failed to transfer blaNDM-1. However, shotgun
cloning of chromosomal DNA transferred blaNDM-1. Sequencing of
the insert conﬁrmed that the NDM-1 gene cassette was chromosomally
located, and was integrated into a gene encoding a putative A. baumannii
major facilitator superfamily (MFS) metabolite/H+ symporter (Figure,
feature A). Adjacent to the MFS gene was a chromosomal homoserine
lactone synthase (cepI). Primer walking from both ends of the MFS
gene revealed that blaNDM-1 was on a 10.5kb gene cassette bracketed
by the insertion sequence ISAba125 (Figure, feature B). BLAST analysis
of ISAba125 revealed that this element appears to be common in
A. baumannii. The IS26 transposase upstream of blaNDM-1 gene that
was described in several reports was missing in the A. baumannii
sequence. The phosphoribosyl anthranilate isomerase gene (trpF) was
truncated (Figure, feature C). In addition, there was a 4kb element
94% similar to that described in E. coli plasmid pEH4H encoding the
chaperonin subunits groS and groL, and the transposase insE (Figure,
feature D). No signiﬁcant DNA homology or open reading frames were
detected between trpF and groS.
Conclusion: These data show that in our isolate the blaNDM-1 gene
was located on the chromosome of A. baumannii. Since it is ﬂanked by
insertion elements, it is likely that blaNDM-1 can be shuttled between
plasmid and genome.
O216 Diversity of genetic structures at the origin of acquisition
and expression of the blaNDM-1 carbapenemase gene
L. Poirel*, R. Bonnin, L. Villa, A. Carattoli, P. Nordmann (Le
Kremlin-Biceˆtre, FR; Rome, IT)
Objectives: NDM-1-mediated resistance to carbapenems is increasingly
reported worldwide. The blaNDM-1 gene is mostly plasmid-located
and mostly from Klebsiella pneumoniae and Escherichia coli. The
blaNDM-1 gene was initially identiﬁed associated to mosaic structures
containing remnants of different genes and insertion sequences. The
aim of our work was to characterize the genetic structures surrounding
the blaNDM-1 gene among our collection of NDM-1-producing isolates
recovered from various countries.
Methods: A series of blaNDM-1-positive isolates were investigated.
Cloning, PCR experiments and whole plasmid sequencing were
performed to identify the upstream- and downstream-located regions
of the blaNDM-1 gene in isolates from different geographical origins
and from different species. Isolates studied included E. coli and
Citrobacter freundii from France, K. pneumoniae from Sultanate of
Oman, K. pneumoniae from Kenya, E. coli from Australia, and
K. pneumoniae from India.
Results: Among the six NDM-1-producing isolates studied, different
genetic structures surrounding the blaNDM-1 gene were detected.
A remnant of insertion sequence ISAba125 (previously identiﬁed in
different Acinetobacter baumannii isolates) was systematically identiﬁed
upstream of blaNDM-1, but different truncations of this IS were
observed. The remaining part of this ISAba125 element contained two
base pairs that were always part of a −35 promoter sequence for
blaNDM-1 expression. Downstream of blaNDM-1, a gene encoding a
putative bleomycin resistance determinant was systematically identiﬁed,
then followed either by genes of unknown functions, insertion sequences,
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or complex sul1-type integrons comprising arrays of resistance genes
and the ISCR1 element. Detailed analysis of the plasmid support of
the blaNDM-1 gene among the different isolates showed a diversity of
plasmid scaffolds, including IncN-type, IncA/C2, and IncL/M features.
Conclusion: This works identiﬁed original structures at the origin of
acquisition of the blaNDM-1 gene identiﬁed in non-clonally-related
enterobacterial isolates. It shows that the current emergence of this
resistance gene is associated with a common ISAba125 sequence which
was truncated at various levels.
O217 Whole genome sequencing of NDM-1-producing Escherichia
coli: focus on antibiotic resistance
L. Poirel*, R. Bonnin, P. Nordmann (Le Kremlin-Biceˆtre, FR)
Objectives: NDM-1-mediated resistance to carbapenems in Enterobac-
teriaceae is increasingly reported worldwide. We recently identiﬁed the
blaNDM-1 gene from an Escherichia coli isolate recovered in Australia
from a patient transferred from Bangladesh. The aim of our work
was to characterize the genomic features of that E. coli strain, with a
special focus on antibiotic rresistance genes and their associated genetic
structures.
Methods: Complete sequencing of the genome of E. coli 271
was performed by the DNA Vision company (Gosselies, Belgium).
Annotations and contig assemblage were performed with softwares
availble over internet.
Results: E. coli 271 was resistant to all b-lactams, including
carbapenems, all aminoglycosides, ﬂuroquinolones, nitrofurantoin, and
sulfamides. It belonged to the ST101 sequence type. It harboured
ﬁve plasmids, on which numerous resistance genes were identiﬁed.
Plasmid p271A carried the blaNDM-1 gene bracketed by two novel
insertion sequences, but no additional resistance genes. Interestingly, that
plasmid possessed the perfect scaffold of an IncN-type plasmid known
to disseminate the carbapenemase gene blaKPC-3, but the replicase
gene was a different and novel one, that makes that plasmid untypeable
by PCR techniques. Plasmid p271B carried the extended-spectrum
b-lactamase blaCTX-M-15 gene that was associated with blaTEM-1.
Plasmid p271C of IncF type carried the rmtB methylase gene together
with blaTEM-1. Plasmid p271D of IncI1 type carried the armA methy-
lase gene together with blaTEM-1. Additional b-lactamases blaOXA-1
blaOXA-9 blaOXA-10 were identiﬁed, together with aminoglycoside
resistance genes aadA6, aphA1, and aac(3′)-II, macrolide resistance
genes ermB, mph2, and mel, trimethoprim resistance genes dfrA1 and
dfr12, rifampin resistance gene arr2, chloramphenicol resistance genes
cmlA5 and catA, sulfonamide resistance gene sul1, and quinolone
efﬂux gene qepA. Resistance to ﬂuoroquinolones was also explained by
substitutions in the chromosmally-located gyrA and parC topoisomerase
genes.
Conclusion: This works identiﬁed an high number of resistance genes
that explained the multidrug resistance pattern. Most of these resistance
genes were plasmid-borne. This suggests successive accumulations of
multiple resistance determinants that might be driven by antibiotic
selective pressure.
O218 Spread of blaNDM-1 gene identiﬁed in enterobacterial
isolates in Switzerland: a molecular analysis
L. Poirel*, J. Schrenzel, A. Cherkaoui, S. Bernabeu, P. Nordmann
(Le Kremlin-Biceˆtre, FR; Geneva, CH)
Objectives: The blaNDM-1 gene that encodes resistance to carbapenems
is increasingly reported worldwide. The aim of our work was to
characterize the genetic structures surrounding the blaNDM-1 gene, to
precise its plasmid support, and identify the genetic background of the
clinical isolates in a series of enterobacterial isolates recovered from
Switzerland from patients originated from the Indian subcontinent and
Serbia.
Methods: Four blaNDM-1-positive isolates recovered from three
patients were investigated, being one Escherichia coli, two Klebsiella
pneumoniae, and one Proteus mirabilis isolates. PCR experiments were
performed to identify the upstream- and downstream-located regions of
the blaNDM-1 gene. Multi Locus Sequence Typing (MLST) was used
to identify the strains at the sequence type level. Mating-out assays
were performed with E. coli J53 as recipient using a selection based on
cefoxitin (10mg/ml) and azide (100mg/ml). PCR based replicon typing
was used to determine the plasmid types.
Results: Among the four NDM-1-positive isolates, different genetic
structures surrounding the blaNDM-1 gene were detected. The insertion
sequence ISAba125 was systematically identiﬁed upstream of the
blaNDM-1 gene. Downstream of the blaNDM-1 gene, a gene encoding
a putative bleomycin resistance determinant was identiﬁed in all but the
E. coli isolates. Transconjugants were obtained with all donor strains,
and analysis of the plasmid support of the blaNDM-1 gene among
the different isolates showed a diversity of the plasmid scaffolds. In
the E. coli isolate, the blaNDM-1 plasmid was 100 kb in size and
belonged to the IncF type. By contrast, the three other blaNDM-1-
plasmids were ca. 160 kb in size and belonged to the IncA/C2 type. Two
of these IncA/C2 plasmids co-harboured the blaCMY-16 gene together
with blaNDM-1.
The E. coli was an ST410 strain, co-producing TEM-1, OXA-1, and
CMY-30. The P. mirabilis co-produced TEM-1, OXA-1, OXA-10, and
CMY-16. The two K. pneumoniae were clonally unrelated, belonging to
ST25 and ST147 types, respectively, and were ESBL positive. The two
K. pneumoniae co-expressed CTX-M-15, SHV-11, TEM-1, OXA-1, and
OXA-10, and one additionally produced OXA-9 and CMY-16.
Conclusion: This works identiﬁed a diversity of genetic structures at
the origin of acquisition of the blaNDM-1 gene among non-clonally-
related enterobacterial isolates. It further underlines the threatening
accumulation of b-lactamase determinants in NDM-1-producers.
O219 A novel ICE mobilising DHA-1 in NDM-1 harbouring
clinical isolates of E. coli and Klebsiella
C. Mata, J. Weeks, T. Walsh, M. Toleman* (Barcelona, ES; Cardiff, UK)
Objectives: NDM-1 producing clinical isolates from India are resistant
to all antibiotics with the exception of tigycycline and colistin. Since
NDM-1 has the ability to give resistance to all b-lactam antibiotics with
the exception of aztreonam, the resistance to aztreonam has to be due
to another resistance mechanism or mechanisms. Plasmid sequencing
strategies indicated that many NDM-1 isolates harboured the class C
b-lactamase DHA-1 and the class D b-lactamase OXA-10 in addition
to NDM-1. Since these enzymes are both able to confer resistance to
aztreonam we sought to understand the mechanism of mobilisation of
these resistance genes.
Methods: NDM-1 and DHA-1 transconjugants were prepared by mating
clinical isolates of E. coli and Klebsiella pneumoniae with azide resistant
J53 overnight without selection followed by growth on meropenem/azide
or ceftazidime/azide selective plates. The genomic location of NDM-1
and DHA-1 in parents and transconjugants was then investigated by S1
digestion of macro DNA followed by Pulsed ﬁeld gel electrophoresis
and probing with 32P labelled NDM-1 and DHA-1 probes. PCR using
primers designed to the phage integrase gene and toxin/anti-toxin genes
of SXT were used to investigate whether the ICE SXT was present in
these isolates.
Results: Selection of transconjugants on merpenem/azide plates
followed by S1 genomic mapping indicated that all parents and
transconjugants harboured NDM-1 on various different sized plasmids.
However, probing of the same parents and transconjugants with DHA-1
indicated that all parents and transconjugants harboured DHA-1 on the
chromosome. Similarly all transconjugants selected on ceftazidime/azide
plates harboured DHA-1 on the chromosome whereas NDM-1 was only
transferred in 20% (2/5) of these transconjugants. All PCR reactions for
SXT genes were negative.
Conclusions: The broad resistance proﬁle of NDM-1 harbouring clinical
isolates is clearly due to many resistance mechanisms in addition to
NDM-1. Here we demonstrate that the class C b-lactamase DHA-1 is
mobilised from chromosome to chromosome from E. coli and Klebsiella
Inﬂuenza H1N1 pandemic and complications S45
clinical isolates to E. coli J53 consistent with that of integrative and
conjugative elements. In addition our initial experiments indicate that
the ICE responcible for the movement of DHA-1 is not SXT and the
mechanism of mobilisation of DHA-1 is more efﬁcient than that of
NDM-1.
The future of hospital antibiotic
stewardship − what should we achieve by
2020?
S233 Interactive E-learning
D. Nathwani* (Dundee, UK)
Education of antimicrobial prescriber’s is one of the key tools that
underpins the implementation of antimicrobial stewardship programmes.
The technical and non-technical competencies that are required to
prescribe appropriately have been described and form a useful basis for
developing teaching. The delivery of this education has primarily been
through traditional models of educational delivery. Examples include:
face to face learning e.g through didactic lectures or workshops with
varying levels of interaction, self directed learning packages, video
or satellite broadcasts to groups, one to one individual training[ less
common as very resource intensive] and others. A more recent method
has been the use of a range of online learning sites or resources
which provide education through the Web. The quality, transparency and
appropriateness of these resources are variable as is their applicability
to many different healthcare settings.
E-learning is the use of various technological tools that are Web
based, Web distributed or Web capable that support the development,
exchange, and application of knowledge, skills, attitudes and aspirations
or behaviours for the purpose of improving teaching and increasing
learner achievement.
For those wishing to undertake the development of e-learning a number
of fundamental principles should be adhered to. For example, it is
important to recognise that e-learning is a means of implementing
education that can be applied within varying education models and
philosophies, it can enable unique form of education that can ﬁt into
existing paradigms, the choice of e-learning tools should reﬂect rather
than determine the pedagogy of a course, can be used for presenting
educational content and or facilitation of educational processes, should
only be use once the beneﬁts and trade-off of online v off line have been
considered, should consider how users will engage with the opportunities
and that the development of material should fall within the context of
the curriculum objectives and not determined by the technology.
This presentation will focus on the application of e-learning methods
to support resources available for antimicrobial stewardship. The
author will illustrate the development, implementation and evaluation
of some resources developed as part of a national stewardship
programme in Scotland [ (http://www.scottishmedicines.org.uk/SAPG/
Scottish_Antimicrobial_Prescribing_Group__SAPG_]
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O236 Aetiology of community-acquired pneumonia in the adult
and the H1N1 inﬂuenza pandemic
A. San Gil*, A. Robles, V. Pascual, E. Calbo, E. Viladot, S. Benet,
B. Barreiro, E. Cuchi, J. Torres, L. Canales, J. De Marcos, J. Perez,
J. Garau (Barcelona, ES)
Background: Viral causes of CAP in the adult are poorly characterized.
Polymerase chain reaction (PCR) based methods have been developed for
many respiratory pathogens. Since the start of the past ﬂu pandemic, we
added PCR tests to standard cultures in all patients with CAP; also, we
compared the clinical and laboratory features of patients with bacterial
(BP) vs. those with viral pneumonia (VP).
Methods: All adults with CAP admitted for at least 24h in a 500-bed
acute care hospital from November 2009 to October 2010 were included.
Demographics, Charlson score, pneumonia severity index (PSI), C
reactive protein (CRP) and procalcitonin (PCT) values, clinical features
and in-hospital mortality were recorded. Microbiological standard
methods included blood and sputum cultures and antigen urinary
detection. New methods included sputum analyzed by Multiplex PCR for
M. pneumoniae, L. pneumophila, C. pneumoniae and B. pertussis and
for 15 respiratory viruses. A speciﬁc PCR for H1N1 in nasopharyngeal
samples was included during the pandemic.
Results: A total of 169 patients were given the diagnosis of CAP. Sputum
was obtained in 131. Using only standard methods we identiﬁed an
etiology in 51.1% (67/131) of cases. In this group, when PCR was
included, a microbiological agent was identiﬁed in 69.4% (91/131) of
cases; 44 had BP (33.5%), 24 had VP (18.3%) and 23 (17.5%) had co
infection (BP and VP). S. pneumoniae [53/91 (58.2%)] was the most
frequent pathogen followed by Rhinovirus 16.5% (15/91, we diagnosed
Inﬂuenza A 8.8% (8/91). No differences were found in terms of age,
gender, Charlson score, PSI, CRP levels, radiological involvement and
mortality between VP and BP patients. PCT median values were 4mg/L
and 0.8mg/L (p = 0.01) in BP and VP, respectively. Curb score [1.4
vs. 0.7 (p = 0.01)], shock [18.2% vs. 0% (p = 0.04)] and shaking chills
[56.3% vs. 6% (p = 0.002)] were signiﬁcantly more frequent in BP as
compared to VP respectively.
Conclusions: S. pneumoniae is still the leading causative agent in CAP,
however more than one third of patients presented a viral infection.
Surprisingly, H1N1 was infrequently identiﬁed as a CAP causative or
co infecting agent. Clinical presentation and PCT values could help to
discriminate between VP and BP.
O237 Vaccination against pandemic inﬂuenza A/H1N1(2009)
among healthcare workers: lessons for the next pandemic
A. Azap*, G. Yilmaz-Bozkurt, M. Bayrak, G. Aksoy, N. Bagid, A. Bayat,
A. Bozkurt, B. C¸akir, F. Temel, S. Tezcan (Ankara, TR)
Objective: To investigate the factors associated with receiving or
refusing pandemic inﬂuenza vaccines among physicians and nurses of a
tertiary care university hospital.
Methods: The study was conducted at a 2000-bed tertiary-care
hospital with a health care worker (HCW) population consisted of
1234 physicians, 1125 nurses, 385 nurse-asistants and 549 medical
technicians. Only physicians and nurses were included in the study.
After the termination of vaccination campaign, a total of 472 HCWs (236
vaccinated, 236 unvaccinated) were randomly selected from the employee
list of human resources and data about demographics, professional
category and work year, history of seasonal inﬂuenza vaccine uptake in
previous year, reasons for accepting or refusing the pandemic inﬂuenza
A/H1N1 vaccine, the source of knowledge on pandemic vaccines of these
HCWs were collected by a structured survey.
Categorical data were analyzed by chi-square test, whereas Student’s
t-test was performed for continuous variables. Bivariate analysis was
done to evaluate the effect of each independent variable on pandemic
inﬂuenza A/H1N1 vaccine uptake. A multivariate logistic regression
analysis was performed to determine independent predictors of refusal
of the pandemic inﬂuenza A/H1N1 vaccine. All statistical analysis was
done by a software (STATA-9.0, Tx, USA) and a P-value of <0.05 was
considered as statistically signiﬁcant.
Results: A total of 472 HCWs (236 vaccinated and 236 unvaccinated)
were included in the study. Of the 472 HCWs, 333 (70.5%) were
female, 253 (53.6%) were physicians and 149 (32.6%) were working in
the surgical wards. Characteristics of surveyed HCWs and vaccination
rates for pandemic inﬂuenza A/H1N1 according to demographics and
professional variables are summarized in Table 1.
By using a multivariate logistic regression modelling; being a nurse
in a surgical department (OR:0.19; 95%CI:0.08–0.45; P< 0.001),
receiving seasonal inﬂuenza vaccine in the previous year (OR:2.59;
95%CI:1.13–5.95; P = 0.024), using internet as the main source of
information (OR:0.31; 95%CI:0.13–0.74; P = 0.009) and being informed
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by attending the meetings held at the hospital (OR:4.54; 95%CI:1.14–
17.9; P< 0.031)were found to be independently associated with
pandemic vaccine uptake.
Conclusion: Interactive informational meetings at institutional level and
high credibility of the policies of national health authorities are essential
factors for promoting vaccination against inﬂuenza.
O238 The impact of European vaccination policies on seasonal
inﬂuenza vaccination coverage rates in the elderly
P.R. Blank*, M. Schwenkglenks, T.D. Szucs (Zurich, Basel, CH)
Background: Despite strong recommendations from the WHO and
the European Union Council, seasonal inﬂuenza vaccination coverage
rates (VCRs) remain insufﬁcient in European countries, even in key
at-risk groups such as the elderly. There is a need for understanding
the impact of vaccination policies and to identify ways of improving
seasonal inﬂuenza VCRs. The main aim of this study was to identify
essential elements of vaccination policies and the inﬂuence of policy-
related driving factors on vaccine uptake rates among the elderly.
Methods: European National Vaccine Industry Groups were included
in a survey (n = 16) to make an inventory of vaccination policies
implemented at a national level. The questionnaire was structured around
four different topics: management of vaccination programmes; inﬂuence
of health care workers (HCWs); role of information and communication
campaigns; and access to vaccine. The information retrieved was put
in relation to current national vaccination rates among the elderly 65
years of age. Correlation coefﬁcients between policy elements and VCRs
were calculated.
Results: The number of implemented policy elements quoted in the
survey varied considerably across countries assessed (Fig 1). Countries
with good monitoring systems regarding VCRs (Spearman’s ø= 0.639,
p = 0.010) or sending personal letters offering free vaccination (ø= 0.728,
p = 0.002) showed on average higher vaccine coverage rates among the
elderly than countries with less developed vaccine management systems.
The association with annual VCRs was stronger in presence of additional
policy items such as deﬁned national VCR objectives, incentives to
HCWs, vaccination reimbursement systems and awareness campaigns
in the mass media. A combination of three elements, namely ﬂyers in
medical waiting rooms, personal invitation letters for free ﬂu vaccine, and
reimbursement of vaccination, showed one of the strongest associations
with VCR among the elderly seen in this study (ø= 0.820, p< 0.05).
Conclusion: There are several ways to increase inﬂuenza vaccination
uptake in elderly, but only few countries take advantage of all
possibilities. This study indicates that key elements of vaccination
policies at national level may include broad information and reminding
systems, strong ofﬁcial recommendations as well as free and easy access
to ﬂu vaccination. The implementation of these policy elements is
expected to help achieving improved inﬂuenza VCRs among the elderly.
O239 Inﬂuenza vaccination of healthcare workers: a case-control
study of its effect on laboratory-conﬁrmed, hospital-acquired
inﬂuenza among patients
T. Be´net*, C. Re´gis, N. Voirin, O. Robert, B. Lina, S. Cronenberger,
P. Vanhems (Lyon, FR)
Objectives: No evidence of a protective effect of healthcare workers
vaccination on proven hospital-acquired inﬂuenza in patients has been
demonstrated. The objective of our investigation was to ascertain the
effectiveness of inﬂuenza vaccination of HCW on laboratory-conﬁrmed,
hospital-acquired inﬂuenza among patients.
Methods: A prospective surveillance study enrolled all ILI patients
hospitalized in 36 units of Edouard Herriot Hospital (Lyon, France),a
tertiary care university hospital, between October 15 and April 15 in
the years 2004−05, 2005−06 and 2006−07. A matched case-control
study based on this surveillance compared 11 patients with laboratory-
conﬁrmed, hospital-acquired inﬂuenza to 44 randomly selected controls
with inﬂuenza-like illness but not related to inﬂuenza, matched per
inﬂuenza season (2004−05, 2005−06 and 2006−07). ILI was deﬁned
as rectal or axillary temperature 37.8ºC, in the absence of antipyretics,
with cough or sore throat. Cases were patients with virologically-
conﬁrmed inﬂuenza occurring 72 hours after admission in the unit,
controls were patients with ILI during hospitalization with negative
results for inﬂuenza after nasal swab testing. All patients underwent nasal
swabbing. A conditionnal regression analysis was done to assess factors
associated with conﬁrmed hospital-acquired inﬂuenza among patients.
Results: Overall, 55 patients were analyzed (Table 1). Median age was
77.3 years, and the male/female gender ratio was 0.34. The median
proportion of vaccinated healthcare workers in the units was 36% (0% to
67%) with a mean of 34%. A proportion of vaccinated healthcare workers
of 35% in the unit protected against hospital-acquired inﬂuenza
among patients (odds ratio=0.046; 95% conﬁdence interval 0.004–
0.58, P = 0.017), independently of patient age and potential patient or
healthcare worker inﬂuenza source in the unit.
Conclusion: Our study indicates a protective effect of a high proportion
of vaccinated HCW on hospital-acquired inﬂuenza in patients. Other
studies based on experimental design are needed to demonstrate the
effectiveness of HCW vaccination in the control of inﬂuenza in
healthcare settings.
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O240 Assessment of the frequency of emergence of oseltamivir
resistance in inﬂuenza A during therapy
T. Barkham*, K.P. Toh, M.L. Goh, W.Y. Tang, Y.S. Leo, M. Inoue
(Singapore, SG)
Objective: The H275Y mutation was reported to have emerged in a
patient infected with pH1N1 within 48 hours of exposure to oseltamivir
(1). As most of the literature on H275Y is from pre-treatment samples,
this work was carried out to assess how frequently resistance, as deﬁned
by the presence of the H275Y mutation, emerges during therapy with
oseltamivir.
Method: Patients found by RT-PCR to be infected with Inﬂuenza A
pH1N1 between May and June 2009 were offered oseltamivir 75mg bd
and isolated until pH1N1 was no longer detectable by RT-PCR. Samples,
comprised of combined nose/throat swabs, were collected daily. RNA
extracted from these samples was stored at −80ºC. With IRB approval we
compiled a list of patients’ samples from the laboratory computer system
and subjected the last available ‘pH1N1 positive’ sample collected
from each subject to pyrosequencing to detect the H275Y mutation as
previously described (1).
Results: Stored RNA was recovered from 93 patients. The number of
subjects tested after variable periods of exposure (days) were 3 subjects,
1 day; 25, 2: 19, 3; 18, 4; 11, 5; 9, 6; 1, 7; 4, 8; 2, 9; 0, 10 and 1,
11. H275Y was not detected in 91 samples. A weak signal, 6%, was
initially detected in two samples but in both cases it became zero on
repeat testing so all 93 were considered ’H275Y not detected’.
Conclusion: The rate of emergence of H275Y was uncommon, about
1% if we include the original case. Minor resistant populations may
have been missed either due to RNA degradation or as Pyrosequencing
cannot reliably detect sequences that comprise <10% of the population.
The exposure to oseltamivir before sample collection appears short, with
50% of samples being collected after fewer than four days of oseltamivir
exposure, but this reﬂects the disappearance of the virus, not a failure
to collect samples. The subsequent sample from each case did not have
any detectable pH1N1 by RT-PCR so further consumption of oseltamivir
in these cases may not equate with further exposure of virus to selective
pressure. Extended treatment of patients with prolonged shedding, such
as in immunocompromised patients, is likely to yield a higher rate of
emergence of H275Y than that reported here.
Reference(s)
[1] Emergence of Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus
within 48 Hours of Treatment. Inoue M, Barkham T, Leo Y-S, Chan
K-P, Chow A, Wong CW, et al. Emerg Infect Dis 2010; Vol. 16, No.
10; 1633–1636 DOI: 10.3201/eid1610.100688
O241 Hospitalised patients with pandemic inﬂuenza A/H1N1 virus
infection had similar outcomes independently of hospital
characteristics
M. Gutierrez-Cuadra, J.L. Gonzalez, P. Rodriguez-Cundin,
C. Farin˜as-Alvarez, J.A. Parra, V. Sanjuan, A. Arnaiz, M. Carrrascosa,
G. Santiago, J.D. Garcı´a-Palomo, M.C. Farin˜as* (Santander,
Torrelavega, Laredo, ES)
Background: The outcome of patients with inﬂuenza A (H1N1) virus
infection taking into account hospital type has not been elucidated.
Objective: To compare risk factors, clinical features, and outcome of
patients admitted to 3 public hospitals with different levels of health
care in Cantabria (Spain).
Methods: Prospective cohort study of all non-pregnant adult patients
admitted to 3 public hospitals in Cantabria (Spain), with conﬁrmed
inﬂuenza A (H1N1) virus infection, from June 1 to December 30, 2009.
Results: 111 patients with a mean age of 49 years (15−89) were
recruited: 52 in hospital 1 (900-beds tertiary teaching hospital), 33 in
hospital 2 (315-beds secondary hospital) and 26 in hospital 3 (150-beds
primary care hospital). Patients in hospital 1 and 2 were younger than
in hospital 3 (P = 0.02). Overall 80% of patients had at least 1 comorbid
condition with no main differences between hospitals. Symptoms or signs
on admission were similar except for cough (P = 0.01) present more
frequently in patients in hospital 1; and dyspnea (P = 0.05), myalgia,
arthralgia (P = 0.04) and hypoxemia (P = 0.009) in patients in hospital 2.
More than half of patients in hospital 2 had pneumonia (P = 0.04). In-
hospital mortality rates were lower in hospital 2 (6.1%) and 3 (3.8%) than
in hospital 1 (11.5%). Level of hospital was not a risk factor for mortality
nor to a crude level (hospital 2 vs. hospital 1: RR 0.52, 95%CI 0.11–
2.44; P = 0.40); (hospital 3 vs hospital 1: RR 0.33, 95%CI 0.04–2.62;
P = 0.26), or in the adjusted analysis for comorbidities. Moreover, in the
stepwise analysis, independent predictors of mortality were pneumonia
on admission and cardiac complications during hospitalization.
Conclusions: The outcome of patients with Pandemic Inﬂuenza
A(H1N1) virus infection was independent of hospital-level character-
istics. Mortality was inﬂuenced for clinical conditions on admission and
complications during hospitalization.
O242 How many lives were saved during the A/H1N1 pandemic
in 2010 in Europe?
R.N. Charrel*, H. Richet, D. Raoult (Marseille, FR)
In countries with temperate climate, mortality increases during the
cold season, part of which is attributed to contagious respiratory
infections, including inﬂuenza. Elderly are the most affected by seasonal
over-mortality. In the UK and in France, and more widely in the
northern hemisphere, the A/H1N1 pandemic stopped at the end of
the year 2009. Interestingly it was not accompanied or followed
by the common seasonal ﬂy peak. This may be related to high
prevalence of asymptomatic infections and/or to a signiﬁcant proportion
of elderly possessing protective antibodies due to ancient contact with
an antigenically-related viral strain. We have examined 2 databases on
global mortality in the UK (number of deaths per 1,000 population) and
in France (number of deaths) to evaluate whether the absence of seasonal
inﬂuenza epidemic had consequences on mortality. We compared the
cold season over-mortality in the whole population and in people aged
75−84 in England and Wales during the ﬁrst quarter of 2010 with the
death rate observed during the preceding years. In the UK, in the whole
population during the cold months (January to march), a reduction of
3% in the death rate was observed in males and 1.9% in females when
the death rate of 2010 was compared to the mean rate of 2007, 2008,
and 2009. the reduction in the death rate was much higher when the
analysis was restricted to the 75−84 age group with a reduction of 8%
in males and 7.7% in females of cold-seasons over-mortality.
France, we compared the mean number of deaths for the month of
January for the years 2007 to 2009 to the number of deaths in January
2010. A mean number of 53,342 deaths were observed for the year
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2007 to 2009 whereas 51,300 deaths were recorded in January 2010,
representing a 3.8% decrease in mortality. The overall mortality rate
decreased from 0.83 per 1000 population for the 2007–2009 period
to 0.80 per 1000 population for January 2010 (p = 0.002). Therefore
we suspect that there is a relation of cause and effect between A/HN
pandemic, the lack of seasonal epidemic, and a reduction of fatality rate
in 75−84 year-old people in 2010 in the UK and in the overall population
in France. Our conclusion is that A/H1N1 pandemic paradoxically and
unexpectedly resulted in a reduction of mortality in elderly, usually the
most affected group of people. This underlines our inability to predict
the consequences of epidemic phenomenon in one direction or the other.
O243 Pandemic inﬂuenza A/H1N1 vaccine in solid organ
transplant recipients: immunogenicity outcomes after whole
virus vaccination
H. Lagler*, J. Leitner, S. Tobudic, G. Andre´s Gualdoni, S. Ro¨dler,
S. Rockenschaub, P. Jaksch, M. Redelberger-Fritz, T. Popow-Kraupp,
H. Burgmann (Vienna, AT)
Objective: During the 2009−10 pandemic the vaccination against H1N1
inﬂuenza was recommended to immunocompromised patients as the key
preventive measure by The American Society of Transplantation and
other health organisations. However, no data regarding the efﬁcacy of any
of the recommended vaccinations were available at that time, neither in
healthy, nor in immunocompromised subjects. The objective of this study
was to evaluate the immunogenicity of the pandemic inﬂuenza vaccine
A/California/07/2009 (H1N1)v in solid organ transplant recipients.
Methods: Patients were recruited from the Medical University Hospital
of Vienna, Austria. The vaccination schedule consisted of 2 doses
of the vaccine Celvapan (whole virion, Vero cell derived, inacti-
vated, A/California/07/2009 (H1N1)v) given with a 3 weeks interval.
Serological analysis was performed by hemagglutination inhibition
assay (HAI) on blood samples obtained before the inclusion and
after each vaccination (bonostix GmbH & Co. KG, Kornwestheim,
Germany). The primary immunological end point was the seroconversion
rate, which was deﬁned as the proportion of subjects with an
individual 4-fold increase in hemagglutination inhibition titer and a
postvaccination hemagglutination inhibition titer of more than 1: 40.
H1N1-Inﬂuenza speciﬁc immunoglobulin was determined by ELISA
(Pandemic New Inﬂuenza A ELISA IgG/IgA Testkit, Genzyme Virotech
GmbH, Ru¨sselsheim, Germany). Seropositivity was postulated when the
measured immunoglobulin levels were above 11 Virotech Units (VE).
Results: Twenty-ﬁve organ transplant patients (16 males, 9 females),
aged 25 to 79 years were vaccinated and had samples taken for
serological analysis. Time since tranplantation was 10 months to 25
years (mean: 9 years; 95%CI: 6−13 years). After two vaccinations 37%
demonstrated seroconversion in the HAI as deﬁned above and 70% of
the patients had an IgG titer above 11 VE. Among the HAI vaccine
responders were 6 of 14 heart transplant recipients and 1 of 4 liver
transplant recipients. Number or kind of immunsuppressive agents did
not signiﬁcantly differ in their effect on immune response.
Conclusion: Our results show that the pandemic A/California/07/2009
(H1N1)v vaccine induced limited but useful protective immune
responses in adult organ transplantat recipients.
O244 Immunogenicity, efﬁcacy, and safety of the pandemic
inﬂuenza A/H1N1 vaccine in solid organ transplant recipients
E. Cordero, A. Perez-Ordon˜ez*, T. Aydillo, J. Pacho´n, J. Torre-Cisneros,
J. Gavalda´, A. Gasch, R. Lara, C. Segura, E. Cabral, O. Len,
P. Perez-Romero the Novel Inﬂuenza A(H1N1) Study Group of the
Spanish Network for Research in Infectious Diseases (REIPI)
Objectives: To asses the immunogenecity, efﬁcacy, and safety of the
pandemic H1N1–2009 vaccine in solid organ transplant recipients
(SOTR).
Methods: We performed a multicenter prospective study in SOTR
receiving one-dose of the pandemic vaccine. Immunological response
was determined in serum samples by microneutralization assays, and
immunoglobulin levels by ELISA. All patients were followed up 90
days after vaccination, or ten months if adverse effects were detected.
Results: Three-hundred and forty-six SOTR (29.2% kidney, 28.9%
liver, 24% heart, 16.5% lung, and 1.4% combined transplantation)
were included. Median time after transplantation in patients receiving
the pandemic vaccine was 4.7 years (IQR: 1.7−8.9) and 24 patients
(6.9%) received the pandemic vaccine between two, and six months
after transplantation. Pre-existing seroprotection was detected in 13.6%
of cases. Overall rates of seroconversion, and seroprotecion after
vaccination were 73.1%, and 82.9%, respectively. Multivariate analysis
demonstrated that age (OR 1.03, 1.00–1.05, P = 0.01), liver disease
(OR 0.27, 0.10–0.70, P = 0.007) and m-TOR inhibitor therapy (OR
0.42, 0.18–1.00, P = 0.048) were independent factors associated with
seroprotection. Patients with chronic liver disease seroconverted less
frequently (P = 0.02). Factors associated with GMT-postvaccination
correlated with factors related to seroconversion and seroprotection.
Lower antibody titers were found in younger patients, and in those with
liver disease or receiving m-TOR inhibitors. Patients with antibody titers
at baseline (GMT 8.1) reached higher antibody levels (GMT 339.4 vs.
121.4, P< 0.001) and a higher rate of seroprotection after vaccination
than those without previous antibody titers (80.3% vs. 100%, RR1.3
CI95% 1.2−1.3, P< 0.001). Four of the patients vaccinated (1.1%)
were diagnosed with pandemic inﬂuenza A(H1N1)-2009 infection in
the follow up period. There were no vaccination major adverse effects,
or rejection episodes.
Conclusions: Pandemic vaccine is safe in SOTR, and elicits an adequate
response although lower than in healthy individuals, especially in young
patients, with liver disease, and m-TOR inhibitor therapy.
O245 Immunogenicity and evaluation of antibodies persistence
of a single-shot of 2009 pandemic inﬂuenza vaccine in
HIV-infected and HIV-uninfected subjects living in a
residential drug-rehabilitation community
E. Pariani*, A. Boschini, A. Amendola, R. Poletti, M. Begnini,
G. Cecconi, A. Zanetti (Milan, Rimini, IT)
Objective: To evaluate the immunogenicity and the antibodies persis-
tence of a single-shot of 2009 pandemic inﬂuenza vaccine in HIV-
infected and HIV-uninfected subjects living in a residential drug-
rehabilitation community.
Methods: 109 (49 HIV-infected and 60 HIV-uninfected) subjects living
in a residential drug-rehabilitation community (San Patrignano, Rimini,
Italy) received intramuscularly a single-shot of a MF59-adjuvanted
2009 pandemic inﬂuenza vaccine, containing 7.5ug hemagglutinin of
A/California/7/2009(H1N1v).
Subjects (26 women and 83 men) had a mean age of 39.2±11.5 years.
HIV-infected patients were mainly (98%) on highly active antiretroviral
therapy (HAART) regimens. They had a mean CD4+ cell count of
386.9±225.6 cells/ul and a suppressed viremia in 91.8% of the cases.
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Blood samples were taken at the time of vaccination, and 1 month and 6
months post-vaccination and were evaluated for anti-A/H1N1v antibody
titers by hemagglutination-inhibition (HI) test.
Results: On baseline evaluation, 4.1−5% had HI-titers to A/H1N1v of
at least 1:40 in both groups. Seroconversion, deﬁned as at least a 4-fold
increase in antibody titers from baseline, was achieved in 49/49 (100%)
HIV-infected subjects and in 59/60 (98.3%) HIV-uninfected ones, with
the overall proportion of patients with protective titers (1:40) being
93.9% (46/49) and 100% (60/60), respectively. The geometric mean
titers (GMTs) signiﬁcantly (p< 0.001) increased in both HIV-infected
and HIV-uninfected subjects.
Six months after vaccination the percentage of HIV-infected subjects
with protective titers was lower (p< 0.05) than that found in
HIV-uninfected subjects. Similarly, 6 months post-vaccination GMTs
signiﬁcantly (p< 0.01) decreased in both groups, but were signiﬁcantly
(p< 0.05) lower in HIV-infected subjects than in HIV-uninfected ones
(Table).
For HIV-1-infected individuals, no signiﬁcant changes either in the CD4+
cell count or in viremia were observed at any time point.
Conclusions: A single-shot of inﬂuenza A/H1N1v 2009 MF59-
adjuvanted vaccine generated antibody responses possibly associated
with protection one month after immunization in successfully HAART-
treated HIV-infected adults, with responses comparable to those achieved
in healthy adults. This 6-month follow-up suggests that protective
antibody titers can be detected after a single vaccine injection in both
HIV-infected and HIV-uninfected patients but with a more appreciable
decrease of antibodies titers in HIV-infected ones.
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O246 Extensively drug-resistant tuberculosis at a tuberculosis
specialised hospital in Shanghai, China: clinical
characteristics and treatment outcomes
S. Tang*, Q. Zhang, J. Yu, Y. Liu, W. Sha, H. Sun, L. Fan, J. Gu,
X. Hao, L. Yao, H. Xiao (Shanghai, CN)
Objectives: Extensively drug-resistant tuberculosis (XDR-TB) has
recently emerged as a global public health problem. To investigate
the clinical characteristics, management, and outcomes of patients with
XDR-TB and HIV-negative at a Tuberculosis Specialized Hospital in
Shanghai, China.
Methods: XDR-TB was deﬁned as TB with resistance to at least
isoniazid, rifampin, a ﬂuoroquinolone, and 1 of 3 injectable second-line
drugs (amikacin, kanamycin, or capreomycin). We analyzed TB Patients
with culture-proven MDR-TB from January 2007 to June 2009 at a
Tuberculosis Specialized Hospital in Shanghai.
Results: Among 1156 TB cases with culture-positive for M. tuberculosis
complex, 785 cases (67.9%) were drug resistant (DR), 494 cases (42.7%)
were classiﬁed as having MDR-TB, accounting for 62.9% of DR-TB.
126 cases (10.9%) were XDR-TB, accounting for 16.1% of DR-TB,
25.5% of MDR-TB. The percentage of female from XDR group was
42.1%, signiﬁcantly higher in comparison with that from other MDR
group (c2 = 7.560, P = 0.006). Median ages in XDR and other MDR
groups were 46 (33.8, 58.0) and 41 (31.3, 51.0) years, respectively.
Signiﬁcant difference in the age could be found between the two groups
(Z = 3.184, P = 0.001). 22.2% of drug resistance belonged to newly
diagnosed patients. At least three lung ﬁelds were involved in 90.5% of
XDR patients and in 80.7% of other MDR patients (P = 0.008). 40.5% of
XDR patients were complicated by diabetes, lung disease, liver disease,
which was signiﬁcantly higher as compared with that of other MDR
patients (c2 = 9.298, P = 0.002). The resistance rates of all drugs except
isoniazid and rifampicin were signiﬁcantly higher in patients with XDR-
TB than in other MDR patients (P< 0.001). Treatment failure was more
common in patients with XDR-TB than in those with other MDR-TB
(72.3% vs. 36.0%, p< 0.001). Cure or treatment completion was more
common in other patients with MDR-TB than in patients with XDR-TB
(53.1% vs. 14.9%; p< 0.001), whereas the mortality and default rates
did not differ signiﬁcantly.
Conclusion: The prevalence of XDR-TB is serious in some areas in
China. Because of its seriousness and shortage of our options, patients
with XDR-TB are more likely to show no response to therapy and their
clinical treatment outcome is usually very poor.
O247 Pulmonary and extrapulmonary infections caused by
non-tuberculous mycobacteria: report of 31 years in a
tertiary hospital, Madrid, Spain
G. Gabilondo*, M.A. Meseguer, R. del Campo, P. Martin-Davila,
J. Fortun, E. Navas, L. Ros, R. Canton, E. Gomez-Mampaso (Madrid, ES)
Objective: To describe the epidemiology of non-tuberculous-
mycobacteria (NTM) causing active infection in our Hospital during
the last 31 years.
Patients and Methods: All patients attended in our Hospital between
1978 and 2009 with disease caused by NTM were included. For
pulmonary disease, only those patients with ATS criteria were included.
Only the ﬁrst episode of disease was considered in each patient (ﬁrst
isolate). Samples were processed and seeded on appropriate media
[Lo¨wenstein-Jensen, Coletsos, ESP II system (BIOMEDICS, Francisco
Soria-Melguizo, Madrid Spain), and Myco F-Lytic medium (BD, Madrid,
Spain). Cultures were maintained at 37ºC for at least eight weeks, except
skin samples (30ºC) and those samples suspecting of Mycobacterium
xenopi (42−45ºC). Identiﬁcation was performed by classical phenotypic
methods and also with a speciﬁc gene probe for Mycobacterium avium
complex (MAC) (Accuprobe, GenProbe Inc., San Diego, USA), and in
the last 6 years PCR ampliﬁcation followed of nucleotidic sequentiation
was also applied.
Results: In the last 31 years we diagnosed 3,623 patients, 3,372 of
them with Mycobacterium tuberculosis and 251 with a NMT (7%)
with a decrease during the last years. From this 251 patients, 146
(58%) were HIV+ and 167 (66.5%) had an extrapulmonary infection.
Considering only those from pulmonary origin (33.5%), 55% of
them positive for MAC followed by Mycobacterium kansasii (32%).
Extrapulmonary patients were two thirds of the total, corresponding
more than 62% to HIV+ patients. A high proportion were associated
with a disseminated disease (n = 97, 58%) and in 14.3%. were
recovered from lymphoadenopathy (n = 24). MAC was isolated in 70% of
extrapulmonary patients, followed by Mycobacterium chelonae (11.3%)
and Mycobacterium scrofulaceum (4.9%). From 105 HIV− patients, 103
were positive for MAC, whereas in the HIV− group, the most prevalent
specie was Mycobacterium chelonae (31%) followed by Mycobacterium
fortuitum (22.6%) and in third place MAC (21%).
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Conclusion: NMT prevalence decreased in the last decade, especially
among the HIV patients. In the respiratory infection, MAC was the
most prevalent specie followed by Mycobacterium kansasii. In the
extrapulmonary infections, prevalence of Mycobacterium fortuitum/
chelonae group increased in the last years, whereas MAC decline, mostly
due to better management of HIV patients.
O248 Novel small RNAs in Mycobacterium tuberculosis:
experimental genome-wide discovery and computational
target prediction
P. Miotto*, A. Ambrosi, D. Pellin, D. Veiga, F. Forti, G. Balazsi,
M.L. Gennaro, C. Di Serio, D. Cirillo (Milan, IT; Houston, Newark, US)
Objectives: This study aims to identify novel smallRNAs (sRNAs) in
Mycobacterium tuberculosis (MTB) and to computationally predict their
targets in post-transcriptional regulatory networks.
Methods: Genome-wide identiﬁcation of sRNAs was performed by
Illumina sequencing on sRNA-enriched fraction (RNAs up to 300 nt
in length) from MTB H37Rv. A custom bioinformatic analysis pipeline
of reads was developed to extract putative sRNAs considering expression
levels, sequence conservation, length, and secondary structure stability.
Candidates were then validated using CombiMatrix microarray tech-
nology. A p-value based on a t-type statistic and computed by mean
of permutations was calculated for each candidate using microarray
results. Candidates with a p-value 0.05 were further analyzed for target
prediction.
Target prediction of candidates was carried out in three main steps:
i. locating sRNA binding sites in the transcriptome using hybridiza-
tion tools that can predict accessible sites in interacting RNA
molecules based on their secondary structures;
ii. ranking sRNA:mRNA interactions using a “binding score” that
considers both an energy term and a location term;
iii. selecting the most promising interactions using p-values and
corresponding false discovery rates (FDR) for each sRNA:mRNA
hybridization.
Results: A total of 9′711′909 reads were obtained by Illumina
sequencing. For the selection of sRNA candidates ﬁltering parameters
and FDRs were applied to intergenic regions that uniquely matched
reads, resulting in 1925 candidates.
We conﬁrmed 331 candidates by microarray analysis. Among these,
122 candidates with a p-value 0.05 were selected for further
characterization by in silico target prediction.
sRNA:mRNA interactions showing a FDR< 0.1 were used to construct
a post-transcriptional regulatory network. Computational results showed
that sRNAs may target from 1 gene up to 99 genes. The putative function
of the genes included in the network was evaluated for functional
enrichment based on the Database for Annotation, Visualization and
Integrated Discovery (DAVID).
Conclusions: We identiﬁed novel sRNA candidates in MTB using
two independent approaches. Moreover, computational sRNA target
prediction and post-transcriptional regulatory network assembly allowed
us to identify functional pathways regulated by 19 sRNAs in MTB.
O249 Clinical characteristics and treatment outcomes of
tuberculosis in hospitals of two large cities in Thailand
W. Manosuthi*, K. Kawkitinarong, G. Suwanpimolkul,
C. Chokbumrungsuk, T. Jirawattanapisal, K. Ruxrungtham, S. Akksilp
(Nonthaburi, Bangkok, TH)
Background: Tuberculosis (TB) is a major public health threat of large
cities in many countries. The current clinical situation of TB in large
cities of Thailand has not been well established.
Methods: A retrospective cohort study was conducted among patients
diagnosed active TB in 6 hospitals in Bangkok and Nonthaburi between
January 2008 and December 2008. Patients were classiﬁed into HIV
sero-positive, sero-negative, and undetermined sero-status; and were
followed until December 2009.
Results: A total of 813 patients were identiﬁed. Mean±SD age was
41±14 years, 62% were male, and mean±SD body weight was 53±11
kilograms. The ﬁrst three co-morbidities included 38% HIV infection,
6% diabetes, and 2% chronic liver disease. Of all, 66% were diagnosed
isolated pulmonary TB. Median (IQR) duration from ﬁrst presentation
to TB diagnosis was 3 (0−10) days. Of all, 43% of patients performed
TB culture and 16% did anti-TB drug susceptibility test. Isoniazid,
rifampicin, and multi-drug resistance were found in 11%, 6% and
5%, respectively. For 1-year TB treatment outcomes, 52.1%, 19.4%,
11.9%, 8.7%, 6.8%, 1.0% were cured/completed treated, transferred out,
defaulted, on-going treated, dead and failed, respectively. Survival rates
at 2, 6, 12 and 24 months were 93%, 85%, 81%, and 81% in HIV
sero-positve group; 96%, 94%, 92%, and 92% in HIV sero-negative
group; 98%, 97%, 97%, and 97% in undetermined sero-status (log rank
test, P< 0.001). Cox’s proportional hazard model showed that death was
associated with TB/HIV co-infection (P 0.001, HR= 2.801), low body
weight (P = 0.005, HR= 1.637), old age (P = 0.005, HR= 1.439), and
extrapulmonary/disseminated TB (P = 0.021, HR= 2.184).
Conclusions: HIV infection and diabetes are the common co-morbidities
in TB patients. Unfavorable outcome of TB treatment is relatively high,
particularly in patients with HIV. Thus, further strategic management
and collaborative treatment is needed to improve TB services.
O250 Optimisation of follow-up samples for patients with
pulmonary tuberculosis
M. Alfa*, K. Manickam, J. Karlowsky, H. Adam, C. Harrop, A. Rendina
(Winnipeg, CA)
Objectives: Patients with AFB smear positive respiratory samples
who are diagnosed with Mycobacterium tuberculosis require three
consecutive AFB smear negative follow-up samples before they can be
removed from airborne precautions. This study was to review the current
follow-up respiratory samples to assess compliance with the protocol
and to determine if a more streamlined algorithm could be developed
as currently AFB microscopy and culture are performed on all samples
submitted.
Methods: The initial diagnostic and follow-up cultures from all patients
in the province of Manitoba, Canada who were diagnosed with
pulmonary tuberculosis in 2010 were reviewed. The AFB smear and
culture results were assessed to determine how long it took for patients
to become AFB smear and culture negative.
Results: There were 53 patients diagnosed with pulmonary TB in 2010.
There were 27/53 (51%) who were AFB smear positive on at least one
of their original three diagnostic respiratory specimens. Of these 22/27
had follow-up samples submitted. Of the 22 there were 17 who did
become AFB smear negative, 3 with no follow-up and 2 whose follow-
up is ongoing. The median time to smear negativity for the 17 who
become smear negative was 22 days (range 6 to 78 days). An algorithm
was developed that provides expedited detection of rapid converters by
initiating the follow-up specimens on day 12 of therapy. Only 2/17
(11.8%) patients who were originally AFB smear positive were AFB
smear negative (3 samples) by day 12. Even by day 21 of therapy only
41.2% were AFB smear negative. Despite the follow-up specimens being
AFB smear negative, 100% of the samples (17/17) were still culture
positive. Our data indicate that although AFB microscopy is needed that
culture is not needed on all three follow-up specimens.
Conclusions: The continued culture positivity of 17/17 patients despite
being AFB smear negative on three consecutive follow-up samples raises
questions regarding potential infectivity of these patients. We recommend
a follow-up algorithm where AFB smear is prepared on all specimens
submitted but culture is only performed on the last of the three samples
submitted.
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O251 Population differences in immune responses following BCG
vaccination in different African settings
J.R. Fitchett*, M.K. Lalor, A. Ben-Smith, A. Crampin, P. Fine,
M.O. Ota, S. Burl, K.L. Flanagan, H.M. Dockrell (London, UK;
Karonga District, MW; Fajara, GM)
Background: Live-attenuated Mycobacterium bovis Bacille Calmette-
Gue´rin (BCG) is currently the only vaccine available to protect against
tuberculosis (TB). Administration of the vaccine in early life induces a
TH1-type immune response and secretion of the cytokine IFN-g. BCG
protects against severe childhood cases of tuberculous meningitis and
miliary TB but confers variable protection against pulmonary TB later in
life, particularly in TB endemic areas. Earlier studies attempting to study
mechanisms behind this discrepancy have shown that Mycobacterium
tuberculosis (M.tb) PPD-stimulated IFN-g concentrations in 6 day
diluted whole blood cultures were much higher in UK BCG vaccinated
infants compared to age-matched Malawian infants given the BCG
vaccine. We have now tested another group of infants and their mothers
using identical laboratory protocols in another TB endemic country, The
Gambia.
Methods: Three-month-old infants vaccinated with BCG in the ﬁrst
week of life and their mothers were recruited into the study. Venous blood
samples were taken from infant-mother pairs for the detection of IFN-g
production by enzyme-linked immunosorbent assay (ELISA) following
diluted whole blood assay stimulation with an array of tuberculous
antigens over 6 days.
Results: 93% of Gambian infants (28 of 30) made a positive IFN-g
response (>62pg/ml) to M.tb PPD stimulation, comparable to previously
studied UK infants (93% vs. 100%), and higher than the proportion of
responders previously detected in Malawi (93% vs. 53%; Lalor MK
et al. JID 2009; 199:795–800). However, the median IFN-g response
from Gambian infants was lower than median IFN-g responses from
UK infants (310pg/ml vs. 1,779pg/ml; p 0.0001). The median IFN-g
responses in Gambian and Malawian infants were comparable (310pg/ml
vs. 289pg/ml; p = 0.7036). The response measured in the Gambian
infants was not associated with the response measured in their mothers.
Conclusions: The study ﬁndings indicate quantitative differences in
cytokine secretion in different African settings in response to M.tb PPD
antigen stimulation. The data are consistent with published evidence
demonstrating lower infant immune responses post-BCG vaccination by
latitude, and the underlying mechanisms inﬂuencing cytokine secretion
post-vaccination warrant further investigation.
O252 Paradoxical worsening in the treatment of tuberculosis after
discontinuation of anti-TNF in patients with inﬂammatory
diseases
C. Rivoisy*, A. Bourgarit, O. Fain, X. Mariette, N. De Castro,
F. Tubach, D. Salmon Ceron (Paris, Bondy, Le Kremlin-Biceˆtre, FR)
Introduction: Paradoxical response in the treatment of tuberculosis is
well-known since the use of active antituberculous antibiotics. This
phenomena is now well described under highly active antiretroviral
therapy in HIV-patients and known as the Immune Reconstitution
Syndrome (IRS). Since the use of anti-TNFa, some cases of paradoxical
worsening of tuberculosis have been reported in these patients.
Methods: We retrospectively report cases of paradoxical aggravation of
tuberculosis in patients treated with anti TNFa from 2 different sources:
a French registry called RATIO collecting all cases of tuberculosis in
France from 2004 to 2006, and a call for cases on internet.
Results: Six cases have been collected: ﬁve women and one man. The
median age at diagnosis of tuberculosis was 64 years old (47−87). They
suffer from various inﬂammatory diseases: rheumatoid arthritis for 2,
psoriasis for 2, ankylosing spondylarthritis for 1 and horton’s disease for
1, and they received different anti-TNFa: adalimumab (3), inﬂiximab
(2) and certolizumab (1). Mean duration of anti-TNF treatment was 5
months (7 weeks-36 months). Three patients receive also steroids and
three receive me´thotrexate.
At diagnosis, there were 4 disseminated, one extrapulmonary and one
pulmonary tuberculosis. Five diagnosis were proven on bacteriological
exams, one on histology. All patients discontinued anti TNF treatment.
They all experienced improvement of their tuberculosis under antibiotics.
But in a mean delay of 17 weeks (6 weeks-39 weeks), they presented
fever, asthenia and inﬂammatory syndrome. For 3 of them, lymph nodes
increased and ﬁstulas appeared. We noticed also two cavitations in
lungs, one cold abscess, and one pleurisy. Four of them suffered from
reactivation of their inﬂammatory diseases.
Treatments were: steroids for three, and surgery for three: bone resection,
lymph node ﬁstulas excision. The mean duration of antibiotics has been
17 months (8−23). All patients have been cured.
Conclusion: Paradoxical response in patients treated with anti TNF who
develop a tuberculosis is a new and real phenomena (11 published cases).
This is a complication in the course of the disease causing morbidities.
Diagnosis is difﬁcult without any criteria or speciﬁc sign. Incidence, risk
factor, treatments of such complications needed to be studied.
O253 IGRAs on paper − speciﬁc diagnosis of latent TB sent via mail
M. Ruhwald*, I. Latorre, J. Diez, J. Maldonado, I. Mialdea, P. Ravn,
J. Dominguez, M.G. Aabye (Copenhagen, DK; Barcelona, Badalona,
Valencia, ES)
Objectives: IFN-g release assays (IGRAs) such as the Quantiferon
test (QFT) are currently the most accurate diagnostic tests for latent
tuberculosis (LTBI). The analysis of IFN-g depends on a very sensitive
ELISA and a laboratory close to the patient, or cooling/freezing capacity
during transportation of the samples. Means to simplify these assays and
moving the diagnosis of tuberculosis closer to the patient is one of the
main targets of the WHO.
IP-10 is a chemokine expressed in concert with IFN-g and we have
demonstrated that the diagnostic accuracy of IP-10 is at par with IFN-g.
IP-10 is released in >100 fold higher levels compared to IFN-g, which
may allow us to use alternative methods of storing and transport of
samples.
The aim of this study was to investigate if ﬁlter paper could be used as
an alternative means of storing stimulated whole blood samples and if
IP-10 in plasma from M. tuberculosis (MTB) antigen stimulated whole
blood could be used to diagnose infection with MTB.
Methods: Whole blood from 67 patients with conﬁrmed TB and 36
healthy unexposed controls was stimulated in the QFT in tube test.
Following incubation the plasma was dried on Whatman903 ﬁlter paper
and stored in sealed gas-impermeable bags with desiccant for at 6 weeks
at room temperature. 2 discs were cut from the ﬁlter paper using a normal
stationary 5.5mm hole punch. IP-10 was measured using an in-house
ELISA by direct elution of the plasma from the discs in the ELISA
plate. Stability of the method was tested on mitogen-stimulated whole
blood from healthy donors.
Results: Median IP-10 responses in TB patients and controls
were 474pg/ml (IQR 176–1022pg/ml) and 5pg/ml (IQR 0−18pg/ml)
respectively, (p< 0.0001) (ﬁgure 1). The Area Under the ROC curve
was 0.96 The IP-10 ﬁlter paper results were relative to IP-10 and IFN-g
measured in plasma (r2> 0.75). Stability testing showed that the recovery
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of IP-10 dried on ﬁlter paper was >90% for >9 weeks storage at room
temperature, and up to 4 weeks at >37ºC.
Conclusion: Plasma from in vitro stimulated whole blood can be dried
on ﬁlter paper, stored at room temperature for a prolonged period of
time and analyzed directly using ELISA.
These results move us closer towards a more simpliﬁed test for the
diagnosis of MTB infection.
*for the conference we will present data from a cohort of 100 TB patients
and 100 controls and data on IFN-g dried on ﬁlter paper (in preparation).
O254 Rapid detection and susceptibility testing of Mycobacterium
abscessus by microcalorimetry
N. Boillat Blanco*, U. Furustrand, K. Jaton, A. Trampuz (Lausanne, CH)
Objectives: Susceptibility testing of mycobacteria is time-consuming
and not well standardized. We evaluated a new method for rapid detection
and susceptibility testing of mycobacteria by real-time measurement of
their growth-related heat production in comparison with the standard
microbroth dilution method.
Methods: A clinical isolate of M. abscessus was used. MIC was
determined by microbroth dilution method after 120 h-incubation.
Microcalorimetry was performed by adding 50ml containing 2±0.7 x107
CFU/ml (= 1±0.5×106 CFU/ampoule) M. abscessus on Middlebrook
7H10 agar supplemented with 10% OADC. For susceptibility testing,
serial two-fold antibiotic dilutions were added to agar. Heat production
was measured at 37ºC and deﬁned positive at 5 microW. The minimal
heat inhibition concentration (MHIC) was deﬁned as the lowest
concentration delaying the heat detection (compared to growth control
[GC]) for 24 h. Experiments were performed in duplicate.
Results: The mean detection time of M. abscessus without antibiotics
was 12.8 h (range, 10.4–15.2 h), reaching a peak of 109 microW (range,
104.8–114.1 microW) after 62.9 h (range, 60.8–65.0 h). With antibiotics,
the heat production was delayed proportionally to antibiotic concen-
tration (Figure 1). The MHIC/MIC were (mg/L): 2/4 (clarithromycin),
4−8/8 (amikacin) and 12/8 (linezolid).
Conclusions: Microcalorimetry allowed rapid detection (within 1 day)
and susceptibility testing (within 2 days) of M. abscessus. The
MHIC correlated with MIC values within one two-fold dilution.
Microcalorimetry might be extended to other mycobacteria, including
slow-growing such as M. tuberculosis. This method has the potential to
accelerate the current diagnosis and antibiotics susceptibility testing of
mycobacteria.
O255 In vitro, ex vivo and in vivo studies indicate that the neu-
roleptic thioridazine cures multidrug-resistant tuberculosis
L. Amaral*, E. Abbate, M. Boeree, S. Gillespie, R. Thanacoody,
Z. Udwadia, J. van Ingen, D. van Soolingen, M. Viveiros (Lisbon,
PT; Buenos Aires, AR; Nijmegen, NL; London, Newcastle upon Tyne,
UK; Mumbai, IN; Bilthoven, NL)
Objectives: To assemble data from in vitro, ex vivo and in vivo studies
that examined the utility of the neuroleptic thioridazine (TZ) in treatment
of multi-drug and extensive drug resistant tuberculosis (MDR and XDR-
TB).
Methods: The effects of TZ in separate use and in combination with
antibiotics have been studied in vitro via the use of the Bactec 460 and
960 systems; ex vivo in a non-killing human macrophage model; in vivo
in therapy of MDR-TB infected mice; and by the treatment of XDR-
TB patients infected with strains that are non-responsive to most of the
anti-tuberculosis drugs currently in use.
Results: TZ at concentrations that range from 15 to 20mg/L inhibits
the in vitro replication of all tested resistant strains of Mycobacterium
tuberculosis. These in vitro minimum inhibitory concentrations (MIC)
are well above what is clinically achievable. However, concentrations
as low as 0.1mg/L which are well below the plasma concentrations
seen in patients treated with TZ for psychiatric disorders have been
shown to promote the killing of antibiotic susceptible, multi-drug
and extensive drug resistant M. tuberculosis bacilli that have been
phagocytosed by human non-killing macrophages. Mice infected with
antibiotic susceptible and multidrug resistant strains of M. tuberculosis
are cured of the infection after treatment with TZ (monotherapy or in
combination with antibiotics). Lastly, 10/12 patients with XDR-TB were
cured within a few months after treatment with TZ in combination with
3 anti-tuberculous drugs.
Conclusion: There is increasing evidence that TZ used in combination
with anti-tuberculous drugs to which the strain is considered resistant can
lead to cure from antibiotic resistant pulmonary tuberculosis infections.
Because TZ is cheap, has been in use for more than four decades, and
the doses anticipated for therapy of tuberculosis are far smaller than
those used for chronic therapy of psychiatric disorders (5 to 75mg/day
vs 600 to 1000mg/day), this minimizes the risk of cardiac toxicity
and, the risk-beneﬁt proﬁle of TZ is shifted in favour of using this
agent for the salvage therapy of patients with extensively drug-resistant
tuberculosis, and potentially for the treatment of MDR-TB and for the
shortening of drug susceptible TB. Nevertheless, patients treated with
TZ should be carefully monitored during treatment for cardiac adverse
effects associated with phenothiazines, particularly prolongation of QT
interval.
Bad bugs, which drugs? Superior potency
for better outcomes in Gram-positive
infections
S264 Applied microbiology: the importance of potency
D. Livermore* (London, UK)
Recent advances in pharmacodynamics emphasize relationships between
MIC and outcome. According to the antibiotic, the critical parameter
is variously: (i) the duration for which drug level exceeds MIC;
(ii) the maximum concentration/MIC ratio or, (iii) the area under
the concentration–time curve/MIC ratio. Nevertheless, other factors
related to ‘potency’ (an elastic term) are important for some settings
or drugs, not just the MIC. Bactericidal, rather than inhibitory
activity is critical in endocarditis, severe bacteraemia and in infections
where the host defences are severely compromised (e.g. neutropenic
fevers). Thus, daptomycin, a rapidly cidal antibiotic, is clinically
effective as monotherapy in staphylococcal endocarditis [1]; linezolid,
a bacteriostatic drug, is not [2]. Nevertheless linezolid is more effective
than vancomycin, a weakly bactericidal antibiotic, in methicillin-resistant
Staphylococcus aureus pneumonia [3], where cidality is less crucial. In
addition, rapid cidal potency is not, in itself, a guarantor of efﬁcacy:
polymyxin is rapidly cidal for Gram-negative bacteria, but few would
argue that it is highly potent; likewise, although aminoglycosides are
useful and rapidly cidal, they are not appropriate as monotherapy outside
the urinary tract. In some settings, most notably those involving bioﬁlms
on synthetic surfaces (e.g. prosthetic devices) the MIC is a poor predictor
of outcome. This largely reﬂects the presence of dormant, difﬁcult-to-kill
cells in the stratiﬁed depths of the bioﬁlm, but perhaps also the physical
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challenge of penetrating the matrix. Some antibiotics with growth-rate-
independent killing, again including daptomycin, have in vitro potency
against sessile cells in bioﬁlms, but it remains to be established whether
this translates into efﬁcacy in device-related infections. Lastly, there
are a few situations where antibiotics with poor in vitro activity are
clinically potent, either because they interfere with bacterial signalling
processes or concentrate in particular compartments, the best example
being the utility of azithromycin in pseudomonal infection of cystic
ﬁbrosis patients and in gastrointestinal disease. In summary, although
pharmacodynamic analysis is a good predictor in many settings, it does
have limits, and potency − although an ambiguous term − is also critical
in some settings.
Reference(s)
[1] Fowler VG Jr et al. New Engl J Med 2006; 355: 653–665.
[2] Boucher H et al. Clin Infect Dis 2010; 51(suppl 2): S183–197
[3] Wunderink RG et al. Chest 2003; 124: 1789–1797.
S265 Hit hard, hit early to improve outcomes in Gram-positive
bacteraemias
A. Soriano* (Barcelona, ES)
Effective empirical antibiotic therapy is essential to reduce the morbidity
and mortality associated with Staphylococcus aureus bacteraemia.
Effective therapy means the selection of an antibiotic with in vitro
activity and administering it at the correct dose to attain, within the ﬁrst
24 hours, the pharmacodynamic (PD) target that predicts its efﬁcacy.
The high mortality rate in S. aureus bacteraemia treated empirically
with the standard vancomycin dose (1 g/12 hours) is, in part, due to the
low probability of achieving the PD target (AUC_24/MIC 400) within
the ﬁrst 24 hours. It is possible to increase the probability of target
attainment by obtaining a trough serum concentration of 15−20mg/l
when the MIC is 1 microgram/ml. In order to achieve this goal within
the ﬁrst 24 hours, it is necessary to infuse a loading dose of 25−30mg/kg
and a maintaining dose of 15−20mg/kg every 8−12 hours. This means,
in general, a daily dose of vancomycin >3−4 g, which has been
associated with a higher rate of nephrotoxicity. In addition, even with
this body-weight-adjusted regimen, when the MIC is 2 micrograms/ml
the probability of PD target attainment is low. These concepts are
supported by clinical experience showing a deleterious impact of MIC
= 2 micrograms/ml on the efﬁcacy of standard vancomycin treatment
and the lack of beneﬁt, in these cases (MIC = 2 micrograms/ml), by
increasing the dosage to reach a trough serum concentration 15mg/l
[1]. In addition, recent data has shown a higher frequency of tolerance
to glycopeptides and vancomycin heteroresistance in methicillin-resistant
S. aureus (MRSA) strains with a MIC >1 microgram/ml than in strains
with a MIC 1 microgram/ml [2]. Taking these data into account,
plus the high prevalence of MRSA strains with high vancomycin
MICs (2 micrograms/ml) and the poor results with vancomycin against
methicillin-susceptible S. aureus, even after switching to b-lactams, alerts
about the need for new anti-staphylococcal agents not only as a deﬁnitive
therapy but also empirically in severe infections where S. aureus is
suspected.
Reference(s)
[1] Soriano A et al. Clin Infect Dis 2008; 46: 193–200.
[2] Sader HS et al. J Antimicrob Chemother 2009; 64: 1024–1028.
S266 Challenges of treating cSSTIs, bioﬁlms and secondary
complications
M. Bassetti* (Genua, IT)
Skin and soft tissue infections (SSTIs) are among the most common
human bacterial infections that result in signiﬁcant morbidity and
mortality among patients, as well as increased healthcare costs.
Complicated SSTIs (cSSTI) can pose considerable diagnostic and
therapeutic challenges. Staphylococcus aureus is the most common
organism isolated from SSTIs, and methicillin-resistant S. aureus
(MRSA) is a rapidly increasing hospital- and community-acquired
pathogen. Where the prevalence of methicillin resistance is high, an
antibiotic with activity against MRSA is mandatory. Glycopeptides
(vancomycin or teicoplanin) remain the gold standard of therapy for
serious MRSA infections. However, there is controversy over the current
utility of these agents. There is a growing body of evidence indicating
that the glycopeptide MIC has a real impact on patient outcomes [1].
Whether this phenomenon is causing serious problems in the treatment of
cSSTI is not clear. Vancomycin and teicoplanin have been also associated
with relapsing bacteraemia and slower clinical response rates [1]. A large
number of novel antibacterial agents have been or are being developed for
the treatment of cSSTIs. Only linezolid, tigecycline and daptomycin are
available for clinical use. The clinical decision-making process around
antibiotic choice in the empirical setting or where cultures are available
is dependent on a variety of factors. Important parameters that appear to
determine the clinical effectiveness of an antibiotic for cSSTIs include
the severity of the illness, patient co-morbidities, presence of bioﬁlm-
associated infections and/or secondary complications, whether the patient
receives appropriate antimicrobial therapy at the onset of illness and
whether this is given as a single-agent or combination approach to
cover a broad range of likely causative organisms. In this context,
daptomycin, a cyclic lipopeptide that is rapidly bactericidal and active
against almost all Gram-positive cocci including MRSA, offers some
interesting advantages. Two studies reported that signiﬁcantly fewer
patients with cSSTIs required prolonged treatment in the daptomycin
arm and that clinical cure was faster than with comparators [2].
Reference(s)
[1] Gould I. Int J Antimicrob Agents 2008; 31(suppl 2): 1−9.
[2] Arbeit RD et al. Clin Infect Dis 2004; 38: 1673–1681.
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S278 Pathogenesis and evolution of Chlamydia: lessons from
genomics of novel chlamydiae
G. Greub* (Lausanne, CH)
Genomic analysis is a powerful tool to get insight into the biology of
Chlamydia and Chlamydia-related bacteria, since there is no genetic tool
to manipulate these obligate intracellular bacteria. To date, three genomes
of Chlamydia-related bacteria have been released:Waddlia chondrophila,
an emerging agent of miscarriage, Parachlamydia acanthamoebae,
a possible agent of pneumonia and Protochlamydia amoebophila, a
microorganism of yet unknown pathogenicity. These Chlamydia-related
bacteria possess genomes ranging from 2100 kb to 3000 kb, respectively,
i.e. two to three times the genome length of classical Chlamydia. Their
genomes display numerous repeated sequences indicating a different
genome dynamic than that of Chlamydia, which almost completely lack
repetitive elements. Noteworthy, P. amoebophila exhibits a tra operon
encoding a type IV secretion system likely involved in DNA conjugative
transfer. This tra operon is encoded on a 100kb genomic island, which
also contains a very large GC-rich ORF (lgrE), with repeats that evolved
by serial duplications.
Genomes analyses revealed that W. chondrophila, P. acanthamoebae
and P. amoebophila exhibit many virulence factors present in classical
Chlamydia, including a functional type III secretion system and a
gene homologous to that encoding CPAF, a secreted protein that
degrades human transcription factors important for expression of major
histocompatibility complexes. Contrarily to classical Chlamydia, all
three Chlamydia-related bacteria possess a large number of factors
likely implicated in the resistance to environmental toxic compounds.
Moreover, these Chlamydia-related bacteria exhibited a higher metabolic
ability than that of Chlamydia, suggesting that the common ancestor of
the modern Chlamydia may have been less dependent to their eukaryotic
host.
Recently, using Solexa and/or 454 technologies, we sequenced the
genomes of three additional Chlamydia-related bacteria: Protochlamydia
amoebophila, Criblamydia sequanensis and Estrella lausannensis,
allowing further comparative genomic analyses and further insight in
the evolutionary history of the members of the Chlamydiales order.
S54 21st ECCMID/27th ICC, Oral presentations
In conclusion, the recent availability of the genomes of Chlamydia-
related bacteria represents an opportunity to better understand the
evolution and the biology of chlamydiae.
S279 Immunogenetics: why do not all women become infertile
following chlamydial infection?
S. Morre´ and the FP6 EpiGenChlamydia Consortium
Chlamydia trachomatis (CT) infections are the world leading cause of
blindness (trachoma) and the most prevalent sexually transmitted disease
which is strongly associated with pelvic inﬂammatory disease, ectopic
pregnancy, and tubal infertility. Twin study-based ﬁndings of members
of the FP6 EpiGenChlamydia Consortium identiﬁed a 40% genetic
predisposition to CT infections. The EpiGenChlamydia Consortium
structured transnational research to such degree that comparative
genomics and genetic epidemiology on large numbers of unrelated
individuals can be performed to identify genetic markers to be used
for patient proﬁling.
Subfertility poses an enormous burden on healthcare and society
throughout the world. Worldwide, 15% of couples trying to conceive
suffer from subfertility. Subfertility generally described as a failure
to conceive after one year of unprotected, regular sexual intercourse.
Approximately half of the couples suffering from subfertility will
conceive spontaneously, or after simple treatment. The other half needs
more complex treatment, such as in vitro fertilization (IVF) or other
assisted reproduction procedures.
There are several causes of subfertility, which can be classiﬁed as
ovulation disorders, male factor subfertility, tubal damage, unexplained
subfertility, and other causes, such as endometriosis and ﬁbroids. In
women, one of the major causes of female subfertility is tubal pathology,
with a prevalence of around 30%. In all of cases of tubal pathology,
C. trachomatis is the single most common cause for infertility.
The reference standard for diagnosing tubal pathology in subfertile
women is laparoscopy performed usually after a CT IgG positive
antibody test which is only positive in 50−60% of women with tubal
pathology. Despite the effectiveness, laparoscopy is costly, invasive and
has a low positive predictive value. Therefore there is a unmet medical
need for better diagnosing tubal pathology in women with subfertility,
a need which could potentially be met by adding genetic proﬁling to
current diagnostic approaches. The current presentation will discuss
immunopathological mechanisms and host based genetic diagnostic
approaches.
Next generation sequencing and clinical
microbiology
S287 Possible use of next generation sequencing in routine clinical
microbiology
M.R. Capobianchi*, I. Abbate (Rome, IT)
The error prone nature of HIV-1 and HBV reverse transcriptase,
combined with the high replicative activity of these viruses, results, in
each infected individual, in the formation of many genetically related
viral variants referred to as quasispecies, in which most viral sequences
slightly differ from each other. This variability is the substrate for the
selective pressure exerted by the immune system or by drugs, leading to
the continuous viral evolution in the infected host and to the occupation
of replicative space in different body compartments.
Traditional analysis of quasispecies, based on the sequencing of clonal
PCR products, has a low resolution power, due to the limited amount of
clones that can be handled in each experiment.
In particular, it is not possible, by traditional approaches, to detect and
quantify minority genomes present in viral quasispecies, that, indeed,
may have biological and clinical relevance. This includes reappearance
of founder viruses during natural history, shifts in coreceptor usage at
different phases of the infection, evolution of drug resistance and re-
emergence of hidden genomes after treatment interruptions.
NGS, with the ultra-deep pyrosequencing (UDPS) approach, provides
a unique opportunity to investigate viral quasispecies. In fact, for each
patient, it provides a data set of clonally ampliﬁed PCR products that
is some order of magnitude higher than any previous conventional
approach. Hence, NGS represents a breakthrough tool to investigate
previously inaccessible aspects of HIV-1 and HBV dynamics, such as
to explore the contribution of different viral reservoirs to replicating
virus along the natural history of the infection, to identify coreceptor
usage in minority viral populations harboured by different cell lineages,
and to investigate the dynamics of development of drug resistance along
antiviral treatment.
Application of NGS to clinical microbiology is in its infancy,
but promising results have been obtained in the detection and
characterization of novel viruses (arenaviruses, pandemic inﬂuenza and
others), in the investigation of the dynamics of resistance development
(HIV abd HBV), and in the establishment of viral tropism at quasispecies
level (HIV).
Equipment simpliﬁcation, methods standardization, development of user
friendly bioinformatic tools represent urgent needs to be met in order
to render more accessible to clinical microbiology the new, potent tool
represented by NGS.
Clinical and microbiological update on
antibiotic-resistant P. aeruginosa
O288 Pseudomonas aeruginosa carbapenem resistance mechanisms
in Spain: impact on the activity of imipenem, meropenem,
and doripenem
E. Riera*, G. Cabot, C. Juan, M. Garcı´a-Castillo, R. del Campo,
R. Canto´n, A. Oliver (Palma de Mallorca, Madrid, ES)
Objective: To investigate the mechanisms of carbapenem resistance
in the 175 P. aeruginosa isolates (39%) showing nonsusceptibility,
according to EUCAST breakpoints, to imipenem (MIC >4mg/L,
35%), meropenem (MIC >2mg/L, 33%), or doripenem (MIC >1mg/L,
33%), recovered in 2008–2009 from 16 Spanish hospitals during the
COMPACT study.
Methods: MICs were determined by Etest and clonal relatedness by
PFGE. The production of metallo-b-lactamases (MBL) was evaluated
with Etest MBL strips and PCR followed by sequencing. Mutation-
driven resistance was investigated in 60 of the 175 isolates, according
to the distribution of doripenem MICs. Fifteen isolates from each of the
following MIC groups were randomly selected: 1mg/L (susceptible),
2−4mg/L (intermediate), 8−16mg/L (resistant but potentially treatable
depending on PK/PD parameters), and 32mg/L (high level resistant).
MBL producers were excluded from this analysis. The expression of
ampC and the genes encoding the 4 major efﬂux pumps (mexB, mexY,
mexD, and mexF) were determined by real time RT-PCR. The presence
of inactivating mutations in oprD was explored through PCR and
sequencing.
Results: 12 (6.9%) of 175 P. aeruginosa isolates were found to be
MBL producers, including 9 VIM-20 (one clone disseminated in a
single hospital), 2 VIM-2, and 1 VIM-13. All MBL producing isolates
showed high level resistance (MICs >32mg/L) to the 3 carbapenems.
Regarding mutation-driven resistance, all but 1 of the 60 isolates were
nonsusceptible to imipenem, linked to oprD inactivating mutations. In
addition, 30 (50%) isolates overexpressed ampC, 20 mexY (33%), 19
mexB (32%), and 9 mexF (15%), while none overexpressed mexD.
Increasing prevalence of ampC overexpression correlated with increasing
doripenem MICs (1, 13%; 2−4, 53%; 8−16, 60%; 32, 73%) while
overexpression of mexB (27%, 27%, 53%, and 20%), mexY (7%, 20%,
73%, and 33%), and mexF (7%, 13%, 27%, and 13%) correlated
only with moderate doripenem resistance. As presented in the Table,
doripenem showed higher activity than meropenem in the complete
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collection of isolates, as well as in those overexpressing ampC, and,
specially, mexB or mexY.
Conclusion: Although the prevalence of MBLs is increasing, mutation-
driven resistance was still far more frequent. Imipenem resistance was
driven by OprD inactivation, while additional AmpC, and, particularly,
efﬂux pumps hyperproduction had a lower impact on the activity of
doripenem when compared to meropenem.
O289 IMP-29, a novel metallo-b-lactamase in Pseudomonas
aeruginosa
K. Jeannot*, M. Robert Nicoud, P. Ple´siat (Besanc¸on, FR)
Objectives: Pseudomonas aeruginosa may become highly resistant to
carbapenems and almost all b-lactam antibiotics by horizontal transfer
of metallo-b-lactamase genes (MBLs). To date, 6 types of MBLs
(IMP, VIM, SPM, GIM, AIM et DIM) have been reported in this
organism. This study describes a novel IMP-type enzyme produced by
two P. aeruginosa clinical strains collected at the teaching hospital of
Besanc¸on (France).
Methods: Strains 10266 and 10298 were isolated from a rectal screening
sample and a blood culture of two patients admitted in 2010, respectively.
Drug susceptibility testing, strain genotyping by PFGE, MBL production,
PCR ampliﬁcation, cloning and sequencing experiments were performed
according to standard protocols.
Results: Double disc synergy tests using imipenem and EDTA indicated
MBL production in these two genotypically related strains only
susceptible to aztreonam and colistin. A gene encoding an enzyme
distantly related to IMP-8 (identity <70%) and referred to as IMP-29
was ampliﬁed by PCR and sequenced. In strain 10298, blaIMP-29 was
located in a typical class 1 integron downstream of gene cassettes aacA4
et dfrII. The genetic environment of blaIMP-29 appeared to be very
different in 10266 as the gene lied alone with the P2 promoter of intL1
on a transferable plasmid of 20 kb. Interestingly, the PU21 tranconjugants
were susceptible to piperacillin (MIC = 8mg/mL), of intermediate
susceptibility to imipenem (8mg/mL) and higly resistant to meropenem
(128mg/mL), doripenem (64mg/mL), ceftazidime (128mg/mL) and
ticarcillin (128mg/mL). A second class 1 integron harboring gene
blaPSE-1 ﬂanked by gene cassettes aacA4 and aadA2 was detected in the
two strains. Finally, the presence of a stop codon in gene oprD accounted
for the high level resistance to imipenem in both isolates.
Conclusion: This new transferable MBL identiﬁed in France provides
P. aeruginosa with an atypical MBL resistance phenotype which can
be misidentiﬁed when additional resistance mechanisms are present
(penicillinase PSE-1, loss of porin OprD). The genetic element carrying
blaIM-29 is subject to signiﬁcant rearrangements.
O290 Carbapenem-resistant Pseudomonas aeruginosa after short
exposure to therapeutic concentrations of ertapenem
S.J. Vainio*, M.L. Schepens, A. Wilhelm, C.M. Vandenbroucke-Grauls,
J.L. Murk, Y.J. Debets-Ossenkopp (Amsterdam, NL)
Objectives: Since the introduction of ertapenem, concerns have been
raised about the potential of this drug to select for resistance to other
carbapenems in nosocomial pathogens, most importantly P. aeruginosa.
In vitro studies have shown that under certain conditions, such cross-
resistance can develop, but conditions resembling clinical settings have
not been tested. In this study, we determined the effects of exposing
P. aeruginosa to a range of ertapenem concentrations that mimics the in
vivo serum concentrations during ertapenem therapy.
Methods: 12 clinical isolates of P. aeruginosa (all with meropenem
MICs <0.25mg/L and imipenem MICs <1.5mg/L; 10 with ertapenem
MICs 0.064−4mg/L, categorized as ertapenem sensitive, and 2 with
ertapenem MICs >32mg/L; categorized as ertapenem resistant) were
incubated at 37ºC in RPMI-medium with ertapenem concentrations
reﬂecting the in vivo concentrations achieved with the standard daily
dose (1 h in each 16, 8, 4 and 2mg/L, 4 h in 1mg/L and 16 h in 0.5mg/L
of ertapenem) for three consecutive days. As a control, the isolates were
incubated following the same scheme but in the absence of ertapenem.
MICs for ertapemen, imipenem and meropenem were determined by
E-tests, and sensitivity to other antibiotics was by Vitek-2.
Results: After the incubation with ertapenem, nine of the ertapenem
sensitive P. aeruginosa isolates exhibited markedly elevated ertapenem
MICs (>32mg/L). Moreover, all these strains displayed diminished
sensitivity or frank resistance to imipenem (MICs 4−>32mg/L) and/or
meropenem (MICs 1.5−>32mg/L) and in some cases, the MICs for
ceftazidime and piperacillin were also elevated. The phenotype was
stable after one month of continuous culturing in the absence of
antibiotics in all but one strain. In the case of one ertapenem sensitive
isolate (ertapenem MIC 0.064mg/L), no viable cells were recovered after
the ertapenem treatment. The incubation with ertapenem had no effect on
the carbapenem MICs of the two ertapenem resistant isolates, and none
of the tested isolates showed changes in the sensitivity to non-blactam
antibiotics.
Conclusions: These data show that exposing P. aeruginosa to clinically
relevant concentrations of ertapenem can rapidly select for diminished
sensitivity to all carbapenems. Thus far, there is no evidence that such
selection would occur in clinical practice, but these results disclose the
need for continued surveillance.
O291 Exposure of Pseudomonas aeruginosa to sub-MIC
concentrations of chlorhexidine leads to increased resistance,
marked phenotypic changes, overexpression of MexG, and
cross-resistance to antipseudomonal antibiotics
Q. Tan, T. Nguyen*, F. Bilocq, D. De Vos, J. Pirnay, P. Cornelis, F. Van
Bambeke, P. Tulkens (Brussels, BE)
Objectives: Biocides carry a risk of resistance and cross-resistance with
antibiotics that still needs to be assessed (Meyer & Cookson, J Hosp
Infect. 2010, 76:200−5). Our aim was to examine whether exposure
of P. aeruginosa (PA) to sub-MIC concentrations of CHX could lead
to resistance to CHX, modify the bacterial phenotype, cause increased
expression of efﬂux transporters, and trigger cross-resistance to anti-PA
antibiotics.
Methods: (i) 6 fully susceptible and 18 multi-resistant isolates of PA
(VAP and burned patients) with initial CHXMIC32mg/l were exposed
to CHX at 0.5 MIC with daily measurement of MIC (microdilution) and
readjustment of the CHX concentration to 0.5× the new MIC value, for
up to 14 days, followed by 10 subcultures on CHX-free agar (revertants).
Clonality was checked by Repetitive Extragenic Palindromic-PCR
[DiversiLab] >95% similarity [Riou et al. IJAA 2010, 36:513−22]).
Bacteria were examined for change in CHX MIC, swarming (agar
plates containing CHX at 0.5 MIC), pyoverdine production (405/660 nm
absorbance ratio), and susceptibility to antipseudomonal antibiotics
(MIC; CLSI methods). Expression of 3 genes (mexA, mexX, mexG)
part of clusters encoding 3 efﬂux pumps was measured by RT-PCR.
Results: All isolates showed an increased CHX MIC (2 to >8-fold; up
to >256mg/L) after 13 days exposure (see Figure for 6 selected strains).
Most CHX-exposed isolates showed reduction in colony size, almost
complete suppression of pyoverdin production, and marked reduction of
swarming. 3 isolates showed increased MIC to amikacin (2 to 4 x), 1 to
piperacillin (2 to >8-x), 3 to cefepime (2 to 4-x), and 5 to ciproﬂoxacin
(2 to 16-x), nut 1 (PA330) showed a decrease in ciproﬂoxacin MIC
(64 to 0.5mg/L). There was a variable overexpression of mexA, mexX,
but mexG was overexpressed in all cases (MexGHI-OpmD facilitates
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cell-to-cell communication, confers resistance to vanadium, promotes
virulence and growth in P. aeruginosa but increases susceptibility to
many antibiotics [Aendekerk et al. Microbiology 2002, 148:2371−81])
Reversion for all the above parameters was partial only.
Conclusion: Exposure to non-lethal concentrations of chlorhexidine
fosters the development of strains with reduced susceptibility and with
cross-resistance to antibiotics. The multiple genotypic and phenotypic
alterations need to be critically assessed, but the data call for caution
against using CHX at non-lethal concentrations.
O292 Levoﬂoxacin-doripenem combination prevents emergence
of resistance among Pseudomonas aeruginosa expressing
mechanisms of resistance impacting susceptibility to one or
both drugs in the combination
P. Lister* (Omaha, US)
Objectives: Previous studies have demonstrated the ability of
levoﬂoxacin-imipenem to prevent the emergence of resistance among
isolates of P. aeruginosa in a two-compartment in vitro pharmacody-
namic model (IVPM). Data from those studies suggested that other
carbapenems could be effective in the combination. Therefore, this
study was designed to evaluate the pharmacodynamics of a levoﬂoxacin-
doripenem combination against P. aeruginosa in an IVPM. The primary
focus of the study was to evaluate the ability of this combination
to eradicate and prevent emergence of higher levels of resistance
from characterized isolates of P. aeruginosa expressing one or more
mechanisms of resistance impacting susceptibility to the drugs in the
combination.
Methods: The strains used in this study included a fully-susceptible
clinical isolate, 4 characterized strains overexpressing mexAB-oprM,
mexCD-oprJ, mexEF-oprN, or mexXY, and one strain lacking a
functional OprD porin. Log-phase cultures (~107 to 108 cfu/ml) were
inoculated into the peripheral compartment of the IVPM and treated with
simulated human doses of 750mg levoﬂoxacin, 500mg doripenem (1h
infusion), or the levoﬂoxacin-doripenem combination. Pharmacokinetics
were adjusted to account for protein binding. Levoﬂoxacin was dosed
at 0h, and doripenem was dosed at 0, 8, and 16h. Pharmacodynamics
were evaluated over 24h, and drug-selection plating was used to evaluate
emergence of resistant subpopulations.
Results: In studies with the susceptible clinical isolate, the OprD-
deﬁcient strain, and strains overexpressing mexAB-oprM, mexCD-oprJ,
and mexXY, the levoﬂoxacin-doripenem combination decreased viable
counts over 6 logs and achieved eradication from the IVPM by 8
to 24h. Furthermore, the combination prevented inoculum regrowth
and emergence of resistance that was observed with each drug
alone. Although levoﬂoxacin-doripenem did not eradicate the strain
overexpressing mexEF-oprN (co-regulated decrease in oprD), viable
counts decreased 4.5 logs by 8h and were maintained at this level
through 24h. This was in contrast with the emergence of more resistant
subpopulations with each drug alone.
Conclusions: These data demonstrate the ability of levoﬂoxacin-
doripenem to effectively prevent emergence of resistance among
P. aeruginosa, even when the target strains express one or more resistance
mechanisms impacting drugs in the combination. Further studies and
clinical evaluation are warranted.
O293 Linear increasing of resistance rates to nine antibiotics
of Pseudomonas aeruginosa strains within a nosocomial
outbreak
J.L. Navarro*, A. Somodevilla, M. Espı´nola, N. Arenal, M.J. Moreno,
T. Alarco´n, M. Lo´pez-Brea (Madrid, ES)
Objectives: Pseudomonas aeruginosa (PA) has been recognized as a
common cause of nosocomial infections, mainly in critically ill or
immunosuppressed patients. Its dramatic ability to exhibit multidrug-
resistance is related to inherent mechanisms and the ready acquisition
of new ones, making PA uniquely dangerous. The aim of this study
was to describe and quantify the increasing of resistance rates to
several antibiotics of serially recovered PA strains from inpatients with
prolonged infection and/or colonization within a nosocomial outbreak at
a University Hospital in Madrid.
Methods: We conducted an observational retrospective study of 822
PA isolates from 371 adult inpatients who were admitted to ‘La
Princesa’ University Hospital during one year. PA strains were isolated
from respiratory samples, urine, stool, intravascular devices, blood
and other sterile ﬂuids. Nine drugs were tested: amikacin (AKA),
gentamycin (GEN), tobramycin (TOB), imipenem (IMI), meropenem
(MER), ciproﬂoxacin (CIP), piperacilin-tazobactam (TZP), ceftazidime
(CAZ) and cefepime (CPE). Several PA isolates were sequentially
recovered from each patient. First PA isolation was marked as “Day
0”. Susceptibilities were determined by a broth microdilution method
and interpreted according to the CLSI breakpoints. Resistance rates
are expressed as proportions. Correlation was studied with Pearson
coefﬁcient and a linear regression model was built. Conﬁdence intervals
of 95% have been used and P-values lower than 0.05 were considered
statistically signiﬁcant.
Results: All R-coefﬁcients resulted over 0.8, but not for AKA (R= 0.46)
between day 0 and day 18. Since resistance rates stabilize around day 20,
changes found from day 21 are irrelevant. CAZ, IMI and MER showed
the best ﬁtness to the linear model (R2=0.95, 0.76, 0.74). Thus, every 3
days, the likelihood of resistance increases [4.4−8.5%] for CAZ, [1.5–
11.8%] for IMI and [1.1–11.1%] for MER. TZP, GEN and TOB are the
less affected ([0.2−9.8%], [0.3−9.3%] and [0.1−9.4%]).
Conclusions: (1) Resistance rates linearly increased in time for all
antibiotics until day 18 except for AKA. (2) Susceptibility to AKA
remained stable. (3) The likelihood of resistance to CAZ, IMI and MER
increases markedly every 3 days. (4) This is less evident for TZP and
aminoglycosides. (5) Short-time treatment with CAZ and carbapenems
must be considered. (6) A good initial combination treatment should
include an amynoglycoside (mainly AKA) and TZP.
O294 Antibiotic resistance trends of Pseudomonas aeruginosa and
Acinetobacter spp. isolates at a teaching hospital in Istanbul,
2004–2010
S. Senbayrak Akcay, A. Inan*, S. Aksaray, S. Cevan, M. Ku¨cu¨kercan
(Istanbul, TR)
Objectives: Antibiotic resistance by intensive care unit pathogens es-
pecially Pseudomonas aeruginosa and Acinetobacter spp. is increasing,
but variations do exist among different countries and hospitals. The local
Clinical and microbiological update on antibiotic-resistant P. aeruginosa S57
resistance data is essential for appropriate therapy of ICU infections. In
this study we reported the antibiotic resistance rates of Pseudomonas
aeruginosa and Acinetobacter spp. strains and alterations in years in a
teaching hospital, Istanbul.
Methods: From January 1, 2004 to December 20, 2010, we obtained a
total of 1583 P. aeruginosa strains and 1855 Acinetobacter spp. strains
from various clinical specimens of patients followed in ICU, which were
regarded as infectious agents. Identiﬁcation of species was performed
with standart methods. Antibiotic susceptibilities of isolated strains were
investigated by Kirby-Bauer disk diffusion method according to CLSI
criteria. Chi-square test was used for statistical analysis.
Results: In 2004 and 2010, resistance to certain antibiotics of Pseudo-
monas aeruginosa was revealed as follows: 48%, 58% (p = 0.2023)
for piperacillin/tazobactam, 66%, 92% (p< 0.0001) for ceftazidime,
25%, 62% (p< 0.0001) for imipenem, 25%, 56% (p< 0.0001) for
meropenem, 2%, 21% (p< 0.0001) for amikacin, and 72%, 59%
(p = 0.0743) for ciproﬂoxacin, respectively. The resistance rates of
Acinetobacter spp. were as follows: 48%, 97% (p< 0.0001) for
ampicillin/sulbactam, 2%, 80% (p< 0.0001) for cefoperazone/sulbactam,
23%, 89% (p< 0.0001) for imipenem, 24%, 92% (p< 0.0001) for
meropenem, 71%, 38% (p< 0.0001) for gentamicin, and 92%, 90%
(p = 0.8048) for ciproﬂoxacin, respectively.
Conclusion:While the resistance to cefoperazone/sulbactam, ampicillin/
sulbactam, imipenem, meropenem have signiﬁcantly increased from
2004 to 2010; gentamicin resistance has decreased for Acinetobacter
spp. The resistance rates of Pseudomonas aeruginosa to imipenem,
meropenem and amikacin have increased; although ciproﬂoxacin
resistance has decreased. In 2010 the resistance rate of P. aeruginosa
to tazobactam/piperacillin has not changed compared with 2004. As
known, insufﬁcient infection prevention strategies and the unnecessary
use of broad spectrum antibiotics are the cause of high-level antibiotics
resistance. Therefore, infection control and antibiotic management
strategies should be reconsidered in our ICU.
O295 Characterisation of resistance mechanisms in clinical isolates
of Pseudomonas aeruginosa with reduced susceptibility to
carbapenems
M. I´n˜igo*, A. Ocampo-Sosa, G. Martı´nez de Tejada,
M. Ferna´ndez-Alonso, E. Roma´n, J. Leiva, L. Martı´nez-Martı´nez
(Pamplona, Santander, ES)
Objective: To characterise the mechanisms of resistance to carbapenems
in clinical isolates of Pseudomonas aeruginosa (Pa) non-susceptible to
these agents collected during an 8-year period.
Material and Methods: Clinical isolates of Pa with MIC of impenem
(IMP) and/or meropenem (MPM) 8mg/l were collected from January
2002 to December 2009. Identiﬁcation and preliminary susceptibility
testing were performed with the Vitek 2 System (bioMe´rieux). The
MICs of IMP and MPM were conﬁrmed by broth microdilution
(CLSI guidelines). MICs of doripenem (DOR) were determined by
Etest method. Production of metallo-b-lactamase was studied by broth
microdilution, Etest and multiplex PCR. The expression of the OprD
porin was analyzed by SDS-PAGE, and inactivating mutations were
determined by sequencing of the entire oprD gene ampliﬁed by PCR.
Both ampC hyperproduction (hipAmpC) and mexB overexpression
(overmexB) expression levels were assesed by real-time PCR. The clonal
pattern of the strains was studied by REP-PCR.
Results: A total of 109 carbapenem-resistant Pa from different patients
were collected in the indicated period, and 26 isolates representative of
the different clonal patterns were further studied. The MIC50/90 (mg/l)
for these 26 strains were 32/64 for IMP, 16/32 for MPM and 32/>32
for DOR, respectively. VIM-2 was detected in 5 (19.2%) isolates (in 2
cases combined with OprD loss and in 1 case with overmexB). Thirteen
isolates had only one of the studied resistance mechanism, including 9
(34,6%) isolates with OprD loss, 2 (7,7%) with hipAmpC and 2 (7,7%)
and the 2 (7.7%) with VIM-2 alone. Loss of OprD plus hipAmpC, and
combination of OprD loss, hipAmpC and overmexB were observed in
30.8% and 7.7% of the isolates, respectively.
Conclusion: The combination of different resistance mechanism was the
main cause for developing resistance to carbapenems, highlighting the
loss of OprD porin as the most prevalent mechanism.
O296 Wide dispersion of ST175 clone despite a high-genetic
diversity of carbapenem-non-susceptible Pseudomonas
aeruginosa clinical strains from 16 Spanish hospitals
M. Garcia-Castillo*, R. del Campo, M. Morosini, E. Riera, G. Cabot,
A. Oliver, R. Canton (Madrid, Palma de Mallorca, ES)
Objective: The prevalence of carbapenem non-susceptible clinical
Pseudomonas aeruginosa isolates detected during the COMPACT-Spain
surveillance study was 35% for imipenem (MIC >4mg/L), 33% for
meropenem (MIC >2mg/L) and 33% for doripenem (MIC >1mg/L).
The aim of the present work was to analyze the genetic diversity and
the population structure of these carbapenem-resistant isolates.
Methods: A collection of 175 carbapenem non-susceptible clinical
Pseudomonas aeruginosa isolates recovered from 16 Spanish Hospitals
between October-2008 and March-2009 was included. Antibiotic
susceptibility was performed by the standard CLSI-microdilution method
and Etest. Genetic diversity was studied by PFGE-XbaI and a
dendrograme based on the Dice’s coefﬁcient was constructed with the
Phoretix 5.0 software. One strain per pulsotype and per hospital were
further selected for MLST typing (n = 84).
Results: All 175 P. aeruginosa isolates showed non-susceptibility to,
at least, one carbapenem (imipenem, meropenem and/or doripenem)
according to EUCAST criteria (2010). Resistance to other antibiotics
were: 51% piperacillin/tazobactam, 47% ceftazidime, 57% cefepime,
73% ciproﬂoxacin, 77% levoﬂoxacin, 68% gentamicin, 48% tobramycin,
58% amikacin, 82% fosfomycin, and 0% colistin. Sixty-ﬁve different
PFGE patterns were observed, and from the 84 isolates that were
selected for MLST, a high genetic diversity was observed: 23 strains
corresponded to a unique ST, 5 of them newly described in our
study (ST1014–1018). The ST175 was the most represented MLST-
type corresponding to 18 isolates recovered from 7 hospitals. Within
these isolates, doripenem exhibited signiﬁcantly lower MIC values (mean
geometric MIC, 16mg/L) when compared with meropenem (33.3mg/L)
or imipenem (50.1mg/L). Other STs that were found in different
hospitals were: ST244 and ST111 (4 in each hospital), ST446 (3
hospitals) and ST235, ST253, ST646, ST308, ST313 (2 in each hospital).
Conclusion: All carbapenem non-susceptible clinical Pseudomonas
aeruginosa isolates in Spain recovered through the COMPACT study
remained susceptible to colistin, whereas high rates of resistance were
detected for other antibiotics. Doripenem MICs were less affected than
those of meropenem and imipenem. Moreover, within this population
and despite a high genetic diversity, the ST175 clone was highly
disseminated.
O297 Comparison of chromogenic and selective media for the
detection of Staphylococcus aureus and Pseudomonas
aeruginosa in respiratory samples from cystic ﬁbrosis patients
A. Nobre Machado*, C. Nonhoff, S. Roisin, A. Vergison, F. Van Bambeke,
N. Legros, G. Hay, P. Buidin, C. Thiroux, O. Denis (Brussels, BE)
Objectives: A hallmark of cystic ﬁbrosis (CF) patients is chronic
respiratory infection caused mainly by Staphylococcus aureus (SA) and
Pseudomonas aeruginosa (PA). The microbiology of CF is complicated
by the emergence of abnormal phenotypes such as small colony variants
(SCV) of SA and PA. The aim of this study was to compare the
performance of chromogenic media to conventional media for the
detection and the presumptive identiﬁcation of SA and PA, including
normal (N) and SCV phenotypes.
Methods: 159 respiratory samples from 64 CF patients were plated
onto Columbia agar (COL), Haemophilus agar (HAEM), MacConkey
agar (MAC), Mannitol Salt agar (MAN), Burkholderia cepacia selective
agar (BCSA), SA chromID (SAID, bioMe´rieux), PA chromID (PAID,
bioMe´rieux). Plates were incubated at 35ºC for 5 days and examined
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daily. Suspected SA and PA colonies, according to the manufacturer’s
interpretative criteria, were subcultured on COL for phenotypic
identiﬁcation. Identiﬁcation of SA isolates was conﬁrmed by multiplex
PCR for 16S rRNA, mecA and nuc genes. PA isolates showing atypical
biochemical proﬁle were characterized by 16S rRNA sequencing.
Results: 79 SA isolates, including 58 N and 21 SCV phenotypes, were
found from 48 samples. The sensitivities of SAID (89.9%) and MAN
(81%) were not signiﬁcantly different (p = 0.107) for SA detection. The
speciﬁcities of SAID and MAN were 67.2% and 77.1% respectively.
SA SCV isolates were more frequently recovered on SAID (n = 21)
than on MAN (n = 18). 133 PA isolates were found from 72 samples.
PAID showed signiﬁcantly higher sensitivity than MAC (88.7% vs
75.9%; p = 0.013) for PA detection. The speciﬁcities of PAID and
MAC were 90.8% and 64.5% respectively. PA SCV isolates were also
more frequently recovered on PAID than on MAC (n = 44 vs n = 31;
p = 0.02) but the mucoid phenotype of PA was less expressed on
the chromogenic medium. On PAID, mucoid colony variants produced
frequently translucent colonies, which could go undetected following to
the manufacturer’s recommendations.
Conclusion: In our CF patients centre, both SAID and PAID
chromogenic media demonstrated better performances than conventional
media for the detection of SA and PA isolates, especially in the recovery
of atypical variants. However, mucoid translucent colonies on PAID
should be identiﬁed to exclude PA.
Tracking antibiotic-resistance in Gram
positive cocci
O298 Colonisation and transmission of resistant bacteria in 13
European intensive care units
L.P. Derde*, M.J. Dautzenberg, P.J. van Duijn, C. Brun-Buisson,
M.J. Bonten on behalf of MOSAR research consortium
Objective: To quantify colonization on admission and ICU-acquired
acquisition with multidrug resistant organisms (MDRO) in 13 Intensive
Care Units (ICUs) throughout Europe participating in the MOSAR ICU-
trial. This is a cluster-randomized trial evaluating different interventions
to limit the spread of MDRO in ICU. MDRO included MRSA, VRE and
ESBL-producing Enterobacteriaceae (ESBL). This abstract refers to the
6-month baseline period in which no interventions were implemented.
Methods: Participating ICUs were in France, Greece, Italy, Latvia,
Luxemburg, Portugal, Slovenia and Spain. The ﬁrst ICU started this
trial in May 2008 and the trial ended in Oct 2009. Screening swabs were
taken from the nose (MRSA), rectum (VRE, ESBL) and wounds (MRSA,
VRE and ESBL) of all patients admitted for 3 days (long-stay patients,
LS) on admission and twice a week, as well as from a sample of patients
admitted for <3 days (short-stay patients, SS). Samples were processed
using a standardized lab protocol, without feedback of culture results. All
screening swabs were dispensed in cryopreservative ﬂuid (microbanks)
and frozen at −80ºC. After a delay of at least 2 months, to prevent
feedback to the clinic, the samples were thawed and plated onto BBL
CHROMagar MRSA II plates (MRSA), ECCV chromagar plates with 8
microg/ml vancomycin (VRE) or Brilliance 2 ESBL plates (ESBL). All
plates were read by a local expert, and suspected colonies were picked
for conﬁrmatory testing. Individual patient data were obtained using a
web based data-capturing protocol (ResearchOnline(R)).
Results: In total, 2887 patients were enrolled, with a median age of
64 yrs (IQR 48−76 yrs), a mean LOS of 11 days (range 1–263 days) and
a median APACHE II (5 sites) of 15 (IQR 10−21) and median SAPS
II (8 sites) of 35 (IQR 22−50). Main admission diagnosis was surgical
in 73.9% of admissions (range 37.0–98.6%) and non-surgical in 26.1%
(range 1.4–63.0%). Admission and ICU acquired colonization rates are
depicted in Table 1.
Conclusions: Throughout Europe, colonization with MRSA, VRE and
ESBL on admission is generally low. Acquisition during admission
occurs relatively frequently, especially with ESBL. Large differences
exist between different ICUs in different countries in Europe.
Quantifying transmission makes it possible to design and evaluate
effective interventions. Future data from the MOSAR trial will give
more insight in the effect of different interventions on the transmission
of these MDRO in these ICUs.
O299 Emergence and evolution of heteroresistant vancomycin
intermediate Staphylococcus aureus in a single hospital over
a 12-year period
S.J. van Hal*, T. Barbagiannakos, J. Mercer, D. Chen, I.B. Gosbell,
D.L. Paterson (Sydney, AU)
Objectives: To determine the evolution of heteroresistant vancomycin
intermediate Staphylococcus aureus (hVISA) in a single institution.
Methods: All methicillin-resistant Staphylococcus aureus (MRSA)
blood stream infection (BSI) isolates between1997 and 2008 were
included in the study. All isolates underwent modiﬁed population
analysis proﬁling (PAP-AUC) with hVISA conﬁrmed if the AUC ratio
of the isolate to the reference (Mu3; ATCC 700698) was >0.9. All
isolates were typed by pulsed ﬁeld gel electrophoresis (PFGE) using
HARMONY criteria against known multi-locus sequence typed (MLST)
controls. Isolates were considered ST239 MRSA if they 1) resembled
the ST239 control; 2) were multi-resistant (resistant to >2 B-lactam
antibiotics); and 3) had a coagulase PCR restriction length fragment
polymorphism pattern of 24. Relationships between PFGE banding
patterns was examined using BioNumerics® (version 6.1).
Results: Of the 465 isolates identiﬁed over the 12 years, 54 (12%)
were classiﬁed as hVISA by PAP-AUC. hVISA emerged in 2000 with a
“biphasic” epidemic curve. PFGE typing categorised 360 (77%) isolates
as ST239, the remaining isolates resembled ST22 [43]; ST1 [20]; ST93
[11]; ST30-like [11]; unclassiﬁed [13]. hVISA was only identiﬁed in
ST239 (p< 0.01). A UPGMA dendogram based on PFGE patterns of
ST239 isolates revealed large diversity with 61 sub-pulsotypes clustering
into 6 distinct clusters. The diversity in individual clusters was large (6
sub-pulsotypes) with two clusters (1 & 4; 296/360; 82%) and 8 sub-
pulsotypes (CL1−1; CL1−2; CL1−3; CL1−4; CL4−1; CL4−7; CL4−9 &
CL4−14; 231/360; 64%) predominating. Temporal relationships existed
for all clusters with cluster 4 peaking in 2002 and replaced by 2008. In
contrast, cluster 1 ﬁrst appeared in 2000 and was the predominant cluster
from 2006 onwards. Although hVISA occurred in 5 of the 6 clusters,
hVISA mainly occurred in cluster 4 (44/54; 81%) and principally
restricting to a single sub-pulsotype (CL4−1; 23/44; 52%). Of note,
hVISA did not occur in the most common sub-pulsotype (CL4−7; 0/53;
0%) but was exclusively found in CL4−5 (4/4; 100%).
Conclusion: The proclivity of different MRSA types and within speciﬁc
MRSA types to select hVISA varies greatly. Furthermore, factors
associated with hVISA emergence remain unclear but are probably
related to evolutionary pressures on the predominant vancomycin
susceptible clones.
O300 Tracking antibiotic resistance along the Silk Road
S. Quinteira, C. Novais*, P. Antunes, J. Campos, A.R. Freitas,
A. Abdukadir, N. Monteiro, L. Peixe (Vila Nova de Famalica˜o, Porto,
PT; Urumqi, CN)
Objectives: Information on the occurrence of antibiotic resistance in
relatively pristine ecosystems is still scarce. Accordingly, the goal of
this study was to evaluate if wild or feral animals, most of which facing
extinction, inhabiting remote areas of the globe (from the Tibetan plateau
to the Gobi desert), carry bacteria that harbour antibiotic resistance
genes.
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Methods: During the SilkRoad2010 expedition (CIBIO and Chinese
Academy of Sciences), faecal samples were collected from ﬁve iconic
mammal species (Mongolian wild ass, Przewalski horse, Grey marmot,
Bactrian camel and Dhole), most of which endangered or in the verge of
extinction. Samples were pre-enriched in peptone water and 0.1ml were
plated in Slanetz-Bartley agar without and with antibiotics (vancomycin-
4mg/L, ampicillin-16mg/L, ciproﬂoxacin-4mg/L, gentamicin-125mg/L,
streptomycin-1000mg/L, tetracycline-8mg/L, chloramphenicol-8mg/L).
Susceptibility to 12 antibiotics was tested by disk diffusion method
(CLSI). Species identiﬁcation (E. faecium-Efm, E. faecalis-Eﬂ), char-
acterization of antibiotic resistance genes (tetM, tetL, tetO, tetK, tetS,
ermB) and putative virulence genes (esp, hylEfm, acmEfm) were done by
PCR. purK gene was ampliﬁed and sequenced for speciﬁc Efm-isolates.
Results: Enterococci were present in all samples, identiﬁed as Efm (14),
Eﬂ (3) and Enterococcus sp (3). Overall a high incidence of antibiotic
resistance was detected: tetracycline-85% (17/20), minocyclin-45%
(9/20), erythromycin-40% (8/20), ciproﬂoxacin-35% (7/20), High Level
of Resistance (HLR) to gentamicin-15% (3/20), HLR-streptomycin-
5% (1/20) and ampicillin-10% (2/20). Resistance to tetracyclines was
associated to tetM+tetL (13 Efm) or tetM (3 Eﬂ), while erythromycin
resistance was linked to ermB (6 Efm). esp and acmEfm genes were
detected in 3 Eﬂ from a Przewalski horse and in all Efm, respectively.
purK1 was identiﬁed in 2 Efm highly resistant to ampicillin and
ciproﬂoxacin, from a Bactrian camel.
Conclusion: Even though inhabiting remote areas with extremely low
human pressure, the critically endangered Silk Road fauna surpris-
ingly harbours bacteria carrying antibiotic resistance and virulence
determinants. Moreover, the unexpected detection of genetic traits
commonly associated with worldwide nosocomial epidemic strains
(purK1, ampicillin and ciproﬂoxacin resistance, acmEfm and esp) shows
that drug resistance, far from limited to hospitals, may be spreading into
the most remote areas of the globe.
O301 Spread of vancomycin-resistance among Enterococcus fae-
calis: the inﬂuence of pAD1 and Inc18-plasmids (1987–2005)
A.R. Freitas, P. Ruiz-Garbajosa, M.V. Francia, C. Novais, M.J. Zervos,
S. Donabedian, L. Peixe, F. Baquero, T.M. Coque* (Porto, PT; Madrid,
Santander, ES; Detroit, US)
Objectives: Vancomycin resistance (VR) is more often associated with
Enterococcus faecium than E. faecalis (Efc). However, the spread of
VREfc is of concern since vancomycin-resistant Staphylococcus aureus
(VRSA) have mostly been isolated in patients co-colonized with Efc
containing Inc18-like VanA plasmids. Plasmid diversity among VREfc
was analyzed in order to better understand the scarce dissemination of
VR within Efc and the potential transferability to other hosts.
Methods: 33 VREfc (28 vanA, 4 vanB, 1 vanG) representative of clonal
outbreaks in 13 countries (Argentina, Australia, Brazil, Chile, Cyprus,
Hungary, Italy, Pola nd, Portugal, Serbia, Spain, UK, and USA; 1987–
2005) were analyzed. They correspond to 19 PFGE types/17 STs, mostly
of CC2, CC9 and CC87. Van-Tns were typed by PCR and sequencing.
Plasmid analysis included transferability assays, determination of size
and plasmid content (PFGE-S1), comparison of EcoRI/ClaI-RFLP
proﬁles of van-plasmids, identiﬁcation of relaxases (rel), replication
initiator proteins (rep), and 5 toxin-antitoxin systems (TA) by PCR.
Results were conﬁrmed by S1/I-Ceu-I-hybridization and sequencing.
Results: VREfc contained a variable number of plasmids (1−4/cell;
20–200kb) with variable sequences: rep [rep-pAD1 (91%), rep-Inc18
(58%), rep-pRE25 (42%), rep-pAMx1 (21%), rep-pAM373 (12%), rep-
pTEF1 and rep-pHTB (9% each)], rel [rel-pAD1 (91%), rel-Inc18
(20%), rel-pAMx1 (36%), rel-pCF10 (24%), rel-pHTB (6%), rel-pRUM
(3%)], and TA systems [par (70%), Axe-Txe and w-e-z (9% each)].
While vanB-Tn5382 and vanG were chromosomally located, vanA-
Tn1546 was identiﬁed on plasmids (30–200kb), some types identiﬁed
in different countries over years. Most vanA-plasmids hybridized with
rel, rep and/or par genes from pAD1 in different combinations, and
often with rep-Inc18. Plasmids from VREfc isolated besides vanA-
S. aureus in Michigan-USA contained rel-Inc18 which was identical
to those of pRE25. Differences in VanA plasmid size and rep/rel/TA
content between wild types and transconjugants were frequent (50%).
Conclusions: Most vanA-plasmids from VREfc are mosaic derivatives
of pheromone-responsive pAD1 and Inc18 plasmids. Both the pAD1
narrow host range and the frequent rearrangements observed during
conjugation are consistent with the maintenance of pAD1-Tn1546 within
the Efc species. The transferability of VREFc plasmids to S. aureus
seems to be associated with the broad host conjugative module of
Inc18 plasmids.
O302 Emergence of MRSA ST130 in humans
C. Cuny*, F. Layer, W. Witte (Wernigerode, DE)
Objective: Staphylococcus aureus ST130 was reported so far from
mastitis in cattle in UK (1), also MRSA ST130 containing a new mec-
determinant was described (2). Here we report the characterization of
mecA negative MRSA ST130 isolates from infections in humans.
Methods: MRSA isolates ST130 were obtained from 6 patients treated
in different German hospitals (5 wound infections needing surgical
intervention, 1 colonization). Typing by means spa- typing und MLST,
and microbroth assay for AST were performed as described previously
(3). For detection of sets of resistance- and virulence associated genes
the microarray platform array-mate “Staphtype” from Alere was used.
Primers for the detection of an alternative mec gene were deduced from
the whole genome nucleotide sequence of S. aureus LGA 251 ([2],
Sanger centre databank).
Results: Of the isolates investigated 5 exhibited MLST ST130, one a
new ST; spa- types were t843, t1736, and t1773. The isolates were
phenotypically resistant to oxacillin and to oxacillin/sulbactam only. PCR
for the alternative mec-gene known for MRSA ST130 from UK (2) was
positive. The isolates were negative for sak, chp, and scn, and as expected
positive for hla, untruncated hlb, and hld, they furthermore contained
edinB, aur, slpA, slpB, slpE. From genes coding for surface and cell
wall associated products the ica-operon, cap8, clfA, clfB, ebpS, fnbA,
fnbB, sdrC were detected but not cna. The isolates were positive for a
number of set determinants and negative for enterotoxin genes and tst,
as well as for eta, and etb. agr-type was III.
Discussion: The alternative mec gene and the pattern of virulence
associated genes widely correspond to S. aureus/MRSA ST130 from
cattle in UK (1,2). Therefore transmission from animal sources and a
zoonotic potential with respect to infections in humans seem likely. The
lack of the innate immune evasion operon is typical for most of S. aureus
isolates of primarily animal origin, probably other enzymes (aur) take
over this function. For the interdisciplinary surveillance of further spread
proper AST and conﬁrmation by PCR for the alternative mec gene are
important.
O303 High prevalence of EMRSA-15 in Portuguese public buses:
a worrisome ﬁnding
M. Aires-de-Sousa*, R.R. Simo˜es, T. Conceic¸a˜o, F. Antunes, P. Martins
da Costa, H. de Lencastre (Lisbon, Porto, Oeiras, PT; New York, US)
Objectives: The nosocomial prevalence of methicillin resistant Staphylo-
coccus aureus (MRSA) in Portugal remains one of the highest in Europe
and is currently over 50%. Transmission of S. aureus, including MRSA,
occurs principally by direct human-to-human skin contact. However,
S. aureus can survive for long periods on inanimate objects, which
may represent an important reservoir for dissemination as well. The
aim of the present study was to explore the role of hand-touch surfaces
in Portuguese public buses as a reservoir of MRSA and provide insights
into the genetic background of the isolates.
Methods: Between May 2009 and February 2010, handrails of 85
public urban buses circulating in Oporto, Portugal, were screened for
the occurrence of MRSA. All isolates were tested for antimicrobial
susceptibility and for the presence of mecA and Panton-Valentine
leukocidin (PVL) genes. Moreover, the isolates were characterized
by pulsed-ﬁeld gel electrophoresis (PFGE), staphylococcal cassette
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chromosome (SCC) mec typing, spa typing, and multilocus sequence
typing (MLST).
Results: Twenty-two (26%) out of the 85 buses showed MRSA
contamination. The molecular characterization of a total of 55 MRSA
clustered the isolates into three clonal types. Nevertheless, the
overwhelming majority (n = 50; 91%) of the isolates belonged to a single
non-multidrug resistant clone (PFGE A, spa types t747, t032, t025 or
t020, ST22, SCCmec type IVh). This clone exhibits the characteristics
of the pandemic EMRSA-15, currently the major lineage circulating in
Portuguese hospitals, namely in the Oporto region. Two additional clones
were found but in much lower numbers: (i) PFGE B, ST5, spa type t002,
SCCmec IVa (n = 3), and (ii) PFGE C, spa type t008, ST8, SCCmec IVa
(n = 2). None of the 55 isolates was PVL positive.
Conclusions: Public buses in Oporto are an important reservoir of
MRSA of nosocomial origin, providing evidence that the major hospital-
associated MRSA clone in Portugal is escaping from the primary
ecological niche of hospitals to the community environment. Infection
control measures are urgently warranted to limit the spread of EMRSA-
15 to the general population and avoid a massive increase of MRSA in
the Portuguese community, which so far remained low.
O304 Epidemiology of invasive group A streptococci in Canada
from 2000–2009
J.N. Kanji*, M. Lovgren, D.E. Low, L. Hoang, A. Bougault, P. Van
Caeseele, G.B. Horsman, G.J. Tyrrell (Edmonton, Toronto, Vancouver,
Sainte-Anne-de-Bellevue, Winnipeg, Regina, CA)
Objective: The objective of this report is to present invasive Group
A streptococcal (iGAS) M typing, antimicrobial susceptibility, iGAS
specimen source and ages affected by iGAS disease from isolates
collected in Canada from 2000–2009.
Methods: From 2000–2009, The National Centre for Streptococcus
received iGAS isolates for analysis. This analysis included serological M
typing (2000-August 2006) and emm typing (September 2006 to 2009)
and patient. Antimicrobial susceptibility was performed using reference
disk diffusion methods as per CLSI.
Results: Over the 10 year period, 9725 iGAS isolates were assayed.
The age distribution of iGAS cases was 14.3% (<1−15 years), 38.5%
(25−45 years), 17.1% (46−59 years), and 30.1% (60–110 years). The
ten most prevalent M types were M1 (2046 isolates, 21%), M3 (700
isolates, 7.2%), M12 (624 isolates, 6.4%), M59 (547 isolates, 5.6%),
M4 (416 isolates, 4.3%), M89 (379 isolates, 3.9%), M28 (347 isolates,
3.6%), M11 (257 isolates, 2.6%), M5 (245 isolates, 2.5%), and M77
(244 isolates, 2.5%). Nontypeable isolates prior to September 2006
comprised 11.6% (1126) of isolates. The three provinces submitting
the highest number of isolates were Ontario (38.1%, 3704 isolates),
Alberta (19.9%, 1938 isolates), and British Columbia (15.5%, 1508
isolates). Together, these three provinces made up 63% of the Canadian
population in 2009. The four most common M types from blood, brain,
and cerebrospinal ﬂuid were M1 (13.7%), M3 (5.4%), M12 (4.3%), and
M59 (3.4%). Antibiotic susceptibility testing showed 11.5% resistance
to erythromycin and 7.9% had inducible clindamycin resistance (ICR).
The highest resistance rates were seen in M12 isolates (10.4% for
erythromycin and 5.3% ICR). M1 isolates showed a clear seasonality
trend as did M12 isolates. M3 showed regular seasonal variation except
between May 2003-December 2004. Overall, there was regular seasonal
variation noted of iGAS disease except for the same period as seen for
M3.
Conclusions: From 2000–2009, ten different M types constituted 60%
of the iGAS isolates M/emm typed in Canada. M1 continues to be the
most common circulating M type. Since our last report, there has been an
increase in M59 iGAS isolates, accounted for by an epidemic that began
in January 2006. An increase in M28 iGAS infections from January
2006 to 2009 compared to 2000–2004 was noted as well. The highest
level of erythromycin and ICR was seen in the M12 strains.
O305 Prevalence and molecular characteristics of MRSA
colonisation among adult patients visiting emergency
department in a medical centre in northern Taiwan
S.-Y. Lu, F.-Y. Chang*, C.-C. Cheng, K.-D. Lee, Y.-C. Huang (Kuei
Shan Hsiang, TW)
Objective: To understand the carriage rate of methicillin-resistant
Staphylococcus aureus (MRSA) among the adult patients visiting
emergency department (ED) in a tertiary care hospital in northern
Taiwan.
Methods: From May 21 to August 12, 2009, a total of 502 adult patients
visiting ED were surveyed for nasal carriage of MRSA. A questionnaire
regarding the risk factors for MRSA acquisition was obtained. All MRSA
isolates were further characterized.
Results: The overall prevalence of S. aureus and MRSA nasal carriage
among the patients was 17.3% and 3.8%, respectively. MRSA carriage
rate of the patients with risk factors (13/219, 5.9%) was signiﬁcantly
higher than that of those without risk factors (6/283, 2.1%). Patients
with urinary complaints, diabetes mellitus (DM), chronic kidney disease
and usage of catheters or tubes were signiﬁcantly associated with MRSA
colonization. After multiple logistic regression analysis, only current
usage of catheters or tubes was the independent predictor for MRSA
nasal colonization. Of the 19 MRSA isolates for molecular analysis, a
total of 6 pulsed-ﬁeld gel electrophoresis (PFGE) patterns were identiﬁed
and most isolates were clustered in three patterns (A, 21%; C, 32%
and D, 26%). Most MRSA isolates belonged to one of two lineages
characterized as sequence type 239/SCCmec III/PVL-negative (32%)
and ST59/SCCmec IV or VT/PVL-positive (58%). The latter linage,
accounting for 83% of 6 isolates from patients without risk factors, is a
community-associated (CA) clone in Taiwan, while the former linage is
among healthcare-associated clones.
Conclusion: In 2009, 3.8% of adult patients visiting ED of a Taiwanese
medical center were colonized with MRSA in nares; the rate was
even higher for those with risk factors. Most isolates were CA-MRSA,
particularly those from patients.
O306 A case-control study comparing infections due
Staphylococcus aureus with Panton-Valentine leucocidin
(PVL) to those without PVL
P. Boan*, J. Pearson, G. Coombs, C.H. Heath, H.L. Tan,
K. Christiansen, J.O. Robinson (Perth, AU)
Objective: Staphylococcus aureus toxin Panton Valentine Leucocidin
(PVL) has been associated with invasive soft tissue infections and
necrotizing pneumonia, but its causative role has been questioned. Thus,
we aimed at comparing clinical and outcome data of PVL positive
(PVL+) and PVL negative (PVL-) Staphylococcus aureus invasive
infections irrespective of methicillin resistance.
Methods: A retrospective case control study of all PVL+ and a random
selection with a 1:1 ratio of contemporaneous PVL− invasive infections
was performed in a tertiary referral centre. PVL detection was performed
systematically on all methicillin resistant strains and on only invasive
infections for methicillin susceptible strains.
Results: From September 2007 to January 2009, 141 PVL+ infections
were identiﬁed and 148 PVL− were randomly selected. In the PVL+
group 62 (44%) isolates were methicillin resistant (MRSA) compared to
56 (38%, p = 0.29) in the PVL− group. PVL+ were signiﬁcantly younger
(median 35 [range 15−86] vs 59 [16−99], p< 0.01), more frequently
indigenous (34% vs 12%, p< 0.01) and intravenous drug users (16%
vs 7%, p = 0.01) compared to PVL-. Furthermore their infection was
more commonly community acquired (62% vs 24%, p< 0.01). However,
PVL+ less frequently had solid tumours (1% vs 10%, p< 0.01) or
haematological malignancy (0% vs 4%, p = 0.02) or been hospitalised in
the past year (36% vs 62%, p< 0.01). Skin/soft tissue infection accounted
for 82% of PVL+ infection compared to 64% for the PVL− group
(p< 0.01) whilst bacteraemia was less frequent (9% vs 25%, p< 0.01).
Need for surgery was more common in PVL+ (73% vs 45%, p< 0.01).
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PVL+ isolates demonstrated lower resistance rates for clindamycin (12%
versus 27%, p< 0.01) and erythromycin (14% versus 28%, p< 0.01).
Clindamycin or linezolid was more frequently added to PVL+ infection
(31% vs 13%, p< 0.01), however the beneﬁt of this strategy was not
evaluable as these antibiotics were probably given to the sicker patients.
Although 7 and 30-day mortality were similar between groups, the length
of stay was shorter in PVL+ compared to PVL− (median 5 [0−81] vs
14 [0–638], p< 0.01).
Conclusion: In our region, more than half of PVL+ S aureus are
methicillin susceptible. PVL is strongly associated with skin/soft tissue
infections in young, indigenous and/or intravenous drug users and is a
burden to our health system as 73% required surgical intervention.
O307 Confounding in determining attributable mortality of
methicillin-resistant Staphylococcus aureus bacteraemia: a
meta-analytical approach
H. Ammerlaan*, M.J. Bonten (Utrecht, NL)
Objectives: It has recently been estimated that, each year, 5400
persons succumb due to nosocomial MRSA infections in Europe.
However, quantifying attributable mortality is difﬁcult as the causal
linkage between infection and outcome can be confounded by multiple
determinants. In this meta-analysis we aimed to quantify the mortality
risk associated with methicillin-resistant [MRSA] vs. methicillin-
susceptible S. aureus [MSSA] bacteraemia, and to determine the effect
of confounding factors hereon.
Methods: PubMed was searched from 1975 through January 2010
using the terms ‘aureus’ and(‘bacteraemia’ or ‘blood stream infection’)
and(‘outcome’ or ‘mortality’ or ‘death’).
Unadjusted odds ratios [OR] and 95% conﬁdence intervals [CI] were
calculated on the basis of the primary data reported in the study. We
pooled adjusted ORs for those studies that reported adjusted ORs and
did subgroup analyses of studies that corrected for key confounding
variables (i.e., adequacy of treatment, comorbidity and severity of
underlying illness (or length of stay before onset as a proxy)). The
attributable mortality risk [AMR], providing information about the
excess risk of dying in patients with MRSA compared with patients
with MSSA bacteraemia, was calculated with the formula: AMR =
p0(OR*(p0/1 − p0)/1 + OR*(p0/1 − p0)), in which p0 = mortality risk for
MSSA bacteraemia. AMR for unadjusted and adjusted ORs are provided.
Results: 73 studies were selected: 42 retrospective en 25 prospective
cohort studies and 6 case-control studies, comparing MRSA and MSSA
related mortality in 6310 and 11812 patients, respectively. The pooled
unadjusted odds ratio [OR] was 2.05 (95%CI 1.82–2.30) (I2 = 39%,
number of studies [n] = 73 (18122 patients), with an AMR of 13%.
Adjustment for confounders was available for 35 studies. The pooled
adjusted OR was 1.66 (95%CI 1.45–1.91) (I2 = 34%, n = 35 (11383
patients)), yielding an AMR of 9%. Adjustment for the key confounding
variables yielded a pooled adjusted OR of 1.25 (95%CI 0.91–1.73) (I2
= 67%, n = 7 (2774 patients)), corresponding with an AMR of 4%.
Conclusion: The results of our meta-analysis demonstrate the dis-
crepancy between unadjusted and adjusted study results, yielding a
decreasing association between methicillin resistance and mortality after
adjustment for treatment, comorbidity and severity of illness. Adjustment
for these variables is mandatory when attempting to quantify attributable
mortality of antibiotic-resistant pathogens.
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O308 Viral respiratory tract infection in preschool children: the
burden and impact of co-infection
Z. Wake, N. Conway, S. Williams, A. Keil, D. Smith, P. Richmond,
C. Blyth* on behalf of the WAIVE study
Objectives: Respiratory tract infection is a frequent problem in
childhood. Contemporary studies are required given the identiﬁcation of
emerging viral pathogens and improved diagnostics. The impact of viral
co-infection remains uncertain. We undertook to describe the virology
of symptomatic respiratory tract infection in preschool children and to
determine the burden and impact of viral co-infection.
Methods: An observational study assessing inﬂuenza vaccine effective-
ness was conducted in Perth, Australia (winter 2008/2009). Preschool
children (6 months-5 years) presenting with fever (>37.5ºC) and
acute respiratory symptoms were eligible. Demographics, risk factors,
clinical features, therapies and outcomes were recorded by parental
questionnaire. Antigen detection, PCR and viral culture were performed
on per-nasal samples.
Results: Per-nasal samples were available from 919/944 subjects.
Frequent symptoms included rhinorrhoea (802; 87.3%), cough (795;
86.5%), poor feeding (687; 74.7%) and irritability (608; 66.2%).
Respiratory viruses were identiﬁed in 711 (77.4%) with outcome data
available for 566 children. Hospital admission was required in 144/566
(25.6%). Rhinovirus (n = 239), RSV (n = 210) and inﬂuenza virus
(n = 179) were most frequently detected followed by human bocavirus
(n = 79), parainﬂuenza viruses (n = 73), coronavirus (n = 64), adenovirus
(n = 49) and human metapneumovirus (n = 20).
Inﬂuenza infection was more frequently associated with hospital
admission compared with other viruses (inﬂuenza 49/151; 32.45% vs.
RSV 27/161; 16.8% vs. other 46/266; 17.3%, both analyses p< 0.002).
The rate of hospitalisation with inﬂuenza in 2008 was not signiﬁcantly
different than in 2009: 29/73 (39.7%) in 2008 compared with 20/78
(25.6%) in 2009.
Viral co-infection was observed in 197/711 (27.70%) with rhi-
novirus/RSV the most frequent co-infection: 41/197; 20.8%. Clinical
features (mean peak temperature; frequency of symptoms) and outcomes
(hospitalisation; antibiotic prescription) were not signiﬁcantly different
between co-infected and non co-infected children. Subgroup analysis
of children with inﬂuenza or RSV didn’t demonstrate any signiﬁcant
differences between co-infected and non-coinfected children.
Conclusions: This study demonstrates the frequent identiﬁcation of
emerging pathogens including coronaviruses, human bocavirusand
human metapneumovirus. Inﬂuenza remains a signiﬁcant pathogen in
young children. Co-infection has little impact on clinical features or
outcome.
O309 Inﬂuence of the respiratory virus species and multiple viral
infections on bronchiolitis severity in hospitalised infants
L. Andreoletti*, A. Huguenin, F. Renois, D. Talmud, L. Moutte,
M. Abely, F. Carrat, N. Leveque (Reims, Paris, FR)
Objectives: Bronchiolitis is an important manifestation of viral
respiratory tract infections (RTIs). However, the inﬂuence of the virus
respiratory species and multiple viral infections on bronchiolitis severity
is poorly understood because of the limited scope and throughput of
conventional viral detection methods.
Methods: We prospectively performed a large viral screening by a RT-
PCR microarray system to detect single and multiple RTIs in 138 infants
aged less than 12 months and hospitalized for bronchiolitis in Northern
East of France from October 2007 to September 2008.
Results: The RT-PCR microarray system detected viruses in a higher
proportion of samples (91%) than did classical immunoﬂuorescence and
viral culture isolation assays (70%) (P< 10−3). The RT-PCR microarray
system identiﬁed 85 multiple infections cases whereas none was detected
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by the classical techniques. The most common associations were:
human respiratory syncytial virus (hRSV) and human bocavirus (32%),
hRSV and adenovirus (29%), hRSV and parainﬂuenza 3 (24%) and
adenovirus and human bocavirus (13%). Infants infected by hRSV had
longer duration of hospitalization in comparison with infants infected
by other viruses (P = 0.006), and our multivariate analysis adjusted on
age indicated an increase in hospitalization length of 1.7± 0.6 days
(P = 0.04). No other virus or association of viruses appeared to have a
signiﬁcant impact on the bronchiolitis severity parameters (P> 0.12).
Conclusion: Our ﬁndings indicated that only hRSV species could
cause more severe bronchiolitis. Given the large panel of multiple viral
infections detected here, larger-scale studies will be necessary to assess
whether speciﬁc viral associations could confer an elevated risk of severe
bronchiolitis.
O310 Group C rotavirus infection and VP6 diversity in children,
Brazil 2007–2010: monitoring a potential impact of rotavirus
vaccination programme
A. Luchs*, S. Morillo, C. Oliveira, M. Timenetsky (Sa˜o Paulo, BR)
Objectives: Group C rotavirus (GpCRV) has a worldwide distribution,
increasingly recognised as a signiﬁcant cause of diarrhoea in children,
however their epidemiology and ecology are still unclear. It seems
important to improve the GpCRV laboratory surveillance system,
especially after 2006 when the RIX4414 rotavirus vaccine was
included in Brazilian Immunization Program, preventing severe rotavirus
gastroenteritis, and inducing signiﬁcant reduction in the frequency of
Group A rotavirus (GpARV) detection in children with gastroenteritis.
Moreover, an evidence for a possible zoonotic role of GpCRV has been
recently postulated for Brazilian children strains. The aim of this work
was to monitor GpCRV in children 15 years with acute gastroenteritis
during 2007–2010 national Brazilian rotavirus surveillance, and perform
the molecular characterization of the major VP6 capsid protein.
Methods: A total of 3019 faecal samples were ﬁrst screened for GpARV.
A total of 2205 GpARV ELISA negative samples were further tested for
the presence of GpCRV by SDS-PAGE, electronic microscopy, and RT-
PCR for the VP6 gene. The genetic diversity of GpCRV was carried out
by sequencing of VP6 gene.
Results: GpARV and GpCRV infection were detected in 27.0%
(814/3019), and 0.3% (8/3019), respectively. GpCRV detection rate
increased from 0.2% (1/422) in 2007 to 1.0% (7/708) in 2008, and no
GpCRV cases were detected in 2009 and 2010. The phylogenetic analysis
indicated that the strains belonged to the human lineage, were related
to each other, since they shared 97–100% amino acid identities in the
VP6 gene. None of the study sequences was closely related to animal
GpCRV strains. GpCRV Brazilian strains showed a genetic relationship
with GpCRV strains from Japan, especially from Yokohama city isolated
in 2008 and 2009.
Conclusions: This study adds further proof that GpCRV is a minor
cause of acute childhood gastroenteritis in Brazil, and does not suggest
that GpCRV may be assume epidemiological importance in the future,
even after the GpARV vaccine introduction. In particular, the molecular
analyses of GpCRV samples in this study do not support the zoonotic
hypothesis. The relationship between Brazilian and Japanese GpCRV
strains may be a reﬂect of the signiﬁcant migration ﬂow. Currently, Brazil
is the country with the largest number of Japanese outside Japan.
O311 Congenital CMV infection: clinical outcome according to
the serological status of the mother
A. Naessens*, I. Foulon, A. Vorsselmans, A. Jansen, M. Leyder,
W. Foulon (Brussels, BE)
Objectives: To determine the type and incidence of sequelae found in
children with a congenital cytomegalovirus infection (cCMV) in relation
to the serological status of the mother during pregnancy.
Methods: In a prospective 13-year study, 18219 mother/infants pairs
were included. In the mother a serological screening was performed
consisting in the detection of CMV IgG and IgM antibodies at the
ﬁrst prenatal visit and at birth. In the neonate CMV urine culture was
performed to diagnose congenital infection. Late trimester abortion or
death in utero were investigated in order to diagnose congenital CMV
infection. Live born infants were evaluated for the appearance of auditive
and neurological sequelae.
Results: 118 consecutive cases of cCMV were detected (0.64%). 54
(46%) were caused by a primary maternal infection, 33 (28%) by a
non primary, and in 31 (26%) the type of maternal infection could not
be determined. Of the 118 cases, 111 were live born, 1 resulted in a
death in utero and in 6 other pregnancies a termination of pregnancy
(TOP) was performed. From the 54 cases of primary infection, 4 TOP
were performed from whom 1 with signs of congenital cytomegalovirus
on ultrasound (US). From the 50 live born children after primary
infection, 1 was born with symptomatic disease, 3 other children
developed psychomotoric retardation all or not with hearing deﬁcit,
and in 4 children isolated hearing loss was found. In the non primary
infection group 1 TOP was performed because of hydrocephalus, 1
infection resulted in a death in utero, 1child suffered from severe mental
retardation and 1 child had bilateral hearing loss. In the unclassiﬁed
infection group, 1 TOP was performed because of US abnormalities, 1
child suffered from severe psychomotoric retardation and 7 demonstrated
isolated hearing loss.
Conclusions: In our population the incidence of cCMV is 0.64%.
Sequelae are found in at least 16% of the cCMV in 7% the sequelae
were considered severe. Severe sequelae are seen in primary as well as
in non primary cCMV.
O312 DEVANI UK clinical screening study for maternal carriage
of Streptococcus agalactiae
B. Afshar*, A. Vickers, K. Morton, E. Demertzi, I. Hassan, S. Stock,
J. Telford, G. Oreﬁci, A. Efstratiou (London, Guildford, Manchester,
Edinburgh, UK; Siena, Rome, IT)
Objectives: Streptococcus agalactiae (Group B Streptococcus, GBS) is a
leading cause of neonatal sepsis, meningitis & pneumonia affecting 1−2
newborns/1000 live births in Europe. The DEVANI (DEsign of a Vaccine
Against Neonatal Infections) programme funded through the European
Commission Seventh Framework and coordinated by Novartis Vaccines
was launched on 1 January 2008 (www.devaniproject.org). The main
objective of this 3.5 year project is to assess European GBS epidemiology
in order to facilitate the design of a new vaccine capable of conferring
broad coverage to immunize neonates against GBS infections through a
durable maternal immune response. A key component of the programme
was to undertake a multicentre surveillance study of maternal GBS
colonisation, maternal GBS antibody levels and neonatal GBS infection
in the UK.
Methods: Four UK centres from different geographical locations
participated. Maternal vaginal/rectal swabs and serum samples were
taken between 34−37 weeks gestation and processed using a standardised
microbiological screening protocol. Samples from neonatal cases (early
onset disease; EOD & late onset disease; LOD) were processed using
local procedures. GBS isolates were characterised at the HPAMSD using
standardised serological and molecular typing methods based on the
Strep-B-Latex agglutination kit & a novel multiplex PCR assay which
detects all ten GBS capsular polysaccharide types (Ia to IX). Maternal
sera from colonised & non-colonised women together with maternal and
neonatal GBS isolates were submitted to Rome for analysis.
Results: A total of 650 pregnant women were recruited between 34−37
weeks gestation, from June 2009 to April 2010, of which 170 were
colonised with GBS (incidence rate ~26%). GBS isolates from 16
neonatal cases (13 EOD & 3 LOD) together with corresponding maternal
sera were also obtained. The most common GBS capsular types were III
(33%), Ia (26%) & V (17%), respectively.
Conclusion: In contrast to most EU countries, the UK does not offer
routine GBS antenatal screening however, results from the clinical
studies that we have undertaken should raise more awareness and support
routine GBS screening for the prevention of early-onset neonatal GBS
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disease in the UK. The maternal incidence rate of 26% is consistent with
the rates quoted in other European countries. The ﬁnal outcomes of the
DEVANI programme should signiﬁcantly contribute to the reduction in
neonatal GBS disease incidence in Europe and beyond.
O313 Retrospective study of Staphylococcus aureus bacteraemia
in an Irish neonatal intensive care unit: epidemiology, risk
factors and management
K.J. O’ Connell*, K. Grundy, T. Clarke, M. Cafferkey (Dublin, IE)
Objectives: The Rotunda Hospital, Dublin is a maternity hospital with
a 39-bedded tertiary level neonatal intensive care unit (NICU). We
examined the prevalence and epidemiology of S. aureus bacteraemia
(SAB) in our NICU, the risk factors for, and management of this infection
over a 78-month period (1st January 2004–30th June 2010).
Methods: The laboratory information system was used to identify
all neonates with SAB in this time period. Case notes were
reviewed for information on demographics, admission days prior
to bacteraemia, whether community-acquired (CA)/hospital-acquired
(HA) or healthcare-associated (HCA), focus of infection, risk factors,
management and outcome.
Results: We identiﬁed 54 episodes of SAB in 54 neonates in the 78-
month time period. 16/54 (30%) episodes occurred in infants of multiple
pregnancies. All S. aureus isolates were meticillin-sensitive. HA-SAB
accounted for the majority: 48/54 (89%) followed by CA-SAB in 5/54
(9%) and HCA-SAB in 1/54 (2%). The age range at onset of bacteraemia
was 2−65 days (average 13 days).
The focus of infection was unknown in 23/54 (43%), peripheral venous
catheter-related in 15/54 (28%), central venous catheter-related in 10/54
(19%), skin infection in 4/54 (7%), bone in 1/69 (1.5%) and urinary
tract in 1/69 (1.5%).
Many neonates had more than one risk factor for SAB. The most
common risk factors included: prematurity in 43/54 (80%), previous
antibiotics in 38/54 (70%), peripheral venous catheter (PVC) in 38/54
(70%), central venous catheter (CVC) in 33/54 (61%), mechanical
ventilation in 30/54 (56%), and blood transfusion in 18/54 (33%).
Treatment was primarily with intravenous ﬂucloxacillin in 51/54 (94%)
neonates. Sterile blood cultures following commencement of antibiotics
were documented in 36/54 (67%). No patient experienced a relapse of
infection but 10/54 (19%) had complications: osteomyelitis in three,
concurrent osteomyelitis and meningitis in one, abscess formation in
ﬁve. One baby born at 25 weeks gestation with a CVC-related SAB
died from extreme prematurity and sepsis. 7 out of 10 (70%) infants
with complications had intravascular catheter-related infections.
Conclusions: There were no cases of SAB caused by meticillin-resistant
S. aureus in the study period. The majority were due to HA-SAB and
all were classiﬁed as late-onset sepsis. The focus of infection was line-
related in 47% of cases.
O314 The prevalence of Helicobacter pylori cagA, vacA, iceA,
babA genotypes in Polish children with gastroduodenal
diseases: impact on histology
M.M. Biernat*, B. Iwanczak, M. Rzeszutko, J. Grabinska, P. Biernat,
G. Gosciniak (Wroclaw, PL)
Objectives: Determination of the occurence of selected virulence-
associated genes, such as: cagA, vacA, iceA, and babA gene in H. pylori
clinical isolates and to characterize their association with histopatological
changes in the gastric mucosa.
Methods: The study was performed on 137 H. pylori strains collected in
years 2006–2009. The strains were isolated from antral biopsy specimens
of children, aged 2−18 years, diagnosed because of dyspeptic complaints.
The diagnosis in children was established on the basis of endoscopic,
histopathological and clinical ﬁndings. Two groups of patients were
evaluated: children with chronic gastritis (n = 114) and with peptic or
duodenal ulcers (n = 23). The H. pylori infection was was determined
by bacteriological and histological examination. The genes encoding
speciﬁc virulence factors, such as: vacA (s1/s2, m1/m2), allelic variants
of iceA gene (iceA1, iceA2), babA were determined by polymerase chain
reaction.
Results: The cagA gene was detected in 86/137 (62,7%) of H. pylori
isolates. The presence of cagA gene was signiﬁcantly associated
with duodenal ulcer and chronic gastritis (p< 0,05). Distribution of
vacA genotype was as follows: vacAs1/m1 was identiﬁed in 46/137
(33,6%) of strains, vacAs1/m2 in 42/137 (30,6%) and vacAs2/m2
in 49/137 (35,8%), respectively. IceA1 gene was present in 59/137
(43,1%) and iceA2 in 31/137 (22,6%) of the samples, respectively.
In 41/137 clinical isolates neither iceA1 nor iceA2, alleles were
detected. Six H. pylori strains isolated from children with chronic
gastritis possessed both iceA alleles 6/137 (4,38%). The babA gene
was detected in 31/137 (22,6%) strains. The presence of triple
H. pylori genotype vacAs1/cagA+/iceA1+/babA− was signiﬁcantly
associated with ulcers (17,4%, p = 0,002). The predominant genotype
in children with chronic gastritis was vacAs2/cagA-/iceA1+/babA-
(21/114,p = 0,00762). The degree of chronic inﬂammation signiﬁcantly
correlated with cagA-positive status and the presence of vacA s1/m1
alleles (p< 0,05) but not with the H. pylori density, activity nor atrophy.
A signiﬁcant correlation was found between the presence of babA and
iceA2 genes and degree of chronic inﬂammation (p = 0,046).
Conclusion: CagA, vacAs1 and iceA1 genes are predominant in children
with ulcers and cagA/vacAs1 genotype is signiﬁcantly associated with
chronic inﬂammation but not with other histopathological parameters.
The role of babA and iceA H. pylori genes in children needs further
studies.
O315 Outcome of prenatal toxoplasmosis: retrospective analysis
for effectiveness of pyrimethamine/sulfadiazine therapy
during pregnancy
A. Hruzik, H. Hlobil, U. Groß* (Go¨ttingen, Sindelﬁngen, DE)
Objectives: Whereas an infection with the protozoan parasite Toxo-
plasma gondii mostly is asymptomatic in immunocompetent patients,
primary infection during pregnancy might be health- or even life-
threatening to the foetus. Depending on the country, different treatment
strategies exist for the prevention of the parasite’s transmission from the
mother to the foetus or/and for the prevention of clinical manifestations
in the child. The German scheme of toxoplasmosis therapy during
pregnancy foresees spiramycin until 16th week of pregnancy (WOP)
followed by at least four weeks combination therapy with pyrimethamine,
sulfadiazine and folinic acid. Infections occurring at later WOPs are
directly entering the combination scheme. In other countries such as
France, only spiramycin is given unless infection of the foetus is proven.
The objective of this study was to evaluate the effectiveness of the
German therapeutical scheme of primary T. gondii infection during
pregnancy.
Methods: Data from 685 women, who showed a serological constellation
for primary infection during pregnancy were retrospectively analysed.
Thereby, (i) timing of initiation and type of toxoplasmosis therapy,
(ii) transmission rates to the foetus, and (iii) the ratio of infected
and clinically symptomatic children in utero respectively neonates was
examined.
Results: As expected, the transmission rate to the foetus increased with
the duration of pregnancy. In our cohort, there seems to be a trend
towards lower transmission rates (4.8%) and clinical manifestations in
the neonates (1.5%) in comparison to data published by other groups,
indicating that the German scheme of therapy seems to be effective.
Most important, an interval of more than 4−8 weeks between time of
infection and initiation of combination therapy seems to have a negative
effect on the clinical outcome of the newborn.
Conclusion: Rapid initiation of combination therapy based on
pyrimethamine and sulfadiazine and folinic acid after T. gondii infection
during pregnancy seems to be beneﬁcial for the child. Optimal screening
should therefore be performed at 4 weeks intervals. Prospective studies
are needed to conﬁrm our ﬁndings.
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O316 Clinical presentation and management of deep neck
infections in an Italian cohort of children and adolescents
F. Mignone*, C. Bertaina, S. Garazzino, C. Scolfaro, I. Raffaldi,
F. Peradotto, C. Gabiano, P.A. Tovo (Turin, IT)
Objectives: Deep neck infections (DNIs), although relatively rare in
children, can cause signiﬁcant morbidity and potentially life-threatening
complications. We analysed clinical and microbiological characteristics
of DNIs, including their relationships with age, in a paediatric case
series.
Methods: We retrospectively reviewed the medical records of children
and adolescents admitted to Regina Margherita Children’s Hospital,
Turin, Italy, for DNI between 2006 and 2010. DNIs were classiﬁed
as retropharyngeal, parapharyngeal, peritonsillar and mixed (with
parapharyngeal and retropharyngeal involvement), according to the site
of infection. Diagnosis of DNI was based on clinical and/or imaging
ﬁndings on CT scan.
Results: Thirty-one patients (21 males and 10 females, mean age 7.4
years, range 0.3–15.4) were studied: clinical and management details
are listed in Table 1. Males were preponderant in retropharyngeal and
parapharyngeal abscesses (80% and 100% respectively).
All children initially received intravenous antibiotics and then switched
to oral treatment, for a mean total duration of 25.4 days; the longest
duration was observed in retropharyngeal abscesses (31.6 days). 48.4%
of patients (mostly with a retropharyngeal abscess) underwent surgery
with incision and drainage or needle aspiration. No signiﬁcant difference
in length of hospitalization between patients who underwent surgery and
those who did not was observed (22 vs 23 days).
Severe complications occurred in 4 patients: two mediastinitis, one sepsis
and one abscess rupture. No patient had signs of recurrence of DNI at
the latest follow-up visit.
Microbiological cultures from infected sites yielded Streptococcus
spp. in 5 cases, mixed ﬂora (including anaerobes and aerobes) in
4 and Pseudomonas aeruginosa, Staphylococcus aureus and Gemella
morbillorum in one case each. Three cultures showed no growth.
Conclusions: Our study conﬁrms that clinical presentation of DNIs
in children may be unspeciﬁc and may overlap with other common
paediatric diseases. A signiﬁcant relationship between age and site of
infection was not observed, although 60% of retropharyngeal infections
involved children aged less than 4 years. Considering DNIs aetiology in
children, a prolonged antimicrobial therapy with a spectrum of activity
including aerobic and anaerobic bacteria is mandatory. Surgery is often
required to prevent life-threatening complications.
O317 Improving clinical quality and patient safety in cystic
ﬁbrosis paediatric patients. First multidisciplinary clinical
audit at a large district hospital of northwest England
R. Sharma*, E. Chang, S. See, A. Guleri (Blackpool, Blackburn, UK)
Background: Cystic ﬁbrosis (CF) is a multisystem disorder with
pulmonary disease the leading cause of morbidity and mortality.
Royal Blackburn hospital in northwest England has a large paediatric
CFunit. Preliminary to proposing an integrated carepathway for CF
management − a multidisciplinary clinical audit was undertaken.
Standards were recommendations of cystic ﬁbrosis trust consensus
(CFTC) [www.cftrust.org.uk].
Methods: Between Jan−Dec 2008, clinical data and laboratory database
on 24 CF patients was audited. Information on demographics, screening,
testing protocols, reporting and management of these patients was
obtained and compared against guidance from CFTC. The data speciﬁc
to Pseudomonas aeruginosa [PSA], MRSA and Burkholderia cepacia
complex [Bcc] is presented here.
Results: 24 paediatric patients aged 1−17yrs [male − 37.5% and female
62.5%] were included in this audit. Data on PSA, MRSA and BCC
is presented here. 33 organisms were isolated [PSA − 36% (12/33);
MRSA − 9% (3/33) and BCC − 6% (2/33)]. Respiratory samples must be
screened every 2-months − a compliance of 71% (17/24) was observed.
All new isolated of BCC and PSA must be sent to a reference laboratory
for genotyping − 100% compliance with BCC and 100% non-compliance
with PSA was noted.
Absolute compliance was noted for use of a combination of nebulised
colistin and oral ciproﬂoxacin for 3-weeks for new isolates of PSA. The
standard has no ﬁrm consensus on screening from non-respiratory sites
or eradication of MRSA. Compliance to screening of non-respiratory
sites [nose and groin] as per local policy remains variable; however cough
swabs and/or sputum are collected on every visit [100% compliance].
IV teicoplanin or vancomycin is used locally for eradication.
62.5% compliance to a turn-around-time of 72-hours was achieved while
the average time to reporting of samples was 77.6-hours. Signiﬁcant non
compliance was observed in local standard operating procedures [SOP]
for processing of samples from cystic patients [to be presented].
Conclusions: CF is one of UK’s most common life-threatening inherited
diseases. A multi-disciplinary team initiated integrated care pathway
for enhancing clinical quality and patient safety was envisaged. Results
from this audit have been used to draw up an action plan. Signiﬁcant
non-compliance were observed with laboratory SOPs; screening of non-
respiratory sites for MRSA; referring new PSA isolates for genotyping.
Details of result to be presented.
Visceral leishmaniasis: an endemic disease
with global impact
S322-S324 Visceral leishmaniasis: an endemic disease with global
impact
J. Alvar, S. Sundar, J.-P. Gangneux (Geneva, CH; Varanasi, IN;
Rennes, FR)
Visceral Leishmaniasis (VL) is the second most common protozoal
infection after malaria worldwide and affects approximately 2 million
people per year predominantly in sub-Saharan Africa and the Indian
subcontinent. Co-infection with HIV has become a major public health
threat in endemic areas. Therapy has been traditionally prolonged,
requiring affected individuals to remain in hospital or under medical
supervision for several weeks. Providing access to medicines is
problematic given the worst-affected regions tend to be poverty-stricken,
geographically remote or affected by conﬂict which makes it difﬁcult for
aid agencies to provide the treatment programmes required to address
the burden of care.
Non-governmental agencies such as the WHO, DNDi and MSF in
collaboration with VL specialists have been working to provide treatment
programmes as well as conduct clinical research with newer or better-
tolerated agents in order to establish shorter treatment times, optimise
therapeutic strategies and assess the cost-effectiveness of different
approaches.
This symposium will address the burden of disease and the steps the
NGO’s have been taking to manage VL as well as review the literature on
VL to discuss optimum therapy. This disease is also endemic in parts of
Europe and infects mostly HIV-infected adults and more rarely patients
with other T cell immune deﬁciencies such as solid organ transplant
patients or those receiving anti-TNF-a antibodies, although rare. The
symposium will also address the issue of VL as a differential diagnosis
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in European patients and whether data from studies in India and Africa
are relevant in Europe or on other continents.
Hospitalised CAP − penicillin/doxy vs FQ or
Ceph3/macrolide?
S339 Penicillin + [doxy or macrolide]
T. Gottlieb* (Concord, AU)
The treatment of hospitalised CAP is increasingly driven by ‘determin-
istic guidelines’. Guidelines take into account trial outcome data and
antibiotic resistance trends, but rarely factor in the ‘law of unintended
consequences’ − ie. that an intervention in a complex system often
creates unanticipated and undesirable outcomes. Guidelines provide an
evidence-based framework for therapy, but can also create a uniformity
that can be deleterious and short-sighted. Hence guideline choice
requires vision. Guidelines set standards of care, but these are nuanced by
different attitudes to the “philosophy” behind antimicrobial therapy and
risk-aversity. As example, using the ceph/quinolone option one can take
an outcome-based individual patient care approach (“broader is better at
all cost”) where fear of failure is paramount. This compares to a more
societal advocacy that favours narrow-spectrum therapy and attempts to
conserve antibiotics, aiming to avoid the collateral damage of increasing
antibiotic resistance (cf: C. difﬁcile, MRSA, ESBLs). It is illustrative
to speculate on the differences in international CAP guidelines wrt
b-lactams and quinolone use, and on the motivations that guide these.
Is the perception (risk) of the immediacy of individual patient failure
overriding concerns for the long-term loss of efﬁcacy and societal costs?
Yes, the use of 3rdG cephalosporins and/or quinolones may guarantee
success in CAP. But are these successes any more than when iv penicillin
is used with less fashionable drugs like tetracyclines or macrolides? And
at what cost? As will be presented, the data does not reveal a difference.
But broad-spectrum antibiotic use does not teach judicious antibiotic
use to impressionable health professionals − eg. resident doctors and
surgeons. It supports a culture of empiricism in ED departments, where
many ceph/quinolone treated patients do not have CAP on review, and
culminates in the domino effect of cephalosporin use. And it damages
the credibility of ID units − paying lip service to the concept of antibiotic
stewardship whilst using antibiotics indiscriminately for CAP.
The ‘Chaos Theory’ explains the behaviour in dynamic (chaotic) systems
that are highly sensitive to initial conditions, (of which healthcare is a
paradigm) ie. where small differences in initial choices yield widely
diverging long term outcomes. Chaos is promoted by broad-spectrum
antibiotics in CAP, penicillin presents a way back toward prescribing
Order.
MALDI-TOF: is it as good as we hoped
O343 MALDI-TOF identiﬁcation from BacTAlert blood cultures
in Cambridge, UK
M.J. Ellington*, N. Bentley, S. Pai, T. Gouliouris, J. Greatorex,
N.M. Brown, S.H. Aliyu (Cambridge, UK)
Objectives: MALDI-TOF mass spectrometry on samples direct from
positive blood cultures can yield a species identiﬁcation result within the
same time period as it takes to obtain a Gram stain result. We assessed
the accuracy of MALDI-TOF direct from blood cultures and the clinical
effect of the rapid MALDI-TOF result as compared to that of a Gram
stain result.
Methods: Positive BacTalert blood cultures from 92 patients were
processed and analysed by MALDI-TOF according to the manufacturers
recommendations (Bruker Daltonics Ltd). Four medical microbiologists
agreed the clinical actions, or recommendations made, on the basis of the
Gram stain result and compared with those retrospectively agreed based
on the MALDI-TOF result. The effects of the MALDI-TOF result were
categorised relative to the Gram stain result as: No difference, altered
patient management for public health purposes, and altered antimicrobial
therapy.
Results: Identiﬁcation: From 92 BacTAlert blood cultures, 83 direct
MALDI-TOF species identiﬁcations were made, three at the genus
level. Five specimens gave no reliable identiﬁcation. Gram stain
and biochemical identiﬁcation agreed with MALDI-TOF results in
82/83 cases, one Pseudomonas hibiscola isolate was identiﬁed as a
Stenotrophomonas maltophilia by biochemical ID. In three cases where
>1 organism was present in the blood culture MALDI-TOF identiﬁed
the primary pathogen.
Clinical impact: Compared with the Gram stain result, a rapid MALDI-
TOF result would have triggered changes to patient management in
17/92 cases. In 16/17 cases MALDI-TOF would have resulted in earlier
changes to empiric antimicrobial therapy; 9 instances of antimicrobial
withdrawal would have included 3 coagulase negative staphylococci,
one Lactobacillus rhamnosus and S. maltophilia, in 9 cases better
targeted antimicrobial(s) would have been added for bacteraemias due
to e.g. L. monocytogenes, K. pneumoniae and E. faecalis. In 6/17 cases
a rapid MALDI-TOF result would have effected changes to patient
management for infection control and public health reasons, including
two salmonellaceae, two S. pyogenes and one N. meningitidis.
Conclusion: MALDI-TOF results direct from BacTalert blood cultures
provided a rapid and accurate tool to aid laboratory diagnosis and
would have positively impacted care in a signiﬁcant proportion of cases.
When used in combination, Gram stain and improved MALDI software
algorithms will reliably identify mixed cultures.
O344 Clinical impact of direct matrix-assisted laser desorption
ionisation time-of-ﬂight mass spectrometry analysis on
positive blood cultures
A.L. Vlek*, M.J. Bonten, E. Boel (Utrecht, NL)
Objectives: Matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS) allows the identiﬁcation of
microorganisms directly from positive blood culture broths. Use of the
MALDI-TOF MS for rapid identiﬁcation of microorganisms from blood
culture broths can reduce the turnaround time to identiﬁcation and may
lead to earlier appropriate therapy of bacteremia.
The aim of this clinical trial was to assess the impact of performing
direct MALDI-TOF MS on positive blood cultures on turnaround time
and antimicrobial management.
Methods: During February and April 2010, direct MALDI-TOF MS was
routinely performed on all positive blood cultures. During December
2009 and March 2010 no direct MALDI-TOF MS was used. All blood
cultures that were positive during the study period were included.
Information on antibiotic therapy was collected from the hospital and
intensive care units’ information systems.
Results: In total, 253 episodes of bacteremia were included of which
89 during the MALDI-TOF period and 164 during the non-MALDI-
TOF period. 284 microorganisms were identiﬁed, mostly aerobic Gram
positive cocci (68.0%) and aerobic Gram negative bacilli (23.9%). 27
bacteremia episodes were polymicrobial.
The direct MALDI-TOF showed a correct identiﬁcation (spectral score
>1.7) in 56.2% of bacteremia episodes during the MALDI-TOF period
(n = 50). No identiﬁcation was obtained in 32.6% (n = 29, of which 5
polymicrobial), no MALDI-TOF was performed in 4.5% (n = 4) and the
MALDI-TOF correctly identiﬁed 1 of the microorganisms in 6 (6.7%)
polymicrobial blood cultures.
Median time from blood culture positivity until identiﬁcation was 16.4
hours (IQR 10.3–42.9) with MALDI-TOF versus 45.2 hours (IQR 35.5–
55.9) without MALDI-TOF (p< 0.001). In the MALDI-TOF period
median time until the ﬁrst switch in antibiotic therapy was 17.5 hours
(IQR 9.8–38.8) versus 24.0 hours (IQR 9.5–47.0) in the non-MALDI-
TOF period (p0.27).
In 57.3% of bacteremia episodes no switch in antibiotic therapy was
made (MALDI-TOF 55.0%, non-MALDI-TOF 58.5%). In 37.2% a
switch was made once (MALDI-TOF 41.6%, non-MALDI-TOF 34.8%)
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and in 5.5% a switch was made twice (MALDI-TOF 3.4%, non-MALDI-
TOF 6.7%).
Conclusions: Routinely performed MALDI-TOF directly on positive
blood cultures signiﬁcantly reduced identiﬁcation time with 28.8 hours.
However, routine implementation of this technique did not signiﬁcantly
accelerate antibiotic switching.
O345 MALDI-TOF mass spectrometry ID of bacteria directly
from cerebrospinal ﬂuid − what you see is what you get
J.V. Bjørnholt*, S.M. Nilsen, I. Noorland, M. Wigemyr, C.H. Løken,
F. Mu¨ller, A. Ingebretsen (Oslo, Nordbyhagen, NO)
Objectives: Fast and reliable identiﬁcation (ID) of bacteria in
cerebrospinal ﬂuid is of pivotal signiﬁcance for the correct treatment
of patients with infections in the central nervous system. Maldi-Tof MS
ID of bacteria from culture is fast and reliable and has in recent years
been introduced in many laboratories. The performance of MS on other
materials than culture is being investigated. We present results from
Maldi-Tof MS ID performed on 183 consecutive clinical spinal ﬂuid
specimens, of whom 14 were positive at culture. Further, spinal ﬂuid
samples were spiked with common pathogens at different concentrations
to evaluate the Maldi-Tof MS performance.
Methods: All Maldi-Tof MS (Bruker Daltonics) were done in parallels.
The cerebrospinal ﬂuid samples were analysed by Maldi-Tof MS without
an extraction step, both centrifugated (1500 g i 15 min., supernatant
discharged) and un-centrifugated for the detection of bacteria. The
impact of electrolyte, protein and cell concentration on the MS results
were analysed by scatter plots. The 14 culture positive samples were
further extracted (ethanol and formic acid) and results were compared to
extracted sterile samples (on culture). Randomly chosen clinical samples,
sterile on culture, and controls in MQ-water, were spiked with bacteria in
10-fold dilution series (S. pneumoniae, H. inﬂuenzae, E. coli, E. faecium
and P. acnes) and undervent Maldi-Tof MS in 5 paralells, with and
without extraction to investigate sensitivity and speciﬁcity.
Results: All the clinical cerebrospinal ﬂuid samples yielded negative
(low score 0,000−1,699) mass spectres, whether centrifugated or not.
Extraction of the culture positive samples did not alter the results.
The spiked cerebrospinal ﬂuids suggests sensitivity for detection of
S. pneumoniae and H. inﬂuenzae to be 105 cfu/Ml, E. coli 106
cfu/Ml and E. faecium and P. acnes 104 cfu/Ml. Protein concentration,
electrolyte concentration and number of cells had little impact on the
mass spectres, importantly no false positive results were present.
Conclusion: Maldi-Tof MS for direct identiﬁcation of bacteria in
cerebrospinal ﬂuid specimens has a sensitivity comparable to acridine
orange microscopy. No false positive identiﬁcations were experienced,
protein/electrolyte concentrations and number of cells had little impact
on mass spectres.
O346 Preliminary results from a comparison of two matrix-assisted
laser desorption ionisation–time-of-ﬂight mass spectrometry
(MALDI-TOF) systems with 16S rRNA gene sequencing for
identiﬁcation of anaerobic bacteria to the species level
U.S. Justesen*, A. Holm, E. Knudsen, L.B. Andersen, T.G. Jensen,
M. Kemp, M. Skov, B. Gahrn-Hansen, J.K. Møller (Odense, Vejle, DK)
Objectives:MALDI-TOF MS is a powerful technology for identiﬁcation
of bacteria. However, anaerobic bacteria have not been investigated to a
larger extent in detail, apart from the Bacteroides fragilis group. A head-
to-head comparison was performed on a collection of anaerobic bacteria
to evaluate the performance of the Bruker Biotyper and the AnagnosTec
SARAMIS MALDI-TOF MS system.
Methods: Clinical anaerobic isolates from blood cultures, other sterile
body sites and suspected Clostridium spp. and Fusobacterium spp. from
any site, which had been identiﬁed to the species level with 16S rRNA
gene sequencing, were included in the study. The isolates were identiﬁed
simultaneously by the Biotyper and the SARAMIS MALDI-TOF MS
systems according to a speciﬁed protocol.
Results: One hundred and twenty isolates, representing 39 species,
belonging to 13 genera (primarily Bacteroides spp., Clostridium
spp., Fusobacterium spp., Lactobacillus spp., Veillonella spp. and
Propionibacterium acnes), were examined (the ﬁnal number of isolates
will be approximately 240). Of the 120 isolates, 103 and 102 were
included in the databases of the Biotyper and the SARAMIS system,
respectively. The number of isolates that were identiﬁed correctly to
the species level was 70 (58.3%) and 60 (50%) by the Biotyper (score
2.0) and the SARAMIS system (score 80%), compared to the 16S
rRNA gene sequencing identiﬁcation. The Biotyper system did not
identify 33 isolates, which were in the database and misidentiﬁed nine
isolates, which were not in the database, as a closely related species
(e.g. Bacteroides dorei as B. vulgatus). The SARAMIS system did not
identify 29 isolates, which were in the database. Only two isolates were
misidentiﬁed (one was not in the database). Eight isolates were correctly
identiﬁed to one of two species (e.g. B. dorei as B. dorei/vulgatus) and
four isolates to the correct genus/family level.
Conclusion: MALDI-TOF is a promising technology for species
identiﬁcation of anaerobic bacteria and much cheaper and faster
compared to 16S rRNA gene sequencing. However, development and
expansion of existing databases needs to be continued. To further
optimize the technology, testing of different pre-analytic procedures
before MALDI-TOF-MS might be performed.
O347 Rapid detection of Salmonella by selective enrichment and
mass spectrometry based on MALDI Biotyper
U. Weller, K. Sparbier, C. Boogen, M. Kostrzewa* (Cologne, Bremen,
DE)
Objective: Salmonella infection causes severe diarrhoea. Employing
standard routine procedures the identiﬁcation of positive specimen takes
at least 2 days. Aim of this work was the development of a rapid approach
for the detection of Salmonella from stool samples.
Methods: Salmonella sp. spiked stool samples were incubated in selenite
bouillon at 37ºC over night. The supernatant of this culture was applied
to 1ml water and centrifuged. Pellets were washed twice with water.
Bacteria were lysed in formic acid and acetonitrile. 1ml of the cleared
lysate was applied on a MALDI sample carrier plate. Dried spots were
overlaid with MALDI matrix.
Patient samples were stroked on Hectoen agar. After incubation at 37ºC
over night, colonies were directly transferred to a MALDI sample carrier
plate and overlaid with MALDI matrix. Selenite cultures were processed
as described above and further plated on selective agar (XLD).
MALDI-TOF MS spectra were acquired on a microﬂex LT and analyzed
with the MALDI Biotyper software for identiﬁcation of microorganisms.
Results: The analysis of the spiked stool samples revealed that
inoculation with less than 800 cfu resulted in an overgrowing of
Salmonella by natural enterobacteria. Spiking with at least 800 cfu led
to an unambiguous identiﬁcation of Salmonella sp. The novel approach
facilitates the direct analysis of the selective liquid culture without further
plating.
This approach was applied to clinical samples. Over a time frame
of 9 months 4847 clinical samples were analyzed according to the
above described protocol. All samples were plated on selective agar to
detect false positive or negative samples. After incubation over night at
37ºC, suspicious colonies were identiﬁed by means of MALDI Biotyper
analysis. Applying this workﬂow, 66 samples were directly identiﬁed
as Salmonella positive from the Hectoen agar. The same samples and
further 34 samples were detected as Salmonella positive from the
selective enrichment culture. In total, 100 samples could be identiﬁed as
Salmonella positive already one day after starting culturing. The residual,
so far negative samples were plated on XLD-agar. Only 8 additional
samples turned out to be Salmonella positive after MALDI Biotyper
analysis. No false positive samples were identiﬁed.
Conclusion: The novel approach facilitates the detection of most of the
Salmonella positive samples at least one day before the standard routine
procedures.
CA-MRSA − what is going on with CA-MRSA? S67
CA-MRSA − what is going on with
CA-MRSA?
O348 High genetic diversity of community-associated
Staphylococcus aureus in Europe
J. Rolo*, M. Miragaia, A. Turlej, J. Empel, O. Bouchami, N.A. Faria,
A. Tavares, W. Hryniewicz, A.C. Fluit, H. de Lencastre and the
CONCORD Working group
Objectives: The worldwide emergence of infections caused by MRSA
in healthy individuals (CA-MRSA) is worrisome. In the USA, the
USA300 clone is responsible for the great majority of MRSA infections
in emergency departments. Nonetheless, a global picture of the
epidemiology of CA-MRSA in Europe remains unclear. In this study,
we aimed to deﬁne the population structure of CA-S. aureus in Europe.
Methods: Six hundred and eighteen S. aureus isolates were obtained
from sixteen of the most populous European countries, from outpatients
or from patients attending hospitals within the ﬁrst 48 hours of
hospitalization. All isolates were characterized by spa typing. Multilocus
sequence typing (MLST) and/or pulsed-ﬁeld gel electrophoresis (PFGE)
were performed for isolates with new or non-speciﬁc spa types. mecA
and PVL were detected by PCR. Staphylococcal cassette chromosome
mec (SCCmec) typing was performed by multiplex PCR. The relatedness
of isolates was assessed by eBURP analysis.
Results: Three hundred and thirty two S. aureus isolates (52%) were
found to be associated to community-associated (CA) lineages. The
great majority of isolates (66%) were related to USA300 clone (ST8,
81 isolates), the European clone (ST80, 52), ST15 (29), Taiwan clone
(ST59, 28) and Southwest Paciﬁc clones (ST30, 28). Moreover, other ten
CA minor lineages were detected. Of all CA isolates, 52% carried PVL
and 52% carried the mecA; SCCmec IV was the most common type
(80%), but SCCmec types V and VI were also found. A high number of
different PFGE types, spa types and SCCmec types were found among
clonal lineages CC8, CC15, CC25, CC30 and CC121. Only 50% of CA-
MRSA isolates belonged to epidemic clones with the typical genetic
features PVL+ and SCCmec IV. eBURP analysis revealed that some
CA-MSSA and CA-MRSA isolates were highly related.
Conclusions: A wide genetic diversity was found among CA-S. aureus
isolates in Europe, in striking contrast with the reality observed in the
USA. The conditions which favored this wide diversiﬁcation still remain
to be clariﬁed. Altogether data resulting from this study suggest that
while some CA-MRSA might have emerged and evolved in Europe,
other seem to have been imported.
O349 Changing trends in the epidemiology of PVL-MRSA in
England
A.M. Kearns*, M. Ganner, L. Hicks, I. McCormick Smith, R. Hill,
B. Pichon, M.J. Ellington, B. Cookson (London, UK)
Objectives: The potential for various clones of PVL-MRSA to cause
severe disease has been a cause for serious concern. This is especially
evident for one clone (so-called USA300) which has reached epidemic
proportions in North America, effectively marginalising other MRSAs.
We sought to map the burden and molecular epidemiology of PVL-
positive MRSA England to examine for trends over a 4 year period.
Methods: Isolates of MRSA recovered from suspected PVL-related
disease (SSTIs, necrotising pneumonia, musculoskeletal infections etc)
from patients in England between 2007 and 2010, were referred
to the national Staphylococcus Reference Unit (SRU). All isolates
were examined for PVL toxin genes and PVL-positive MRSA were
characterised by various techniques including: MLST, spa typing, toxin
gene proﬁling, SCCmec typing and/or pulsed-ﬁeld gel electrophoresis.
MICs of a wide range of antibiotics were determined and susceptibility
interpreted according to BSAC/EUCAST criteria. Associated patient
demographic and clinical data were analysed.
Results: The data show an approximate 1.5-fold annual increase in the
number of PVL-MRSA identiﬁed, ranging from 477 in 2007 to >900
in 2010. Patients were aged 0 to 100y (median 31y); the male:female
ratio was 1.2:1 and ca. 70% presented with SSTIs. At least 10 different
lineages of PVL-MRSA were identiﬁed, 3 of which were dominant:
European, South West Paciﬁc and USA300 clones (ST80-IV, ST30-
IV and ST8-IV respectively). In 2009, USA300 became the major
PVL-MRSA clone in England, displacing the European clone which
dominated in 2007 and 2008. USA300 strains were typically resistant to
erythromycin with variable resistance to ciproﬂoxacin; representatives
of the European clone were usually resistant to tetracycline and
fusidic acid. The number of cases due to the multiply-resistant
Bengal Bay clone (ST772-V) increased 6-fold from 10 in 2007 to
61 in 2009. Overall, most PVL-MRSA infections were community-
acquired and sporadic in nature, although occasional clusters involving
transmission of PVL-MRSA in community and healthcare settings were
identiﬁed.
Conclusion: PVL-MRSA in England are polyclonal, with 3 lineages
predominating. The emergence of multiply-resistant strains as a cause
of community- and healthcare-associated infection has important
implications for recognising, diagnosing and managing such infections.
Continued vigilance is essential to map the burden and molecular
epidemiology of PVL-MRSA internationally.
O350 High prevalence of hospital-associated Staphylococcus aureus
epidemic clones in the community in Portugal: evidence for
blurring of community/hospital boundaries
A. Tavares*, M. Miragaia, R. Mato, J. Rolo, J. Melo-Cristino, L.M. Lito,
F. Martins, E. Gonc¸alves, G. Ribeiro, L. Boaventura, J. Amorim,
R. Campainha, A. Fonseca, M. Guimara˜es, M. Gonc¸alves, A.M. Costa,
J. Mairos, S. Francisco, M.A. Guimara˜es, C. Lameiras, M. Ribeiro,
L. Branco, D. Tuna, A. Faustino, M.T. Vaz, M. Gia˜o, P. Paixa˜o, C. Febra,
M.A. Read, M.J. Soares, M.J. Nunes, A. Coutinho, M. Carvalho,
T. Sardinha, L. Sancho, G. Sousa, P. Correia, R.M. Barros, C. Gouveia,
M. Pinto, M.J. Brito, I. Daniel, G.C. Ferreira, A. Morais, I. Valadares,
H. de Lencastre (Oeiras, Lisbon, Coimbra, Santo Tirso, Cascais, Porto,
Braga, Portima˜o, Matosinhos, E´vora, Amadora, PT; New York, US)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) were
traditionally conﬁned to hospitals (HA-MRSA) but in the 1990s
emerged in the community (CA-MRSA). CA-MRSA present speciﬁc
genetic backgrounds, an enhanced virulence potential, carry the smallest
staphylococcal cassette chromosome mec (SCCmec IV or V) types and
produces Panton-Valentine leukocidin (PVL).
Recent data indicates that the boundaries between the hospital and the
community are blurring and that CA-MRSA have already conquered
the hospital becoming more resistant to antibiotics. In spite of the CA-
MRSA relevance, no data exist concerning the frequency of CA-MRSA
in Portugal. In the present study we aimed to evaluate the S. aureus
population structure in the Portuguese community.
Methods: A total of 139 isolates were collected from infection in
individuals with no risk factors for HA-MRSA acquisition. For all
isolates pulsed-ﬁeld gel electrophoresis (PFGE) and spa typing were
performed and mecA and PVL genes (lukS-PV and lukF-PV) were
detected by PCR. Multilocus-sequence typing (MLST) was carried
out to ascertain clonal type in speciﬁc cases. SCCmec typing and
antimicrobial susceptibility testing for a panel of 22 antimicrobial agents
was performed for MRSA isolates. Isolates relatedness was analyzed by
eBURP.
Results: We found a relatively low frequency of CA-MRSA causing
infection in Portugal (5%, 7/139), related either to predominant CA-
MRSA clones (USA300, ST80 and ST398) or to less disseminated
clones (ST121, ST22 and ST1810). Two out of seven CA-MRSA found
were multidrug resistant. Moreover, S. aureus population structure was
composed by diverse CA-MSSA clones (41.7%) and an unexpected high
proportion of isolates (30.2%; 19 MSSA, 23 MRSA) belonging to HA-
MRSA epidemic clones (EMRSA15, New York/Japan, EMRSA16, and
Berlin). Only 2.9% of isolates carried PVL. Most of isolates were from
SSTI (47%) and pneumonia (7%). CA-MRSA and CA-MSSA isolates
with highly related spa types were found.
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Conclusion: The majority of CA-MRSA isolates in Portugal belonged to
both epidemic and minor clones; the latter might have emerged from an
extant MSSA population. The ﬁnding of CA-MRSA isolates that were
multidrug resistant and of isolates belonging to HA-MRSA epidemic
clones recovered from individuals with no health-care related risk factors,
suggests that CA-MRSA already entered into the hospital and that HA-
MRSA epidemic clones may have already gained a foothold into the
community in Portugal.
O351 Rise of USA300 hospitalisations in the US during 2004–2008
R.M. Mera*, J.A. Suaya, H.A. Madsen, P.F. O’Hara, L.A. Miller
(Durham, Philadelphia, Upper Providence, US)
Objectives: To estimate the prevalence and rates of US300 in S. aureus
hospitalizations in the US for the period 2004–2008 by combining data
from a national bank of isolates and a national hospitalization survey.
Methods: Data sources consisted of a randomly selected subset of
isolates from the US TSN S. aureus surveillance collection (Euroﬁns
Medinet) and the Nationwide Inpatient Sample (Healthcare Cost and
Utilization Project). 421 S. aureus inpatient isolates were genotyped
using multilocus sequence typing to characterize clonal complexes (CC).
The Panton-Valentine leukocidin (PVL) status and antibiogram were also
obtained. Three major groups, corresponding to 89% of all isolates,
were identiﬁed: (a) USA300 (CC 8 PVL+ MRSA), (b) CC 5 PVL−
MRSA and (c) PVL− MSSA. Hospitalization rates for S. aureus and
those attributable to each one of the identiﬁed groups were computed.
Rates, standard errors, proportions and rate ratios were obtained using
appropriately weighted data that included the variance of the molecular
epidemiology study.
Results: Overall, S. aureus hospitalization rates per 1,000 discharges
have signiﬁcantly increased from 14.1 +0.25 in 2004 to 15.1 +0.24
in 2008 (p< 0.05). USA300 represented 7.3% of all S. aureus
hospitalizations in 2004, with a hospitalization rate of 1.03 + 0.08. By
2008 USA300 had increased 3.5 times (p< 0.001) and now represented
23.9% of all S. aureus hospitalizations with a rate of 3.62 +0.24 per 1,000
discharges. CC5 PVL− MRSA was the most common hospital genotype
in 2004 (41.3% of all S. aureus hospitalizations, with a rate of 5.83
+0.14), but by 2008 it had declined signiﬁcantly (p< 0.01), becoming
the second most common group (28.3%, hospitalization rate 4.28 +0.11
per 1,000 discharges). The polyclonal MSSA PVL− group did not change
signiﬁcantly over time accounting for 39.7% of all hospitalizations (rate
of 5.59 +0.19) in 2004 and 38.5% of all S. aureus hospitalizations in
2008 (rate of 5.83 +0.19 per 1,000 discharges).
Conclusion: Although the overall S. aureus hospitalization rate increased
moderately during the period of observation, the share of USA300
isolates dramatically increased from 1 out of 13 S. aureus hospitalizations
in 2004 to 1 out of 4 in 2008. USA300 partly replaced the CC5 PVL−
MRSA, as the latter group declined signiﬁcantly, while the share of
MSSA PVL− remained stable over time. The signiﬁcant increase of
S. aureus hospitalizations in the US can be explained by the rise of
USA300.
O352 Prevalence of Panton-Valentine leukocidin in methicillin-
susceptible and -resistant Staphylococcus aureus from
Australia and New Zealand, 2009
J. Stepnell, J. Bell, P. Andersson, J. Turnidge* (North Adelaide, AU)
Objectives: Panton-Valentine Leukocidin (PVL) is accepted as a marker
of disease severity in staphylococcal infections. The aim of this study was
to assess the prevalence of PVL among Staphylococcus aureus isolated
from Australia and New Zealand, and determine any association with
speciﬁc clonal complexes.
Methods: Non-duplicate S. aureus isolated from hospitalised patients
with bacteraemia or skin and skin structure infections, collected during
the 2009 SENTRY Surveillance were examined. Oxacillin-resistance was
determined using broth microdilution (CLSI). The lukF-PV and lukS-
PV genes coding for the PVL toxin, were detected using a real-time
PCR (Roche LC480). Isolates were assigned to a clonal complex (CC)
using high resolution melt analysis of PCR fragments obtained from
ampliﬁcation of six house-keeping gene targets (Minim assay).
Results: A total of 468 S. aureus, 112 oxacillin-resistant (MRSA) and
356 oxacillin-susceptible (MSSA) were evaluated. MRSA were more
common from AUS than NZ (29% vs 11%). PVL genes were detected
in 21.6% of MRSA and 15.0% of MSSA from Australia, and 60.0% and
31.7% from NZ (see Table). In both countries, all MRSA isolates that
contained PVL belonged to either ST93 or CC30. More diversity was
found among MSSA isolates; in Australia, CC121 and ST93 were the
dominant clones, while in NZ, CC121, CC1 and CC30 predominated.
Conclusion: PVL producing MSSA are more common than previously
recognised in Australasia, and belong to speciﬁc clonal complexes.
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O353 High prevalence of ESBL-producing Escherichia coli in
chicken meat imported into Sweden
S. Bo¨rjesson*, M. Egerva¨rn, M. Finn, I. Tillander, C. Wiberg,
S. Englund (Uppsala, SE)
Objectives: Investigate if chicken meat imported into Sweden from
South America and Europe may be a potential source for extended
spectrum b-lactamase (ESBL) producing Escherichia coli.
Methods: In total, 115 samples, 36 South American and 79 European,
from imported fresh, tenderized and frozen chicken meat were collected
in retail stores and outlets during 2009 and 2010. The meat was subjected
to stomaching, put in pre-enrichment broth containing cefotaxime and
incubated overnight. Potential ESBL-producing E. coli was isolated
using CHROMagar™ ESBL and CHROMagar™ supplemented with
cefotaxime. ESBL-producing E. coli was veriﬁed by Etest® ESBL.
Antibiotic susceptibility to 11 antibiotics, belonging to 7 classes, was
assessed using VetMICTM GN-mo microtitre plates. The presence
of antibiotic resistance genes, including the ESBL gene groups,
was identiﬁed using Identibac AMR-ve ArrayTube™. The speciﬁc
gene variants responsible for ESBL production were determined by
sequencing using BigDye® v1.1.
Results: In total 42% of the chicken meat was identiﬁed to contain ESBL
producing E. coli. The meat from South America was positive in 92%
of the cases and in the European meat 19% was positive. The following
ESBL gene variants were identiﬁed: cmy-2, ctx-m1, ctx-m1 + tem-1,
ctx-m2, ctx-m2 + tem1, ctx-m8, ctx-m8 + tem-1, ctx-m14 and tem-135.
The ctx-m8 and ctx-m14 were only identiﬁed in isolates from South
American meat and ctx-m1 and tem-135 were only identiﬁed in isolates
from European meat. Resistance to chloramphenicol (4 isolates) and
ﬂorfenicol (1 isolate) were exclusively found among the South American
isolates from South American meat. One isolate from Chilean meat was
susceptible to colistin only. Overall, isolates from South American meat
showed resistance to a wider range of antibiotics and carried more genes
encoding antibiotic resistance compared to the isolates from European
meat. Isolates from Danish meat were the most susceptible generally
showing resistance to b-lactams only.
Conclusion: ESBL-producing E. coli were frequently identiﬁed in
chicken meat imported into Sweden, indicating it as a possible source for
gut colonization. Chicken meat from South American had a much higher
prevalence of ESBL-producing E. coli than chicken meat imported into
Sweden from Europe.
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O354 High prevalence of ESBL-producing Enterobacteriaceae
carriage in Dutch patients visiting their general practitioner
E.A. Reuland*, N. al Naiemi, J.S. Kalpoe, M.C. Rijnsburger,
S.A. Raadsen, I. Ligtenberg-Burgman, P.H. Savelkoul,
C.M. Vandenbroucke-Grauls (Amsterdam, Enschede, NL)
Objectives: The aim of this study was to determine the prevalence of
carriage of ESBL-E in the region of Amsterdam, to characterize the
ESBL genes and plasmids involved, and to type the ESBL-positive
strains to gain understanding of the epidemiology of this emerging
resistance in the Dutch outpatient population.
Methods: Fecal samples were obtained between April 12 and May 19,
2010, from patients presenting to their GP with mild gastrointestinal
discomfort. Screening for ESBL-E was performed with selective
enrichment broth and inoculation on a selective screening agar,
containing cefotaxime and ceftazidime. ESBL production was conﬁrmed
with the double disc synergy test with clavulanic acid. Species
identiﬁcation and antibiotic susceptibility testing were performed with
the Vitek-2 system (bioMe´rieux). ESBL genes were characterized by
microarray (Check-KPC ESBL Check-Points), PCR, and sequencing.
The strains were analyzed for genetic relatedness by AFLP. Identiﬁcation
of plasmids was done by PCR-based replicon typing (Carattoli,
J. Microbiol. Meth. 2005).
Results: We obtained 471 samples from 471 patients. The median
age of patients was 46 years (range: 0−92), 54% were females. Fifty
(10.6%) samples yielded ESBL-E: 49 Escherichia coli strains and 1
Shigella sonnei strain. Of these isolates, 14/50 (28%) were resistant
to gentamicin, 22/50 (44%) to ciproﬂoxacin, and 33/50 (66%) to co-
trimoxazole; 12% (6/50) were multiresistant (to b-lactams, gentamicin,
ciproﬂoxacin and co-trimoxazole). The presence of genes encoding
ESBLs was conﬁrmed in 49 isolates; these comprised 4 blaCTX-M-1, 24
blaCTX-M-15, 1 blaCTX-M-14, 7 blaCTX-M-14b, 4 blaCTX-M-27, 7
blaSHV-12, 1 blaSHV-2a, 1 blaTEM-52 genes. AFLP showed a few small
clusters of isolates with identical AFLP patterns, although there was no
epidemiological relation between the patients. The following plasmids
were identiﬁed: ColE (20/50), Frep (8/50), R (6/50), FIA (4/50), IncI1
(4/50), and P (1/50).
Conclusion: This high prevalence of ESBL-E in Dutch outpatients was
unexpected. We noted a high percentage of co-resistance to ciproﬂoxacin,
co-trimoxazole and gentamicin. Strain typing showed no evidence for
clonal spread of particular strains in the community. ColE was the most
prevalent plasmid; this plasmid has been found previously in strains of
Salmonella and Klebsiella isolated from humans. The signiﬁcance of
the frequent occurrence of ColE plasmids in E. coli in Dutch outpatients
needs to be explored further.
O355 Complex epidemiology of KPC-producing
Enterobacteriaceae in a university hospital in Madrid (Spain)
after an outburst of KPC3-producing Klebsiella pneumoniae
P. Ruiz-Garbajosa*, T. Curiao, M. Tato, M. Morosini, F. Baquero,
T.M. Coque, R. Canto´n (Madrid, ES)
Objective: We previously described the ﬁrst outburst of KPC-3-
producing Klebsiella pneumoniae (Kpn) in Spain (Sept-09 to Feb-10)
(Curiao et al. JAC 2010; 65:1608−14). Seven patients were infected/
colonized by the ST384 KPC-3-Kpn clone and another one with
the ST388 Kpn-KPC-3 clone. In this study we present the on-going
epidemiology of several KPC-producing Enterobacteriaceae in our
hospital after the emergence of KPCs.
Methods: From March-09 to Nov-10, all Enterobacteriaceae isolates re-
covered from clinical or surveillance cultures with decreased carbapenem
susceptibility and a positive modiﬁed Hodge test were screened for
the presence of carbapenemase genes (PCR and sequencing). Antibiotic
susceptibility was performed by the semiautomatic Wider system (Fco.
Soria-Meguizo, Spain). PFGE and MLST were achieved to assess clonal
relatedness. Clinical records of infected and/or colonized patients with
KPC-producing isolates were reviewed.
Results: 16 KPC-producing Enterobacteriaceae isolates [12 Kpn, 2
Escherichia coli (Eco) and 2 Enterobacter cloacae (Eclo)] were
recovered from 15 patients (mean age 64-y; 6 female) during the follow-
up period. Patients were admitted in 8 different wards (40% admitted
at ICU, 33% in medical and 26% in surgical wards). In the 80% of
the cases, KPC-producers were recovered from surveillance cultures. By
PFGE, 5 Kpn (identiﬁed by MLST as ST20, ST454, and unassigned new
STs), 2 Eco and 1 Eclo clones were recognized. The blaKPC-3 gene was
detected in 4 Kpn and 1 Eco clones, whereas the blaKPC-2 gene was
detected for the ﬁrst time in our institution in one each Kpn, Eco and
Eclo clones. The KPC-3-Eco clone was isolated from one carrier of
KPC-3-Kpn. All clones (n = 8) were resistant to all b-lactams, including
imipenem and meropenem (MIC range 4−>8mg/L), and showed co-
resistance to ﬂuoroquinolones (n = 6; 75%) and aminoglycosides (n = 1;
12%).
Conclusions: A complex penetration of blaKPC genes involving
different genetic lineages of several Enterobacteriaceae were detected
after the emergence of a KPC-3-Kpn-ST384 clone in our institution.
This allodemic situation was present with a high colonization pressure.
Moreover, the co-colonization by two different bacterial species carrying
the blaKPC-3 gene suggests the in vivo transfer of this gene.
O356 Epidemiology of invasive disease due to serotype 6A and 6C
Streptococcus pneumoniae from 2002 to 2009 in France
C. Janoir, A. Lepoutre, S. Grondin, S. Simon, L. Gutmann, E. Varon* and
The French Regional Observatories of Pneumococcus (ORP) network
Objectives: Since the introduction of the 7-valent conjugate vaccine
(PCV7) in 2003 in France, the incidence of serotype 6B invasive
pneumococcal disease (IPD) has dramatically decreased from 5.2 and 2.3
cases/100,000 in children <2 years and adults >64 years, respectively,
to 0.4 cases/100,000 in 2007–2008 in both age groups. By contrast,
during the same period, IPD due to serotype 6A/C slightly decreased
in children <2 years (1.1 to 0.6 cases/100,000), but increased in adults
>64 years (0.7 to 1.4/100,000). The aim of our study was to compare the
prevalence and the susceptibility proﬁle of the newly recognized serotype
6C, a serotype 6A-variant, in IPD between pre- and post-PCV7 period.
Methods: Out of 5501 IPD isolates, 186 (bacteraemia 56%, meningitis
44%) were identiﬁed as serotype 6A/C by conventional serotyping
method using antisera from the Statens Serum Institut. Among the
latter, serotype 6C and 6A were further distinguished using PCR to
determine the respective length of their wcin gene (wcin6C= 1.8 kb;
wcin6A= 2 kb). Antimicrobial susceptibility testing was performed by
agar dilution (penicillin, amoxicillin, and cefotaxime) or disk diffusion
method (erythromycin, clindamycin, tetracycline, chloramphenicol, and
cotrimoxazole) according to Ca-SFM. Selected representative strains
were studied by MLST.
Results: The prevalence of serotype 6C IPD, which was low at the pre-
PCV7 period, signiﬁcantly increased in the post-PCV7 period in adults
>64 years, but not in the children <2 years. Half of the serotype 6C
isolates were penicillin-non susceptible (MIC90 =0.125mg/L) while yet
susceptible to amoxicillin and cefotaxime, and resistant to erythromycin
(MLSB inducible) and tetracycline. MLST results indicated that 6C
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sequence-types (STs) were distinct from those of 6A strains, and were
grouped mainly in the clonal complexes (CCs) 156, 386, and 395.
Conclusions: These results suggested a direct effect of PCV7 on original
serotype 6A IPD in children <2 years. The increase in 6A/C IPD
observed in adults was due to an increase in the new non-PCV7 serotype
6C related to the spread of different clones, while original 6A IPD
remained stable (no PCV7 indirect effect). Thus, serotype 6C has become
in 2009 the most prevalent type of the group 6 in adults IPD in France.
O357 Group B streptococcal neonatal infection in the Barcelona
area: 18-year surveillance
E. Martins*, M. Gimenez, M. Sierra, M. Lite, J. Melo-Cristino,
M. Ramirez on behalf of the microbiologist group for the study of
vertical transmission infections from the Catalan Society for Clinical
Microbiology and Infectious Diseases
Objectives: We undertook the analysis of 212 group B streptococci
(GBS) isolates from invasive infections in newborns in the Barcelona
area, between 1992 and 2009, with the aim of documenting changes
in prevalence of serotypes, antimicrobial resistance patterns and genetic
lineages and evaluating their association with either early-onset (EOD)
or late-onset disease (LOD).
Methods: All isolates were serotyped and assigned to clones according
to their pulsed-ﬁeld gel electrophoretic (PFGE) proﬁles and MLST-
based sequence types. Susceptibility to penicillin, chloramphenicol,
tetracycline, levoﬂoxacin, erythromycin and clindamycin was tested by
disk diffusion according to the CLSI guidelines. Macrolide-resistant
isolates were further classiﬁed by phenotype and were tested by PCR
for the presence of the erm(B), erm(A) and mef genes. Presence of the
surface protein genes bca, alp2, alp3, alp4, eps and rib genes was also
tested by PCR.
Results: The isolates were grouped into 18 PFGE clusters and serotypes
III (ST17) and Ia (ST23/ST24) were the most frequent. PFGE-based
clones showed a very good predictive power over serotype (as evaluated
by the Wallace coefﬁcient, W= 0.955). Serotype III was found to
be signiﬁcantly associated to LOD. The overall rate of erythromycin
resistance was 14.2%, all isolates displaying the cMLSB phenotype
(76.7% associated to erm(B) gene and 23.3% to erm(TR) gene). All
isolates carried an a or a-like protein, with speciﬁc associations between
surface proteins and serotypes such as: Ia and eps; Ib and II and bca;
III and rib; and V and alp3.
Conclusions: The characterization of the population of GBS causing
invasive infections in neonates in the Barcelona region revealed the
existence of a large number of genetically distinct lineages that were
present over a signiﬁcant time-span. The stability and dominance of
a few lineages that are responsible for the majority of infections, in
spite of continuous antibiotic and immune selective pressures, suggest
that these are extremely well adapted to their particular niche. Although
most of these lineages are widely disseminated worldwide, we have also
identiﬁed seemingly regionally successful clones, raising the possibility
of an ongoing selection and expansion of speciﬁc virulent GBS clones.
Lyme borreliosis, toxoplasmosia
O358 Direct detection of early Lyme borreliosis from whole blood
M. Eshoo*, C. Crowder, M. Rounds, H. Mathews, M. Soloski,
A. Schwarzwalder, S. Schutzer, J. Aucott (Carlsbad, Baltimore, Newark,
US)
Objectives: Early treatment for Lyme Borreliosis is crucial for long
term prognosis. The ability to provide a physician with diagnostic results
from whole blood collected during the initial patient visit will allow for
treatment to begin earlier in the infection and potentially reduce the risks
of adverse conditions. To address this need we have developed an assay
to detect Borrelia directly from whole blood collected during the initial
patient visit.
Methods: Samples of whole blood from patients with erythema
migrans were tested for Lyme borreliosis by the CDC two-tiered test.
Nucleic acid extracts from these patient specimens were made using
a combination of mechanical and chemical lysis and magnetic bead
puriﬁcation. The extracts were then tested with and without a nested
isothermal ampliﬁcation prior to use in multi-locus broad-range PCR
and electrospray ionization mass spectrometry PCR.
Results: The nested isothermal PCR increases the amount of Borrelia
DNA in the extracts enabling its detecton by broad-range PCR and
electrospray ionization mass spectrometry ionization mass spectrometry.
Using our methods we detected Borrelia in 65% (13/20) of samples that
were positive by CDC criteria on either the initial visit with the blood
draw or a subsequent follow-up visit 3 weeks later. In patients that were
positive by CDC criteria at the time of the blood draw we detected
Borrelia in 64% (9/14) of the patients. We detected Borrelia in 66.7%
(4/6) of patients that were negative by the two-tiered test at the time
of the blood draw but were positive on the follow-up demonstrating the
ability to detect Borrelia infection prior to being seroconversion.
Conclusion: We demonstrate that our Borrelia detection assay can
detect instances of early Lyme borreliosis directly from whole blood
specimens. Additionally, we show that we can detect Lyme borreliosis
prior to seroconversion when patients are still negative by CDC two-
tiered testing. This assay could provide physicians with actionable results
while other tests would remain negative or inconclusive. In addition the
test can provide genotypic information on the Borrelia strain.
O359 Survey of pathogens in nymphal ticks from the Czech
Republic
C. Crowder, M. Rounds, H. Matthews, V. Honig, L. Grubhoffer, B. Luft,
M. Eshoo* (Carlsbad, US; Prague, CZ; Stony Brook, US)
Objectives: Many tick-borne diseases have similar symptoms and are
found in the same vector. Active surveillance of ticks can provide health
agencies with data for population risk assessments and inform physicians
as to the possible pathogens patients may encounter. We developed and
used an Ibis PLEX-ID assay to screen ticks from the Czech Republic to
identify the pathogen frequency and landscape.
Methods: We used a multi-locus assay utilizing 11 different loci with
to detect a wide range of tick-borne pathogens including bacteria,
protozoa, and viruses. Total nucleic acids were extracted from ticks
collected at sites in the Czech Republic and screened on the assay.
Electrospray ionization mass spectrometry of the PCR amplicons was
used to determine their base composition. These base composition
signatures were subsequently used to identify the organisms found in
the samples.
Results: Extracts from 148 ﬁeld collected nympal Ixodes ricinus ticks
were screened for a variety of pathogens. Pathogens were found in
66.8% (99/148) of the ticks. We detected Borrelia, Anaplasma, Rickettsia
helvetica, Babesia, and a high prevalence of TBEV. Additionally a 25%
(25/99) of the ticks containing pathogens contained 2 or more pathogens
with TBEV being the most common co-pathogen.
Conclusions: We demonstrate broad-range detection of tick-borne
pathogens in a single assay using ticks from the Czech Republic. The
Ibis assay detected a diverse range of bacteria, protozoa, and viruses
associated with ticks including a high prevalence of TBEV and ticks
confected with two or more pathogens. The Ibis PLEXID system, which
can be completed within ﬁve hours from specimen processing to result
reporting, provides rapid and accurate detection and identiﬁcation of a
broad range of pathogens causing tick-borne human infections.
O360 Toxoplasma seroprevalence studies: what are we looking at?
L.M. Kortbeek*, A. Hofhuis, P. Teunis (Bilthoven, NL)
Objective: To discuss the outcome of Toxoplasma seroprevalence in
different age groups in population based studies in the Netherlands.
Methods: Sera from a nationwide serum bank of the general population
were tested with an in house Toxoplasma IgG ELISA, using the same
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methods in two studies: Pienter study 1995/1996 (1) and Pienter2 study
in 2006/2007 (2). The OD value of the samples were compared with a
cutoff sample and a ratio was calculated (the OD value of the sample
divided by the OD value of the cutoff) In both studies a sample was
positive when the OD ratio was 1. The log transformed OD ratios of
the serum samples were plotted against the age.
Results: Sera and data of participants of 7521participants in 1996/1997
and 5541 participants in 2006/2007 were available for analysis. The
overall seroprevalence was 40.5% in 1995/1996 and 26.0% in 2006/2007.
There is a difference between the young age group (<10−20 years) and
the older age group (>20 years) in distribution of OD ratios with highle
variable OD ratios in the young age groups that are not clearly distinct
from low OD ratios, whereas at older ages there seems to be a clear
distinction between negative and positive sera.
Discussion: The detection method used is the same in both studies
and part of the samples of 1996/1997 were retested in 2010, with the
same outcome (data not shown). Both studies show the same pattern of
clear distiction of positive and negative results in the older age category,
and lack of it in the young. We are looking for an explanation of this
phenomenon. As these highly variable OD ratios are found up to ages
of about 20 years, maternal immunity or aspeciﬁc vaccine effects seem
unlikely. Could children be exposed to a different source, with antigen of
nonviable oocysts causing seroconversion followed by antibody decay?
And does this implicate that seropositive children revert to a seronegative
state and are then not protected against toxoplasmosis?
Reference(s)
[1] L.M. Kortbeek, H.E. de Melker, I.K. Veldhuijzen, M.A.E. Conyn-
van Spaendonck. Population-based Toxoplasma seroprevalence study
in The Netherlands. Epidemol. Infect. 2004,132: 839−45.
[2] Hofhuis A, Van Pelt W, Van Duynhoven YT, Nijhuis CD, Mollema L,
Van der Klis FR, Havelaar AH, Kortbeek LM. Decreased prevalence
and age-speciﬁc risk factors for Toxoplasma gondii IgG antibodies
in The Netherlands between 1995/1996 and 2006/2007. Epidemiol
Infect. 2010 May 24:1−9 [Epub ahead of print].
O361 How to detect signiﬁcant changes in Borrelia burgdorferi
antibody reactivity in a follow-up sample
R.B. Dessau* (Naestved, DK)
Introduction: For the laboratory diagnosis of Lyme borreliosis it is
not generally recommended to take repeated samples. However this is
nevertheless done and may be relevant in selected cases. However no
criteria exist to evaluate whether the difference between to measurements
of antibody reactivity are signiﬁcant. The purpose of this study was to
analyse repeated routine samples from consecutive patients in order to
develop criteria for detection of signiﬁcant changes, especially a rise, in
serum antibody reactivity beyond random measurement error.
Materials and Methods: 22342 samples from 18193 patients were
routinely analysed from 2001–2010. Two or more samples were available
from 2779 patients retested from 0–3000 days apart. 2038 patients had
just two samples taken and above 5 samples were rare. The same ELISA
(IDEIA™ Borrelia burgdorferi IgM and IgG; Oxoid, Cambridgeshire,
UK) based on puriﬁed native ﬂagella antigen was used during the whole
period. Patients retested less than 7 days apart were assumed to represent
random measurement only.
Results: Using 510 samples from patients retested within one week the
upper and lower 2.5% quantiles were set as cutoff for the relative change
in arbitrary units between the ﬁrst and any subsequent sample. The upper
and lower cutoffs for a relative change in units for IgG was 3.3 and 0.6
and for IgM 2.2 and 0.5. Sample if 0.4 Units of IgG was measured on
the ﬁrst sample then 0.4*3.3=1.32 units or above on the second sample
was considered signiﬁcant. Using these criteria a rise in IgG antibodies
was found in 4% of samples, in 90% no change and a decrease in 6%. A
rise in IgM antibodies was found in 7% of samples, in 82% no change
and a decrease in 11%. Low readings on the ﬁrst sample below 0.4 units
were deﬁned as not decreasing.
Conclusion: A method to establish the minimal detectable change in
antibody reactivity is proposed based on statistical criteria, using readily
accessible routine samples. In a Danish clinical routine laboratory 15%
of patients tested for Lyme borreliosis were tested twice or more. A
rise in antibody reactivity was found for IgG in 4% and IgM in 6% of
patients. This has of course to be interpreted in the clinical context. The
clinical status and symptoms of the patients in this study are not known.
However the sample size is large and representative and it is considered
safe to conclude that it is not possible to detect a change for IgG in 90%
and IgM in 82% of the repeated samples.
O362 Childhood neuroborreliosis does not lead to long-term
cognitive disturbances
H. Schmidt*, K. Drenck, J. Wiefek, J. Blocher, K. Rostasy, N. von
Steinbu¨chel, H. Eiffert, K. Brockmann (Go¨ttingen, DE; Innsbruck, AT)
Objectives: Adult patients after NB acquired after the age of 18 years
have signiﬁcantly lower z-values for frontal executive functions, and their
performance is in all other domains poorer than in the control group,
whilst still in the normal range. The aim of this study was to evaluate
the long-term cognitive outcome of adults who acquired NB earlier in
their childhood.
Methods: 30 patients who had been treated 14.8 + 3.3 years ago at the
University hospital of Goettingen, Germany, Dept. of Paediatrics. These
patients were examined neuropsychologically with tasks addressing
verbal learning and memory, non-verbal learning and memory, attention,
executive functions, and visuo-spatial functions. 23 healthy control
persons were examined likewise.
Results: The two groups were matched for age (mean + SD 23.2 + 3.7
[NB] vs. 24.0 + 3.5 [C] years, t-test p = 0.4) and for the years of scholar
education (mean 11.4 + 1.5 [NB] vs. 11.8 + 1.4 [C] years, t-test p = 0.3).
The gender distribution was matched as well (m/w 19/11 [NB] vs. m/w
15/8 [C]; Fisher’s exact test p 0.05).
All results of the applied neuropsychological exams of the NB group
were comparable with the control group. Signiﬁcant differences were
not detectable between the groups.
Conclusion: In contrast to adults after Neuroborreliosis acquired after
the age of 18 years, adults after childhood NB have an excellent outcome
with cognitive functions as good as their matched control group.
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O363 Genotypic (V3 sequencing) determination of co-receptor
usage in HIV-infected patients carrying non-B subtypes
N. Chueca*, M. Alvarez, V. Guillot, J. Lo´pez-Bueno, M.D. Merida,
A. Pen˜a, A.B. Lozano, J. Herna´ndez-Quero, F. Garcia for the CoRAO
Objective: To evaluate the success in ampliﬁcation and the prevalence
of non-CCR5 using strains in a panel of non-B subtypes representative
of non-B distribution in Southern Spain.
Methods: We have tested a panel of reference pure non-B clones
(A1−3, B1−3, C1−4, D1−3, E1−3, F1−2, G1−3 Y H2) and 63 samples
of patients infected with non-B subtypes (using rapid subtyping of
pol sequences). Ampliﬁcation was done with primers E80/E105 for
RT PCR and ES7/E125 for nested PCR. Sequencing was done with
Cy5.0 and Cy5.5 labeled ES7/E125 and the Trugene platform. 46.8%
of HIV-1 infected patients were naı¨ve [69,8% male, median age 42,5
(35,5−47,2), median viral load 4.6 [3.9−5.2] log10 copies/ml. copies/ml.
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V3 sequences were analyzed using different bioinformatic approaches
and matrixes (geno2pheno, web-PSSM) and a combinatorial method
previously described by our group (Chueca et al., JMV 2009; 81(5):
763−7).
Results: All reference pure non-B clones were successfully ampliﬁed
using E80/E105 and ES7/E125. Pol subtype distribution for the HIV-1
infected patients studied was: 29 Circulating Recombinant Forms [CRFs,
46% (22 CRF02_AG, 9 Unique Recombinant Forms − URFs, 14%, 25
pure non-Bs)]. 10 samples could not be successfully ampliﬁed (16%);
2 had low viral loads (<1000 copies/ml), 4 were CRFs (3 CRF02_AG),
and 6 were from patients carrying pure pol non-Bs (3 C; 2 G, 1 F1).
Non CCR5 viruses were detected in 23% of the patients. No signiﬁcative
differences between the detection of non-R5 viruses in naı¨ve (28.6%) or
treated (30%) patients, or CD4 count (371.12 cells/mL for R5 vs 335.80
cells/mL for non-R5), and no association between non-R5 usage and
recombinant forms was observed.
Conclusions: Successful ampliﬁcation rate for non-B subtypes using
E80/E105 and ES7/E125 set of primers is slightly lower than previous
reports for B subtypes. Use of alternate primers, specially for RT-PCR
for certain non-B subtypes may be recommended. CRF02_AG infected
patients, the most prevalent non-B subtype in our area, are not infected
by a higher proportion of non-CCR5 viruses.
O364 Fine epitope speciﬁcity of circulating autoantibodies to
endogenous erythropoietin, in HIV-1 infected patients,
reveals molecular mimicry with HIV-1 p17 Gag protein: a
potential pathogenetic mechanism for HIV-1-related anaemia
A. Tsiakalos*, I. Routsias, T. Kordossis, A. Tzioufas, H. Moutsopoulos,
N. Sipsas (Athens, GR)
Objectives: HIV-1 infection is characterized by autoimmune phenom-
ena, including the production of several autoantibodies. Circulating
autoantibodies to endogenous erythropoietin (anti-EPO) were detected in
a substantial proportion of patients with HIV-1 infection and represent
a risk factor for anemia. The aim of this study was to identify the linear
B-cell epitopes on erythropoietin (EPO), recognized by anti-EPO, and to
investigate whether these epitopes are similar to those on HIV-1 antigens.
Methods: The EPO epitope mapping was performed using twelve
sequential 20-mer synthetic peptides, seven amino acids overlapped each,
covering the entire sequence of EPO. Anti-EPO were detected by ELISA;
EPO was quantiﬁed by radioimmunoassay. Sixteen sera from each of the
following groups were tested against the overlapping synthetic peptides:
Sera from HIV-1 infected patients with anti-EPO; without anti-EPO; and
from age/sex-matched healthy blood donors.
Results: Only sera from HIV-1-positive patients with anti-EPO
presented showed binding to the following EPO-epitopes: 1−20aa
(Ep1), 54−72aa (Ep5), 147–166aa (Ep12). Inhibition tests conﬁrmed
the speciﬁc antibody binding to Ep1, Ep5 and Ep12. Structural
analysis of EPO revealed that Ep1 and Ep12, which cover the
NH2- and C-terminal ends of EPO respectively, are connected with a
disulﬁde bond, comprising the interaction interface with EPO receptor
(EPOR). Binding of anti-EPO to this speciﬁc region is predicted to
block the EPO-EPOR interaction resulting to blunted erythropoiesis.
This phenomenon was indicated by the higher EPO [45.23 (28.7)
vs. 24.1 (9.2) IU/ml, p< 0.001] and lower hemoglobin levels [12
(1.8) vs. 14.3 (1.9) g/dl, p< 0.001] of anti-Ep1 positive patients
compared to anti-Ep1 negative. Ep1 exhibited a 63% similarity with
the 34LVCASRELERFAVNPGLLE52 fragment of the HIV-1 p17gag-
matrix protein. All sera binding to Ep1 peptide recognized the HIV-
p17gag analogue but not the scrambled peptide constructed from the
same region. Furthermore inhibition tests veriﬁed the speciﬁc binding
with values for Ep1 and HIV p17gag as 54% and 52% respectively.
Conclusion: EPO contains linear B-cell epitopes, recognized by anti-
EPO antibodies, located in the binding site of EPO to its receptor. Ep1
shows molecular similarity with p-17 matrix protein of HIV-1 suggesting
a molecular mimicry mechanism. The presence of Ep1 is associated with
anemia and blunted EPO response in HIV-1 infected patients.
O365 The role of hepatitis B virus co-infection in immunologic
progression among patients with primary human
immunodeﬁciency virus type 1 infection in an area of
hyperendemicity for HBV infection
M. Tsai*, Y. Lo, H. Sun, W. Sheng, W. Liu, C. Hsieh, C. Hung,
S.C. Chang (Taipei, TW)
Objectives: Hepatitis B virus (HBV) co-infection is common in human
immunodeﬁciency virus (HIV)-infected patients and has been reported to
be associated with accelerated progression to acquired immunodeﬁciency
syndrome. However, it remains unclear whether HBV affects the natural
history of primary HIV infection. We studied the impact of HBV on
immunologic progression among patients with primary HIV infection.
Methods: Patients aged 18 years or greater who did not start
antiretroviral treatment during the ﬁrst 3 months after the diagnosis of
primary HIV infection were identiﬁed from a prospective observational
cohort at two major medical centers for HIV care in northern Taiwan,
from January 1997 to December 2010. Primary HIV infection was
deﬁned as an interval of 6 months or less between negative and
positive HIV serologic tests by enzyme-linked immunosorbent assay;
an incomplete Western blot ﬁnding; or a negative HIV serologic test in
the presence of HIV viremia by real time polymerase chain reaction.
HBV infection was deﬁned as presence of hepatitis B surface antigen in
the serum. Immunologic progression was deﬁned as the occurrence of a
CD4 cell count <350 cells/mm3 3 months or greater after diagnosis of
primary HIV infection. We identiﬁed clinical and virologic predictors of
immunologic progression by Cox Proportional Hazards model.
Results: In the 14-year study period, 112 patients with untreated
primary HIV infection were included for analysis; the majority (95%)
of them were men who have sex with men and 15 patients (13.4%) had
chronic HBV infection. During a median follow-up duration of 248 days
(range, 99–1980), 60 (53.6%) experienced immunologic progression.
patients with HBV co-infection had a higher incidence of immunologic
progression than those without HBV co-infection patients: 8.37 vs. 0.33
per person-year of follow-up (P< 0.01). In multivariate analysis, HBV
co-infection (adjusted hazard ratio [aHR], 4.15; 95% conﬁdence interval
[CI], 1.23–13.96) and a lower initial CD4 cell count (aHR= 1.74 per
100 cells/mm3 CD4 decrease; 95%CI=1.18–2.58) were independent
predictors of immunologic progression.
Conclusions: The risk of immunologic progression after primary HIV
infection is higher in patients who have chronic HBV co-infection and
a lower baseline CD4 count. Early initiation of antiretroviral therapy
should be strongly considered in this speciﬁc group.
O366 Prevalence of high-risk genotypes human papillomavirus
in anal samples with cytological changes from homosexual
patients attending in a tertiary hospital, Madrid
G. Gabilondo*, B. Romero, T. Hellin, J. Chacon, I. Sanz, M. Mateos
(Madrid, ES)
Objective: The aim of this work was to determine the prevalence of high
risk genotypes of human papillomavirus (HR-HPV) in anal samples from
homosexual men with cytological changes, as well as the frequency of
cytological lesions and its association with the human immunodeﬁciency
virus (HIV).
Methods: We included 100 homosexual men attended at the Sexual
Transmitted Disease Unit of the Ramo´n y Cajal Hospital from June 2009
to October 2010. Anal samples were collected with cervical brushes
(Cervix-Brush®) and stored in PreservCyt® medium. Cytological
analyses were performed using the Bethesda classiﬁcation and HPV
genotyping (Linear Array®, Roche Diagnostics, Mannheim, Germany).
Results: Patients’ average age was 35.3 years (range 17−65 years), and
47% of them were HIV positive. Cytology lesions were only detected
in 46 anal samples from 43 patients, and were as follows: 8.7% Atypic
Squamous Cell Unknown Signiﬁcance (ASCUS), 69.5% Low Squamous
Intraepithelial Lesion (LSIL), 8.7% Indeterminate Squamous Intraep-
ithelial Lesion (ISIL) and 13.1% High-Grade Squamous Intraepithelial
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Lesion (HSIL). HIV positive patients presented 74% of LSIL and 11%
of HSIL versus 63% and 15.7% respectively in the non infected ones
(p> 0.5). Negative results for HPV were observed in 4 samples with
cytological lesions (3 LSIL and 1 ASCUS). From the HPV positive
samples, 93% showed a mixed co-infection (from 2 to 11 genotypes),
being the coexistence of three different genotypes in the same sample
(19%) the most frequent trait. In the overall analysis, HPV-51 was the
most frequent genotype detected (30%), followed by HPV-31 and HPV-
66 (both 26%), and ﬁnally genotypes HPV-16 and 18 were found in
24% and 13%; respectively. An 80.4% of anal samples carried a HR-
HPV (68.4% in HIV negative versus 88.8% in HIV positive, p = 0.08).
The most frequent HR-HPV in HIV negative and HIV positive patients
was HPV-31 and HPV-51; respectively. Both HR-HPV-16 and 31 were
the most prevalent genotypes in patients with LSIL whereas in the group
of HSIL these were represented by HPV-51 and HPV-58.
Conclusions: The most prevalent HPV genotype in anal samples of
homosexual men that presented an altered cytology was HPV-51 (almost
all in samples from HIV positive patients), followed by HPV-31 and
HPV-66. Infection with only a HPV genotype is rare (7%). There is no
difference in the frequency of LSIL, HSIL and HR-HPV between HIV
negative and positive patients.
O367 High rate of adverse events and serious adverse events after
antiretroviral therapy initiation in a resource-limited setting:
preliminary data from a prospective study
S. Kiertiburanakul*, N. Rajatanavin, A. Charoenyingwattana,
A. Rojanawiwat, W. Wangsomboonsiri, W. Manosuthi, P. Kantipong,
A. Apisarnthanarak, W. Chantratita, S. Sungkanuparph (Bangkok,
Nonthaburi, Nakornsawan, Chiang Rai, Pratumthani, TH)
Background: The World Health Organization’s commitment to the
global scale-up of antiretroviral therapy (ART). Most antiretroviral drugs
cause adverse effects (AEs). A prospective data regarding AEs among
patients in resource-limited settings is limited. We hypothesize that AEs
rate might be high in this setting where NNRTI-based regimen has been
widely used for scale-up ART. We aimed to describe AEs among naı¨ve
HIV-infected patients whom ART were initiated in Thailand.
Methods: This study is a sub-study of Genotype Based Personalized
Prescription of Nevirapine (GENPART) (NCT00986063) which mainly
aimed to compare the incidences of nevirapine (NVP) associated rashes
in patients who are initiated NVP guided by genetic tests and using
standard of care approach. Patients were randomized to receive a ﬁxed
dose combination of stavudine or zidovudine plus lamivudine and NVP.
The overall rate of AEs in all participants was prospectively monitored.
Results: Up to August 2010, 366 HIV-infected patients were enrolled and
141 (38%) patients experienced AEs. A total of 195 AEs were reported
which 54 (28%) patients developed more than one AE. Of these, 42
(21%) events were serious adverse events (SAEs) which 28 (14.3%)
events were hospitalization, and 4 (2%) events were death. Cutaneous
reactions were reported in 73 (37%) events which one-third events were
grade 3 and 4. Hepatitis was reported in 39 (20%) events. Most events
were grade 1 and approximately half were symptomatic. Median (IQR)
duration of AEs was 14 (7−29) days. Overall, 24 (12%) events were
deﬁned as deﬁnitely related to antiretroviral drugs. ART needed to be
stopped and new regimens were initiated in 47 (24%) patients after
AEs were improved. Over all, 67 (34%) events were ongoing, 55 (28%)
events were improved, and however, 11 (6%) events were improved with
sequelae, such as hyperpigmentation, cardiomegaly, and neuropathy.
Conclusion: A high proportion of naı¨ve HIV-infected patients experi-
enced SAEs in a resource-limited setting. Close monitoring and health
education by health-care provider after ART initiation is crucial to
prevent AEs and improve HIV care.
Quality control: is it needed?
S370 Quality control in molecular diagnostics
A. van Loon*, W. MacKay, P. Wallace (Utrecht, NL; Glasgow, UK)
Due to their high level of sensitivity and speciﬁcity, nucleic acid
ampliﬁcation tests (NAT’s) have in many cases rapidly become the gold
standard for diagnosis of infectious diseases and for monitoring treatment
of patients with chronic or latent (viral) infections.
However, multicentre studies in the mid 1990’s had revealed serious
problems in speciﬁcity (false-positivity rates up to 40%) and sensitivity,
as well as large variations in quantitative results and units used to express
results. These problems have been addressed by a variety of approaches.
For example, cross contamination of samples was addressed by various
measures as spatial separation of the different steps in the procedure
(reagent preparation, extraction, ampliﬁcation and detection), the use
of anti-contamination reagents (UNG system) and the development of
real-time PCR assays allowing to avoid opening reaction tubes after
ampliﬁcation.
Standardisation was improved when diagnostic companies entered the
ﬁeld, and was further improved when International WHO Standards were
developed, however at that time mainly for the detection of blood-borne
viruses, C. trachomatis and N. gonorrhoeae. The lack of sensitivity due
to sequence variation of the target gene was improved by more careful
selection of (combinations of) primers and probes, and quantitation of
viral loads was greatly helped by the introduction of real-time PCR.
Similarly, more labs have recently started to use internal controls to
monitor extraction and ampliﬁcation efﬁcacy.
However, the proof of the pudding of molecular diagnostic testing
by laboratories is in external quality control (EQA) i.e. the blind
testing of proﬁciency panels. For this purpose Quality Control for
Molecular Diagnostics (QCMD) was established in 2001. Since the start,
QCMD’s EQA programs have conﬁrmed the progress that has been
made since the mid 1990’s, but also identiﬁed remaining problem areas.
These include: large differences (>1000-fold) in sensitivity between
laboratories, persisting problems with false-positivity, albeit at a much
lower level (<5%), and wide variation in quantitative results. These
results stress that high quality molecular diagnosis can only be achieved
by careful development and validation of assay protocols and meticulous
execution of the assays.
S371 Quality control in MALDI-TOF
G. Greub* (Lausanne, CH)
The matrix-assisted laser desorption-ionization time-of-ﬂight (MALDI-
TOF) mass spectrometry is increasingly used in clinical diagnostic
laboratory for microbial identiﬁcation, since this new technology allows
easy and cheap bacterial identiﬁcation. Accuracy of the identiﬁcation at
species level is generally good and MALDI-TOF may even be used for
typing given species.
MALDI-TOF results may however be impaired by problems arising
during extraction, for instances (i) when testing encapsulated bacteria
(Streptococcus pneumoniae, Klebsiella pneumoniae), (ii) when testing
bacteria such as Streptomyces, that exhibit a particular cell wall that
reduces the yield of protein extraction, (iii) when the extraction protocol
is not properly conducted, or (iv) when the reagents used for extraction
are outdated or impaired by inadequate storage. If problems i& ii,
due to intrinsic bacterial properties, may only be circumvented by the
development of speciﬁc extraction protocols, the two latter problems
(iii & iv) might be prevented by an adequate quality program.
MALDI-TOF results may also be impaired by inadequate deposit of the
sample on the microplate, by poor cleaning of the microplate between
runs, by poor maintenance of the MALDI-TOF and by other technical
factors. Moreover, despite adequate maintenance and correct procedures,
some clade will repeatedly be misidentiﬁed due to poor content of some
databases.
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Thus, it appears critical to implement a quality control program. A
quality control program is especially warranted when using MALDI-
TOF for direct bacterial identiﬁcation from positive blood culture bottles
given the high impact of results on patients care.
The performance of the extraction step and of the MALDI-TOF mass
spectrometer may be checked by routinely testing a few selected bacterial
strains, which spectra are available in the database. This control should
ideally be done in parallel with and without a speciﬁc extraction step.
MALDI-TOF microplates need also to be checked before use for the
absence of residual proteins trace. Moreover, frequency of maintenance
of the MALDI-TOF should be increased if the apparatus is heavily used
or located in a crowded/dusty area.
In conclusion, quality controls might help to improve the quality
of proteins extraction, MALDI-TOF analysis and completeness of
databases. This will further improve the accuracy and usefulness of
MALDI-TOF.
Recent advances in the pathogenesis of
cytomegalovirus (CMV) and Epstein-Barr
virus (EBV)
S375 Recent advances in the pathogenesis of EBV infection
J. Minarovits* (Budapest, HU)
Epstein-Barr virus (EBV) initiates productive (lytic) infection in the
epithelial cells of the oropharynx upon oral transmission. On the
contrary, in EBV infected B lymphocytes the viral genomes usually
persist as latent, circular episomes, co-replicating with the cellular DNA.
Latent EBV genemes are associated with a series of malignant tumors
as well. These include lymphomas (Burkitt’s lymphoma, Hodgkin’s dis-
ease, T/NK-cell lymphoma, post-transplant lymphoproliferative disease,
AIDS-associated lymphoma, X-linked lymphoproliferative syndrome),
carcinomas (nasopharyngeal carcinoma, gastric carcinoma, carcinomas
of major salivary glands, thymic carcinoma, mammary carcinoma), and
a sarcoma (leiomyosarcoma). In tumor cells the expression of latent
EBV genomes is highly restricted and cell type speciﬁc, due to the
epigenetic control of the viral promoters. DNA methylation, histone
modiﬁcations and binding of key cellular regulatory proteins contribute
to the regulation of alternative promoters for transcripts encoding the
nuclear antigens EBNA 1 to 6 and affect the activity of promoters for
transcripts encoding transmembrane proteins (LMP1, LMP2A, LMP2B).
In addition to viral oncoproteins, non-translated RNAs (EBER1 and
2, microRNAs) may also contribute to EBV-mediated tumorigenesis.
The epigenetic marks left by cellular enzymes and macromolecular
complexes on latent EBV genomes deﬁne distinct viral epigenotypes that
differ in transcriptional activity in spite of having an identical (or nearly
identical) DNA sequence. Whereas latent EBV genomes are regularly
targeted by epigenetic control mechanisms, EBV encoded proteins may,
in turn, affect the activity of a set of cellular promoters by interacting
with the very same epigenetic regulatory machinery. EBNA2 interacts
with histone acetyltransferases, and EBNALP (EBNA5) coactivates
transcription by displacing histone deacetylase 4 from EBNA2-bound
promoter sites. EBNA3C (EBNA6) seems to be associated both with
histone acetylases and deacetylases, although in separate complexes.
LMP1 affects both systems of epigenetic memory, DNA methylation and
the Polycomb-Trithorax group of protein complexes. In epithelial cells
LMP1 up-regulates DNA methyltransferases and in Hodgkin lymphoma
cells it induces the Polycomb group protein Bmi-1. In addition, LMP1
modulates the levels of microRNAs (miR-146a, miR-155) implicated in
tumorigenesis. These interactions may result in epigenetic dysregulation
and disease development.
Mycobacterium tuberculosis
O382 Drug-resistant Mycobacterium tuberculosis in Taiwan,
2003–2008
R. Jou*, T.F. Wang, C.Y. Yu (Taipei, TW)
Objectives: Global surveillance of drug resistance has shown that a
substantial proportion of tuberculosis patients are infected with drug-
resistant Mycobacterium tuberculosis strains. The prevalence of drug
resistance is a very important concern of the National Tuberculosis
Program (NTP). To understand the extent of drug resistance in Taiwan,
we initiated the Taiwan Surveillance of Drug Resistance in NTP in 2002.
Methods: The rates of drug resistance were analyzed according
to a laboratory-based surveillance system. The system consists of
nine contract laboratories distributed in different regions of Taiwan.
Approximately, 50% of annually isolated M. tuberculosis was underwent
antimicrobial drug susceptibility testing in the system. The external
quality proﬁciency test was conducted by the national reference
mycobacteriology laboratory using a M. tuberculosis panel provided
by the World Health Organization supranational reference laboratory
network. Since the clinical data were not available, only combined
(primary plus acquired) drug-resistant rates were analyzed.
Results: In 2003–2008, the population in the survey ranged from
22,562,663 to 23,037,031. The conﬁrmed tuberculosis cases and the
incidence rate per 100,000 population were 15,042 and 66.7 in 2003,
16,784 and 74.1 in 2004, 16,472 and 72.5 in 2005, 15,378 and 67.4 in
2006, 14,480 and 63.2 in 2007, and 14,265 and 62.0 in 2008, respectively.
The survey showed that the combined drug resistance rates were 9.5%-
12.4% to isoniazid, 5.2%-7.5% to rifampin, 2.1%-5.8% to ethambutol,
8.2%-10.6% to streptomycin, 17.5%-20.4% to any drug, and 4.0%-5.3%
to multiple drugs (Figure).
Conclusion: The incidence rates of drug-resistant tuberculosis remain
relatively stable during the recent six years in Taiwan. However,
this survey needs to be extended to analyze patient’s clinical and
epidemiologic data to reveal the reasons of drug resistance.
O383 Drug-resistant tuberculosis among foreign-born persons in
Italy
A. Mustazzolu, G. Piccaro, M. Pardini, P. Filippini, F. Giannoni,
E. Borroni, P. Miotto, D. Cirillo, L. Fattorini* and the TB-CCM Study
Group
Objectives: Multidrug-resistant tuberculosis (MDR-TB) is caused by
Mycobacterium tuberculosis strains resistant at least to isoniazid (I) and
rifampin (R). In industrialized countries with high levels of immigration,
MDR-TB among foreign-born persons is a serious problem but no
information is known for Italy; the aim of this study was to address
the extent of it in 2008–2009.
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Methods: 29 laboratories were enrolled in 2007 in 18/20 Italian regions
for proﬁciency testing (PT) of I, R, streptomycin (S), ethambutol (E) by
the WHO Supranational Reference Laboratory of the Istituto Superiore
di Sanita` (ISS). MGIT960, BACTEC460 and proportion method in solid
media were used for drug susceptibility testing (DST) in 22, 3 and
4 laboratories, respectively. DST data of patients born abroad (PBA),
patients born in Italy (PBI), new cases (NC), previously treated cases
(PTC) were annually sent to ISS.
Results: Efﬁciency (correct results/total results) of PT was high (95.5%
for S, 97.6% for I, 95.7% for R, 96.2% for E). In 2008 and 2009
the TB cases in the PBA were 60.7 and 61.3% (1035/1704 in
2008 and 1528/2489 in 2009), due to immigration from 53 and 75
countries, respectively. The top-5 countries were Romania, Morocco,
Peru, Pakistan, Senegal in 2008, and Romania, Morocco, India, Pakistan,
Senegal in 2009. Monoresistance to I/R was 5.9/0.4% and 3.6/1.3% in
PBA/PBI in 2008, and 4.8/0.5% and 2.7/0.5% in PBA/PBI, in 2009. As
to MDR-TB, 89 and 92% of NC and 84 and 79% of PTC occurred in
the PBA in 2008 and 2009, respectively; in the NC the top-5 countries
(2 cases) were Romania, Ukraine, Morocco, Moldavia, Peru in 2008
and Romania, China, Moldavia, Ukraine, Morocco in 2009. The highest
rates of MDR-TB in NC were from Ukraine (19 and 11% in 2008) and
Moldavia (8 and 13% in 2009). In 2009, in 27 MDR strains from the
PBA, resistance (as determined by MGIT) to I, R, S, E, pyrazinamide,
ethionamide, kanamycin, amikacin, capreomycin, oﬂoxacin, linezolid
and moxiﬂoxacin was 100, 100, 74, 26, 37, 33, 19, 19, 19, 11, 11
and 7%, respectively. A case of XDR-TB (extensively drug-resistant,
i.e. MDR resistant to any ﬂuoroquinolone and an injectable drug) was
observed.
Conclusion: In 2008–2009 about 90% of the MDR-TB in the NC was
due to foreign-born persons migrated in Italy from the former Soviet
Union and other countries. Fluoroquinolones and linezolid were still
quite active against these difﬁcult-to-treat strains (Supported in part by
the Italian CCM Projects).
O384 Six-year laboratory data report on drug-resistant
tuberculosis in Lisbon health region, Portugal
J. Perdiga˜o, R. Macedo, C. Silva, C. Pinto, C. Furtado, L. Brum,
I. Portugal* (Lisbon, PT)
Objective: Multidrug-resistance (MDR) and extensive drug-resistance
(XDR) pose a serious threat to tuberculosis (TB) management. In
Portugal, the high TB incidence rates (28.7 cases/100 000 Pop in 2008)
cause difﬁculties in the transmission control of this infectious disease.
The country has high TB incidence rates in comparison with the other
European Union countries. Furthermore, the high MDR- and XDR-
TB rates in regions such as Lisbon Health Region hamper the TB
management.
In this study we have retrospectively analyzed 3 025 Mycobacterium
tuberculosis clinical isolates, recovered over a six-year period (2001–
2006), in Lisbon Health Region.
Methods: The analysis was focused on ﬁrst-line and second-line drug-
resistance. The clinical strains were isolated in the Portuguese National
Institute of Health − Dr. Ricardo Jorge which receives the majority of
clinical specimens from Lisbon Health Region. Moreover, the clonality
of a subset of isolates was assessed by 12-loci Mycobacterial Interspersed
Repetitive Unit − Variable Number of Tandem Repeats (MIRU-VNTR)
genotyping.
Results: We have found 22 different resistance proﬁles with MDR-TB
rates ranging between 9.9–15.2% and, XDR-TB rates between 44.3–
57.3% (excluding one year here considered as an outlier). Six MIRU-
VNTR clusters were associated with MDR-TB and, of which three
(Lisboa3, Lisboa4 and Q1) had XDR-TB isolates.
Conclusion: Through the present study we conclude that transmission
of MDR- and XDR-TB is occurring mainly due to a limited number of
genetic clusters, the majority belonging to Lisboa family. Implementation
of genotyping in the diagnostic routine would most probably be useful
in a timely detection of more serious types of resistance, like XDR-TB.
A stronger and more efﬁcient contact-tracing program would also bring
some advantages to the halt transmission of primary drug-resistant TB.
O385 High-resolution melting analysis for rapid detection of
rifampicin resistance in Mycobacterium tuberculosis clinical
isolates
M. Nica*, A. Dascalu, T. Biolan, E. Turcu, E. Ceausu, P. Calistru,
I. Apostol, T. Hainisteanu, O. Moldovan (Bucharest, RO)
Objectives: The worldwide emergence of multidrug resistant Mycobac-
terium tuberculosis (MDR-TB) has been reported in both developed and
developing countries. Fast detection of rifampicin (RIF) resistance in
M. tuberculosis is crucial for implementation of appropriate treatment
and management of infected patients. The main objective was to
elucidate the characteristics of the rpoB gene mutation in RIF-R
M. tuberculosis strains.
Methods: Conventional methods results (Ziehl-Neelsen smear,
Lowenstein-Jensen, MB/BACT cultures) were correlated with identi-
ﬁcation of M. tuberculosis speciﬁc sequences, by Real Time PCR
technique (Primer Design TB Kit, LightScanner 32, Idaho Technology).
The susceptibility tests were performed using CDC standard proportion
method on LJ medium containing rifampicin (RIF) 40mg/L, isoniazid
(INH) 0,2mg/L, ethambutol (EMB) 2mg/L, ethionamide (ETH) 20mg/L,
streptomycin (SM) and kanamycin (K) 20mg/L. Control was standard
strain of M. tuberculosis H37Rv. The high-resolution melting (HRM)
curve analysis, which detects single nucleotide polymorphisms, was used
to identify rpoB mutations responsible for rifampicin (RIF) resistance.
For the samples genotyping we used two-step reaction. First step is
the ampliﬁcation using custom Idaho primers and LightScanner Master
Mix. The second step is HRM, and we used a 3′-blocked, unlabeled
oligonucleotide probe (Idaho custom design) and the saturating dye
LCGreen Plus to generate melting curves typical to the genotype under
the probe.
Results: 525 nonrepetitive M. tuberculosis strains were enrolled in this
study, between Jan. 2009 and Dec. 2010; all specimens were tested
for drug susceptibility. 63 isolates from 525 (12%) were resistant to
RIF (only RIF-R/2,1%; both RIF and INH-R/9,9%). From 63 MDR-
TB, 16 strains were resistant to EMB, 22 to SM, 10 to K, 3 to
ETH. We performed genotyping (HRM) for 35 MDR-TB strains: higher
frequencies of mutation bearing sites found in codons 531 (21/35) and
526 (6/35) − total 77,1%. For 8 strains the mutations are under study,
on other codons inside the 81 pb region of the rpoB gene.
Conclusions: This study demonstrates an association between the
mutations of rpoB gene and their correlation with the predominant
nucleotide change in codons 531 and 526. The mutations in codon 531
were more commonly identiﬁed in cases with high level RIF-resistance,
in the MDR-TB isolates from our geograﬁc area.
O386 Inhibiting the b-lactamase of Mycobacterium tuberculosis
(Mtb) with novel Boronate-Transitional-State-Analogs
(BATSAs)
S.G. Kurz*, C.R. Bethel, L.W. Tremblay, J.S. Blanchard, E. Caselli,
F. Prati, R.A. Bonomo (Cleveland, New York, US; Modena, IT)
Introduction and Rationale: Currently, 4-drug regimens are the
cornerstone of treatment against Mtb pulmonary infections. Against
infections with multiple- (MDR) and extensively-drug-resistant (XDR)
strains, therapeutic choices are limited and new options are sought.
b-lactams and b-lactamase inhibitors are not routinely used to treat
Mtb infections, since mycobacteria are considered to be resistant. BlaC,
a b-lactamase expressed in Mtb, is identiﬁed as the major enzyme
responsible for this resistance. BlaC which is capable of inactivating
a broad range of penicillins and cephalosporins belongs to the class
of b-lactamases which are usually susceptible to inhibitors such as
clavulanate (Ambler Class A). The combination of carbapenems and
clavulanate recently attracted attention as this combination was found
to be very effective in sterilizing Mtb cultures, including extensive drug
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resistant (XDR) strains. However, kinetic studies revealed that clavulanic
acid, compared to its effect in other Class A enzymes, is not as potent
an inhibitor. This poor inhibition may set the ground for development
of inhibitor-resistance. Therefore, novel b-lactamase inhibitors that are
effective against BlaC could play an important role in the treatment of
MDR or XDR infections.
We hypothesized that boronate-based compounds, which sterically
resemble the quarternary transition state of the b-lactam (Boronic-Acid-
Transitional-State-Analogs, BATSAs) would inhibit Mtb b-lactamases
with promising results. To this end, we tested a panel of 20 BATSA
compounds in order to ﬁnd candidates with excellent inhibitory
properties against BlaC.
Methods: The blaC gene was cloned and expressed in E. coli
BL21(DE3) and puriﬁed. Spectrometric assays were performed using
Nitroceﬁn as a reporter substrate to determine the Ki of 20 BATSA-
compounds.
Results: 5 compounds demonstrated Ki values of less than 5 microM:
Ki (microM ±10%)
EC19 0.65
SM23 1.46
EC04 2.76
CO10 3.34
TaxTSI 4.13
Conclusion: From a collection of 20 compounds, we identiﬁed 5 novel
BATSAs with effective inhibitory properties against Mtb BlaC. EC19,
a cefoperazone analog, demonstrated sub-micromolar Ki. Comparing
the structure of 6 cefoperazone analogs, we advance that a benzene-
carboxylate moiety is crucial for effective inhibition. Systematic analysis
of how structural variation inﬂuences binding gives insight into the role
speciﬁc amino acids play in stabilisation of the transitional state.
Cellular and molecular immunology
O387 Characterising pandemic H1N1 cross-reactive inﬂuenza
cytokine and T-lymphocyte responses induced by seasonal
intranasal live-attenuated inﬂuenza vaccine
Y. Keynan*, A. Meyers, M. Kimani, J. Kimani, F. Plummer, T. Ball,
K. Fowke (Winnipeg, CA; Nairobi, KE)
Objectives: Re-assortment of inﬂuenza viruses leads to changes in
surface glycoproteins, rendering the antibody responses directed at
hemagglutinin largely ineffective. Generating cross protective responses
has been the “holy grail” of inﬂuenza vaccine development. Various
studies suggest that the use of a live-attnuated, mucosally administered
vaccine may result in better induction of cellular immunity and thus
a potential for cross protection., however the presence of blocking
antibodies at the mucosa, may decrease the ability of live virus to
generate the desired cellular immune response. We sought to determine
the cross reactive responses induced by live attenuated inﬂuenza vaccine
(LIV) in a vaccine naive population.
Material and Methods: Flumist LIV was purchased from MedImmune.
The research was approved by local ethics boards. We enrolled 60 HIV
negative Women from a commercial sex workers cohort in Nairobi,
Kenya. Blood and mucosal samples were obtained prior to vaccine
administration and after 1,7, 30 days and 4−6 month after enrolment.
Plasma levels of cytokines were determined using 19 cytokine bead
array (Millipore). PBMC’s were stimulated ex-vivo with Inﬂuenza
A/H1N1Brisbane (BRIS) corresponding to the H1N1 strain included in
the seasonal formulation as well as with Inﬂuenza A/H1N1 Mexico 2009
(MEX) and analyzed using multi-parametric ﬂow cytometry including
markers of cell lineage, memory subsets (CCR7, CD45RA) and immune
activation using CD38, HLA-DR, CCR5. Cytokine production was
measured using intracellular staining. Proliferation and NK function were
assessed using two separate panels. Levels of cytokines in the culture
supernatant following stimulation were measured using 19 cytokine bead
array (Millipore).
Results: Immune activation and cytokine production by CD4 and CD8 T
lymphocytes increased in response to the vaccine component as well as
cross reactive responses against MEX were demonstrated. The kinetics
and levels of immune activation, cytokine production and proliferation
in response to antigen speciﬁc stimuli will be presented.
Discussion: The study illustrates the ability of a LIV to induce cross-
reactive inﬂuenza responses as measured by activation and cytokine
production of CD4 and CD8 lymphocytes. It remains to be determined
whether the cross reactive responses afford cross protection against a
heterotypic inﬂuenza challenge.
O388 Mannose-binding lectin concentrations and infections in
haemato-oncology patients: preliminary results
L. Berry*, M.M. Ceesay, H. Sikondari, A. Pagliuca, J. Wade, M. Smith
(London, UK)
Objectives: Mannose-binding lectin (MBL) is a secreted pattern
recognition receptor capable of binding pathogens and activating the
classical complement cascade. MBL deﬁciency is frequent due to genetic
polymorphisms. We describe preliminary results of a study of serum
MBL concentrations and infection in haemato-oncology patients.
Materials and Methods: Adults likely to be rendered neutropenic
were recruited. MBL was assayed in baseline serum samples by ELISA.
Patients were followed until death, discharge or four months after last
admission for chemotherapy and/or transplantation. Microbiology results
were recorded prospectively. Categorical and continuous variables were
analysed by Fisher’s exact and Wilcoxon Ranksum tests, respectively.
Results: Of the ﬁrst 100 recruits, baseline sera were available for 95:
age range 19−73y (median 52y; inter-quartile range 40−59y); 52 (54%)
were female; follow-up time: 4–468d (212d;107–315d). Baseline MBL
concentrations ranged between the ELISA limits of 5 and 4000 ng/mL
(1600;390–3500ng/mL); one and 20 patients had 5 and 4000 ng/mL,
respectively. Firstly, patients with baseline MBL 1500ng/mL (n = 47)
were compared to those with MBL >1500ng/mL (n = 48): these groups
did not differ with respect to age, sex and follow-up time, but a
laboratory-conﬁrmed bacterial or fungal infection was identiﬁed in 77%
and 58%, respectively (P = 0.08), and in 75% and 50%, respectively,
in the ﬁrst 75d (P = 0.02). Time to ﬁrst Enterobacteriaceae positive
blood culture was shorter in the lower MBL group (median 8 vs. 21d;
P = 0.033). Secondly, patients with baseline MBL <500ng/mL (n = 26)
were compared to those with MBL 500ng/mL (n = 69): these groups
did not differ with respect to age, sex and follow-up time, but median
time to ﬁrst positive blood culture (any organism) was shorter in the
low MBL group (8 vs. 17d; P = 0.0275) as was median time to ﬁrst
Enterobacteriaceae positive blood culture (6 vs. 19d; P = 0.023).
Conclusions: This preliminary analysis suggests an association between
a lower serum MBL concentration and increased infection risk. Analysis
of the completed cohort may clarify whether there is a speciﬁc risk
of infection with Enterobacteriaceae rather than all Gram-negatives,
including others encountered in these patients (eg Pseudomonas
aeruginosa and other ‘non-fermenters’).
O389 Pseudomonas aeruginosa vs. the innate immune system:
understanding bacterial response to macrophage engulfment
L.K. Green*, A.C. La Flamme, D.F. Ackerley (Wellington, NZ)
Objective: Pseudomonas aeruginosa, an emerging multi-drug resistant
human pathogen, encounters innate immune system defences like the
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release of reactive oxygen species (ROS) by macrophages upon host
infection. Based on our previous work which demonstrated a role for
soluble quinone oxidoreductase (QOR) enzymes in protecting a related
bacterium (Pseudomonas putida) from oxidative stress, we hypothesized
that P. aeruginosa would similarly utilize QORs to withstand ROS.
However, when individual genes encoding QORs are deleted from
P. aeruginosa, no apparent ROS sensitivity is seen. Our main objective
now is to characterize the global genetic proﬁle of macrophage-
challenged P. aeruginosa thereby identifying genes promoting virulence
of the bacterium by enabling it to resist host oxidative defences, including
the oxidative burst of activated murine macrophages. In doing so,
we hope to identify potential therapeutic targets for the treatment of
P. aeruginosa infections.
Methods: In the process of characterizing the P. aeruginosa response
to murine macrophages, we have developed a method for isolating
internalized bacteria for analysis. Murine macrophages are infected with
P. aeruginosa. Non-internalized bacteria are then killed by antibiotic
application and washed away. The bacteria-containing macrophage is
then allowed to mature up to 8 hours under normal culture conditions.
The infected macrophages are then lysed by detergent. The internalized
bacteria are isolated by a series of differential spins, analyzed by ﬂow
cytometry, confocal microscopy and by microarray.
Results: Preliminary results indicate that P. aeruginosa undergoes a
potential phenotypic switch two hours post infection not previously
seen by conventional survivability measurements (e.g. colony forming
unit counts). Additionally, we have identiﬁed several New Zealand
clinical isolates of P. aeruginosa that respond differently to macrophage
interaction when compared to the laboratory strain.
Conclusions: The application of an in vivo approach to assessing
bacterial response to infection may allow us to observe a more “realistic”
infection scenario for P. aeruginosa. Initial results incorporating ﬂow
cytometry have allowed us to select ideal candidates for microarray
analysis. This work will give us a global view of the genetic response
P. aeruginosa undergoes when encountering the innate immune system,
thus taking us one step closer to identify therapeutic targets to counter
P. aeruginosa infections.
O390 Cytokine response of Th17 and oral lactobacilli in chronic
periodontitis
A.K. Szkaradkiewicz*, T.M. Karpinski, M. Wyganowska-Swiatkowska,
A. Zeidler (Poznan, PL)
Objectives: Etiopathogenesis of chronic inﬂammation in periodontitis
still remains unclear. Therefore, present study aimed at analysis of Th
17 cytokine response and of oral lactobacilli involvement in chronic
periodontitis.
Methods: The studies were conducted on 24 patients (35−49 years
of age) with chronic periodontitis. Clinical criteria (GI, Pl.I, CAL)
permitted to distinguish the following research groups: 14 patients with
moderate chronic periodontitis (group 1) and 10 patients with severe
chronic periodontitis (group 2). The research material involved gingival
ﬂuid sampled with 1ml syringe with a thin needle from three most
deep periodontal pockets. The obtained gingival ﬂuid was tested for
presence of IL-17, TNF-a and bacteria of Lactobacillus genus, producing
or not producing H2O2. Estimation of gingival ﬂuid IL-17 and TNF-a
levels were conducted by ELISA, using Quantikine Human IL-17 and
Quantikine HS Human TNF-a Immunoassay kits (R&D Systems). In
turn, Lactobacillus spp. were cultured on Rogosa agar and the cultured
isolates obtained in anaerobic conditions were identiﬁed using API 50
CHL (bioMerieux). For detection of hydrogen peroxide production by
the isolated Lactobacillus spp. TMB-Plus agar was applied.
Results: In both groups of patients periodontal pockets contained
high concentrations of studied cytokines. In group 1 mean values
of IL-17 and TNF-a amounted, respectively, to 19.66±6.1 pg/ml and
4.95±0.91 pg/ml. In turn, in group 2 mean values of IL-17 and TNF-a
amounted to 34.7±6.65 pg/ml and 6.68±0.72 pg/ml, respectively, and
proved to be higher than those obtained in group 1 (p = 0.0028 and
p = 0.0003, respectively). In group 1 presence of Lactobacillus spp.
producing H2O2 was disclosed in 10 (71.4%) patients, in group 2 such
bacteria were present in 2 (20%) patients while in 3 (30%) patients
Lactobacillus spp. bacteria were present which did nor produce H2O2.
Conclusion: Chronic inﬂammation of periodontal tissues is associated
with cytokine response of Th 17 cells. Intensity of the response
may determine progression of the pathological process, while oral
lactobacilli which produce H2O2 may restrict development of infection
with periodontal pathogens.
O391 Increased expression of CD11A and CD45 and TH2
predominant immune response in isolated coronary artery
ectasia patients
A. Adiloglu*, A. Ocal, T. Tas, S. Onal, S. Kapan, B. Aridogan (Ankara,
Isparta, TR)
Objective: Aneurysm and ectasia have similar pathological pathways.
TH2-associated cytokines are stimulated by aneurismal tissse and
correspondingly lack mediators associated with TH1 response. We
detected serum TNF-a and IL-18 levels which are strong TH1
stimulating cytokines and also investigated the expression of adhesion
molecules CD11a, CD11b, CD18; and CD45 on leukocytes and anti
Chlamydia pneumoniae and Helicobacter pylori serum antibodies in
coronary artery ectasia (CAE) patients and normal coronary artery
(NCA) controls.
Methods: 51 isolated CAE patients free of atherosclerosis, and 37 NCA
controls were included in the study. Cell surface adhesion molecules were
detected by ﬂow cytometry using ﬂuorescence conjugated monoclonal
antibodies. Serum TNF-a, IL-18, C. pneumoniae IgG and IgM and
H. pylori IgG levels were detected by ELISA method.
Results: The mean ﬂuorescent intensities of CD11a on granulocytes,
monocytes and lymphocytes (10.01±8.2 vs. 6.79±3.49, p = 0.04;
15.84±8.64 vs. 11.56±5.27, p = 0.016; 29.58±9.98 vs. 20.02±9.66,
p< 0.001; respectively)and CD45 on granulocytes and monocytes
(7.58±5.03 vs. 4.57±3.05, p = 0.003 and 18.73±12.38 vs. 10.74±7.38,
p = 0.004 respectively) were signiﬁcantly higher in CAE patients, when
compared with NCA group. TNF-a levels were signiﬁcantly lower in
patient group (18.76±7.07 vs. 24.29±8.46; p< 0.001) and IL-18 levels
were lower in patient group without signiﬁcance, when compared with
controls (519.47±221.35 vs. 621.65±287.76; p = 0.063). The percentage
of granulocytes was higher in CAE group when compared with control
(NCA) group (65.52±14.91 vs. 52.28±15.37; p = 0.002). C. pneumoniae
serum IgG levels were signiﬁcantly higher in patient group when
compared with controls (81.62±48.53 vs. 63.79±33.83; p = 0.045). In
CAE patients, TNF-a levels were signiﬁcantly correlated with CD45+
granulocyte (0.525, p< 0.001), CD45+ monocyte (0.469, p = 0.001) and
lymphocyte (0.376, p = 0.013) mean ﬂuorescent intensity levels.
Conclusion: The decreased levels of TNF-a and IL-18 may indicate
TH2 predominant and TH1 lacking immunity in CAE patients, similar
as in aortic aneurysm patients. Increased levels of cell surface adhesion
molecules in CAE may be an indicator of activation of leukocytes for
adherence and transmigration through the vessels for the initiation of
inﬂammation.
Under your skin: skin manifestations of
parasitic diseases
S398 Toxocariasis in patients with skin disorders
C.M. Cretu* (Bucharest, RO)
Toxocariasis is a disease consequent to visceral migration of dogs’
and cats’ ascaris larvae, Toxocara canis or T. cati. People become
infected accidentally eating Toxocara infected eggs or eating row
tissue (cow/lamb liver). Tissue migrating larvae are trapped in
eosinophilic granulomas, mostly in liver and lungs, but any organ
including eye or CNS can be involved. Clinical forms: Visceral Larva
Migrans, Ocular Larva Migrans, Covert Toxocariasis and asymptomatic
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patients. VLM is considered when following signs are present: hepato-
splenomegaly, diarrhea, digestive disorders, dry cough, wheezing,
fever, limphadenopaty, anorexia, malnourishment, skin disorders, pallor,
asthenia, anorexia, cardiac and neurological signs. Positive serology and
hipereosinophylia are the most relevant markers of infection activity.
Skin disorders are present in about 24% of symptomatic cases. Urticaria
and angioedema are quite often associated with allergic reactions, like
asthma, rhinitis, conjunctivitis. About 17−65% of cases with chronic
urticaria are conﬁrmed with VLM, or have a positive serology for
Toxocara with good evolution after antiparasitic treatment. Facial oedema
and even laringial angioedema, requiring emergency interventions, can
be present, as well as palpebral and lips edema. Pruritus is very common
in Toxocariasis; sometime scratched skin is associated (all skin lesions
are very itching). Acute or chronic pruritus, sometimes generalized or
localized either on sole and palms, or on thorax, sacrum or nodular
pruritus can be noticed. Skin rash (papular or purpuric), polymorphic
eritema, hypodermal lesions and even Fiessinger-Leroy-Reiter syndrome
can be associated. Eczema, dishydrotic or nodular lesions occur on palms
and soles. Atopic eczema can be aggravated by Toxocariasis. Toxocara
spp. is considered now etiologic factor for Wells syndrome (eosinophilic
cellulites), together with other parasites, insect bites, infections or
hematological disorders. In atopic patients, co-infection with Toxocara
spp. ampliﬁes the symptoms; sero-prevalence of Toxocariasis is higher
in asthmatic patients than in normal population. Total and speciﬁc IgE
anti-Toxocara are increased in RAST positive patients. CT associates
skin manifestations and allergies together with asthenia, bronchospasm,
hepatomegaly, digestive complaints, limphadenopaty, myalgia, asthenia.
OLM is almost always an independent condition, being rarely consequent
to VLM. Any ocular segment can be involved.
S399 Maggot debridement therapy
G. Cazander*, M.W. Schreurs, C.M. Vandenbroucke-Grauls,
G.N. Jukema (The Hague, Rotterdam, Amsterdam, NL)
Maggot therapy is successfully used for the treatment of wound
infections. The underlying mechanisms of action of maggot therapy are
unknown, but could provide information for a novel treatment modality
against infection, which is important in these times of increasing
antibiotic resistance. Therefore, in this research the effect of living
maggots on planktonic cells was investigated. Furthermore, the inﬂuence
of maggot excretions/secretions (ES) on planktonic cells, on bacterial
bioﬁlms and on complement activation was tested.
Sterile tubes were ﬁlled with living maggots in a bacterial suspension
and every two hours samples were cultured and compared with controls.
A turbidimetric assay was performed to test the susceptibility of six
bacterial species to ES. Bacterial bioﬁlms were formed in vitro on
polyethylene, stainless steel and titanium and ES were added to test their
inﬂuence. The effect of ES on complement activation was investigated
in healthy donor sera and in pre- and postoperatively gained sera from
trauma patients. Different immunoassays, that are also clinically used
to determine complement deﬁciencies in patients, were performed in
absence or presence of maggot ES.
The results show that living maggots as well as their ES stimulate
the bacterial growth of S. aureus, E. faecalis, CNS, S. pyogenes and
K. oxytoca (all p-values 0.0002). The strongest bioﬁlms in vitro were
formed by S. aureus, S. epidermidis and P. aeruginosa. ES were added
to these bioﬁlms and reduced these on all biomaterials. The maximal
bioﬁlm inhibition by ES was seen on polyethylene: 82% for P. aeruginosa
(p< 0.0001), 61% for S. aureus (p< 0.0001) and 92% for S. epidermidis
(p< 0.0001). Furthermore, ES reduced complement activation in sera
from healthy and postoperatively immune-activated sera up to 99.9%
(p< 0.0001), via all three pathways of complement activation.
This study shows that nor living maggots, neither maggot ES have direct
antibacterial properties. However, ES do reduce bioﬁlms and complement
activation. The bioﬁlm reduction and the immunosuppressive effect of
maggot ES may explain part of the improved wound healing caused by
maggot therapy. Furthermore, the bioﬁlm- and complement-inhibitor(s)
present in maggot ES could provide novel treatment modalities for
various diseases, e.g. (chronic) infections in trauma patients. Future
research focuses on the identiﬁcation and isolation of the effective
substance(s) in ES of the Lucilia sericata larvae.
Infective endocarditis: lights and shadows
S404 The changing epidemiology
R. Utili* (Naples, IT)
Epidemiology of endocarditis has considerably changed in the last
decades as a consequence of medical progress, although geographical
differences still exist. The median age of incidence in developed
countries has grown from 40 years in the ﬁfties to 70 years at
present. Risk factors have changed accordingly. Rheumatic valve disease
and drug addiction are still more frequent in developing countries
and in younger patients, whereas in the western world nosocomial
acquisition, immunosuppression, dialysis, diabetes mellitus and cancer
predominates in the elderly population. In these countries the proportion
of responsible organisms have changed as well. Instead of viridans
Streptococci that were the most common etiological agent in the
past, Staphylococcus aureus represents nowadays the leading pathogen,
and community-acquired methicillin-resistant Staphylococcus aureus is
emerging. Similarly, the increase of invasive procedures in elderly
patients and the growing number of cardiac device implants has caused
an increase of infections by skin bacteria such as coagulase-negative
Staphylococci and Propionibacterium acnes, that in the past were
considered as contaminants. The increase in population age has also
caused an increase of infections due to bacteria that are commensals
of intestinal and genitourinary ﬂora such as Streptococcus gallolyticus,
particularly in mediterranean countries, and Enterococci. Furthermore,
we are facing the return of Gram negative bacteria and a worrying
increase of fungi of nosocomial origin. Lastly, the introduction of new
serological and molecular diagnostic tests have highlighted the major
role of difﬁcult to grow organisms, such as Coxiella, Bartonella, and
Tropheryma whipplei in cases that were considered in the past culture-
negative endocarditis. Hospital-acquired organisms harbour antibiotic
resistant genes that cause problems in treatment. Therefore, despite
the progresses in diagnosis and surgical treatment, mortality from
endocarditis remains high.
S406 Culture-negative endocarditis: a diagnostic conundrum
P.E. Fournier* (Marseille, FR)
Blood culture negative endocarditis (BCNE), i.e. endocarditis in which
no causative microorganism can be grown in a culture taken from
a blood sample using usual laboratory methods, acount for 2.5 to
31% of all cases of endocarditis. This variation in incidence among
hospitals may be explained by several factors including: i) differences
in the diagnostic criteria used; ii) variations in early use of antibiotics
prior to blood sampling; iii) involvement of unknown pathogens; iv)
speciﬁc epidemiological factors, as for fastidious zoonotic agents and v)
non-infectious aetiologies. Among fastidious microorganisms, Coxiella
burnetii, the agent of Q fever, and Bartonella sp. appear to be the
most common. Other bacteria, including Brucella sp., Abiotrophia
sp., Tropheryma whipplei, Legionella sp., and mycobacteria are less
frequent. Since 2001, we have used a systematic protocol that included
serology assays, detection of auto-antibodies, PCR from blood and,
when available, culture and PCR from valvular specimens. To this
protocol were added in 2009 the detection of antibodies to pork in
patients who had a porcine valvular bioprosthesis. Over 10 years, we
studied 1,334 patients with blood culture negative endocarditis, including
1,230 classiﬁed as possible or deﬁnite using the Duke criteria. Our
strategy enabled us to identify an aetiological agent in 775 patients,
including C. burnetii in 54.2% of cases, Bartonella sp. in 19.2%, and
other fastidious bacteria in 4.1% (T. whipplei 2.6%). Overall, fastidious
bacteria accounted for 77.5% of all diagnoses. In addition to infectious
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causes, we detected 10 cases of marantic endocarditis, 12 cases of
Libmann-Sacks endocarditis, 4 other auto-immune diseases, and one case
of relapsing BCNE in whom the only possible cause was allergy to pork.
We suggest that investigation of BCNE should systematically include
C. burnetii and Bartonella sp. serologies, broad range PCR assays and
histological examination when valvular specimens are available, and
detection of auto-antibodies.
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O408 Upsurge of human enterovirus 68 infections in patients with
severe respiratory tract infections
J.C. Rahamat-Langendoen*, R. Borger, A. Riezebos-Brilman,
A. Brandenburg, E.H. Scho¨lvinck, H.G. Niesters (Groningen,
Leeuwarden, NL)
Objectives: Human enterovirus 68 (EV68) is member of human
enterovirus species D. It is unique among enteroviruses because it has
properties of both enteroviruses and human rhinoviruses (HRV). EV68 is
found to be highly similar to HRV87 and is almost exclusively associated
with respiratory disease. Reports of EV68 infection are uncommon;
however, during the second half of 2010 we detected an increased amount
of patients with EV68 infection in association with serious respiratory
disease. In order to determine if changes in the virus could account for
the upsurge of EV68 infections, we characterized the clinical isolates
and compared these with isolates found in 2009. We furthermore related
these ﬁndings to clinical data.
Methods: EV68 clinical isolates were identiﬁed by sequencing of the
VP4/VP2 genomic region. Further characterization of the isolates was
done by partial sequencing of the VP1 capsid gene (728 base pairs).
Sequences were aligned with Clustal W 2.0, and phylogenetic trees were
constructed by the neighbour-joining method using MEGA 4.0. Clinical
data were systematically collected.
Results: From August till November 2010, 22 patients were identiﬁed
with EV68 infection (out of 111 patient samples collected for respiratory
viral detection). Clinical isolates of 4 patients collected in 2009 were
added. Sequence data showed that the majority of the isolates detected in
2010 were phylogenetically distinct from those found in 2009. The 2010
isolates contained a 3 nucleotide deletion in the VP1 genomic region as
compared with the isolates of 2009. Hospital admission was necessary in
22 out of 26 patients. Median age of patients with EV68 infection was
6 years (range 0−72). 84% of the patients had a chronic underlying
illness. Detection of EV68 was associated most notably with lower
respiratory tract infections (pneumonia, exacerbation asthma, wheezing).
Two patients required mechanical ventilation because of infection with
EV68. All but one patient had only EV68 detected as possible viral cause
of illness. No bacterial cause of infection was identiﬁed. All patients
recovered.
Conclusions: In the second half of 2010 an upsurge of EV68 detection
in patients with severe respiratory tract infections was observed. Genetic
changes in the virus might be associated with these observations.
O409 Occurrence and characteristic of viral agents in respiratory
tract infection in Nigerian children
O.M. Akinloye*, E. Ro¨nkko¨, C. Savolainen-Kopra, T. Ziegler,
M. Deji-Agboola, B. Iwalokun, A. Oluwadun, M. Roivainen, F. Adu,
T. Hovi (Ago-Iwoye, NG; Helsinki, FI; Ibadan, NG)
Acute respiratory infections (ARI) are the most common cause of death
in children in developing countries and little information is available
on risk factors for mortality among African children presenting with
symptoms compatible with acute respiratory.
Objectives: The study was designed to identify viral agents responsible
for respiratory infections among young children in Nigeria, to deﬁne
the incidence of respiratory viral agents in children suffering from ART,
and to identify the role of newly discovered viruses among West African
children.
Methods: Using conventional real time RT-PCR, we discovered that all
major respiratory viral pathogens are well represented in specimens of
the children.
Results: Out of 246 nasal and throat specimens collected from ARI
patients, 77 percent contained the genome of at least one viral agent,
as shown by molecular techniques. Human rhinoviruses (HRVs) was the
most prevalent present in 87 (36%) of cases, followed by parainﬂuenza
virus (PIV) type 3, detected in 50 (20.3%), human enterovirus, 35
(14.2%); PIV type 2, 21 (8.5%); PIV type 1, 15 (6.1%); adenovirus, 12
(4.9%); inﬂuenza virus C, 12 (4.9%); human metapneumovirus (hPMV),
7 (2.8%); human bocavirus (HBoV), 6 (2.4%); inﬂuenza virus A, 3
(1.2%); inﬂuenza virus B, 2 (0.8%); respiratory syncytial virus (RSV),
1 (0.4%). HRV strains were subjected to partial genomic sequencing
in the VP4/VP2 capsid protein coding region followed by phylogenetic
analysis. We disclosed the genetic type of 17 of these strains.
Conclusion: Our study underlines the importance of viruses in the
pathogenesis of respiratory infections of children in Nigeria. These
results are among the ﬁrst genetic typing results of HRV in the African
continent and conﬁrm the global circulation of the novel HRV-C strains.
O410 Clinical impact of HSV-1 detection in the lower respiratory
tract from hospitalised adult patients
C. Costa*, A. Saldan, F. Sidoti, S. Gambarino, M. Terlizzi, S. Astegiano,
A. Curtoni, M. Bergallo, R. Cavallo (Turin, IT)
Objectives: HSV types 1 and 2 are highly prevalent alfa-herpesviruses,
that may reactivate from latency in favouring conditions. HSV
(particularly, but not exclusively HSV-1) has been detected in respiratory
specimens from different categories of patients, as well as in up to
5% of asymptomatic adults. Occasionally, HSV has been associated to
pneumonia in immunocompromised and critically ill patients. Given the
availability of an effective antiviral agent (i.e. acyclovir), it is relevant
to evaluate the potential clinical impact of HSV in the lower respiratory
tract. Herein, the occurrence and clinical role of HSV in bronchoalveolar
lavage (BAL) specimens from hospitalized adult patients were studied.
Methods: In a one-year period 265 BAL specimens from 203 patients
(129M/74F, mean age 56.2 years; 85 transplant recipients, 27 other
immunocompromised patients, and 91 immunocompetent individuals)
were tested for HSV-1 and -2 by real-time PCR (R-gene™, Argene). A
diagnostic panel including community-acquired respiratory viruses and
other herpesviruses, bacteria, and fungi was also evaluated. Demographic
and clinical features, including mortality within 28 days, were evaluated.
Results: HSV-1 resulted positive in 75/265 (28.3%) specimens from
66/203 (32.5%) patients, with no difference according to age-group,
immune status, transplant status or other clinical features. Two specimens
were positive to HSV-2. Viral load was 652970 genome copies/ml BAL
(mean) and <1.5×104 for HSV-1 and -2, respectively, and tended to be
higher in patients with a discharge diagnosis of pneumonia. Co-infections
with other respiratory pathogens were detected in 16.6% of specimens.
HSV-1 resulted signiﬁcantly more frequent in mechanically ventilated
vs non-ventilated patients (p< 0.01). Mortality within 28 days occurred
in 21 cases, 12 of which HSV-1 positive (p = n.s.). Acyclovir treatment
resulted efﬁcacious in the remaining patients (HSV-negativity conﬁrmed
at subsequent sampling in 73% of cases).
Conclusion: HSV-1 DNA is frequently detected in different categories
of patients, without distinction according to immunological status,
transplant status, or other clinical features. Critically ill patients (i.e.
mechanically ventilated) appear to be a category at particular risk of
lower respiratory tract involvement by HSV. The availability of an
efﬁcacious treatment suggests the need to include HSV in the diagnostic
panel for respiratory pathogens.
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O411 PMOplus™ antisense oligomers protect nonhuman primates
against Ebolavirus and Marburgvirus
T. Warren, A. Shurtleff, J. Wells, N. Garza, L. Dong, D. Mourich,
S. Crumley, P. Iversen*, S. Bavari (Fredrick, Bothell, US)
Objectives: Zaire ebolavirus (ZEBOV) and marburgvirus (MARV) are
highly virulent emerging RNA viruses of the family Filoviridae and
are causative agents of viral hemorrhagic fever (VHF). Currently,
no antiviral therapeutics or vaccines are licensed for treatment or
prevention of ebolavirus or marburgvirus infections. The postexposure
therapeutic efﬁcacy of a new class of phosphorodiamidate morpholino
oligomers (designated PMOplus), containing positively charged piper-
azine moieities, was explored using nonhuman primate (NHP) models
of ZEBOV and MARV infection.
Methods: Infected with a lethal dose of ZEBOV, NHPs were treated
using i.v. injection with either one of four doses of AVI-6002 [a PMOplus
combination therapeutic speciﬁc to ZEBOV viral protein (VP) 24 and
VP35], a negative-control PMOplus agent, or PBS beginning 30−60 min
following infection and continuing through day 14. NHPs infected with
a lethal dose of MARV were treated i.v. with either one of three doses of
AVI-6003 [a PMOplus combination targeting MARV nucleoprotein (NP)
and VP24], a negative-control PMOplus agent, or PBS according to same
postexposure regimen used for the EBOV investigation. Both studies
were conducted using randomized, single-blind experimental methods
and all PMOplus treatments contained 4−5 animals. Animal health was
monitored at least twice daily for 28 days, and blood was sampled
periodically during the study to monitor viremia and clinical pathology
parameters. Additionally, viral genomic material obtained from infected
animals was sequenced to evaluate potential development of resistance
to the therapies.
Results: While control NHPs succumbed to ZEBOV infection by day 8,
60% of the animals treated with either 28 or 40mg/kg AVI-6002 survived
to study termination. Treatment of 30mg/kg AVI-6003 completely
protected NHPs against lethal MARV challenge and protected 60%
of animals when delivered at 7.5 and 15mg/kg doses. AVI-6002 and
AVI-6003 ameliorated VHF disease signs, reduced circulating levels of
hepatocellular markers of liver damage, and generally decreased viremia
in surviving animals. Preliminary viral genomic sequence analyses
suggest that neither ZEBOV nor MARV readily adapted to the antiviral
selective pressure of AVI-6002 or AVI-6003, respectively.
Conclusions: These results establish PMOplus as effective therapeutic
agents against multiple highly virulent human pathogens and support the
further development of PMOplus therapies for use in humans.
O412 The role of WU and KI viruses: pathogens or passengers?
A. Riezebos-Brilman, R. Xue, J.C. Rahamat-Langendoen*,
T. Schuurman, H.G. Niesters (Groningen, NL)
Objectives: In 2007, two new human Polyomaviruses, KI polyomavirus
(KIV) and WU polyomavirus (WUV), were discovered. Genetically these
viruses are related to JCV and BKV, but cluster into a separate lineage.
In contrast to JCV and BKV, WUV and KIV have predominantly been
found in respiratory tract secretions from pediatric patients. Information
on their prevalence and disease associations are still ongoing. It has
been suggested that these viruses more likely reactivate in immuno-
compromised patients and might be responsible for disease.
The objective of our study was to determine the prevalence of WUV
and KIV infections in respiratory samples and to collect and analyse
the clinical information of patients tested positive within the University
Medical Center Groningen. This is a tertiary referral hospital for both
adults and children and has a large solid organ transplant program.
Methods: Respiratory samples collected from September 2007 to August
2009, were tested using RT-PCR methods. In total 1964 respiratory
samples from 1126 patients were tested, regardless of age, underlying
disease or immune status. Subsequently, clinical information of the
patients tested positive for either WUV or KIV were retrospectively
collected.
Results: 60 (3.05%) samples tested positive for KIV and 71 samples
(3.62%) tested positive for WUV.
No signiﬁcant seasonal distribution was found for WUV and KIV.
Co-infections with other respiratory pathogens were found in 35 (58%)
of the KIV and 47 (66.2%) of the WUV positive samples. Three samples
were found positive for both WUV and KIV.
In total, 57 patients tested positive for WUV, 6 of these patients were
adults and all adults were co-infected with other respiratory pathogens.
WUV mainly infected young children without severe respiratory
symptoms. In contrast, 18 of the 40 patients tested positive for WIV
were adults. Half of these adults were found without a viral co-infection
and 72% of these adults were severely immuno-compromised.
Conclusions: High percentages of co-infections with other respiratory
pathogens complicated the interpretation of the clinical features in these
patients. However, interestingly, the majority of adults only positive
for KIV were immuno-compromised patients. These results indeed are
suggestive that KIV and to a lesser extent WUV may reactivate in solid
organ transplant and stem cell transplant patients.
O413 Asymptomatic Crimean-Congo haemorrhagic fever infection
in endemic regions
I. Koksal*, G. Yilmaz, F. Aksoy, S. Erensoy, H. Aydin (Trabzon, TR)
Objectives: Crimean-Congo haemorrhagic fever (CCHF) is a disease
generally transmitted to humans by infected tick bites or through
contact with blood and tissues from viremic animals, and causes viral
haemorrhagic fever. The virus may cause asymptomatic disease in
animals, though its asymptomatic course in humans is unknown.
This study was intended to investigate the seroprevalence of Crimean-
Congo haemorrhagic fever virus (CCHFV) in patients conﬁrmed
as having undergone CCHF and in volunteers in the same high-
risk environment, and to determine whether the disease occurred
asymptomatically, together with the risk factors involved.
Methods: CCHFV IgG from serum from friends/relatives of patients
monitored with a diagnosis of CCHF at our clinic in 2004–2008 and
sharing the same epidemiological characteristics was examined using
the ELISA technique at the Reﬁk Saydam Institute of Hygiene virology
laboratory.
Results: Serum specimens were taken from 625 volunteers and analyzed
using ELISA and speciﬁc IgG antibodies. IgG positivity was determined
in 85 volunteers (13.6%). None of the volunteers with IgG positivity
had a history of symptomatic infection. Age (P = 0.005), working in
animal husbandry (P = 0.021: OR 1.84), contact with animals (P = 0.029;
OR 2.31), contact with ticks (P = 0.00002; OR 3.45), removing ticks
by hand (P = 0.0003; OR 2.48) and living in rural areas (P = 0.001;
OR 4.05) were determined as statistically signiﬁcant risk factors in these
individuals who had undergone the disease asymptomatically. Living
in the same house as a patient did not constitute an additional risk
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(P = 0.481), but living in the same environment and under the same
conditions did represent a major risk factor (Table 1).
Conclusion: Our study shows that CCHF can be undergone asymp-
tomatically. Living in an area in which CCHF is endemic and contact
with ticks was established as the most important risk factors.
O414 Prevalence of the newly described human enterovirus 109
in infants with acute respiratory disease in Italy
A. Piazza*, M. Debiaggi, F. Canducci, E.R. Ceresola, M. Sampaolo,
R. Brerra, M. Clementi (Pavia, Milan, IT)
Objectives: A novel human Enterovirus (HEV) type within the species
HEV-C, named EV109, was discovered and characterized from a case
of acute respiratory illness in a Nicaraguan child in September 2010;
EV109 isolates were then detected in 1.6% of respiratory samples
of children with inﬂuenza like illness (ILI) in Managua, Nicaragua.
Given the very recent discovery, no studies have been still performed
to evaluate epidemiological features nor the distribution of EV109 in
the different countries all over the world. In addition, due to the wide
variety of enterovirus-associated diseases the full spectrum of EV109
disease association have to be evaluated.
In the present study, the presence and the role of EV109 were
examined retrospectively in infants with acute respiratory disease (ARD)
hospitalized in a pediatric department in northern Italy.
Methods: From June 2005 to September 2006 a total of 149
nasopharingeal aspirates were collected from patients and tested for
the presence of EV109 by reverse transcription-PCR (RT-PCR). The
presence of Respiratory Syncytial viruses (RSV), human Metapneu-
moviruses (hMPV), human Bocaviruses (hBoV), human Coronaviruses
(hCoV), Adenoviruses, Inﬂuenza A and B viruses, Parainﬂuenza viruses
(PIV1−3) and human Rhinoviruses was also assayed by PCR and clinical
symptoms were evaluated.
Results: Four out of 149 samples (2,68%) tested positive for EV109
genomic sequences. Positive specimens were found in infants with a
median age of 3,5 months (range 2−6 months) and occurred in winter (3
cases) or in late autumn (one case). Infants positive for EV109 infection
had bronchiolitis (3 cases) or asthmatic bronchitis (one case). Single
EV109 infection was detected in only one infants, whereas the remaining
three cases were co-infected with RSV (2 cases) or hCoV HKU1 (one
case).
Conclusions: Overall, results obtained in this study, suggests that
EV109, in hospitalized infants with ARD in Italy, have a circulation
slightly higher than that observed in children with ILI in Nicaragua.
Furthermore, given the presence, in the majority of EV109-positive
infants, of other viruses, including RSV, larger studies are needed to
best investigate the pathogenetic role of the novel human enterovirus
both in single infections and co-infections.
O415 Different rates of spontaneous clearance of HPV infections
in anal and cervical lesions
P. Ravanini*, E. Omodeo-Zorini, F. Fila, S. Costantino, A. Godino,
V. Ilaria, L. Krizmancic, L. Servino, C.M. Antonacci, F. Pagano,
R. Beretta, G. Orlando, M. Bandi, A.M. Nicosia, M.G. Crobu (Galliate,
Milan, Biella, Novara, IT)
Objectives: HPV is a risk factor for the onset of both cervical and anal
carcinoma. The aim of the study is the estimate of the persistence and
clearance of the different genotypes of HPV in male anal and female
cervical samples during a one-year follow-up period.
Methods: We analyzed 440 cervical samples from 220 female patients
(CF group) and 46 anal samples from 23 male immunodeﬁcient patients
(AM group). For each patient, two samples were collected after an
interval of one year. 52 female and 11 male patients underwent a
biopsy within the follow-up period. The remaining 172 female and 12
male patients did not undergo a biopsy. The samples were tested for
the presence of HPV-DNA and genotyped by a PCR-based molecular
method.
Results: The genotype prevalence results considerably different between
the two groups. In AM group, the most frequent genotypes are, in order
of frequency, HPV 31, 11, 16, 6, 52, while in CF group the most frequent
ones are HPV 53, 16, 31, 66, 58. The persistence rate results higher
in AM group than in CF group (51.1% vs. 37.5%). The biopsy does
not seem to play any role in regression or persistence (not signiﬁcant
differences between biopsy and non-biopsy groups). Interestingly, some
genotypes show different rates of persistence compared to the others.
While HPV 6, 11, 16, 33, 53 show a higher persistence rate in AM group,
HPV-31 shows a higher rate of spontaneous clearance in AM group
(80.0%) than in CF group (64.7%). In the AM group, the difference
between the persistence rate of genotype 11 (88.9%) and 31 (20.0%) is
statistically signiﬁcant (p< 0.01).
Conclusion: Our data point a different rate of spontaneous clearance and
persistence of HPV genotypes between two groups of patients that differ
for the immunitary status (immunodeﬁcient vs. immunocompetent) and
for the site of infection (anal vs. cervical). The high rate of spontaneous
clearance of HPV-31 in anal samples from immunodeﬁcient patients in
comparison with cervical samples is opposite of the low rate of clearance
of the other genotypes. It can reﬂect a different mechanism of persistence
or of response of the immune system or both. Interestingly, the genotype
that seems to persist in a higher proportion of cases is HPV-11, a low-risk
type, instead of HPV-31, a high-risk type. Further evaluations are needed
to assess whether these differences are primarily due to the different type
of mucosal tissue or to the different degree of immune response.
O416 Rhinovirus-induced basic ﬁbroblast growth factor release
from bronchial epithelial cells mediates airway remodelling
features
C.L. Skevaki*, S. Psarras, E. Volonaki, H. Pratsinis, I.S. Spyridaki,
M. Gaga, V. Georgiou, S. Vittorakis, A.G. Telcian, P. Maggina,
D. Kletsas, D. Gourgiotis, D.A. Kafetzis, S.L. Johnston, A. Tsakris,
N.G. Papadopoulos (Athens, GR; London, UK)
Objectives: Human rhinoviruses (RV), major precipitants of asthma and
chronic obstructive pulmonary disease (COPD) exacerbations, induce
lower airway inﬂammation and mediate angiogenesis. On the other hand,
asthma is characterized by remodeling of the bronchial tree, expressed
as epithelial shedding, exaggerated number of goblet cells, thickening of
the basement membrane, hypertrophy and hyperplasia of smooth muscle,
and increased collagen deposition. The objective of our study was to
assess whether RV may also contribute to the ﬁbrotic component of
airway remodeling.
Methods: Levels of basic ﬁbroblast growth factor (bFGF) mRNA
and protein were measured following RV infection of both primary
and continuous bronchial epithelial cell lines. The proﬁbrotic effect
of epithelial products was assessed by tritiated thymidine uptake of
primary ﬁbroblasts and matrix metalloproteinase (MMP) activity assays.
Moreover, epithelial cells were exposed to supernatants from cultured
peripheral blood mononuclear cells, obtained from adult healthy donors
or atopic asthmatic subjects and subsequently infected by RV, and bFGF
release was estimated. bFGF was also measured in respiratory secretions
from atopic asthmatic children before and during virologically conﬁrmed
RV-induced asthma exacerbations.
Results: Rhinovirus epithelial infection stimulated mRNA expression
and release of bFGF, the latter being positively correlated with cell
death under conditions promoting RV-induced cytotoxicity. Supernatants
from infected cultures induced lung ﬁbroblast proliferation, which was
inhibited by the addition of an anti-bFGF antibody, and demonstrated
increased MMP activity. Rhinovirus-mediated bFGF release was signif-
icantly higher in an in vitro simulation of atopic asthmatic environment
and, importantly, during RV-associated asthma exacerbations.
Conclusion: Rhinovirus infection induces bFGF release by bronchial
epithelium, and stimulates stroma cell proliferation contributing to
airway remodeling in asthma. Repeated RV infections may promote
asthma persistence, particularly in the context of atopy; prevention of
such infections may inﬂuence the natural history of asthma.
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O417 Outcome of pregnant patients post-VZIG
J. Troughton*, L. Duffy, J. Devlin, P. Coyle (Belfast, UK)
Objectives: Varicella immunoglobulin (VZIG) is the current standard of
care in the UK for pregnant patients in contact with varicella zoster virus
(VZV), provided it can be administered within 10 days of contact. This
study investigated the outcome of pregnant patients exposed to varicella
in 2009.
Methods: Pregnant patients tested for VZV immunity were identiﬁed
from laboratory records. Patients’ general practitioners were contacted
by telephone or letter for clinical outcome data, including breakthrough
infection, neonatal, and pregnancy outcome.
Results: Pregnant women tested for VZV immunity totalled 887; 157
were non-immune; 108 received VZIG, costing £114000. Twenty patients
(18%) received VZIG on day 9 or 10 post-exposure; 17 presented beyond
the 10-day cut-off, including 7 with active varicella, and did not receive
VZIG.
Post VZIG, 4/66 patients (6%) miscarried; 4/66 patients (6%) developed
varicella, with 2 neonates requiring VZIG.
VZV exposure via their own child occurred in 47/114 patients (41%);
and in 12 (11%) through occupational exposure.
Multiple VZIG dose were issued to 6/108 patients (6%), 2 in previous
pregnancies, comprising 3 nursery workers/teachers and 2 healthcare
workers.
There were no cases of neonatal varicella or varicella syndrome.
Conclusions: Although preliminary, these data conﬁrm that VZIG use
does not afford complete protection amongst non-immune pregnant
women.
These include late presentation, breakthrough infection and subsequent
VZIG administration to neonates. Moreover the impact of VZV and
VZIG exposure upon miscarriage rates has not been fully characterised,
as miscarriages may not be investigated for infective causes. VZIG is
a human blood product with potential associated risks, yet 6 patients
required multiple doses.
VZIG is a high cost intervention; half of VZIG issued could have been
prevented by a targeted vaccination strategy of “at-risk” occupations or
post-partum vaccination of primigravidas. VZIG requirement in the UK
could be minimized by introducing VZV vaccination, at the time of HPV
vaccination, for females with no remembered history of varicella.
VZIG versus a vaccination strategy should be re-visited on the basis of
clinical governance, ﬁnance and impending VZIG shortage.
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O418 High rates of multidrug-resistant Streptococcus pneumoniae
in Europe. Pneumococcal activity proﬁle from GLOBAL 6
surveillance (2009–2010)
C. Pillar*, J. Deane, D.F. Sahm (Chantilly, US)
Objective: It is important to take into account anticipated resistance
among target pathogens when selecting an empiric therapy for the
treatment of community acquired pneumonia (CAP), because the
selection of an appropriate initial agent is critical with respect to
beneﬁcial clinical outcome. Local and regional surveillance data can
be used to understand resistance patterns within hospitals and across
countries, as resistance rates are known to vary based on geography
and patient population. This study reports current resistance among
S. pneumoniae, a prevalent CAP pathogen, as determined by GLOBAL
surveillance conducted across Europe in 2009–2010.
Methods: As part of GLOBAL 6, non-duplicate clinical isolates of
S. pneumoniae were collected from Belgium, France, Germany, Italy,
Spain, and the United Kingdom from 2009–2010. Isolates were centrally
tested for susceptibility by broth microdilution (CLSI M7/M100).
Multidrug-resistant Streptococcus pneumoniae (MDRSP) were deﬁned
as those resistant to 2 of penicillin (oral), azithromycin, cefuroxime,
trimethoprim-sulfamethoxazole, and tetracycline.
Results: The current activity proﬁle of evaluated agents against
S. pneumoniae in Europe is shown in the table below. Of evaluated
agents, SP were most susceptible to levoﬂoxacin (99.1%), and
sitaﬂoxacin had the lowest MIC50/MIC90. Overall, 27% of SP in
Europe were multi-drug resistant (MDRSP), though rates varied by
country (36−38% in France, Italy, and Spain; 12−13% in Germany
and the UK). 97% of MDR-SP were susceptible to levoﬂoxacin,
87.9% were susceptible to ceftriaxone, 83.8% were susceptible to
amoxicillin/clavulanate, 42.4% were susceptible to cefuroxime, 21.0%
were susceptible to penicillin (oral), and 20.4% were susceptible to
azithromycin.
Conclusions: MDRSP were prevalent in Europe, though variable by
country. MDRSP were highly susceptible to ﬂuroquinolones relative
to other evaluated agents. Given the limited activity of many of the
commonly utilized respiratory agents against MDRSP, the rates of MDR-
SP among several European countries are concerning. It is important to
consider an initial therapy that will cover these resistant phenotypes when
treating CAP in these countries.
O419 Antimicrobial resistance of S. pneumoniae in Russia:
ten-year (1999–2009) prospective study PEHASus
R. Kozlov*, O. Sivaya, N. Ivanchik for the PEHASus project group
Objectives: To investigate the level and phenotypes of antimicrobial
resistance of Streptococcus pneumoniae in different regions of Russia
and to evaluate their dynamics in period from 1999 to 2009.
Methods: This study was conducted in Central, North-Western,
Southern, Volga, Urals, Siberia, Far-Eastern regions of Russia from 1999
to 2009. Identiﬁcation of the strains was done on the basis of colony
morphology, Gram stain, optochin susceptibility and bile solubility
tests. Susceptibility to 13 antimicrobials was performed using cation-
adjusted Mueller-Hinton broth (BBL, USA) with 2−5% lysed horse
blood, inoculum 0,5 MacFarland. Microtiter plates were incubated for
24 h at 35ºC and 5% CO2. Breakpoints were those of Clinical and
Laboratory Standards Institute (CLSI).
Results: A total of 2,419 of non-duplicate clinical S. pneumoniae were
included to the study in ten-year period (1999–2009). The majority of
strains in 1999–2003, in 2004–2005 and in 2006–2009 were isolated
form respiratory samples (sputum, BAL, sinus aspirate, middle ear and
pleural ﬂuid) − 87.4%, 86.7% and 88.0%, respectively.
The susceptibility testing results are presented in the Table.
Conclusions: Thus b-lactams (penicillin G, amoxicillin/clavulanate),
macrolides, lincosamides, respiratory ﬂuoroquinolones retained the good
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in vitro activity against S. pneumoniae. High resistance to tetracycline
and co-trimoxazole dictates the necessity to limit their usage for
treatment of pneumococcal infections. During the 10-years period, no
substantial changes occurred in the level of resistance, indicating the
circulation of relatively susceptible pneumococcal population.
O420 Decrease in antibiotic resistance of Streptococcus pneumoniae
between 2003 and 2009 in France and changes in serotype
distribution: ongoing survey of the French Pneumococcus
Network
A. Gravet*, M. Kempf, A. Lepoutre, M.C. Ploy, E. Varon on behalf
of the French Regional Pneumococcal Observatories (ORP) Network
Background: The French regional pneumococcal observatories (ORP)
network was created in 1995, it participates to the close monitoring of
the trends in antimicrobial resistance and serotype distribution with the
National Reference Centre for Pneumococci (NRCP) and the Institut
de Veille Sanitaire (InVS). The aim of this survey was to assess the
antibiotic resistance and the distribution of vaccine and non-vaccine
serotypes in invasive pneumococcal disease (IPD) in adults and children
as well in otitis in children in France in 2009.
Methods: Antimicrobial susceptibility testing was performed on 5,194
isolates of S. pneumoniae recovered from cerebrospinal ﬂuid (CSF),
blood, middle ear ﬂuid (MEF) and pleural ﬂuid during the year 2009 by
the 23 ORP. MICs of penicillin (P), amoxicillin (AMX) and cefotaxime
(CTX) were determined by the agar dilution method and interpreted
according to the Antibiotics Committee of the French Society of
Microbiology breakpoints. Serotyping was performed at the NRCP with
serotype-speciﬁc antisera, by latex agglutination test.
Results: Results of susceptibility between 2003 and 2009 to P are
presented in Table 1. The pneumococci with decreased susceptibility
to penicillin G (PDSP) decreased signiﬁcantly in all types of samples
except for MEF’s isolates in children between 2007 and 2009. In the
global population, the percentage of I+R (2003 vs 2009) decreased
signiﬁcantly for AMX (30.3% versus 9.6%) and for CTX (18.2% versus
10.5%). Strains highly resistant (MIC >2mg/L) remained rare: 0.4%,
1.1% and 0.2% for P, AMX and CTX respectively. The most frequent
capsular types in CSF were 3, 7F, 19A, 6C, 23B for adults and 7F,
19A, 3, 33F and 15B for children. Serotypes included in the PCV-7 and
PCV-13 vaccine accounted in children for 4% and 51% respectively and
in adults for 12% and 48% respectively. By contrast, the serotype 19A
remained highly predominant (80%) among MEF isolates.
Conclusions:We observed a signiﬁcant decrease of PDSP between 2003
and 2009 (50.2 to 33.0%). The decrease coincided with the introduction
of PCV7 and with a general reduction in levels of antibiotic consumption
in France. This continuous survey is necessary to underline modiﬁcation
in serotype distribution in France after PVC13 introduction (June 2010).
O421 Invasive pneumococcal disease: serotypes and antimicrobial
susceptibility in adult patients from Madrid
A. Correa, C. De las Cuevas*, A. Guiu, M. Lopez-Brea, J. Sanz
(Madrid, ES)
Objectives: After the introduction of the pneumococcal seven valent
conjugate vaccine (7-VCV) in the systematic immunization schedule
for children in November 2006, changes in serotypes distribution and
in the resistance antimicrobial patterns of Streptococcus pneumoniae
have been observed in Madrid. These changes could affect no only
paediatric isolates. The aim of this study was to describe the distribution
of serotypes, its antimicrobial susceptibility proﬁles and the relation with
vaccines in pneumococcal invasive strains isolated from adult patients
attending a public hospital in Madrid during a three year period.
Methods: From July 2007 to June 2010, all pneumococci isolated
in our laboratory from blood cultures were serotyped by latex
agglutination (Pneumotest Latex) and Quellung reaction (antisera from
the Statens Serum Institut, Denmark). Antimicrobial susceptibility
testing to penicillin (PEN), cefotaxime (CT), erythromycin (ERY) and
levoﬂoxacin (LEV) was performed by the E-test method (Biome`rieux,
France). The susceptibility break points considered were according to
the Clinical Laboratory Standard Institute guideless (CLSI).
Results: A total of 68 isolates from 67 adult patients were studied
(one patient had 2 recurrent infections). The coverage of 7-VCV and
thirteen valent conjugate vaccine (13-VCV) were respectively of 16.4%
and 55.2%. Twenty-two strains (32.8%) were serotypes covered only
by the 23 valent vaccine (23-VPV) but not by conjugate vaccines. Ten
serotypes hampered 71.6% of the isolates: serotype 3 (11.9%), 22F
(11.9%), 19A (7.5%), 7F (7.5%), 1 (6.0%), 8 (6.0%), 6A (6.0%), 4
(6.0%), 12F (4.5%) and 14 (14.5%). PEN MICs (mg/L) were: 0.06
(82.1%); 0.12−1 (14.9%), and 2 and <8 (3.0%). Only one strain
(1.5%), belonging to the serotype 6B, showed intermediate susceptibility
to PEN according the 2008 CLSI criteria (4mg/L). Three strains were
intermediate susceptible to CT (serotypes 6B, 14 and 19A). None strain
showed resistance to LEV. Resistance to ERY was 19.4%. Four out of
13 ERY resistant strains (30.8%) belong to serotype 19A.
Conclusion: The 13-VCV covered most of the serotypes found in our
hospital in adult patients. No resistance to PEN, CT or LEV was found.
Serotype, 19A is a cause of clinical and epidemiological concern by its
resistance to ERY. Among non conjugate vaccine strains serotypes 22F,
8 and 12F seems to be in increased.
O422 Activity of ceftaroline against serotyped Streptococcus
pneumoniae isolates from Europe (2007–2008)
I. Morrissey*, A. Leakey, J. Ambler (Fordham, UK; Waltham, US)
Objective: Ceftaroline (CPT) fosamil, the prodrug of the active
compound CPT, is a broad-spectrum, parenteral cephalosporin recently
approved in the USA for the treatment of community-acquired bacterial
pneumonia (CABP) and acute bacterial skin and skin structure infections.
The aim of this study was to determine CPT activity against
Streptococcus pneumoniae (SP) causing CABP from Eastern Europe
(Czech Republic, Greece, Hungary, Poland, Russia and Turkey) and
Western Europe (Austria, Belgium, Denmark, France, Germany, Ireland,
Italy, the Netherlands, Portugal, Spain, Sweden and the UK).
Methods: 70 European centres submitted 803 SP isolates causing CABP
during 2007–2008. These were re-identiﬁed and serotyped (using Latex
and Quellung reaction). MICs for CPT and comparators were determined
by CLSI broth microdilution at a central laboratory. Data were analysed
by region, age group and serotype (where N> 30).
Results: Summary CPT MIC data are shown in the Table [cefotaxime
(TAX), penicillin G (PEN) and erythromycin (ERY) data are shown as
a reference]. CPT was on average 4-fold more active than TAX and
6-fold more active than PEN. Overall, SP were ~97% susceptible to
TAX or PEN and 76% susceptible to ERY. Although no differences in
CPT activity based on age or geography were observed (data not shown),
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serotypes 3, 1, 7 and 11 were more susceptible to CPT (and the reference
antibiotics) than the population as a whole (All SP).
Conclusions: These data from a large collection of European SP isolates
with varying serotypes conﬁrm the excellent activity of CPT against SP
causing CABP.
O423 The associated mortality of invasive pneumococcal disease −
Why are we not vaccinating?
C. Rock*, J. Fitzgerald, C. Sadlier, A. Brown, S. Kelly, C. Dowling,
C. Bergin (Dublin, IE)
Invasive pneumococcal disease (IPD) has an all cause mortality
rate of 5−35% in the developed world. Vaccination with 23-valent
pneumococcal polysaccharide (PPV 23) is recommended for many
chronic conditions including include HIV infection, malignancy, alcohol
abuse, hepatitis C infection, cigarette smoking, asthma and chronic
obstructive pulmonary diseases. Uptake of the PPV23 in speciﬁc
risk groups in Ireland is unknown. In Ireland 7-valent pneumococcal
conjugate vaccine was introduced into routine childhood vaccination
schedule in 2008. We describe the epidemiology, clinical characteristics,
serotype distribution, vaccination rates, outcome of IPD cases from 2006
to 2010 diagnosed in a tertiary referral hospital in Ireland.
Electronic patient record and patient case notes were examined for
baseline demographics, clinical characteristics, risk factors, mortality and
vaccination status.
There were 122 episodes in 116 patients during the study period.
Table one describes demographics and risk factors for each patient.
One hundred and twenty of the 122 total (98.4%) had one or more
risk factors for which PPV23 vaccination is recommended. Eighty six
patients (70.5%) had two or more risk factors. Only 2 patients (1.6%)
had no risk factor. However, only 11 (9%) of the 122 patients had
received PPV23 prior to IPD infection. Seven of these (77.8%) were
HIV-1 seropositive with average CD4 count of 301 (5–591). Serotypes
were known for 6 of these isolates, 4/6 were in PPV 23 and there
was no difference between infecting serotypes in this group and the
group overall. Forty nine of 76 known serotypes (64.5%) were contained
in the PPV23 vaccine, 37/76 (48.7%) contained in CPV 7 and 47/76
(61.8%) in CPV 13. The most commonly infected serotypes were 4,7F,
9A, 18C, 19A and 23F. Twenty six of 122 patients died during this
hospital admission, giving an overall mortality rate of 21.5%. IPD has a
signiﬁcant associated mortality. Health care providers need to be aware
of importance of vaccination. Patient education and SMS text reminders
may help adherence. Dedicated HIV vaccination services increase uptake
in this at risk cohort. Expansion of vaccination services to include
drug treatment centres may facilitate uptake. Vaccination at lower CD4
counts should be considered for those unlikely to immune reconstitute
secondary to non adherence to highly active antiretroviral therapy.
O424 Epidemiology of community-acquired pneumonia requiring
hospitalisation after introduction of the conjugated
pneumococcal vaccine in Switzerland
B. Betsch, K. Mu¨hlemann* (Berne, CH)
Objective: To compare the epidemiology of hCAP before (years 2002 to
2005 = PreVY) and after (years 2007 to 2008 =PostVY) the introduction
of PCV7 in Switzerland in 2006. PCV7 is recommended on a voluntary
base to all infants at the age of 2 and 4 months with a booster dose at
12 months of age. Estimated vaccine coverage was 80% in 2010.
Methods: National hospitalization data were obtained from the Federal
Institute of Statistics for the years 1998 to 2008 including the primary
diagnosis (ﬁrst-listed; International Classiﬁcation of Diseases (ICD-
10)), up to 7 additional diagnoses, and other parameters characterising
hospitalisation. hCAP was deﬁned by a primary diagnosis of pneumonia
or meningitis/septicaemia plus a code for pneumonia. Pneumococcal
CAP (SpnCAP) was deﬁned as hCAP with a pneumococcal disease
code. Hospitalization rates for hCAP and SpnCAP were calculated by
segmented regression analysis.
Results: There were 67′723 hCAP in the PreVY and 33′759 in the
PostVY with an annual average of 16′931 (PreVY) and 16′880 (PostVY)
hCAP. SpnCAP was coded in 5.02% of hCAP in PreVY versus 7.47%
of hCAP in PostVY. Annual hCAP rates varied by age group. The
highest rates were seen among infants and elderly people, but rates
did not change signiﬁcantly after the introduction of PCV7: <2 years
olds 369 hCAP per 105 population during PreVY versus 352 hCAP
per 105 population during PostVY (p = 0.69) and >80 years olds 1509
hCAP per 105′ during PreVY versus 1594 hCAP per 105 during PostVY
(p = 0.64). Males predominated (56.5%) among hCAP cases. Average
duration of hospital stay was 12.4 days (PreVY) versus 11.0 (PostVY)
days. Case fatality rate was 7.8% (PreVY) vs. 7.3% (PostVY) (p = 0.006)
overall with most (87%) fatal cases occurring in the elderly. Admission to
intensive care treatment was needed in 6.5% (PreVY) vs. 7.9% (PostVY)
of CAP (p< 0.001).
Conclusion: Hospitalisation rates for community acquired pneumonia
did not change two years after the introduction of PCV7 in Switzerland
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despite high vaccine up-take among infants. However, a slight increase in
severe hCAP requiring ICU admission among the elderly was observed.
Serotype redistribution might account for a lack of herd immunity and
trend towards more severe hCPA among the elderly.
O425 Immunogenicity and safety of a 13-valent pneumococcal
conjugate vaccine in adults 70 years of age and older
previously vaccinated with 23-valent pneumococcal
polysaccharide vaccine
L. Jackson*, A. Gurtman, K. Rice, K. Pauksens, R. Greenberg,
T. Jones, D. Jayawardene, J. Love, D. Scott, E. Emini, W. Gruber,
B. Schmoele-Thoma (Seattle, Pearl River, Minneapolis, US; Uppsala,
SE; Lexington, Collegeville, US; Munich, DE)
Objectives: To compare the immunogenicity of 13-valent pneumococcal
conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide
vaccine (PPSV23) in adults 70 years of age and older previously
vaccinated with a single dose of PPSV23 at least ﬁve years prior to
enrollment.
Methods: We performed a randomized, double-blind, comparative trial
of PCV13 vs. PPSV23 in 938 adults 70 years of age and older who
had previously received PPSV23. At one year after the enrollment
vaccination (PCV13 or PPSV23), all subjects received a dose of
PCV13. Serotype-speciﬁc opsonophagocytic antibody (OPA) titers were
measured in blood samples obtained prior to and at one month after each
vaccination.
Results: At one month after the enrollment vaccination, the OPA
geometric mean titers (GMTs) were signiﬁcantly higher in the PCV13
group compared with the PPSV23 group for 10 of the 12 serotypes
common to both vaccines, non-inferior for the other 2 common serotypes
(3 and 14), and signiﬁcantly higher for 6A (not contained in PPSV23)
(Table). In analyses stratiﬁed by age, OPA GMTs were lower in subjects
80 years of age and older but the responses to PCV13 were greater than
to PPSV23 in all age groups.
In both study groups, OPA titers declined in the year following the
enrollment vaccination, and increased in response to the PCV13 given
at one year, but the responses to the dose of PCV13 given at one year
were generally higher in the group that received PCV13 at enrollment
compared with the group that received PPSV23 at enrollment. The OPA
GMTs following the one year PCV13 were signiﬁcantly higher in the
PCV13/PCV13 group than in the PPSV23/PCV13 group for 12 of the
13 serotypes. In the PCV13/PCV13 group, the responses to the second
PCV13 administration were similar to the post dose one responses.
After the enrollment vaccination, local reactions were more common in
the PPSV23 group (64%) than the PCV13 group (57%) (p = 0.03). After
the PCV13 dose given at one year, the frequency and severity of local
reactions were similar between PCV13/PCV13 and the PPSV23/PCV13
groups.
Conclusion: In adults 70 years of age and older previously vaccinated
with PPSV23, PCV13 was at least as immunogenic for all common
serotypes and was signiﬁcantly more immunogenic than PPSV23 for 10
of those 12 serotypes. The OPA GMTs following the dose of PCV13
at one year indicate that a prior dose of PPSV23, but not PCV13,
diminishes the response to a subsequent dose of PCV13.
O426 Immunogenicity and safety of a 13-valent pneumococcal
conjugate vaccine in pneumococcal vaccine naı¨ve adults,
50−64 years of age
L. Jackson*, A. Gurtman, M. van Cleeff, K. Jansen, D. Jayawardene,
C. Devlin, D. Scott, E. Emini, W. Gruber, B. Schmoele-Thoma (Seattle,
Pearl River, Cary, Collegeville, US; Munich, DE)
Objectives: To compare the immunogenicity of a single dose of
13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent
pneumococcal polysaccharide vaccine (PPSV23) in adults 60−64 years
and to compare the immunogenicity of PCV13 in adults 50−59 years
with that in adults 60−64 years.
Methods: We performed a randomized, double-blind, comparative trial
of PCV13 vs. PPSV23 in 835 pneumococcal vaccine naı¨ve adults
aged 60−64 years. An additional group of 404 adults aged 50−59
years received open-label PCV13. For all subjects, serotype-speciﬁc
opsonophagocytic antibody (OPA) titers were measured at baseline and
at one month and one year after vaccination.
Results: Among adults 60−64 years, the one month postvaccination OPA
geometric mean titers (GMTs) in the PCV13 group were signiﬁcantly
higher than in the PPSV23 group for eight of the 12 serotypes (serotypes
1, 4, 6B, 7F, 9V, 18C, 19A, 23F) common to both vaccines, signiﬁcantly
higher for 6A (not contained in PPSV23), and were comparable for the
other four common serotypes (Table).
In comparisons of the response to PCV13 in the younger and older age
groups, the OPA GMTs at one month after vaccination were signiﬁcantly
higher in subjects 50−59 years than in subjects 60−64 years for nine
serotypes and were comparable for the other four serotypes. In both age
groups OPA titers declined from one month to one year after PCV13
administration but remained higher than baseline titers.
PCV13 was well tolerated in both age groups. Among subjects 60−64
years, any local reaction was reported by 82% of subjects in the PCV13
group and by 76% of subjects in the PPSV23 group (p = 0.05).
Conclusion: These data support a potential beneﬁt of PCV13 in
pneumococcal vaccine naı¨ve older adults.
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O427 Pneumococcal vaccination and invasive pneumococcal
disease in East Yorkshire, UK
J. Elston*, A. Newton, J. Meigh, V. Allgar, M. Porter, T. Allison,
G. Richardson, R. Meigh, G. Barlow (Hull, York, Willerby, East
Yorkshire, UK)
Background: Vaccination with pneumococcal polysaccharide vaccine
(PPV) has been recommended to persons 65 years in the United
Kingdom (UK) since 2005, although in Hull and the East Riding
of Yorkshire (ERoY) since 2002. Controversy remains concerning the
effectiveness of PPV in older adults. Pneumococcal conjugate vaccine
(PCV) has been recommended routinely in UK children since 2006.
Objectives: To explore the epidemiology of invasive pneumococcal
disease (IPD) in Hull & ERoY and to determine the impact of
vaccination at the population level.
Methods: Microbiology databases were interrogated to identify pneu-
mococcal isolates retrieved from sterile sites from 1st January 2002 to
31st December 2009 inclusive, from all (seven) hospitals that routinely
receive residents of Hull & ERoY. Demographic details of cases,
information concerning the isolate and pneumococcal serotype were
recorded. Only individuals resident in Hull & ERoY were included. One
isolate per patient episode was selected for calculation of incidence rates.
Information on vaccination uptake for both PPV and PCV were retrieved
from data held nationally (Department of Health) and or locally (Health
Protection Unit).
Results: 727 isolates (91.5% blood cultures) concerning 660 individuals
(355 male, median age 67 years) were included. The number of cases
of IPD increased almost year on year (65 in 2002, 101 in 2009) and
incidence rates of IPD appeared to increase (11.8 to 16.7 per 100,000
overall and 39.7 to 44.5 per 100,000 in those 65 years, 2002−9) despite
increased PPV vaccination uptake over the 8 year study period (49% to
70%) and high uptake of PCV (98%, 2009), [Figure 1]. There was no
increase in blood culture sampling or signiﬁcant change in the diagnostic
methodology used. The burden of IPD was highest in the elderly and
very young and was unequally distributed geographically across the
region. A rise in the proportion of cases of IPD caused by non-vaccine
pneumococcal serotypes was noted following PCV introduction whilst
those due to PCV serotypes have fallen.
Conclusions: The introduction and improved uptake of PPV has
not resulted in a reduction in the rates of IPD at the population
level. Determinants for the continuing burden of IPD and its unequal
geographical distribution should be investigated. Ongoing surveillance
of pneumococcal serotypes is imperative to inform PCV vaccine
formulation. Policy makers may wish to reconsider recommendations
on the use of PPV.
Figure 1. Pneumococcal vaccination and invasive pneumococcal disease 2002–
2009.
Decision points in the management of
invasive Candida infections: navigating the
choices for optimal patient care
S428 Susceptibility, breakpoints, and resistance to antifungals
among Candida species − where are we in 2011?
M. Cavling Arendrup* (Copenhagen, DK)
Candidaemia and other invasive Candida infections are the most
common invasive fungal infections in the hospital setting, and are
associated with a crude mortality rate of 30−40% or more. In the EPIC
II study of ICU infections, Candida spp were the third most common
pathogens behind Staphylococcus aureus and Pseudomonas spp, and
accounted for almost 90% of diagnosed fungal infections.
An epidemiological shift from C. albicans to other Candida spp has
been discussed widely in recent years, with each Candida species
having distinct antifungal susceptibility proﬁles. C. krusei is intrinsically
resistant and C. glabrata shows reduced susceptibility to ﬂuconazole; a
recent Danish nationwide survey also detected decreased ﬂuconazole
susceptibility (MIC of >4mg/ml) in C. albicans (0.6% of isolates),
C. dubliniensis (3.1%), C. parapsilosis (6.0%), and C. tropicalis (6.7%).
Between 2004–2009, the proportion of Candida blood isolates showing
full susceptibility to ﬂuconazole decreased from 79.7% to 68.9%.
In another recent study, 19% of 243 candidaemia episodes at two
tertiary centres in the US involved isolates with decreased ﬂuconazole
susceptibility, one third of which were from normally-susceptible species
displaying acquired resistance. Although echinocandin-resistant strains
of Candida have not been isolated from echinocandin-naı¨ve patients, they
have been documented in some patients after relatively short periods of
treatment. Such acquired resistance has been associated with mutations
in the FKS gene.
In 2008, the CLSI proposed a single breakpoint (susceptible: 2mg/ml)
for all 3 echinocandins for Candida spp. However as these breakpoints do
not reliably identify isolates with resistance mechanisms associated with
treatment failures revised compound and species speciﬁc breakpoints
have recently been approved. Recent data suggest that the revised
breakpoints (lower than the original CLSI breakpoint) help differentiate
Candida isolates with FKS mutations from those which remain fully
susceptible. Revised and speciﬁc CLSI breakpoints have also been
developed for ﬂuconazole ensuring harmonisation with the EUCAST
breakpoints and a better classiﬁcation of isolates of C. glabrata, many
of which were susceptible using the former CLSI breakpoint even though
clinical response rates to ﬂuconazole were lower than to those observed
for other species. In addition to the EUCAST and CLSI broth dilution
methods for susceptibility testing of Candida species, other approaches
(Etest®, agar dilution, disk diffusion) are available, which can differ from
the reference methods in their detection of resistance to echinocandins.
S429 Early, effective treatment of Candida infections − implications
for patient, physician and hospital
R. Masterton* (Luton, UK)
The importance of early antifungal therapy is well established, with
delays associated with increased mortality in patients with candidaemia.
Treatment is often initiated before a deﬁnitive diagnosis is obtained, and
is subsequently modiﬁed on the basis of blood culture results. In many
centres, ﬂuconazole remains the treatment of choice for initial treatment.
Given the shifts in the epidemiology of Candida species, there is an
increased risk for infections caused by ﬂuconazole-insensitive isolates.
The identiﬁcation of such an isolate in patients receiving ﬂuconazole
usually necessitates a change in treatment (often switching to another
class of antifungal), thus delaying the onset of effective treatment. An
alternative to this “step-up” approach is to start therapy with a broad-
spectrum antifungal agent, such as an echinocandin, and step down to
ﬂuconazole, if appropriate, once the isolate has been characterised.
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To investigate the potential utility of an approach involving initial
treatment with micafungin with the option of stepping down to
ﬂuconazole, a model of systemic Candida infections was developed. The
model included epidemiological, susceptibility, and cost data from the
UK, and assumed that all patients had blood cultures and susceptibility
testing undertaken within 24 hours of the ﬁrst suspicion of invasive
candidiasis, with the results available on day 3. For patients receiving
step-up treatment (starting with ﬂuconazole), all those with ﬂuconazole-
insensitive isolates were taken to be switched to micafungin on day 3,
while those receiving the step-down approach (starting with micafungin)
were modelled as switched to ﬂuconazole on day 3 if ﬂuconazole-
sensitive isolates were identiﬁed.
Results from the initial model showed an incremental cost-effectiveness
ratio (ICER) per quality-adjusted life year (QALY) of between £17,500
and £27,400, depending on the projected duration of survival for patients
surviving an episode of candidaemia. Based on the speciﬁc variables
included in the model’s base case, the step-down approach appears to be
cost-effective, as the ICER per QALY is below the estimated threshold
used to guide such assessments in the UK. The model also indicated
that when compared with the step-up approach, in addition to the cost-
effectiveness of step-down therapy, there was also an impact on mortality,
with one extra life being saved for every 100 patients treated.
Impact of molecular diagnostics on public
health and patient care
S431-S434 Impact of molecular diagnostics on public health and
patient care
C. Boehme, F. Fang, H. Westh, J. Schrenzel (Geneva, CH; Seattle,
US; Hvidovre, DK)
Molecular diagnostics play a pivotal role in the rapid detection of
infectious agents, enabling effective treatment and patient management
strategies to be initiated promptly. For both healthcare-associated and
community-based infections, rapid detection can limit exposure of
patients to contagious illnesses, thus reducing transmission. However,
two major limitations of molecular diagnostics as currently utilized
are not reporting results in a clinically actionable timeframe due to
batch processing and the inability to perform the tests where they are
needed most, such as in developing countries. This session will focus
on four areas in which rapid, decentralized molecular detection may
have a profound impact on improving public health and patient care.
First, the rapid detection of multidrug resistant strains of tuberculosis
using rifampin resistance as a surrogate marker in less than two hours
may, according to the World Health Organization, revolutionize the
treatment of tuberculosis, especially in developing countries. Second, in
the hospital setting, two decades of using insensitive tests for Clostridium
difﬁcile has led to dramatic increases in the prevalence of these
infections. New molecular ampliﬁcation tests that provide identiﬁcation
of C. difﬁcile in as little as 30 minutes, with both high sensitivity and
speciﬁcity, are optimizing both patient management and infection control
efforts in healthcare settings. Third, the availability of highly accurate
molecular tests on demand for detecting sexually transmitted diseases,
such as chlamydia and gonorrhea, has the potential of improving public
health efforts to control the spread of disease. Finally, the rapid and
accurate identiﬁcation of the etiologic agents of sepsis, both bacterial and
fungal, using novel molecular technologies will likely improve therapy
and outcomes for the most critically ill patients. The impact of rapid
diagnostics on improving health, especially in developing countries, is
just now beginning to be realized.
Bridging the gap of innovation − what we all
could do
S449 Antibacterial pipelines − what to expect in the future
U. Theuretzbacher* (Vienna, AT)
Antibacterial resistance is rising dramatically in various community and
hospital speciﬁc bacteria creating a critical need for new antibiotics
without cross-resistance to existing drugs. Yet, antibacterial pipelines
fail to reﬂect this medical urgency and novel compounds focused
on new targets or with new mode of action, especially in Gram-
negative bacteria, cannot be expected in the near future. Most novel
compounds with activity against Gram-negative bacteria are in research
or early development phase. Hence, resistance will continue to outrun
our antibacterial development efforts. Driven by concern regarding this
rapidly worsening global health crisis and the confounding lack of robust
drug pipelines, international recognition of the problem and several
multinational campaigns have initiated broad discussion and put action
plans in place. These campaigns create a ray of hope as innovative
models of research and development may translate into promising
pipelines during the next decade. Until then we can only address the
problem of multi-drug resistant bacteria with a multifaceted set of
solutions based on currently available tools.
Infectious disease with liver involvement −
an update
S454 Hepatitis B treatment. Current guideliness in Latin America
and variability in access to treatment
E. Savio* (Montevideo, UY)
The most effective approach to prevent chronic HBV infection and its
sequlae is to implement appropriate immunization programs. Over the
past 15 years numerous immunization campaigns have been developed
with varying degrees of success in Latin America. Further, there is
already a signiﬁcant number of people with chronic hepatitis B acquired
in the past for which the National Health Systems must provide
diagnostic testing and the best possible treatment. About 400 million
people worldwide are chronically infected with HBV. Approximately
2% of the Latin American population is chronically infected with HBV.
The highest prevalence is observed in the Northeast of Brazil, Venezuela
and Colombia, and the lowest prevalence is in Chile and Uruguay. The
globally prevalent serotypes are A, D and F. Genotypes A and B are
associated with high rates of response to pegylated interferon. There
is as yet no solid evidence regarding the relationship of “genotype to
treatment response”, and, thus, determination of genotype has not yet
been incorporated into therapeutic decision making. Since 2009, the role
of liver biopsy has been widely discussed in Latin America. Currently,
the value of liver biopsy for treatment decisions is primarily restricted to
patients who do not clearly meet criteria based on HBV DNA levels, ALT
and, in some special cases, related to age (>40 years old). The Brazilian
Guidelines for Treatment of Chronic Hepatitis B are more speciﬁc in
regard to the indications for liver biopsy.
Treatment guidelines in most cases have been based on the recommen-
dations of national scientiﬁc societies (Infectious Diseases, Hepatology)
but in other countries have been initiated at the national government level
(Chile, Argentina, Brazil). Throughout the region, the drugs of choice
are entecavir, adefovir, telvibudina tenofovir and pegylated interferon,
but access to such treatment is asymmetrical in the area. Not all drugs
are registered and available in all countries of the region, which does
not allow a common and comparable assessment of treatment outcomes.
Tenofovir still has some limitations to its widespread use. Most countries
still consider Tenofovir the drug of choice for HIV-HBV co-infection, but
they have not destablished programs for the treatment of non-coinfected
chronic HBV patients.
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Antimicrobial-resistant bacteria in food and
potable water: a recipe for disaster?
S458 Antibiotic-resistant bacteria in food: from farm to fork
L. Peixe* (Porto, PT)
In the last few years links between humans and food, mainly of
animal origin, with regard to some antimicrobial resistance of human
clinical relevance have been reported. One of the new concerns is
the increasing occurrence of bacterial strains producing extended-
spectrum b-lactamases (ESBL) and/or acquired AmpC b-lactamases
causing difﬁcult to treat severe infections in humans and their possible
link to food or food producing animals. Bacterial strains producing these
b-lactamases are resistant to third and fourth generation cephalosporins,
antimicrobials considered to be critically or highly important medicines
for humans. The genes encoding resistance to these cephalosporins are
transferrable and often linked to other resistance genes. Use of third and
fourth cephalosporins selects for resistance, but cross and co-selection by
other antimicrobials is also likely to inﬂuence prevalence of resistance.
The increasing occurrence of ESBL and/or AmpC producers in animals
for food producing and food is highlighted and discussed in this review
with respect to the circulation of these resistance traits and potential risk
factors that favours its emergence and spread.
S459 Antibiotic-resistant bacteria in potable water: tapping into
the problem
M. Cormican* (Galway, IE)
The microbial ﬂora of the gastrointestinal tract is an important
environment for the emergence and spread of antimicrobial resistance.
Consumption of water by humans and animals represents a continuing
opportunity for the addition of new elements to the diversity
of microorganisms and mobile genetic elements in this habitat.
Antimicrobial resistance in Enterobacteriaceae, in particular in E. coli
is a particular concern because of their importance in both extra-
intestinal infection (urinary tract and invasive infection) and intestinal
infection. However criteria for potable water include E. coli and coliform
bacteria (Enterobacteriaceae) not detectable in a 100ml sample therefore
potable water by deﬁnition should not have antimicrobial resistant
Enterobacteriaceae at readily detectable levels. However water consumed
by human and food animals in many areas of the world including parts of
Europe may fail to meet this requirement with resulting opportunities for
introduction of new viable Enterobacteriaceae with potential transferable
antimicrobial resistance mechanisms into the gastrointestinal tract.
Bacteria other than Enterobacteriaceae are present normally in potable
water and may introduce new resistance elements. Even in the absence of
viable bacteria potable water may contain and introduce new resistance
determinants to the genetic diversity of the gastrointestinal tract. The
extent of contamination of drinking water sources and derived potable
water with antimicrobial resistant bacteria and antimicrobial resistance
determinants is an indicator of the extent to which antimicrobial use has
altered the microbial biodiversity of aquatic environments. It is prudent
to consider ways to limit such impacts both from a direct human health
perspective (in particular with respect to novel resistance determinants)
but also with a view to minimising unintended ecological disturbance. As
drinking water distribution systems now frequently serve much greater
populations than in the past there may be greater potential for potable
water to contribute to mixing of microorganisms or microbial genetic
material in the gastrointestinal tract although there is little evidence to
support this and it may be impractical to eliminate it. The fundamental
disturbance of this aspect of microbial ecology that must be controlled
is almost certainly intense selective pressure related to the antimicrobial
use rather than changes in water distribution.
Genetic predisposition and the outcome
of infection: time to include genetic
polymorphisms in routine diagnostic
work-up?
S464 Genetic dissection of host resistance to Mycobacterium
tuberculosis
S. Kaufmann* (Berlin, DE)
Combinations of biomarkers can provide insights into host resistance
against tuberculosis (TB). A tailored biosignature composed of carefully
selected essential markers will be required. Globally more than 2 billion
individuals are infected with Mycobacterium tuberculosis (Mtb). Of
these, 10% will remain latently infected without clinical signs and 10%
will develop disease later. Hence, comparison between these two groups
can provide insights into the mechanisms that discriminate between
active TB and latent infection. Moreover, biosignatures:
• will help in better understanding biology of infection, immunity and
pathogenesis;
• will allow monitoring of vaccine and drug trials;
• can predict risk of disease reactivation in latently infected individuals.
We have studied gene expression proﬁles in latently infected and non-
infected individuals and compared them with patients with active TB.
We found that a handful of biomarkers sufﬁces for robust distinction
between the three groups. These include Fc-g receptor, guanylate-binding
protein, granzyme A and defensin-a. In a more sophisticated approach,
we deﬁned biosignatures in selected T cells. We found that members
of the JAK/STAT pathway involved in T cell regulation provided robust
biomarkers for discrimination of patients with active TB, individuals
with latent infection and non-infected healthy controls. Additional
analysis focused on metabolomics. Of 370 different metabolites, ca. 20
were sufﬁcient for robust discrimination between the three groups of
study participants. Hence, biosignatures (i) provide deeper insights into
mechanisms underlying host resistance and (ii) serve as a platform for
the development of novel intervention measures against TB.
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O466 Experimental leptospiral infection in transgenic/mutant
mice: attenuated nephritis in inducible nitric oxide synthase
knock-out C57BL/6 mice and pulmonary haemorrhages
in SCID CB17 and recombinase activating gene Rag-1
knock-out C57BL/6 mice
D. Athanazio*, M. Bandeira, C.S. Santos, E.C. Azevedo, A.D. Chagas
Jr., L.M. Soares, S. Marchi, J.O. Macedo, C.L. da Silva, A.J. McBride,
F.W. McBride, M.G. Reis (Salvador, BR)
Objectives: (1) To investigate the frequency of pulmonary hemorrhage in
mice unable to differentiate functional B and T lymphocytes; in the light
of the hypothesis that pulmonary hemorrhages in leptospirosis are related
to immunopathogenesis/auto-antibodies, and previous inconsistent data
on the frequency of this complication in SCID mice of the C3H and
C3H/HeJ backgrounds; and (2) To explore the effect of the genetic
deﬁciency of inducible nitric oxide synthase (iNOS) on the frequency/
severity of interstitial nephritis in vivo, in the light of previous in vitro
data suggesting that leptospiral products induce renal tubular cells to
express pro-inﬂammatory genes such as iNOS.
Methods:We studied the outcome of infection by the virulent Leptospira
interrogans serogroup Icterohaemorrhagiae Cop strain. Animals used:
iNOS-knock out (KO) mice (B6. 129 P2-Nos) and the control wild-
type C57BL/6 (B6) strain, in three experiments (7−15 per group)
by intraperitoneal inocula (103 and 106); C57BL/6 129S(Cg)-Rag1
(Rag-1 KO) and CB17 SCID, and the respective B6 and BALB/c
controls, in three experiments (5−15 per group) by intraperitoneal inocula
(106 and 107).
Studying infectious diseases in vivo S89
Results: iNOS KO and B6 survived with no signs of disease. Leptospiral
load counted in kidney samples, anti-Leptospira agglutinating antibody
titres and speciﬁc anti-Leptospira IgG (by ELISA) did not differ between
wildtype and transgenic infected animals. Some degree of interstitial
nephritis was observed in 87% and 73% of B6 mice and 57% and 25%
of iNOS-KO mice infected with a low or high inoculum, respectively.
The frequency of severe nephritis was also lower in iNOS KO mice. All
SCID and Rag-1 KO animals died of acute disease (median of days to
death: 7 and 9 at 107, 7 and 10 at 106 inoculum, respectively) while B6
and BALB/c survived. The frequency of pulmonary haemorrhages was
10/12 (83%) and 30/30 (100%) in SCID and 4/7 (57%)and 16/17 (94%)
in Rag-1 KO mice, at 107 and 106 inocula, respectively, and not detected
in wild-type controls.
Conclusions: The lack of a functional iNOS gene in murine models
has minimal effect on the outcome of leptospiral infection, except for
a reduced susceptibility for the development of interstitial nephritis
in iNOS-deﬁcient mice. In addition, the absence of functional B
and T lymphocytes does not preclude the occurrence of pulmonary
haemorrhages. This is strong evidence against the hypothesis that
pulmonary hemorrhages in leptospirosis are related to autoimmune
mechanisms.
O467 Bacterial translocation is the major driver to death in
experimental multiple organ dysfunction
K. Louis*, A. Kotsaki, A. Alexis, J. van der Meer, M. Netea,
E.J. Giamarellos-Bourboulis (Athens, GR; Nijmegen, NL)
Objectives: The role of bacterial translocation in multiple organ
dysfunctions (MODS) is debatable. To investigate this, a model of sterile
MODS is needed i.e. MODS induced after challenge by microbial ligands
and not by live bacteria.
Methods: MODS was induced in 176 male C57B6 mice (male C57Bl6)
by the sequential ip injection of lipopolysaccharide (LPS 40 mcg)
followed after 6 days by zymosan (ZM). Mice were divided into four
groups: A sham; B LPS; C LPS + 0.6 mcg/g ZM; and D LPS + 1.2 mcg/g
ZM. Survival was recorded. Mice were sacriﬁced at 24 and 48 hours
for quantitative tissue cultures; splenocytes were isolated and stimulated
with LPS for the release of IL-10 and IL-17; cytokines in serum and
supernatants were measured by ELISA. Mice challenged with LPS +
1.2 ZM were treated im with placebo/ertapenem 250mg/kg bid for ﬁve
days. Survival was recorded; tissue bacterial growth was measured upon
sacriﬁce at 48 hrs.
Results: Median survival of group B was 240 hrs; of group C
240 hrs; and of group D 36 hrs (p: 0.002). Total tissue recovery
of enterobacteriaceae and enterococci is shown in the ﬁgure. Mean
respective splenocyte apoptosis of groups A, B, C and D was 25.4,
45.6, 19.1, and 55.0% (pNS) at 24 hrs; and 17.4, 16.4, 11.6 and 17.8%
at 48 hrs (pNS). At 48 hrs mean respective serum IL-6 was 20, 240.9,
158.5 and 468.7 pg/ml (pNS). Mean respective release of IL-10 was
24.0, 66.6, 253.4 and 241.6 pg/ml (pNS) at 24 hrs; and 15.4, 48.2, 121.0
and 65.3 pg/ml at 48hrs (pNS). Mean respective release of IL-17 was
15.0, 15.8, 24.9 and 19.3 pg/ml at 24 hrs (pNS); and 15.0, 15.2, 13.3
and 13.3 pg/ml at 48 hrs (pNS). Median survival after treatment with
ertapenem was 7 days compared with 2 days of placebo (log-rank:
5.174, p: 0.023). Mean log10 bacteria in liver, lung, spleen and kidney
was 5.51, 5.75, 5.27 and 5.30 in placebo-treated mice respectively; they
became 2.22, 1.40, 1.45 and 1.38 in ertapenem-treated mice (p< 0.0001
vs placebo).
Conclusions: Bacterial translocation is early implicated even when
MODS is induced by sterile ligands. Major changes of the immune
response do not occur. Findings imply a need for appropriate adaptation
of antimicrobials upon early signs of MODS.
O468 A model of tick-borne encephalitis in rats infected with
Langat virus
C. Mafﬁoli, D. Grandgirard, O. Engler, S. Leib* (Berne, Spiez, CH)
Objectives: Tick borne encephalitis virus (TBEV) and Langat virus
(LGT) are closely related viruses within the mammalian group of tick-
borne ﬂaviviruses that cause menigoencephalitis in humans. The lethality
rate of TBEV infections in Europe can reach 6.3% and causes permanent
neurofunctional sequelae in up to 45% of the survivors. LGT, a naturally
attenuated member of the TBEV-complex, has been previously used as
a live vaccine against TBEV but its use has been abandoned since
it caused meningoencephalitis with permanent neurological deﬁcits in
0.005% of the vaccinees. The pathogenesis of TBEV and the mechanisms
of brain injury underlying the neurofunctional sequelae of TBE are
poorly understood and currently no effective therapy is available. Here
we established a rat model of TBE using LGT strain TP21, with the aim
to extend the understanding of the disease mechanisms and to develop
novel treatment strategies.
Methods: Eleven-days old Wistar rats were inoculated intracisternally
with 25 ul of saline (controls; n = 11) or with 25 ul saline containing
increasing concentration of LGT ranging from 102(n = 4), 103 (n = 4),
104 (n = 4) to 105 (n = 8) focus forming units (ffu). After injection
animals were monitored for clinical symptoms of disease by assessing
appearance, roaming, feeding and weight over 10 d. Neurofunction was
scored at 2, 4, 7 and 9 d after infection by assessing performance in
behavioural tests i.e. rotating rod and open ﬁeld. At predetermined time
i.e. at 4, 7 and 9 d after infection animals were sacriﬁced, brains removed
and analysed for histopathology.
Results: Over 90% (7/8) of rats infected with the highest concentration
of LGTV (105 ffu) showed symptoms of menigoencephalitis including
gait disturbances, hypokinesia, and reduced weight gain or weight loss.
Hind leg paralysis and loss of balance was evident in 4/8 infected animals
at 4 d after infection. On the rotating rod, infected animals showed a
signiﬁcant (p< 0.05) higher frequency of falls within 120 sec. compared
to controls at 4 d after infection. Brains of infected animals exhibited
characteristic histopathologic features of TBE including subarachnoid
pleocytosis, perivascular cuffs, glial nodules and neuronal rarefaction.
Conclusions: The newly established rat model of tick-borne ﬂavivirus-
menigoencephalitis provides the opportunity to investigate mechanisms
of disease and to develop therapeutic strategies for TBE where currently
no effective treatment is available.
O469 Dengue fever, Dengue haemorrhagic fever, Dengue shock
syndrome modelled in the ferret, Mustela putorius furo
T. Voss*, J. Barbercheck, R. Brocato, M. Chen, R. Cross, C. Garry,
T. Hartley, D. Minor, G. Manukian, B. Kaplan, D. Mourich, S. Naveen,
P. Iversen (New Orleans, Bothell, US)
Objectives: Dengue virus is a mosquito-borne ﬂavivirus responsible for
human Dengue fever, Dengue hemorrhagic fever, and Dengue shock
syndrome. Dengue infection in humans occurs in an estimated 50–
100 million cases annually with 22,000−26,000 deaths attributed to
Dengue infection. Dengue viruses exist in nature in four antigenically
distinct serotypes with primary infection with any serotype responsible
for Dengue fever. While murine and non-human primate models of
Dengue virus infection exist, there are limitations to each model for
understanding the role of innate, humoral, and cellular immune responses
to primary and secondary infection by Dengue viruses. Our laboratory
is focused on understanding the role of virus-host interactions in the
pathogenesis of Dengue virus infection. Our laboratory utilizes the ferret
(Mustela putorius furo) as a model of acute respiratory (inﬂuenza and
coronavirus) infection and has been focused on the development of
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the ferret as a model of Dengue fever, Dengue hemorrhagic fever, and
Dengue shock syndrome.
Methods: IP Inoculation of ferrets with Dengue virus type 2 (DV2) led
to primary Dengue infection with clinical signs of Dengue fever. Animals
were assessed for clinical signs (fever, weight loss, activity changes) daily
for 10 days, and blood or tissues harvested for virology, immunology,
and pathology studies. Animals were administered a secondary Dengue
challenge with Dengue virus type 1 (DV1) in an attempt to model
Dengue hemorrhagic fever/Dengue shock syndrome using the above-
described parameters. Additionally, vascular leak was assessed using
Evan’s blue dye (EBD) administration followed by quantiﬁcation of EBD
in tissues, gross and histopathological examination of tissues.
Results: Dengue virus antigen was detected in peripheral blood
mononuclear cells, viral genome detected in serum and multiple tissues
for up to 10 days post challenge. Humoral responses to Dengue viruses
were detected early in infection with neutralizing antibody detected to the
challenge virus serotype, but not to heterologous serotypes. Re-challenge
of of ferrets after primary infection led to demonstrated evidence of
vascular leak modeling Dengue shock syndrome.
Conclusions: Taken together, these results support the ferret as a
model of Dengue fever, Dengue hemorrhagic fever, and Dengue shock
syndrome. This novel model of Dengue infection may have utility
in understanding Dengue pathogenesis and in therapeutic and vaccine
development.
O470 Brain inﬂammation in a new mouse model for meningococcal
meningitis
T. Davidsen, C. Castellanos, D. Frydenlund, E. Antal, S.A. Frye,
O.P. Ottersen, T. Tønjum* (Oslo, NO)
Objectives: Meningococcal disease is a leading cause of meningitis
worldwide, and brain edema is among the serious consequences of
meningococcal meningitis. Aquaporin-4 (AQP4) is a water-channel that
is highly expressed in the brain, predominantly in astrocyte endfeet and
that is involved in the development of brain edema. Few models for
bacterial meningitis exist, and here we present a new mouse model for
the induction of meningitis by direct inoculation of bacteria into the
subarachnoid space.
Methods: Mice from three strains (CD1, C57BL/6 and Aqp4 null
mice in C57BL/6 genetic background) underwent intrathecal injection
of either Neisseria meningitidis serogroup B (the meningococcus, Mc),
Streptococcus pneumoniae (the pneumococcus, Pc) or puriﬁed Mc lipo-
oligosaccharide (LOS). The degree of inﬂammation and aquaporin
expression in the brain was quantiﬁed both morphologically and by
assessing the gene expression of relevant markers quantitative real-time
PCR.
Results: The Mc infection that developed was histologically char-
acterized by acute inﬂammation primarily with meningeal inﬁltration
of neutrophil granulocytes and an absence of parenchymal abscess
formation, as well as ultrastructurally by pronounced edema. In Mc mice,
the Tnf-a expression levels were increased after 9 h, predominantly in
deep brain tissues. After 30 h, the inﬂammation was mostly conﬁned to
the brain surface. In Pc-injected animals, Tnf-a expression was increased
in the brain surface at 9 and 30 h, and the inﬂammation was histologically
more severe. In LOS-injected mice, Tnf-a levels were increased both
in the brain surface and core brain. Locomotion was more severely
reduced in mice inoculated with Mc than in those inoculated with Pc or
LOS. Aqp4 null mice with meningitis were more active in locomotion
than wildtype mice with meningitis, consistent with a clinically more
favorable picture.
Conclusion: This is the ﬁrst study of intrathecal inoculation of Mc in
different mouse strains and monitoring Aqp4 null mice in the context
of Mc meningitis. Our meningitis model shares many of the features
characteristic of human meningitis and is the ﬁrst to allow for a direct
comparison between the two major bacterial pathogens, Mc and Pc.
The model reveals that the two bacterial species differ signiﬁcantly in
regard to histological inﬂammation and involvement of different brain
structures. Aquaporins are implicated in the pathogenesis of both types
of meningitis.
O471 Demyelination in murine cerebral malaria is reversed by
neuroprotective erythropoietin treatment
C. Hempel, C. Jendresen, P. Hyttel, T. Staalsø, J.R. Nyengaard,
J.A. Kurtzhals* (Copenhagen, Aarhus, DK)
Objectives: Cerebral malaria (CM) is the most severe complication of
malaria, causing high risk of mortality and neurological sequelae in
survivors. The development of an adjunct neuroprotective treatment re-
quires improved knowledge about the underlying pathophysiology. Post-
mortem investigations of fatal human cases suggest that demyelination
may play an important role in CM pathogenesis. We have previously
reported that erythropoietin (EPO) signiﬁcantly improves survival in
experimental murine CM. We tested the hypotheses that, a. experimental
CM is associated with marked demyelination of cerebral white matter
and, b. EPO treatment reverses this demyelination.
Methods: C57BL/6 mice were infected with Plasmodium berghei
ANKA, which leads to CM approximately one week post infection (p.i.),
or mock infected as controls. EPO treatment or vehicle was administered
on day 4−7 p.i. The four experimental groups − CM, CM EPO, Control,
EPO control − were terminated on day 8 when CM mice were terminal.
Clinical signs of CM were assessed by body temperature plus behavioural
and coordination tests. Brains were perfusion- and immersion ﬁxed and
processed for immunhistochemistry (for myelin basic protein and cell
markers) by light microscopy and electron microscopy plus stereology.
All microscopies were done blindly. The national board for animal
studies approved all experiments.
Results: EPO treatment protected clinically against CM. In CM consid-
erable patchy demyelination was seen in the white matter, particularly
in the cerebellum, concurring with the occurrence of coordination
impairment. There were multiple infarcts in the corpus callosum,
which was selected for ultrastructural stereological assessments. The
thickness of myelin was not decreased in CM, but a signiﬁcant number
of axons had degenerated myelin sheaths (Figure). A considerable
number of activated microglia inﬁltrated the areas of demyelination and
phagocytosis of myelin debris was seen. EPO treatment signiﬁcantly
reduced demyelination and microglia activation.
Conclusion:We demonstrate considerable myelin damage in experimen-
tal CM. This is reversed by neuroprotective treatment with EPO.
O472 Grafted neuronal stem/progenitor cells differentiate and
functionally integrate at the site of pneumococcal-induced
hippocampal brain injury in vitro
S. Hofer*, V. Magloire, J. Streit, S. Leib (Berne, CH)
Objectives: Survivors of bacterial meningitis (BM) frequently suffer
long-term sequelae, including learning and memory deﬁcits. The
neurofunctional deﬁcits are associated with the occurrence of apoptotic
cells in the subgranular zone of the hippocampal dentate gyrus in
experimental BM. Here we screened neural precursor cells (NPCs) for
their potential to migrate, differentiate and integrate into organotypic
hippocampal slice cultures (OHCs) injured by challenge with live
Streptococcus pneumoniae.
Methods: Green ﬂuorescence protein-expressing NPCs from the fetal
hippocampus and subventricular zone, and from adult bone marrow were
grafted into the hilus region of the dentate gyrus of injured slices and
controls. The migration and differentiation of grafted cells was assessed
by immunohistochemistry. Patch clamp and multielectrode array (MEAs)
recordings were used to document the functional integration of the
grafted cells.
Results: Seven days after engraftment histomorphologic analysis
revealed migration of grafted NPCs from the site of injection to the
molecular layer of the dentate gyrus in control slices. In contrast, when
grafted in slices challenged with bacteria, NPCs migrated to the site of
hippocampal damage in the granular layer of the dentate gyrus. Bone
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marrow-derived stem cells failed to migrate and differentiate. Whole
cell patch-clamp and MEA recordings of grafted NPCs demonstrated
that grafted cells developed properties of mature neurons and became
functionally integrated into the host neuronal network.
Conclusions: In OHCs, grafted NPCs migrated to the pneumococcal
induced area of hippocampal damage and differentiated into neurons that
functionally integrated into the hippocampal network. The transplanta-
tion of neurosphere derived NPCs may hold promise for regenerative
therapies aimed at repair of apoptotic brain damage in the hippocampus
after BM.
O473 Host response during Pseudomonas aeruginosa adaptation
to cystic ﬁbrosis lung
C. Cigana, N.I. Lore`, S. Schwager, M. Juhas, L. Eberl, A. Bragonzi*
(Milan, IT; Zurich, CH)
Objectives: Cystic ﬁbrosis (CF) lung disease is characterized by
transient airway P. aeruginosa infections and excessive neutrophil-
dominated inﬂammation early in life followed by permanent chronic
infection that causes persistent respiratory symptoms and a decline
in lung functions. Here we aimed to dissect the host response to
P. aeruginosa patho-adaptive strains during acute and chronic infection.
Methods: We analysed the pathogenicity of sequential clonal strains
isolated from a CF patient during a period of up to 7.5 years
in a multihost system including four different models, namely,
Caenorhabditis elegans, Galleria mellonella, Drosophila melanogaster
and mouse. In addition, the epithelial bronchial cells of CF origin IB3−1,
their wt-like isogenic cells C38 and macrophage-like cells THP-1 were
used to sustain the ability to provoke inﬂammation or damage during
early or late phases of P. aeruginosa infection.
Results: P. aeruginosa strains at the onset of infection are more
pathogenic than late isolates from the same patient when tested in
C. elegans, G. mellonella and D. melanogaster. In murine model of
acute infection, the early P. aeruginosa strain induced higher mortality
than late clonal strains. Although attenuated in mortality, P. aeruginosa
late isolates retained their capacity to persist in mouse models of chronic
infection. H&E, PAS-staining and Tunnel assay of lung tissue sections
showed that early strain induced pronounced leukocytes recruitment
indicating strong inﬂammatory response while late strains increased
numbers of mucin-positive goblet cells and apoptotic cells, a typical
hallmark of damage in the airway chronic diseases.
To establish the “pathological drift”, IB3−1 cells were infected with early
and late P. aeruginosa clonal strains from CF patients and subjected
to microarray analysis. Results indicated a decreased inﬂammatory
response, including down-regulation of leukocyte receptors and adhesion
molecules, and an increased damage mediated by tissue remodelling, due
to late strains compared to early strains.
Conclusion: Our ﬁndings suggest that during long-term infection
P. aeruginosa revises its interaction with CF host by activating alternative
pathways including evasion of the immune response, non-inﬂammatory
cell death and those relevant for tissue damage and remodelling process
to ultimately result in chronic disease and decline in lung functions.
O474 In vitro and in vivo reduced ﬁtness and virulence in
ciproﬂoxacin-resistant Acinetobacter baumannii
Y. Smani*, R. Lo´pez-Rojas, J. Domı´nguez-Herrera, F. Docobo-Pe´rez,
S. Marti, J. Vila, J. Pacho´n (Seville, Barcelona, ES)
Objectives: Antimicrobial resistance confers a biological ﬁtness cost on
bacteria that may be manifested as a decreased growth rate, and reduced
virulence. However, there are limited experimental data on the relative
ﬁtness and virulence of antimicrobial resistant A. baumannii. The aim of
this study is to assess the ﬁtness cost caused by ciproﬂoxacin resistant
A. baumannii, as well as its virulence relative to the susceptible parental
wild type (wt) strain in in vitro and in vivo murine peritoneal sepsis
(MPS) model.
Methods: Two A. baumannii strains: 77wt (susceptible to ciproﬂoxacin)
and its derivative 77R (resistant to ciproﬂoxacin) were used. Bioﬁlm
formation was determined using crystal violet assay. Cellular viability
of human lung epithelial cells (A549) was assessed using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
Live/Dead®, and lactate dehydrogenase (LDH) assays after addition of
77wt or 77R (108 cfu/mL) for 24 h. Moreover, mortality and competition
ﬁtness between both strains was monitored in vitro and in vivo in a MPS
model during 24 h.
Results: The acquisition of ciproﬂoxacin resistance by 77R strain
reduces the formation of bioﬁlm observed with the 77wt strain by
50%. A549 cells infected with 77R strain showed lower decrease in the
cell death and release of LDH (86.53±2.44% and 5.98±1.81%) than
77wt strain (66.23±4.01% and 48.38±3.5%), respectively. Additionally,
the assessment of A549 cells survival by Live/Dead® showed less
dead cells, stained with ethidium homodimer-1 producing a bright red
ﬂuorescence, in A549 cells infected with 77R strain than with 77wt
strain. Furthermore, resistance to ciproﬂoxacin acquired by 77R strain
decreases the mortality of animals in MPS from 100% (observed with
77wt strain) to 20% at initial inoculum of 8.3 log cfu/mL. This resistance
to ciproﬂoxacin slow the growth of 77R strain in vitro and in vivo MPS
model in competition with the 77wt strain by 1.7 and 2.02 log at 24 h,
respectively, compared to 77wt strain alone; thus, the in vitro and in vivo
competition index were 0.02 and 0.03, respectively.
Conclusion: Our ﬁndings reveal the presence of an in vitro and in
vivo ﬁtness cost and reduced virulence of ciproﬂoxacin resistance
in A. baumannii. The understanding of the gap between antibiotic
resistance, biological ﬁtness and virulence of A. baumannii will be useful
to improve the antibiotic therapy against A. baumannii.
O475 Relationship between the gut microbiota and obesity in
children and adolescents
V. Vankerckhoven*, L. Bervoets, K. Van Hoorenbeeck, C. Lammens,
S. Chapelle, C. Vael, K. Desager, H. Goossens (Antwerp, Hasselt, BE)
Objectives: Obesity is considered as one of the most important public
health problems of our times. The last few decades the prevalence
of obesity, especially among children and adolescents, has increased
dramatically worldwide. The aim of our study was to determine whether
the composition of the gut microbiota is related to obesity in childhood.
Methods: A cross-sectional study was set-up to examine the gut
microbiota using faecal samples from 22 obese children and 33 non-
obese children aged 6−16 years. The microbial composition in the
faecal samples was analyzed by quantitative plating for Staphylococcus
spp., Bacteroides fragilis group, Clostridium spp., Lactobacillus spp.
and for Biﬁdobacterium spp.; matrix-assisted laser-desorption/ionization
time-of-ﬂight mass spectrometry (MALDI-TOF MS) for identiﬁcation
of species of the Bacteroides fragilis group and quantitative real-
time polymerase chain reaction (qRT-PCR) to determine the number
of Staphylococcus spp., Bacteroides-Prevotella-Porphyromonas group,
Clostridium coccoides-Eubacterium rectale group, Clostridium leptum
subgroup, Lactobacillus spp., and Biﬁdobacterium spp. For statistical
analysis, the BMI z-score was used as dependent variable thereby
correcting for age and gender. A P-value of <0.05 was considered
statistically signiﬁcant.
Results: Both quantitative plating and qRT-PCR showed that the faecal
concentration of the Bacteroides fragilis group in obese children was
signiﬁcantly lower than in non-obese children (P = 0.017 and 0.018,
respectively). Additionally, MALDI-TOF MS analysis demonstrated that
obese children were colonized more frequently with B. fragilis than non-
obese children (19.18% and 7.33%, P = 0.039) whereas colonization with
B. vulgatus was signiﬁcantly higher in non-obese children compared to
obese children (8.14% and 18.91%, P = 0.016). Furthermore, B. fragilis
was signiﬁcantly positively correlated to the BMI z-score (P = 0.03).
Higher colonization with B. fragilis could therefore be associated with an
increase in weight. The microbiota of obese children was also associated
with a higher Firmicutes/Bacteroides ratio (P = 0.02).
Conclusions: Signiﬁcant differences were found in the composition of
the fecal microbiota of obese and non-obese children. These results
indicate that changes in the gut microbiota during childhood and
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adolescence could lead to the development of obesity and that the gut
microbiota could be an additional risk factor for obese-prone children.
Antifungals: in vitro and in vivo activity,
pharmacokinetics and resistance
O476 EUCAST susceptibility testing of Candida species to
echinocandins: improved separation between wild type
isolates and fks mutants by supplementation of BSA to the
test medium
M. Cavling Arendrup*, S. Park, J.L. Rodriguez-Tudela, W. Hope, C. Lass-
Flo¨rl, P. Donnelly, M. Cuenca-Estrella, D.S. Perlin (Copenhagen, DK;
Newark, US; Madrid, ES; Manchester, UK; Insbruck, AT; Nijmegen, NL)
Background: MICs of the three echinocandins against isolates with fks
mutations from clinical failure cases are higher than those relative to wild
type isolates, but the ranges of these susceptible and mutant populations
either overlap or are just separated by 1−2 dilution steps. A recent
preliminary study (Garcia-Effron, ICAAC M-352, 2009) reported that
the addition of BSA to the growth medium leads to a better separation
between wild type and mutant isolates using the CLSI method. We here
investigated if this was also true for the EUCAST method.
Methods: MICs were determined for anidulafungin, caspofungin and
micafungin by the EUCAST method without (EDef7.1) and with addition
of 50mg/mL BSA. A total of 94 clinical isolates including (no. of wt/no.
of mutants) C. albicans (10/10), C. glabrata (9/11), C. dubliniensis (1/1),
C. krusei (13/3), C. parapsilosis (19), and C. tropicalis (15/4) isolates.
Three isolates harbour mutations outside the resistance hot spots and are
regarded as wild type concerning echinocandin susceptibility because of
their normal kinetic inhibition properties.
Results: The addition of BSA to the growth medium resulted in higher
MICs for all isolates and all three compounds (Table). The increase
was greatest for anidulafungin and micafungin, and notably greater for
fks mutants compared to WT isolates. Among WT isolates the greatest
increase was observed for C. parapsilosis which intrinsically harbours a
“hot spot mutation”.
Conclusion: Addition of BSA to the EUCAST growth medium enhances
the MIC differences between fks hot spot mutants and wild-type isolates
and thus increases the ability of the susceptibility test to differentiate
between susceptible isolates and those harbouring resistance mutations.
O477 Comparison of in vitro fungicidal activities of echinocandins
against C. albicans in different peritoneal dialysis ﬂuids
S. Tobudic*, H. Schranz, C. Kratzer, W. Poeppl, H. Burgmann (Vienna,
AT)
Objectives: Continuous ambulatory peritoneal dialysis used in the
treatment of patients with end-stage renal failure is often complicated
by peritonitis. The current guidelines advocate the use of intermittent in-
traperitoneal (IP) antimicrobial management for peritoneal dialysis (PD)-
associated fungal peritonitis. IP administration results in very high
antimicrobial concentrations at the site of infection. Peritoneal dialyses
ﬂuids (PDFs) affect inhibitory efﬁcacy on the microorganisms’ growth,
which may compromise the affectivity of some antibiotics. However,
there is no data about activity of antifungal agents in PDFs. The purpose
of this study was to investigate in vitro the fungicidal effectiveness of
three echinocandins in diverse PDFs.
Methods: The fungicidal efﬁcacy of caspofungin, anidulafungin and
micafungin against C. albicans ATCC 90029 was studied in the
PDFs: Dianeal PD4® (glucose 1.36%, 2.27%, 3.86%), Physioneal 40®
(glucose 1.36%, 2.27%, 3.86%), Extraneal® (7.5% icodextrin), and
Nutrineal PD4® (1.1% amino acid) using time-kill curves. The protein
concentration of the PDFs was adjusted to 2 g/l with human serum
albumin (HSA) and the pH adjusted to 7.4 with NaOH, corresponding
to conditions of used PDFs after a 4−6 h intraperitoneal dwell. Sabouraud
buillon (SAB) was used as a control broth. Ten milliliter of diverse PDFs
and SAB containing yeast inoculum of approximately 106 CFU/ml was
incubated for 2 h at 37 ºC. Following incubation, the echinocandins at
concentrations: 1×MIC, 4×MIC, 8×MIC were added. Samples were
taken at 0, 2, 4, 6, 8, 10 and 24 h and the number of CFU/ml was
determined.
Results: No difference in fungicidal activity between different
echinocandins was shown. However, echinocandins were signiﬁcant
less active in PDFs then in control broth (p< 0.01) In SAB all
three echinocandins at the concentration of 1×MIC attained 100%
reduction of viable cells. In contrast, at concentration of 1×MIC
echinocandins achieved no fungicidal activity (reduction <1 log10
cfu/ml). At concentration of 4−8×MIC the highest decrease was detected
in icodextrin containing PDF Extraneal®, however for 1.5 log10 cfu/ml
only.
Conclusion: Based on these in vitro data, we conclude that PD ﬂuids
using in clinical settings could impact the activity of echinocandins.
O478 Prospective surveillance of azole-resistance in Aspergillus
fumigatus in the Netherlands
J.W. van der Linden, E. Snelders, G.A. Kampinga, B.J. Rijnders,
E. Mattsson, Y.J. Debets-Ossenkopp, E. Kuijper, F.H. van Tiel,
W. Melchers, P. Verweij* (Nijmegen, Groningen, Rotterdam, Utrecht,
Amsterdam, Leiden, Maastricht, NL)
Objectives: Antifungal azoles are the cornerstone of the management
of Aspergillus diseases. However, acquired azole resistance of aspergilli
is increasingly reported, which compromises the use of this class of
antifungals. The prevalence and spread of azole resistance in clinical
A. fumigatus isolates is currently unknown.
Methods: We performed a prospective multicentre surveillance study
to determine the prevalence of azole-resistance in Aspergillus species.
Between June 2007 and January 2009 medical microbiology laboratories
of 7 Dutch University Medical Centres screened all clinical Aspergillus
isolates for resistance to itraconazole (ITZ) using Sabouraud agar-slants
supplemented with 4mg/l of ITZ. Phenotypic susceptibility proﬁle and
the mechanisms of resistance were determined for resistant isolates.
Patient characteristics were also collected.
Results: In total 2,062 Aspergillus isolates from 1,385 patients were
screened of which 87% were identiﬁed as A. fumigatus. 82 isolates were
ITZ-resistant, of which 79.8% was also resistant to voriconazole and
16.7% to posaconazole. In 90.2% of ITZ-resistant A. fumigatus isolates
a L98H substitution combined with a 34 base pair duplication in the
Cyp51A-gene promoter region was found. The overall prevalence of
ITZ-resistance in A. fumigatus was 5.3% (range 0.8 to 9.5%). Patients
with a hematologic/oncologic disease were more likely to harbour an
azole-resistant isolate compared to patients groups with other underlying
diseases (p = 0.02). 64% of patients in whom a resistant isolate was
recovered were azole-naı¨ve and the mortality-rate of patients with azole-
resistant invasive aspergillosis was 88%.
Conclusion: Multi-azole-resistance in A. fumigatus is wide-spread in
the Netherlands and is associated with a poor outcome in patients with
invasive aspergillosis.
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O479 In vitro secondary azole resistance in A. fumigatus isolates
does not necessarily involve mutations in the cyp51A gene
P. Escribano, S. Recio, T. Pela´ez, A. Simo´n, E. Bouza, J. Guinea*
(Madrid, ES)
Background: Most Aspergillus fumigatus isolates showing phenotypic
antifungal azole resistance have mutations at codons 54, 98, 138, 220,
or 448 of the cyp51A gene. Secondary azole resistance in A. fumigatus
isolates has been described in patients taking long-term itraconazole
(ITRA) therapy. We searched for the presence of cyp51A mutations in
A. fumigatus isolates after prolonged in vitro exposure to increasing
ITRA concentrations.
Methods: We selected 20 A. fumigatus sensu stricto isolates without
mutations at codons 54, 98, 138, 220, or 448 in cyp51A. ITRA,
voriconazole (VORI), and posaconazole (POSA) MICs were determined
using the CLSI M38-A procedure (MICinitial). Isolates were grown on
Sabouraud dextrose agar, and adjusted conidia inocula (3x107 c.f.u./mL)
were prepared in water. Twenty microliters of each suspension was
stroked on plates containing ITRA at concentrations one-fold below
the MICinitial. The plates were incubated for 7 days at 35ºC. When
fungi grew, another adjusted suspension was prepared and propagated
to a different plate containing the next two-fold ITRA concentration
(to a maximum of 16mg/mL). From the plate containing the highest
ITRA concentration allowing fungal growth, a conidia suspension was
prepared to calculate the MIC of the three azoles (MICﬁnal). The cyp51A
sequence was obtained and STRAf genotyping of each isolate performed
before and after exposure to ITRA to demonstrate that the strain was the
same, ie, it had not been contaminated by other isolates.
Results: The percentages of isolates able to grow on plates containing
different concentrations of ITRA were 95% (2 mg/mL), 75% (4mg/mL),
70% (8mg/mL), and 50% (16mg/mL). Antifungal susceptibility of the
isolates before and after ITRA exposure is shown in the table.
The MICﬁnal of the three azoles obtained by the CLSI M38-A procedure
was signiﬁcantly higher than the MICinitial (P 0.001). No mutations
were found in the cyp51A gene at codons 54, 98, 138, 220, and
448 of isolates growing at the highest concentration of ITRA. STRAf
demonstrated that the genotype did not change before or after exposure
to ITRA.
Conclusions: Our results indicate that prolonged exposure of A. fu-
migatus isolates to increasing ITRA concentrations leads to a loss
of susceptibility to ITRA, VORI, and POSA. Secondary phenotypic
resistance to azoles does not necessary involve the presence of mutations
at codons 54, 98, 138, 220, or 448 in the cyp51A gene.
O480 Multidrug resistance transporter genes play a potential role
in Aspergillus fumigatus azole resistance
R. Rajendran*, R. Wotherspoon, E. McCulloch, B. Jones, C. Williams,
M. Bromley, P. Bowyer, G. Ramage (Glasgow, UK)
Objectives: Mutation of the CYP51A gene locus is a common azole
mediated mechanism of resistance in Aspergillus fumigatus. Recent
data suggests that mechanisms other than these mutations contribute
to resistance and treatment failure. Efﬂux pump mediated resistance has
been described is in pathogenic fungi, therefore, the aim of this study was
to examine the expression and function of multidrug resistance (MDR)
efﬂux pumps on azole resistance.
Methods: Expression of AfMDR1−4 genes was assessed in vitro
on three phases of ﬁlamentous growth (8, 12 and 24 h) by qPCR
analysis using three cystic ﬁbrosis A. fumigatus strains. In addition,
qPCR analysis was performed on lung samples (day 1 to 5) obtained
from an animal model of invasive aspergillosis±posaconazole treatment.
AfMDR1−4 were then knocked out by fusion PCR, which were then
characterised biochemically and using molecular techniques.
Results: AfMDR1−4 were differentially expressed in vitro, with
AfMDR2 showing the highest levels of constitutive expression for
all phases of growth, followed by AfMDR1, AfMDR4 and AfMDR3.
AfMDR1 and AfMDR4 showed an increasing trend over time towards
up-regulation, whereas AfMDR3 showed a transient up-regulation.
Within the animal model AfMDR1 was preferentially expressed,
followed by AfMDR2−4. AfMDR3−4 exhibited apparent up-regulation
following posaconazole treatment. Deleting these genes improved
sensitivity towards the azoles.
Conclusion: This study has shown that each of the AfMDR efﬂux
pumps have deﬁned roles, and which are also expressed within an
infection model. Azole treatment appeared to stimulate A. fumigatus by
altering the expression of efﬂux pumps, which may have implications
to refractory azole therapy. Deletion of these genes impacted azole
sensitivity, implying that these pumps have a possible role as a resistance
mechanism.
O481 Azole-resistance in Aspergillus fumigatus: collateral damage
of fungicide use?
E. Snelders*, S.M. Camps, A. Karawajczyk, C.H. Klaassen, G.H. Kema,
W. Melchers, P. Verweij (Nijmegen, Wageningen, NL)
Objectives: Since the year 1998 the emerge of multi-azole-resistance in
A. fumigatus isolates has been reported in clinical isolates containing
the TR/L98H mutations in the cyp51A gene. Is has been postulated that
the TR/L98H mutations have been introduced in A. fumigatus in the
environment due to the agricultural use of azole fungicides.
Methods: All licensed azole fungicides between 1970 and 2010 were
purchased and tested for in vitro activity against azole susceptible and
azole resistant TR/L98H mutated A. fumigatus isolates. Docking studies
were performed by using a CYP51A homology model to determine
similarities in docking of medical and fungicide azole compounds.
Microsatellite typing was used for genotyping the TR/L98H isolates and
subsequently used for evolutionary study to determine the origin of the
TR/L98H mutations in the A. fumigatus population.
Results: Five out of all 30 licensed Dutch azole fungicides show cross-
resistance against the TR/L98H isolates, from which four fungicides
also showed the highest similarity in docking-studies when compared
with the medical azoles. The four agricultural fungicides that show
cross-resistance have been introduced between 1990–1996. Analysis of
microsatellite data showed that the TR/L98H mutated isolates have been
introduced in the Dutch A. fumigatus population around the year 1997
(95%CI:1993.7–1999.7).
Conclusion: By providing the link between fungicide use and
TR/L98H multi-azole resistance A. fumigatus a route of azole resistance
development is given which could not be explained by the medically
known resistance development within patients. Wind-dispersion of
fungal spores and high levels of azole compounds will provide perfect
conditions for further spread of TR/L98H azole resistant A. fumigatus
isolates. As already observed, global spread of azole resistance in
A. fumigatus can be anticipated.
O482 Caspofungin exposure in patients with haematological
malignancies is a risk factor for fungaemia due to decreased
susceptible Candida spp.: a case-control study in Paris
E. Blanchard*, O. Lortholary, M. Desnos-Ollivier, F. Dromer,
D. Guillemot (Paris, FR)
Objectives: Candida spp. bloodstream infections (BSI) are associated
with poor outcomes in haematological patients. Caspofungin is among
recommended ﬁrst line treatments in invasive candidiasis especially
in patients preexposed to ﬂuconazole and as empiric therapy in
febrile neutropenic patients. There are increasing reported infections
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due to resistant isolates in patients receiving caspofungin therapy.
We here aimed at identifying and quantifying factors associated
with BSI due to Candida spp. with intrinsically (C. parapsilosis,
P. guilliermondii) or acquired (C. albicans, C. glabrata, C. lipolytica)
reduced susceptibility to caspofungin (CRSC) in adults suffering from
haematological malignancies.
Methods: We used data from an ongoing surveillance program in the
Paris area to build a nested matched case-control study considering
Candida spp. BSI in patients 17 y-o suffering from haematological
malignancies from October 2002 to February 2010 and using EUCAST
method (AM3 medium) with a MIC cut-off of 0.5mg/L. Fifty-one cases
were matched to 102 controls on hospital and 1 year-time criteria. Cases
were patients infected with CRSC and controls were those infected with
Candida spp. susceptible to caspofungin. Univariate and multivariate
analysis were performed and associations were estimated by odds ratio
(OR) with 95% conﬁdence interval (CI) using conditional logistic
regression.
Results: In univariate analysis exposure to caspofungin within the past
30 days preceding fungemia was associated with CRSC (OR= 6.31, CI
95% [2.06–19.33]) as was age 65 years (OR= 3.81, CI 95% [1.51–
9.57]). In multivariate analysis, exposure to caspofungin within the past
30 days preceding fungemia remained associated with CRSC (OR= 5.25,
CI 95%[1.68–16.35]), as was age 65 years (OR= 3.27, CI 95% [1.26–
8.50]).
Conclusion: Recent exposure to caspofungin increases the occurrence of
Candida spp. BSI with reduced susceptibility to caspofungin. This study
adds evidence to previous report on the inﬂuence of recent preexposure
to caspofungin on the epidemiology of Candida spp. BSI.
O483 Efﬁcacy of anidulafungin and caspofungin against a
caspofungin-resistant isolate of Candida albicans in a murine
model
K.V. Clemons, M. Martinez, V. Chen, M.E. Johansen, D.A. Stevens*
(San Jose, US)
Objectives: Echinocandin resistance in Candida is unusual, and rarely
there are differences between echinocandins. Our aim was to assess in
vivo efﬁcacy of caspofungin (CAS) and anidulafungin (ANID) against
a CAS-resistant isolate.
Methods: Our large culture collection was screened for an isolate with
discrepant echinocandin susceptibility, and only one was found, #03–
248. CD-1 mice were infected iv with various inocula of CAS-resistant,
03–248, or susceptible, 98–144, strains of C. albicans. Treatment with
CAS or ANID ip, QD, began 4 days later. One day after 7 days of
therapy, CFU in the kidneys of survivors was determined.
Results: 100% inhibition/80% inhibition (CLSI)/MFC of 03–248 was
25/6.25/50 to CAS and 6.25/0.78/6.25 to ANID. After an inoculum of
3.8×105 of 03–248, no dose (0.1, 5 or 20mg/kg) of CAS or ANID
prolonged survival nor were there differences among ANID treatment
groups. A replicate study with 4.4×105 03–248 gave similar results. In
a 3rd study using 03–248, inoculum 1.2×107, CAS or ANID at 10mg/kg
prolonged survival versus controls (P 0.04); 20mg/kg doses trended to
signiﬁcance (P >0.05 <0.08). Mice carried signiﬁcant burdens of 03–
248; no treatment was superior to controls nor were there signiﬁcant
differences among dosages or comparing drugs. Against the CAS-
susceptible 98–144 (MIC/MFC 0.1/0.3, CAS and ANID), ANID at
20mg/kg signiﬁcantly reduced kidney CFU of 98–144 versus controls
(P = 0.0001), similar to our published data on CAS-susceptible isolates.
Conclusions: In vitro susceptibility predicts in vivo outcome. Resistance
to CAD>ANID does not translate to in vivo efﬁcacy by ANID; in vitro
resistance to CAS predicted in vivo resistance for both. Resistance to
CAS or ANID in vivo does not depend on the severity of infection,
ANID and CAS demonstrated the lack of efﬁcacy against 03–248 in
disease differing from moderate to severe. These data suggest resistance
in vitro to any echinocandin should caution the use of any echinocandin
in therapy, regardless of in vitro differences.
O484 In vitro posaconazole pharmacokinetics
P. Campoli*, R. Robitaille, M. Laverdiere, D. Sheppard (Montreal, CA)
Objectives: Infections due to Aspergillus fumigatus (AF) remain a
critical concern after allogeneic stem cell transplants and in patients with
hematologic malignancy. Posaconazole prophylaxis has proven highly
effective in preventing these infections, despite relatively low serum
concentrations. We have shown that posaconazole concentrates over
several hundred fold within the membranes of pulmonary epithelial cells,
and that this level of posaconazole can inhibit AF growth and protect
host cells from injury. The objectives of this study were to deﬁne the
pharmacokinetics of posaconazole within pulmonary epithelial cells, and
to determine the level of posaconazole required to inhibit fungal growth.
Methods: A549 pulmonary epithelial cells were exposed to different
concentrations of posaconazole and then analyzed at varying times
after the drug was removed. Decay kinetics of posaconazole were
determined through sequential harvesting of cells after drug exposure
and analyzed using HPLC. Concentrations of posaconazole required for
fungal inhibition, posaconazole exposed cells were infected at ﬁxed time
intervals after drug removal. To monitor fungal growth, serial samples of
culture supernatants were taken and analysed for galactomannan (GM)
content using the Aspergillus EIA Platelia assay.
Results: A549 cells exposed to 2mg/ml of posaconazole inhibited the
growth of AF when immediately infected. However, when the cells
were infected >6h after drug removal, AF growth was not inhibited.
GM content analysis conﬁrmed the visual breakthrough: A549 cells
infected >6h after loading with 1 and 2mg/ml posaconazole, GM content
progressively increased over time. In contrast, A549 cells exposed to 4
and 8mg/ml were able to inhibit fungal growth when infected at time
points up to 48 hours post drug exposure. HPLC analysis suggests a
two phase decay model: a rapid initial decay to approximately 25% of
the initial intracellular concentration within the initial 6 hours, followed
by a plateau. As expected, observed fungal growth correlates with the
decrease in drug levels.
Conclusion: These results demonstrate that posaconazole exhibits
unique pharmacokinetics that differ from the reported pharmacokinetics
of the serum compartment. These data support a re-examination of the
approach to therapeutic drug monitoring during antifungal prophylaxis
with posaconazole, and may provide an explanation for the observed
lack of correlation between efﬁcacy and serum levels of this agent.
O485 Pharmacokinetics and pharmacodynamics of micafungin,
anidulafungin and caspofungin for disseminated candidiasis
due to Candida glabrata
S.J. Howard*, J. Slater, A. Sharp, J. Goodwin, L. Gregson,
A. Alastruey-Izquierdo, D.S. Perlin, P. Warn, W. Hope (Manchester,
UK; New Jersey, US)
Objectives: Echinocandin agents are increasingly considered ﬁrst line
agents for the treatment of disseminated candidiasis. Candida glabrata
is the second most common cause of disseminated candidiasis and is
frequently resistant to triazoles. Currently there are limited data to guide
the optimal echinocandin dosage for neutropenic hosts infected with
C. glabrata. Here we use a neutropenic murine model of disseminated
candidiasis to study the pharmacokinetic and pharmacodynamic relation-
ships of the echinocandins against this medically important opportunistic
pathogen.
Methods: The MICs of micafungin, anidulafungin and caspofungin
against C. glabrata (ATCC 2001) were 0.06, 0.03, and 0.5mg/L
respectively (using CLSI methodology). Each drug was administered
5 hours post-inoculation and every subsequent 24 hours at 0.1,
1, 5 and 20mg/kg intraperitoneally. Echinocandin concentrations in
plasma and kidney were determined between 0−96 hr using HPLC.
The fungal burden in the kidney was simultaneously quantiﬁed. A
pharmacokinetic-pharmacodynamic mathematical model was used to
link drug concentrations with the antifungal effect, and to deﬁne the
drug exposure that produced near maximal fungicidal activity.
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Results: In untreated mice there was a progressive rise in kidney
fungal burden throughout the experimental period. The pharmacokinetics
of each agent were linear. For each agent, the rate of killing was
relatively slow with progressive antifungal effect with higher dosages.
Near maximal antifungal effect of micafungin and caspofungin was
observed following a dosage of approximately 5mg/kg, whereas dosages
>5mg/kg of anidulafungin were required to achieve this same endpoint.
For micafungin, these drug exposures are higher than those associated
with currently licensed human regimens.
Conclusion: The echinocandins exhibit fungicidal activity against
C. glabrata. Higher echinocandin dosages may be required to achieve
near maximal antifungal effect in profoundly neutropenic hosts infected
with this organism.
Travel medicine: tropical and parasitic
diseases
O486 Dientamoeba fragilis DNA detected in eggs of Enterobius
vermicularis by conventional and real-time PCR
D. Ro¨ser*, J. Carlsgart, P. Nejsum, H.V. Nielsen, C. Stensvold
(Copenhagen, DK)
Objectives: For more than 50 years it has been hypothesised that
Enterobius vermicularis (EV) can serve as a vector for Dientamoeba
fragilis (DF), an intestinal protozoan parasite with suspected pathogenic
potential. While some authors have been able to show higher than
expected co-incidence of EV and DF in clinical samples, not all studies
have been able to do so, and successful culture of DF trophozoites from
the eggs of EV has yet to be demonstrated. The objective of this study
was to show DF speciﬁc DNA in eggs of EV, harvested from a patients
co-infected with both species.
Methods: Cellophane tape- and faecal samples were collected from
the patient simultaneously, and positive identiﬁcation of EV was made
using microscopy and of DF by real-time PCR. An intact EV female
was recovered from the Cellophane tape sample, and eggs harvested by
compressing the worm in a solution of 0,5% NaClO (hypochlorite). The
eggs were then both centrifuged (1500 xg, 5 min.) and washed with
DNA-free H20 three times. Thirty visibly intact eggs were individually
transferred into PCR tubes and treated with proteinase K, followed by
heat-inactivation (100ºC, 15 min.). Eggs 1−10 were tested with real-time
PCR for DF, eggs 11−20 with conventional PCR for EV, and eggs 21−30
with conventional PCR for DF. Ampliﬁed PCR-products were sequenced.
Results: 2 of eggs 1−10 were tested positive for DF (Ct-values of 30
and 32), eggs 11−20 all showed positive bands for EV, and eggs 21−30
showed 1 positive band for DF. An internal positive control was used for
the real-time PCR, and all PCR’s had 5 negative controls, using water
from the last washing step. Results were conﬁrmed in repeated testing,
often with more eggs tested positive for DF (at most 6 out of 10 with
real-time PCR).
Conclusion: We have shown that DF-speciﬁc DNA sequences can be
ampliﬁed from DNA extracted from EV eggs that have been surface-
sterilised with hypochlorite. Not all eggs were found to be positive
for DF though. These ﬁndings have important implications for our
understanding of the transmission of D. fragilis and therefore also for
control and public health measures, as well as antimicrobial interventions
related to both of these common intestinal parasites.
O487 Long-term sonographic follow-up of inactive echinococcal
cysts of the liver
L. Piccoli*, F. Tamarozzi, C. Filice, E. Brunetti (Pavia, IT)
Objectives: Ultrasound is the ideal tool to diagnose, guide percuta-
neous treatments, and monitor abdominal cystic echinococcosis. The
sonographic classiﬁcation proposed by WHO Informal Working Group
on Echinococcosis (WHO-IWGE) allows the distinction in active,
transitional and inactive cysts, thus facilitating selection of treatment
modalities (Fig. 1). As for uncomplicated, inactive cysts (CE4, CE5),
recent expert opinion recommends they should be left untreated and
monitored, but no data exist on the safety and effectiveness of this
approach. To ﬁll this gap, we report our experience with long-term
sonographic monitoring of inactive cysts.
Methods: Records of patients who presented at our clinic and were
diagnosed with inactive echinococcal cysts of the liver were searched.
Inclusion criteria for the retrospective evaluation were:
– presence of cysts exclusively in inactive stage at the time of diagnosis;
– follow-up with abdominal ultrasound performed every 6 or 12 months;
– minimal length of follow up: 24 months.
For each patient demographic details, number and location of the cyst
within the liver, complications, if any, were obtained.
Results: From March 1994 to March 2010, 68 patients with exclusively
inactive liver cysts were seen in our clinic, but 38 were excluded because
their follow-up period was shorter than 24 months. Of the 30 patients
who met the inclusion criteria, 14 were males and 16 females (mean age
at time of diagnosis 48, range: 14−86), harbouring a total of 38 cysts.
Twenty-two patients harboured 1 cyst each, 8 patients harboured 2 cysts
each. 29 cysts were located in the right lobe, 2 in the left lobe and 7 in
the fourth segment. Nineteen patients were diagnosed with inactive cysts
at our clinic, while 11 were diagnosed in other centres. The mean follow-
up period was 79 months (range: 25–453) and in 29 patients (97%) the
cysts remained in inactive stage (reactivation occurred only in 1 patient
during follow-up).
Conclusion: The idea of leaving certain cyst types untreated is the
consequence of the observation that a proportion of cysts become
completely inactive, without any treatment, and cysts that reached this
stage are likely to remain inactive. Our experience conﬁrms that watch
and wait is a viable management option for inactive liver cysts.
O488 The United Kingdom National External Quality Assessment
Service (UKNEQAS) for parasitology: will the participants
never learn?
M. Manser*, A. Saez, P. Chiodini (London, UK)
Objectives: In 2003 we examined performance in UKNEQAS Parasitol-
ogy for evidence of improved standards in parasite diagnosis in clinical
specimens and found that although there was an overall improvement,
the study still highlighted problem areas in both faecal and blood
parasitology. (1)
Methods: Performance of Blood and Faecal Parasitology Schemes was
analysed from 2003 to2011 in particular those areas of concern that
were established in the 2003 study. The problem areas identiﬁed in
the faecal parasitology scheme were difﬁculty in recognising small
protozoan cysts, differentiating vegetable matter from parasites and
detecting ova and cysts when more than one species is present. In the
blood scheme, participants had problems in identifying mixed malarial
infections, distinguishing between P ovale and P vivax, and estimating
the percentage parasitaemia.
Results: In this study, it was noted that although performance continues
to improve for the detection of one parasite present in a specimen, it has
not improved in the aforementioned problem areas despite the teaching
sheets targeting these areas.
Conclusion: This study showed that participants continue to have
problems in faecal parasitology with recognizing small protozoan cysts,
differentiating vegetable matter from parasites and detecting ova and
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cysts when there is more than one species present. In Blood parasitology
participants continue to have difﬁculty in differentiating the malaria
species, estimating the percentage parasitaemia and identifying mixed
malaria infection. This is despite the educational aspect of the UK
NEQAS Parasitology Schemes.
O489 Discordance with World Health Organization 2009
admission criteria in outpatient conﬁrmed adult Dengue
patients in Singapore
V. Gan*, T.L. Thein, F. Dimatatac, D. Lye, Y.S. Leo (Singapore, SG)
Objectives: World Health Organisation (WHO) 2009 dengue guidelines
classiﬁed non-severe dengue with and without warning signs and severe
dengue as alternatives to WHO 1997 criteria of dengue fever, dengue
haemorrhagic fever (DHF) and dengue shock syndrome. Hospitalisation
is recommended for patients with warning signs or severe dengue. We
aim to assess their utility in our prospective adult dengue study.
Methods: Adults with undifferentiated febrile illness referred to
Communicable Disease Centre were recruited prospectively. Dengue
polymerase chain reaction and non-structural protein-1 antigen testing
was performed. Positive cases (n = 62) were managed daily until recovery.
We analysed cases requiring only outpatient care.
Results: Males comprised 84% with a mean age of 33.7 years (range
20−54 years); 98% of subjects had no co-morbidities. Cases were
followed up for a mean of 3.2 days (range 1−5 days). All fulﬁlled
WHO 2009 clinical deﬁnition of probable dengue, while 88% fulﬁlled
WHO 1997 deﬁnition. None had DHF. Warning signs (WHO 2009) in
order of frequency at presentation were: lethargy (98%), mucosal bleed
(30%), abdominal pain/tenderness (13%), persistent vomiting >3/day
(3%), with no incidence of clinical ﬂuid accumulation, hepatomegaly
or haematocrit 20% above baseline with platelet <50000/mm3. All had
at least one warning sign; if lethargy was excluded this dropped to
38%. There was one case of severe dengue with transaminases >1000
units/L. Of two cases with possible severe bleeding, one with a history
of melaena was not corroborated on examination or investigation, and
one with menorrhagia was well-controlled on progesterone. All cases
had complete resolution of symptoms, signs and laboratory parameters
at convalescent follow-up on day 21−30.
Conclusions: In our cohort of outpatient conﬁrmed adult dengue
patients, at least 38% with one or more warning signs would have been
hospitalised under WHO 2009 guidelines. Three cases of severe dengue
were appropriately managed as outpatients. None was identiﬁed as DHF
by WHO 1997 criteria. We propose that current WHO 2009 guidelines
may lead to over-hospitalisation and suggest further reﬁnement to
optimise scarce clinical resources.
O490 Adventure tourism and schistosomiasis: serology and clinical
ﬁndings in a group of Danish students after white-water
rafting in Uganda
D. Ro¨ser*, S. Bjerrum, M. Helleberg, L. Abel, H.V. Nielsen, K. David,
S. Thybo (Copenhagen, Nakskov, DK)
Objectives: Returning travellers with schistosomiasis are known to
present few if any symptoms, especially if the infection is light. In
July 2009 a group of Danish students travelled to Uganda, where
they participated in white-water rafting and swimming on the river
Nile (Jinja). Upon return a single person sought medical attention for
symptoms developed (macroscopic haematuria), and was found to have
eosinophilia as well as schistosoma-antibodies. Subsequent testing of
the entire group revealed a large number of sero-positives, all with no
previous history of schistosomiasis. The objective of this study was to
describe serology and clinical ﬁndings in a group of returning travellers,
with possible exposure to Schistosomiasis.
Methods: From each patient 2 serum-samples were collected, with
1 sample collected later than 3 months after exposure. Serology
was performed using IFAT for Gut Associated Antigen (GAA) and
Membrane Bound Antigen (MBA). 24-hour urine-samples were collected
from 33 out of 40 patients and examined using microscopy. A patient-
response questionnaire was sent to the group to address exposure, travel
behaviour and patient experienced symptoms. Medical records were
retrieved to access laboratory results, physician noted symptoms and
clinical ﬁndings.
Results: 36/40 patients were exposed to fresh water (rafting and/or
swimming), 14/36 developed a positive serology (positive GAA and/or
MBA) in the follow-up period (1 year), and 4/14 sero-converted later
than 2 months. 3/14 developed a positive MBA before GAA, and
1 MBA-positive patient never developed GAA. No schistosoma eggs
were found in the urine samples, and 4/14 had eosinophilia. In the
questionnaire 12/14 reported symptoms upon return, mainly GI-related
symptoms interpreted by patients as travel diarrhoea, and 5/14 reported
fever. Medical records showed that only 1/14 (index patient) had multiple
symptoms (3, non-GI) clinically consistent with Katayama fever, and
physical examination of all patients were with normal ﬁndings. Higher
degrees of exposure (swimming) showed a trend towards higher risk
of sero-conversion. All sero-positive patients were offered and received
treatment with praziquantel 40mg/kg.
Conclusion: Even brief exposure to fresh water in schistosoma-endemic
regions can carry a high risk of infection, in some cases with late
development of antibodies, and overall few or misinterpreted symptoms.
O491 Multilocus sequence typing of Blastocystis sp. subtype 3
C. Stensvold*, C.G. Clark (Copenhagen, DK; London, UK)
Objectives: Blastocystis is possibly the most common non-fungal
eukaryotic organism found in the human intestinal tract. Its clinical
signiﬁcance is not settled. It is possible that variation in the clinical
outcome of Blastocystis carriage is linked to differences in genetic make-
up of the parasite, which, based on SSU rDNA analysis, comprises
at least 9 subtypes (STs) in humans. Aims of this study included
the development of a MLST assay for the most common subtype of
Blastocystis, ST3, and its application to the analysis of ST3 strains from
humans and non-human primates.
Methods: Three genomes from mitochondrion-like organelles of ST3
strains were sequenced and aligned to identify candidate MLST loci.
Five suitable loci were chosen and 82 ST3 strains, 26 of which were
from patients with irritable bowel syndrome (IBS) and 13 of which were
from non-human primates, were analysed. Concatenated sequences were
analysed using phylogenetic methods and allele frequency distribution
was analysed using the Arlequin software.
Results: The MLST assay had a discriminatory index of 0.996 and
was able to differentiate 70 sequence types (SQTs) among 82 samples.
Phylogenetic analysis showed that concatenated sequences segregated
into two clades supported by high bootstrap values. One clade contained
7 non-human primate strains and 1 from a monkey handler. The other
clade comprised all other human strains and 6 non-human primate
strains. Signiﬁcant differences in allele distribution were associated
not only with host species, but to some extent also with differences
in clinical status. Hence, the nad4 locus allele frequency distribution
differed signiﬁcantly between random patients and patients with IBS.
Conclusion: A robust and highly discriminatory MLST for ST3 was
developed. Extensive genetic diversity in the MLO genome is not
reﬂected at the SSU rDNA level. At least two major clades exist within
ST3, and one of them appears to be restricted mainly to samples of non-
human origin. Evidence of zoonotic transmission was uncovered. Future
studies should aim at developing MLST assays for the other common
STs in humans, identifying differences in alleles that may be useful for
predicting both patterns of transmission and potential links to intestinal
symptoms.
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O492 Anti-Wolbachia antibodies and acute lymphadenopathy in
lymphatic ﬁlariasis
E.M. Salvana*, K. Gentil, A. Hise, E. Pearlman, F. Hazlett, J. Kazura
(Manila, PH; Cleveland, US)
Background: Lymphatic ﬁlariasis (LF) afﬂicts 120 million people.
While the most profound images of LF are elephantiasis and
hydrocoele, acute disease in the form of lymphadenopathy, malaise and
fever collectively termed adenolymphangitis (ADL) causes signiﬁcant
economic disenfranchisement and suffering in resource poor areas. The
pathogenesis of acute LF is not well understood but the endosymbiont
Wolbachia has been implicated, and has been shown to activate toll-like
receptors. This study aims to examine adaptive immunity to Wolbachia
and whether this affects development of acute disease.
Methods: Two studies were formulated using a pool of banked sera
from a previous Mass Drug Administration (MDA) study in Papua New
Guinea from 1993–1998. The ﬁrst study looked at anti-WSP levels in
individuals with a recent (within 30 days) ADL event using a case
control design with age and sex-matched endemic controls. The second
study was a retrospective cohort which looked at anti-WSP levels in
longitudinal sera over a 6-year period with ADL as the primary outcome.
ELISA using recombinant Wolbachia surface protein (WSP) was used to
detect anti-Wolbachia antibodies. ELISA to detect anti-ﬁlaria antibody
against crude Brugia antigen (BmA) was also performed.
Results: Antibody levels against WSP for the ADL group in Study 1
were signiﬁcantly lower than the non-ADL group (p = 0.0006). Anti-
BmA levels were not signiﬁcantly different. In Study 2, anti-WSP
levels in the pretreatment year were signiﬁcantly lower (p = 0.0016)
for those who developed ADL within the six year period. Odds ratio
of developing ADL was 3.31 (p = 0.011) for an anti-WSP level lower
than the median of the ADL group in the pretreatment year. Anti-WSP
levels in succeeding sera in the subsequent treatment years were not
signiﬁcantly different between groups. Antibody levels for the entire
cohort signiﬁcantly increased from the pretreatment year to the post-
treatment year (p = 0.0363). Anti-BmA levels were not signiﬁcantly
different between groups for all blood draw years.
Conclusion: Individuals exposed to LF with low anti-Wolbachia WSP
antibody titers have a signiﬁcantly higher risk of developing acute
lymphadenopathy. This relationship holds whether the ADL event is
recent or over six years. MDA results in a signiﬁcantly higher anti-
WSP antibody titer over time. These ﬁndings support an association
between the pathogenesis of acute LF and adaptive immune response to
Wolbachia endosymbionts.
O493 Protection against diarrhoea and fever without localising
signs associated with asymptomatic Giardia lamblia infection
is lost with multi-nutrient supplementation: a prospective
study among rural Tanzanian children
T.G. Mank*, J. Veenemans, R. Olomi, J. Wielders, H. Savelkoul,
H. Verhoef (Haarlem, Wageningen, NL; Moshi, TZ; Amersfoort, NL;
London, UK)
Objective: Asymptomatic infections with Giardia lamblia are common
among children in developing countries, but the role of giardiasis
as cause of diarrhea in such settings has been questioned. Impaired
linear growth and cognition have been associated with giardiasis,
presumably mediated by malabsorption of nutrients. In a prospective
cohort study, we aim to compare rates of diarrhea in pre-school
children with and without Giardia infection. In addition, we assessed
how micronutrient supplementation inﬂuenced the relationship between
Giardia and diarrhoea rates, and to what extent Giardia modiﬁes the
effect of supplementation on nutritional status.
Methods: Data were collected in the context of a randomized placebo-
controlled trial with 2x2 factorial design assessing the effects of multi-
nutrients (with or without zinc) on morbidity. Children (N= 612, aged
6−59 months and height-for-age z-score −1.5 SD) from a poor rural
area were followed for at least 7.4 months after enrolment. Outcome
measures were episodes of diarrhea and fever without localizing signs,
as detected by clinic-based surveillance. G lamblia was detected in
stool samples by enzyme-linked immunosorbent assay. Multivariate Cox
regression analysis was used to compare disease rates between groups,
and to assess interaction effects.
Results: Asymptomatic Giardia infection was associated with a
substantial protection against diarrhea (HR 0.32; 0.15–0.66) and fever
(HR 0.56; 0.36–0.87), but only so among children who dit not receive
multinutrients; no such protection was observed among children who
received multi-nutrients (p-values for interaction between G. lamblia and
multi-nutrients 0.03 for both outcomes, after adjustment for age, HAZ
scores and distance to the dispensary.
Conclusions: Although causality af the Giardia-associated reduction in
morbidity cannot be established, the data also show that multi-nutrient
supplements neutralise this protection and are thus likely to inﬂuence the
proliferation or virulence of G lamblia or associated intestinal pathogens.
O494 The occurrence of Demodex spp. in blepharitis patients and
healthy people a 3-year observational study
M.M. Biernat*, J. Rusiecka-Zio´lkowska, J. Grabinska, E. Piatkowska,
I. Helemejko, A. Kania, G. Gosciniak (Wroclaw, PL)
Objectives: Two species of Demodex: D. folliculorum and D. brevis
are supposed to be correlated with human skin and ocular diseases.
However the clinical signiﬁcance of Demodex spp. infection remains
still controversial, partially because single parasites can be found in
asymptomatic subjects. The aim of the study was to estimate the
prevalence of Demodex infection in patients with blepharitis and healthy
population in correlation to patients’ characteristics.
Methods: The study was carried out in years 2007–2010. The enrolled
patients were divided in two groups: the ﬁrst consisted of 544 patients
(362 women and 182 men, aged from 5−88 years) with blepharitis,.
The control group was composed from 100 healthy individuals (78
women and 22 men, aged from 17 to 88 years) without history of ocular
pathologies. A sample of 6−10 eyelashes was taken aseptically from each
eye of examined person and later studied under a light microscope. The
host factors, such as: sex, age, history of facial rosacea, ocular symptoms
like: itching, redness, blurred vision and pain in eyes were documented.
The determination of 4−5 Demodex spp. was accepted as positive.
Results: Demodex spp. was found in 58,45% (318/544) of patients
in ﬁrst group and in 24% (24/100) of controls. The difference was
statistically signiﬁcant, indicating that incidence of ocular Demodex
infestation was much higher in ﬁrst group compared to controls
(p = 0,001, OR= 0,006). The overall prevalence was 51,10% (342/644) in
all examined subjects. Among patients with blepharitis and demodicosis,
8,8% (28/318) had history of facial rosacea. The presence of Demodex
infection increased with age in both groups, whereas the highest
prevalence was noted in subjects >65 years 75,7% in ﬁrst group and
43,3% in controls, respectively. A signiﬁcant correlation for Demodex
infection was found between males and females (104/204 vs 241/440,
p< 0,05).
Conclusion: The prevalence of ocular demodicosis is signiﬁcantly
correlated with blepharitis and increases with age. The incidence of
Demodex infection is higher in women than in men. Considering long
and difﬁcult treatment of chronic demodectic blepharitis, there is need to
develop the clear diagnostic standards for recognizing Demodex infection
of the eye.
O495 Mitochondrial phylogenetic analysis of Portuguese samples
of Echinococcus granulosus
S. Beato*, R. Parreira, M. Calado, M.A. Gra´cio (Lisbon, PT)
Introduction and Objectives: Hydatidosis is a worldwide zoonosis
caused by the larval stage of the tapeworm Echinococcus granulosus.
The taxonomy and phylogeny of the genus Echinococcus has been a
controversial issue for several years but with the use of molecular tools
has helped the characterization of this parasite. As a result, a new
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classiﬁcation has been proposed, and is now widely accepted. The aim
of this work was to determine the range of genetic variability within,
and between, Portuguese E. granulosus isolates.
Methods: The Portuguese isolates obtained from sheep, goat and cattle
were characterized using mitochondrial COI, ATP6, CYTB, NDI 12S and
16S partial gene sequencing. The sequences were aligned and compared
with those present in the GenBank using a molecular phylogenetic
approach.
Results: Preliminary results showed that the Portuguese isolates were
E. granulosus sensu stricto (G1-G3 cluster). In addition, phylogenetic
analysis of E. granulosus isolates, using the partial nucleotide sequence
of several mitochondrial markers was performed using neighbour-joining
(Kimura 2-parameter correction) and Bayesian analyses.
Conclusion: The ﬁndings showed some degree of variance within single
isolates and a signiﬁcant degree of variance between the cluster G1-G3,
where our isolates were, and the other Echinococcus sp. Despite the
variance found among Portuguese isolates, they were all localized within
one robust cluster.
Fundings: Unidade de Parasitologia e Microbiologia Me´dicas and
SFRH/BD/60408/2009
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O496 Differential risk of Clostridium difﬁcile infection with Proton
pump inhibitor use by level of antibiotic exposure
V. Stevens*, G. Dumyati, J. Brown, E. van Wijngaarden (Buffalo,
Rochester, US)
Objectives: Clostridium difﬁcile Infection [CDI] is a major cause of
hospital-acquired diarrhea worldwide. The objectives of this study were
to determine the risk of CDI associated with the use of acid suppressive
agents (proton pump inhibitors [PPI] and Histamine-2 receptor [H2]
blockers), and to determine whether this risk varies by number or type
of antibiotic (high or low CDI risk) received during hospitalization.
Methods: Retrospective cohort study of hospitalizations among adult,
non-psychiatric patients at a tertiary academic teaching hospital in
Rochester, New York, US during which two or more days of antibiotics
were prescribed. Data on pharmacologic exposures and outcomes
were obtained from pharmacy and microbiology records. Multivariable
marginal Cox proportional hazards models with time-varying exposures
were used to examine time to the development of CDI while controlling
for the effects of potential confounders.
Results: 10,154 hospitalizations and 241 cases of CDI, deﬁned as
detection of C. difﬁcile toxin in a diarrheal stool sample within 60
days of discharge, were identiﬁed. PPI and H2 blockers were prescribed
during 6,322 (62%) and 1,083 (11%) of hospitalizations, respectively.
PPI use was associated with an increased risk of CDI (adjusted hazard
ratio [HR] 5.5, 95% conﬁdence interval [CI]=3.0–10.3) independent
of number and class of antibiotics and other medications received.
Among hospitalizations during which one, two, three or four, and
ﬁve or more antibiotics were prescribed, the adjusted HRs for PPI
use were 20.6 (CI=8.8–48.1), 6.4 (CI=3.0–13.4), 4.9 (CI=2.3–10.7),
and 2.9 (CI=1.3−6.4), respectively (p for interaction <0.01). Among
hospitalizations during which patients received high risk antibiotics, PPI
use was associated with a 3.7-fold (CI=1.6−8.6) increase in risk of CDI,
but among those that received low risk antibiotics that estimate increased
to 50 (CI=18.9–132.0) (p for interaction <0.0001). H2 blockers were not
associated with increased risk of CDI (HR 1.7, 95%CI=0.7−4.1) and
there was no evidence of interaction.
Conclusions: The prescription of PPI is common among patients
receiving antibiotics during hospitalization. The greater risk of CDI
in relation to PPI among hospitalizations during which fewer or low-
risk antibiotics were prescribed suggests a potentially clinically relevant
interaction between antibiotics and PPI. Further study is needed to
elucidate possible mechanisms for the observed effect.
O497 The changing epidemiology before, during and after an
outbreak of CD027 in Denmark
B. Olesen*, K.E. Olsen, R.L. Andersen, D.S. Hansen, M. Thorpdal,
S. Bacci, B.G. Bruun (Hillerød, Copenhagen, DK)
Objectives: To describe the changing epidemiology before, during and
after the ﬁrst large outbreak of Clostridium difﬁcile infection with PCR
ribotype 027 (CD027) in Denmark.
Methods: All stool samples from patients with diarrhea from October
1, 2008 to November 30, 2010 from four hospitals located north of
Copenhagen were examined for C. difﬁcile. Detection was done by
culture and production of toxin A and B using ImmunoCard (Meridian),
and from May 2009 by a real-time PCR directly on stool samples,
demonstrating both the tcdC gene and deletions of 18 bp and 39 bp.
The antibiotic susceptibility to 6 antibiotics was tested by agar diffusion
using discs (Oxoid). C. difﬁcile isolates resistant to moxiﬂoxacin and/or
deletion positive by PCR were further characterized by determining the
genes for toxin A, toxin B and the binary toxin and by PCR ribotyping.
Recurrence was deﬁned as the detection of C. difﬁcile a minimum of 4
weeks later than the ﬁrst positive sample.
Interventions: National, regional and local surveillance of CD027; focus
on hand washing prior to disinfection; on-line registration of all isolated
patients; daily disinfection of rooms with chlorine-containing agent was
introduced; focus on reduced use of ﬂuoroquinolones; and localisation
of where the patient was infected.
Results:
• 593 cases (ﬁrst episodes) of diarrhea due to C. difﬁcile were found,
of which 94% were detected in hospitalized patients. In total, 36%
of isolates were deletion negative, 55% were deletion positive (35%
CD027, 4% CD078, 2% CD66, 1% other PCR ribotypes and 13%
were unculturable, wherefore PCR ribotyping could not be done), and
9% were not primarily examined with PCR
• 38% of patients with CD027 had one or more recurrences versus
18% of patients with deletion negative CD, p< 0.00005. No signiﬁcant
difference was found between the number of recurrences caused by
CD027 (38%), CD078 (27%) and CD66 (33%)
• The percentage that CD027 constituted of all CD cases per month
reached a peak May 2009, and declined hereafter
Conclusion:
• The epidemiology of C. difﬁcile changed during the study period.
When CD027 declined, the number of deletion negative isolates began
to increase and there also was a tendency towards a rise in the number
of cases with CD078 and CD066 (both deletion positive)
• Signiﬁcantly more recurrences were found among the deletion positive
isolates
• Surveillance ought to comprise all toxin-producing C. difﬁcile, even
in an outbreak situation
O498 Community versus healthcare-associated Clostridium difﬁcile
infection: a surveillance-based study
N. Khanafer*, T. Benet, P. Vanhems (Lyon, FR)
Context: C difﬁcile disease is mainly considered as a nosocomial disease
associated with broad-spectrum antibiotics. Since early 2003, both the
incidence and the severity of CDI appear to have increased. Recently, C
difﬁcile infection (CDI) has been reported outside health care institutions
in persons previously thought to be at low risk.
Objective: To characterize epidemiological of patients with CDI
regarding the infection presumed acquired in the community or in the
hospital.
Design, Setting, and Patients: Between November 2006 through
August, 2010, a prospective surveillance study of CDI was conducted in
French University Hospital. A case of healthcare-associated CDI (HCA-
CDI) is deﬁned as one in which symptom onset occurs more than 48 h
after admission to, or within 4 weeks of discharge from, a healthcare
facility. A case of community-associated CDI (CA-CDI) is deﬁned as
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one in which symptom onset occurs within 48 h of admission and over
4 weeks following discharge from a healthcare facility
Results: Of 218 cases of CDI, 65 (29.8%) were CA-CDI and 153
(70.2%) were HCA-CDI. The mean age of patients was 66 and 65.3
years in CA and HCA cases respectively (P = 0.8) and 7.8% of CA cases
were under 20 years. In CA cases, women were more frequent (66.7%
vs 48.4% in HCA-CDI, P = 0.02). CA group had lower rate of recent
antimicrobial exposure (47.5% vs 81.3% in HCA cases, P< 0.001) whilst
showing higher rate of severity compared to HCA group (41% and 9.4%
respectively, P< 0.001). Colitis related to CDI was observed in 6 cases
(9.2%) of CA-CDI and in 9 cases (5.9%) of HCA-CDI.
Conclusions: We found that approximately 30% of all CDI cases
were CA and most of half was not exposed to antimicrobial drugs,
a classical risk factor of CDI. Monitoring and active surveillance of
C. difﬁcile infection is needed continually improve our understanding of
the changing epidemiology of the disease.
O499 Investigation of outcome in cases of Clostridium difﬁcile
infection due to isolates with reduced susceptibility to
metronidazole
J. Purdell, W. Fawley, J. Freeman, M. Wilcox* (Leeds, UK)
Objectives: Reduced susceptibility to metronidazole (RS-M) among
epidemic C. difﬁcile (CD) PCR ribotypes has been reported in recent
years. We have examined clinical outcomes for CDIs caused by strains
with RS-M and compared these with data for matched controls.
Methods: 22 RS-M CD (MICs 4mg/L) were identiﬁed from patients
CDI in Leeds, UK, between December 2005 and November 2006.
Clinical outcome data were compared for these cases with those for
controls (22 patients, CD MIC 0.5−2.0ml/L, matched for age, sex,
hospital location and CD PCR-ribotype (001), by retrospective searching
of medical and electronic records. Differences between cases and
controls in terms of death by day 30 (from time of positive cytotoxin
test), rate of recurrence, and need for vancomycin therapy were assessed
by McNemar’s test; days from treatment to resolution of symptoms were
compared by paired t test.
Results: 3 RS-M cases and 3 controls were excluded due to
unavailability of clinical data. No signiﬁcant differences were observed
between cases and controls for demographic variables (median age: 82 vs
81 years; mean days from symptoms to specimen taken: 4.0 vs 3.8; mean
number of cytotoxin-positive specimens in previous 12 months: 0.4 vs
0.4; 74% of cases and 68% of controls were male. 16% (n = 3) patients
with CDI due to RS-M were dead by day 30 vs 21% (n = 4) controls
(p = 1.00). In M-treated patients, there was no difference between RS-M
CDI cases and controls for number of days from treatment to symptom
resolution (mean days: 8.0 vs 7.3, range 1−16; p = 0.75). 16% (n = 3)
patients with RS-M associated CDI had a recurrence compared with 26%
(n = 5) control patients (p = 0.69). Equal numbers (n = 3) of cases and
controls received supplementary vancomycin (V) treatment (p = 1.00).
Conclusions: Despite evidence of RS-M in epidemic CD isolates, we
found no signiﬁcant differences in clinical outcome for cases (RS-M CD)
vs matched controls (M-susceptible CD). Response to metronidazole was
generally poor (slow and prone to recurrence). Notably, patients were
typically elderly and frail with very poor outcome (21% mortality rate
by day 30). Previous M treatment in most patients who then received V
precluded conclusions regarding V efﬁcacy. Much larger study groups,
ideally with less frail patients, are needed if the true clinical signiﬁcance
of CD isolates with RS-M is to be delineated.
O500 Success of a national service, Clostridium difﬁcile Ribotyping
Network for England & N. Ireland (CDRN), to help control
epidemic strains and incidence of C. difﬁcile infection
M. Wilcox*, W. Fawley, M. Shemko, P. Coen, A. Birtles, E. Bolton,
M. Curran, S. Green, D. Fairley, K. Hardy, P. Hawkey, P. Hawtin,
J. Magee, B. Patel, A. Sails, N. Shetty, E. Walpole, M. Wren on
behalf of the Clostridium difﬁcile Ribotyping Network for England &
N. Ireland (CDRN)
Objectives: To describe the key epidemiological ﬁndings concerning
C. difﬁcile infection (CDI) in England in 2009−10 versus the previous
two years as determined by The Clostridium difﬁcile Ribotyping Network
for England and N. Ireland (CDRN).
Methods: CDRN provides ribotyping and enhanced DNA ﬁngerprinting
to identify cross-infection, reduce transmission, optimise management
of outbreaks and determine the epidemiology of C. difﬁcile.
Results: In 2009/10 CDRN processed 5,720 faecal samples from 172
healthcare facilities, which was a 22% increase over 2008/09 when
4,682 samples were received 190 healthcare facilities. Thus, on average
33 and 25 samples were submitted to CDRN by each participating
hospital in 2009/10 and 2008/09, respectively. The number of reports of
C. difﬁcile recorded by the mandatory scheme in England has decreased
from 55,498 to 36,095 to 25 604 (in the ﬁnancial years 07/08, 08/09 &
09/10). Submissions to CDRN have continued to increase year-on-year;
in 2009−10 almost a quarter of the C. difﬁcile cases in England were
submitted for ribotyping by the CDRN. Marked changes in ribotype
prevalence have occurred in the 3 years since CDRN was launched
in 2007 (Table). There was a striking decrease in the prevalence of
C. difﬁcile ribotype 027 (from 55% to 36% to 22%), with ‘compensatory’
increases in the other main types, including ribotype 078. Ribotype
106 has also declined markedly. There was a signiﬁcant association (in
univariate and multivariate analyses) between all cause mortality and CD
027 (OR= 1.9; p< 0.001).
Conclusions: Since CDRN was introduced in 2007 there has been a
marked decrease in incidence of CDI and associated deaths in England.
The changes coincided with a 60% decrease in the relative prevalence of
ribotype 027 cases. The improvements may reﬂect the success of control
measures to reduce cross-infection in hospitals caused by epidemic
strains. Access to timely typing data is important for infection control
teams to identify and control transmission of C. difﬁcile.
O501 Does C. difﬁcile infection per se or other factors lead to
death in severe disease
J. Leitner*, D. Schmid, H. Kuo, F. Allerberger, P. Tesik, V. Michl,
C. Wenisch (Vienna, AT)
A prospective hospital-based cohort study was performed for analysing
the effect of infection with C. difﬁcile (CDI) on the risk of death in
185 hospitalized patients with CDI (CDI patient) compared with all the
other hospitalized patients (non-CDI patient, n = 38644). The outcome of
interest was pre-discharge mortality. The measures of the effect of CDI
on risk of pre-discharge death were risk ratio, attributable risk (i.e. excess
mortality per 100 hospitalized patients) and mortality fraction (%).
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Death risk ratio was calculated by death risk in the CDI-patients
(exposed group)/death risk in non-CDI-patients (non-exposed group)
and the attributable risk of death (attributable mortality) was calculated
death riske − death risku. The attributable risk percent, AR% (mortality
fraction) was calculated by AR% = 100×(death riske − death risku)/
death riske. The Population attributable risk percent (PAR%) was calcu-
lated by PAR% = 100×(death risk total − death risku)/death risk total.
The difference in risk of death was calculated by using Chi-squared test
or Fisher’s exact test. A stratiﬁed analysis and a poisson regression model
were applied to adjust the relative and attributable risk of death for sex,
age and co-morbidity using Charlson Index. In the CDI group mean
age was 74.3 yrs (72.3–76.4) versus 51.9 yrs (51.6–52.1) in the non CDI
group; and low/high comorbidity was 136 (73.5%)/49 (26.5%) versus
32107 (83.5%)/6352 (16.5%), respectively. 153 (82.7%) were health-
care-facilities associated cases, 27 (14.6%) community associated cases
and 5 (2.7%) were of unknown origin. Independent risk factors for
death were age (<65/>65: adjusted RR 5.15; 95%CI 4.44–5.98), sex
(m/f: RR 1.21; 95%CI 1.07–1.36) Co-morbidity (moderate+severe/low:
RR 2.24 95%CI 1.97–2.54) and CDI (CDI : Non-CDI: RR 2.74 95%CI
1.82–4.10).
Compared with all the other hospital patients the absolute risk of pre-
discharge death in hospital patients with CDI due to CDI is 10.3/100
individuals, regardless of the co-morbidity. Thus, removing CDI would
result in 79.2% reduction of hospital mortality in this patient group. Only
20% of hospital patients with CDI, who die during hospital stay, will
die due to other reasons than CDI. The PAR% due to CDI in the total
hospital population of the study hospital was found to be insigniﬁcant.
Therefore, elimination of CDI from the study hospital not impact the
hospital mortality in this hospital.
O502 A national enhanced DNA ﬁngerprinting service to
investigate potential C. difﬁcile infection case clusters
sharing the same ribotype
M. Wilcox*, W. Fawley on behalf of the Clostridium difﬁcile Ribotyping
Network for England and N. Ireland (CDRN)
Objectives: To describe the use of the centralised enhanced DNA
ﬁngerprinting service of the CDRN for the investigation of potential CDI
case clusters sharing the same ribotype. To determine the likelihood that
clusters of cases sharing the same ribotype are found be highly related/
indistinguishable using multi-locus variable number of tandem repeat
analysis (MLVA).
Methods: We investigated potential case clusters (deﬁned as patients
related in time and/or place yielding isolates with the same ribotype)
submitted to CDRN from institutions in England. Enhanced DNA
ﬁngerprinting was carried out using MLVA. Case clusters were deﬁned
according to the summed total of tandem repeats between isolates
(STRD). Cases with isolate STRD 2 were considered to be related
(REL); conversely, if isolates were clearly distinguishable than cases were
not related (NOT REL); case clusters containing both highly related and
clearly distinguishable isolates were termed mixed (MIX).
Results: Between 2008–210 we investigated 279 C. difﬁcile isolates from
54 potential CDI case clusters (2−41 patients) in 27 institutions that
shared one of 10 ribotypes (001, 005, 014, 014, 017, 023, 027, 078, 106,
277). The most common ribotype investigated was 027 (192 isolates in
32 case clusters). Of the 54 case clusters, 24 (44%) and 17 (32%) were
found to be REL and MIX, respectively. Of the NOT REL potential case
clusters, 8/13 were caused by ribotype 027 isolates.
Conclusions: Despite suspicion of case clustering, enhanced DNA
ﬁngerprinting by MLVA determined that in 24% of instances isolates
sharing the same ribotype, including epidemic 027 strains, were not
related. These ﬁnding emphasise the value of MLVA to conﬁrm or
refute case clusters. Access to timely typing and ﬁngerprinting data is
important for infection control teams to identify and control transmission
of C. difﬁcile.
O503 Time-interval of increased risk for Clostridium difﬁcile
infection after exposure to antibiotics
M.P. Hensgens*, A. Goorhuis, O.M. Dekkers, E. Kuijper (Leiden, NL)
Objectives: Clostridium difﬁcile infections (CDI) are common in
developed countries and affect more than 25,000 people annually in
England and 250,000 in the United States. The most important risk factor
for the disease is antibiotic therapy. Development of CDI is associated
with certain antibiotic classes (e.g. cephalosporins and clindamycin), the
number of antibiotics used, their dosage and the duration of therapy. The
exact time-interval of increased risk for CDI after exposure to antibiotics
is however unknown.
Methods: A case-control study was performed in nine hospitals in the
Netherlands. Each hospital participated for a minimum of six months
between March 2006 and May 2009. Hospitalized patients with diarrhoea
and a positive test for the toxin of Clostridium difﬁcile (CDI patients)
were matched on hospital, ward and time of diagnosis to patients
without diarrhoea (non-diarrhoeal). Besides antibiotic classes, number
and quantity of antibiotic therapy as risk factors for CDI, we evaluated
the time-interval of increased risk for CDI after exposure to antibiotics
by means of a conditional logistic regression.
Results: In total, 362 CDI patients and 348 non-diarrhoeal patients
were included in the analysis. All antibiotic classes, except for ﬁrst
generation cephalosporins and macrolides, were signiﬁcantly associated
with CDI. Cephalosporins and carbapenems were the most potent risk
factors for CDI. Patients with CDI used a larger amount of antibiotics
and more antibiotic classes, compared to non-diarrhoeal patients. At time
of diagnosis, CDI patients more frequently used an antibiotic compared
to non-diarrhoeal patients (36% vs. 24%). During antibiotic therapy and
the ﬁrst month after cessation of the therapy, patients had a six to ten fold
increased risk for CDI. This risk declined in the period between one and
three months after the antibiotic was stopped (OR 2.72; 95%CI: 1.20 to
6.15).
Conclusion: Antibiotic use increases the risk for CDI during therapy
and in the period of three months after cessation of antibiotic therapy.
A six to tenfold higher risk is found in the ﬁrst month after cessation of
the antibiotic.
O504 Immunosuppression and the risk of death, cure rates and
disease recurrence among patients with Clostridium difﬁcile
infection
Y. Golan*, K. Mullane, T. Louie, M. Miller, K. Weiss, A. Lentnek,
Y. Kean, Y.K. Shue, S. Gorbach (Boston, Chicago, US; Calgary,
Montreal, CA; Georgia, San Diego, US)
Objectives: CDI is emerging in hospitals and is associated with
substantial morbidity and cost of care. It is associated with increasing
frequency of treatment failure and mortality. While some microbial
factors, such as the BI/NAP1 strain, are linked to more severe CDI,
the relation between the host immune status and CDI outcome is less
clear. We examine the role of immunosuppression (IS) on CDI outcome.
Methods: We used data from 2 large, randomized phase 3 clinical trials
in which adults with CDI symptoms and a positive toxin test received oral
ﬁdaxomicin or vancomycin for 10 days. IS was characterized according
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to its severity, and type. The net state of IS, encompassing host and
iatrogenic factors, was calculated. The independent effect of IS on CDI
outcome was assessed using multivariate analysis.
Results: Of the total of 1105 patients in the mITT population, treatment
failure, death and CDI recurrence rates were observed in 13%, 7% and
20%, respectively. Mortality was higher among those with a net state
of IS (11% vs 3%; p< 0.01), those receiving any IS medications (9%
vs 6%; 0.04) and speciﬁcally systemic steroids (14% vs 5%; <0.01),
moderate or high-dose steroids (25% vs 5%, <0.01), and those with
neutropenia (16% vs 6%; 0.01). In those with a non-BI/NAP1 strain,
92% of all deaths occurred among IS patients. Mortality was lowest
among immunocompetent patients infected with a non-BI/NAP1 strain
(0.6%). CDI cure rates were lower among immunosuppressed patient
and particularly among those receiving moderate or high-dose steroids
(75% vs 88%; <0.01). IS was not associated with CDI recurrence.
In a multivariate analysis, IS remained independently associated with
higher mortality and a lower cure rate. Cure and mortality rates were
similar between ﬁdaxomicin and vancomycin. Rates of CDI recurrence
among those treated with ﬁdaxomicin were substantially lower among
both immunocompetent (13% vs 26% for vancomycin; <0.01) and IS
(16% vs 27%; <0.01).
Conclusion: The net state of IS is predictive of CDI outcome. IS is
associated with higher death and lower CDI cure rates. The rate of
CDI recurrence remains substantially lower among patients treated with
ﬁdaxomicin regardless of their level of immunosuppression.
Young Investigator Award
K509 Emergence of antimicrobial resistance, linked to optimal
prescribing
S. Malhotra-Kumar* (Antwerp, BE)
Laboratory testing is often a critical component in the proper diagnosis
and optimal management of patients presenting with a broad range
of disease states. This is especially true of infectious disease, where
presenting signs, symptoms, and history are often insufﬁcient to
identify a pathogen, or sometimes even suggest an infectious etiology.
Practitioners often rely on laboratory values as an aid in the differential
diagnosis of infection. Increasingly, laboratory assays are being paired
with imaging modalities to further increase diagnostic accuracy. One
recent synergy is the use of an in vitro blood test for liver ﬁbrosis
(ELF™*) in conjunction with an ultrasound-based imaging technology
(ARFI*) that may enhance analysis of hepatic damage through
assessment of liver elasticity along with evidence of ﬁbrosis. In patients
with chronic viral hepatitis or other forms of hepatic disease, such an
approach could potentially reduce the risk and discomfort associated
with a liver biopsy through use of less-invasive methodologies. This
presentation will focus on key contributions of the laboratory in the
accurate identiﬁcation of an infectious origin by utilizing two separate
patient proﬁles. The case histories will be discussed to exemplify
the value of laboratory and other ﬁndings in the respective diagnosis
and management of two common conditions associated with infection:
bacterial sepsis and viral disease.
*Not available in the US.
Enterococci − where are we now?
S513 Current epidemiology of vancomycin-resistant enterococci in
Europe
G. Werner* (Wernigerode, DE)
Objective: To give an overview about prevalence of VRE in Europe and
speculate on possible routes of emergence and spread and reservoirs of
vanA/B type resistance.
Main topic: Eight types of acquired vancomycin resistance in
enterococci are known; however, only VanA and VanB are widely
prevalent. The major reservoir of acquired vanA/B type resistance is in
E. faecium; mainly among clinical strains. Ampicillin- and vancomycin-
resistant E. faecalis remain still rare. The supposed non-hospital reservoir
of vanA type E. faecium in animal husbandry and of the vanB gene
clusters in non-enterococcal, intestinal colonizers could be signiﬁcant but
their exact impact on a corresponding resistance gene pool in hospital
strains cannot be assessed properly so far.
Population analysis of E. faecium has revealed a distinct subpopulation
of hospital-associated strain types increasingly prevalent among the
nosocomial setting and showing higher rates of acquired antibiotic
resistances. Acquired ampicillin resistance and increased number of
high-level ciproﬂoxacin resistance are important phenotypic markers of
hospital-acquired E. faecium in Europe and experience has shown that
these features often precede increasing rates of vancomycin resistance
with a delay of several years. Hospital-associated strains can be
differentiated by molecular typing methods (MLVA, MLST) from human
commensal and animal strains and have additional genomic contents
(accessory genome) including several factors known or supposed to be
virulence-associated.
Several conditions are known to promote VRE colonisation, transmission
and subsequent infection; however, despite having populations with
similar predispositions, rates of vancomycin resistance vary all over
Europe between <2% and >30% among all clinical E. faecium
isolates. Nevertheless, VRE rates were constant during recent years
and signiﬁcant trends could not been identiﬁed. Few exceptional
developments will be discussed.
Outlook: A deeper molecular analysis of the population structure
of (hospital-associated) E. faecium and E. faecalis strain types and
their mobile genetic elements encoding vancomycin resistance including
detailed transposon, plasmid and genome analyses up to complete
genomic sequencing is inevitable for a better understanding of the
epidemiology of VRE and will allow establishing models of emergence
and spread of vanA/B type resistance among enterococci.
Do you know the concept of anti-anaerobic
quinolones?
S518 Clinical signiﬁcance of anti-anaerobic quinolones in VAT and
VAP
H. Mikamo*, Y. Yamagishi (Aichi, JP)
Ventilator-associated pneumonia (VAP), ventilator-associated bra-
chiotronchitis (VAT) and aspiration pneumonitis (AP) represent a
spectrum of aspiration syndromes. All diseases are common problems
encountered in the ICU, with VAP occurring in approximately 25% of
patients undergoing mechanical ventilation, and AP commonly occurring
in patients admitted to the ICU with an altered level of consciousness.
AP follows macroaspiration of oropharyngeal and/or gastric contents
in patients with an altered level of consciousness, dysphagia, or bowel
obstruction. VAP is widely believed to result from the microaspiration of
oropharyngeal material colonized by pathogenic microorganisms. In fact,
anaerobic bacteria have been frequently isolated from the oropharyngeal
ﬂora, their pathogenetic role in VAP, VAT and AP has been established.
In general, anaerobes have been considered to be common pulmonary
pathogens, and they have been believed to play a major role in aspiration
and nosocomial pneumonia. These are based on many studies conducted
in the 1970s, when transtracheal aspiration was used for the collection
of uncontaminated respiratory secretions. Consequently, antimicrobial
agents with anaerobic coverage would be recommended in patients with
aspiration pneumonia and nosocomial pneumonia.
Older ﬂuoroquinolones, such as ciproﬂoxacin and oﬂoxacin, are inactive
or only partially active against anaerobic bacteria. Newer quinolones,
such as sparﬂoxacin and levoﬂoxacin, have improved in vitro activities
against anaerobic bacteria but still have limited activities against certain
Gram-positive and Gram-negative anaerobic bacilli. Some of the newer
quinolones, such as moxiﬂoxacin, sitaﬂoxacin, and garenoxacin, and so
on, are much more active to both Gram-positive and Gram-negative
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anaerobic bacteria. Those antianaerobic quinolones would be useful for
the treatment of VAP, VAT and AP, which would be highly associated
with anaerobes.
Microbiol pathogenesis, pathophysiology of
infections diseases
O519 Relative ﬁtness of tigecycline-susceptible versus resistant
isolates of Acinetobacter baumannii recovered from a single
patient
M. Hornsey*, N. Woodford, D.W. Wareham (London, UK)
Objectives: Acinetobacter baumannii is an important nosocomial
pathogen that is of increasing concern owing to the many isolates that
are resistant to nearly all available antimicrobials. Tigecycline usually
remains active against otherwise multidrug-resistant A. baumannii
(MDRAB) though there are reports of resistance emerging, including
during tigecycline therapy. The ﬁtness cost of such resistance was
investigated in vitro, under normal and stressed laboratory growth
conditions and in vivo, using an insect model of A. baumannii infection
and a pre- and post-treatment pair of clinical isolates.
Methods: The emergence of efﬂux-mediated tigecycline resistance
during on-label usage in a representative of the A. baumannii UK lineage
‘OXA-23 clone 1’ has been described recently. The in vitro ﬁtness
cost of tigecycline resistance was determined using the pre-therapy
isolate, AB210 and the post-therapy isolate, AB211 in LB broth and
a microtitre plate-based growth kinetics assay. The inﬂuence of stress
was investigated by growing the isolates in: (i) LB at pH 4.5; (ii) LB
supplemented with 200 mM NaCl; (iii) one-third strength LB diluted in
saline; (iv) LB supplemented with 200mM 2,2’-dipyridyl (iron chelator).
Relative ﬁtness was calculated as follows: doubling time of parent/
doubling time of derivative. The ability of the isolates to form a bioﬁlm
was assessed in a microtitre plate using a crystal violet-based assay.
Virulence of AB210 & AB211 was assessed using a Galleria mellonella
(greater wax moth caterpillar) model of infection. An in vivo competition
assay was performed with a starting ratio of 1: 1 (AB210: AB211).
Results: The results of the in vitro studies are summarised in Table 1.
Pre-therapy isolate AB210 performed better than its tigecycline-resistant
counterpart, post-therapy isolate AB211, both under normal (full strength
LB broth) and stressed laboratory conditions except iron-limitation (LB
supplemented with 200mM 2,2’-dipyridyl). AB211 was better able to
form bioﬁlms than AB210. AB211 outcompeted AB210 in vivo by a
median ratio of 6: 1.
Conclusions: In comparison with the pre-therapy, tigecycline-susceptible
isolate (AB210), the post-therapy, tigecycline-resistant isolate (AB211)
was: (i) less ﬁt in vitro under all conditions except iron-limitation; (ii)
a better bioﬁlm producer and hence may persist longer; (iii) able to
outcompete AB210 in vivo and thus may be better adapted for survival
within the host.
O520 Hospital- and community-acquired methicillin-resistant
Staphylococcus aureus differ greatly in their ability to invade
bone cells, persist intracellularly and induce cell damage
J.P. Rasigade*, S. Trouillet, Y. Lhoste, T. Ferry, S. Tigaud, J. Etienne,
F. Vandenesch, F. Laurent (Lyon, FR)
Objectives: Staphylococcus aureus is the leading cause of bone and joint
infections (BJIs). Most methicillin-resistant S. aureus (MRSA) causing
BJIs are hospital-acquired (HA-MRSA), but community-acquired (CA)-
MRSA are an emerging cause of BJIs in outpatients. HA- and CA-
MRSA belong to distinct genetic backgrounds and are associated with
varying clinical presentations, CA-MRSA causing often more severe and
acute BJIs than HA-MRSA, which are frequently associated with relapse.
Underlying mechanisms for these differences are not fully elucidated. We
compared the intracellular persistence of, and cytotoxicity induced by
S. aureus clinical isolates belonging to major HA-MRSA and CA-MRSA
genetic backgrounds, in a model of intracellular bacterial challenge of
cultured osteoblasts.
Methods: In a gentamicin protection assay, osteoblastic MG-63 cells
were infected for 2h using clinical isolates (1 isolate per clone)
representative of HA-MRSA (ST8-Lyon and ST5-Geraldine clones) and
CA-MRSA (ST80-European clone). An ST80 MSSA variant was also
included to assess whether methicillin resistance impacts virulence.
Viable intracellular bacteria after 3, 24 and 48h incubation were
enumerated by plate counting after host cell lysis. Cytotoxicity was
assessed by lactate deshydrogenase (LDH) release assay after 24 and
48h incubation. Differences were tested for statistical signiﬁcance using
Mann Whitney U-test.
Results: The number of viable intracellular bacteria per well after 3,
24 and 48h incubation was 5.8-, 9.5- and 34.0-fold higher, respectively,
for HA-MRSA isolates than for CA-MRSA/ST80 isolates (p< 0.0001
for all differences). Conversely, excess LDH release after 24 and 48h
incubation was 2.9- and 2.0-fold higher in CA-MRSA/ST80- than HA-
MRSA-infected cells (p< 0.0001 for both differences). ST80 MRSA and
MSSA yielded identical phenotypes, ruling out a role for methicillin
resistance in this model.
Conclusion: S. aureus clinical isolates differed greatly in their ability
to invade and persist within bone cells. HA-MRSA isolates were able to
survive intracellularly while inducing moderate cell damage. Conversely,
CA-MRSA/ST80 isolates were highly cytotoxic and exhibited impaired
intracellular survival, a ﬁnding consistent with the acuteness of CA-
MRSA BJIs.
O521 Immunological and molecular mechanisms induced in an in
vitro model of co-culture of Helicobacter pylori and dendritic
cells
A. Hoce`s De La Guardia, C. Staedel, I. Kaafarany, A. Cle´ment,
P. Blanco, F. Me´graud, P. Lehours* (Bordeaux, FR)
Objectives: In gastric MALT lymphoma (GML) the B lymphocyte
proliferation is not directly induced by the contact with H. pylori but
is dependent on the presence of tumour inﬁltrated T lymphocytes (TL).
These TL recognize H. pylori probably via the dendritic cells (DCs).
GML occurs in a Th0/Th2 inﬂammatory context in contrary to the Th1
duodenal ulcer. Our aim is to understand this phenomenon and among
the developed research axes, the in vitro interaction between human DCs
and H. pylori is studied.
Methods: DCs were generated from monocytes isolated from human
blood by immunomagnetic sorting on CD14 and differentiated in the
presence of IL-4 and GM-CSF. These DCs were co-cultivated for 48h
with GML H. pylori strains. The impact of Multiplicity Of Infection
(MOI) and of released bacterial factors (Transwell model) was also
tested. The activation of DCs was evaluated by measuring the expression
of activation markers (CD40, CD80, CD83, CD86, CD197, HLA) by
ﬂow cytometry and by analyzing the production of cytokines by ELISA
and ﬂow cytometry. The expression of two microRNAs, miR146 and
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miR155 was quantiﬁed by RT-PCR. H. pylori activated DCs were co-
cultivated during 5 days with autologous TL. Their ability to induce TL
proliferation was measured by BrdU incorporation.
Results: All 9 tested strains were able to induce a signiﬁcant DC
activation, a strong production of INF-g, IL-10, IL-6, TNF-a, IL-8 and
IL-23, and an overexpression of miR146 and miR155. Activation markers
and miR155 decreased when MOI increased, and miR146 increased
with MOI. The cytokines adopt a Th1 proﬁle at low MOI but a Th2
proﬁle at high MOI. Pulsated DCs in the Transwell model expressed
HLA and miR146 only. The other activation markers, cytokines and
miR155 were thus contact-dependent. The pulsated DCs were able to
induce autologous TL proliferation, in a MOI-dependent manner. TL
then created a Th2 type environment. TL proliferation was not maximal
in presence of pulsated DCs in a Transwell model.
Conclusion: H. pylori strains associated with GML are thus able to
activate human DCs, and to promote an autologous TL response, in a Th2
type environment favourable to the GML development. They also induce
the expression of microRNAs that probably regulate the inﬂammatory
response. The The NFkB pathway seems to be here the major regulator
of this signalisation, in particular via the TLRs recognition.
O522 MicroRNA expression proﬁle in human macrophages
infected with Mycobacterium tuberculosis
L. Furci*, E. Schena, P. Miotto, P. Mantegani, D. Cirillo (Milan, IT)
Objectives: M. tuberculosis (Mtb) can persist alive and replicate into the
host due to its ability to interfere with the cellular mechanisms that allow
inactivation and clearance of bacteria inside macrophages. MicroRNAs
have been recently reported to be critical regulators of the mammalian
immune system through the dynamic ﬁne-tuning of gene expression.
Bacterial pathogens have been described to overcome host defense by
encoding proteins that suppress pathways regulated by these miRNAs.
Aim of this study is to search for miRNA expression proﬁles in human
macrophages infected with M. tuberculosis complex members.
Methods: Monocyte derived macrophages (MDM) were isolated from
healthy, Mantoux negative, donors PBMCS by plastic-adhesion and
differentiated in vitro for 7−10 days. Differentiated MDM were infected
with a virulent Mtb strain (H37Rv), either live or formaldehyde-
inactivated, and an attenuated Mtb strain (BCG). At selected time-points
cells were collected and solubilized for total mRNA extraction and retro
transcription. MicroRNA expression was measured and quantiﬁed by
qRT-PCR using TaqMan Array Human MicroRNA Card, a 384-well
micro ﬂuidic card containing dried TaqMan primers and probes for the
miRNAs best characterized up to now. Analysis of miRNA targets was
performed using the public database, Targetscan 4.2.
Results: We have examined changes in miRNA expression level in
four pools of 10 donors before and after infection: 2hr, to evaluate
which miRNAs are inﬂuenced by the attachment-entry of Mtb; 24hr and
72hr, to study miRNAs involved in the processes of Mtb persistence/
elimination from the host cells. Formaldehyde inactivated Mtb was
selected in order to discriminate the active effect of live Mtb from that
mediated by antigenic components of the Mtb wall. We found that Mtb
infection signiﬁcantly modulated (cut off 1.7 fold) 107 miRNA over 377
miRNA analyzed. Among these we could discriminate a set of miRNAs
differentially expressed during the early phase of the infection process
and others speciﬁcally associated with the intracellular persistence of
mycobacteria into the target cells.
Conclusion: This work describes for the ﬁrst time the miRNAs
expression proﬁle of human macrophages infected with M. tuberculosis.
The identiﬁcation of miRNAs crucially involved in Mtb persistence in
target cells will be a fundamental step towards the comprehension of the
pathogenesis of tuberculosis and the design of new drugs and vaccine
strategies.
O523 Toll-like receptor 4 polymorphism Asp299Gly and its
association with nasopharyngeal colonisation of Moraxella
catarrhalis in Finnish infants
J. Vuononvirta*, L. Toivonen, L. Lindholm, J. Mertsola, V. Peltola,
Q. He (Turku, FI)
Objectives: Nasopharynx is a cpmplex ecosystem that contains various
bacteria species among which Moraxella catarrhalis is a common one.
M. catarrhalis is an exclusively human pathogen and is responsible for
15%-20% of acute otitis media episodes in children. Toll-like receptors
(TLRs) are key components of human innate immunity and act as a
ﬁrst line of defence against invading microorganisms. TLR4 is involved
in recognition of bacterial lipids. Single nucleotide polymorphisms
(SNPs) in gene encoding TLR4 have been reported. TLR4 Asp299Gly
is associated with decreased response to lipopolysaccharide of Gram
negative bacteria. The aim of this study is to investigate whether
there is an association between nasopharyngeal bacterial colonization of
M. catarrhalis and TLR4 polymorphism Asp299Gly in Finnish infants.
Methods: From August 2008 to August 2010, 489 nasopharyngeal
swabs (NPs) and 412 blood samples were taken from 3-month-old
asymptomatic Finnish infants in a prospective cohort study carried out in
Turku, Finland. The semi-quantative culture was used for identiﬁcation
of different bacterial species and the pyrosequencing-based method was
used for detection of TLR4 polymorphism Asp299Gly.
Results: Of the 489 NP swabs, 290 (59%) were positive for at least one
of the four bacterial species:
122 (25%) for Staphylococcus aureus, 114 (23%) for M. catarrhalis, 55
(11%) for Streptococcus pneumoniae and 3 for Haemophilus inﬂuenzae.
Only 24 (5%) swabs were bacterial culture negative. The prevalence
of other bacterial species was 27% for Streptococcus sp, 21% for
Staphylococcus sp, 48% for Corynebacterium sp, 1% for Neisseria sp
and 0.5% for Haemophilus parainﬂuenzae. Of 412 infants with blood
samples, 72 (17%) were found to have polymorphism Asp299Gly of
TLR4. Colonization rate of M. catarrhalis was signiﬁcantly higher in
infants with TLR4 polymorphism Asp299Gly than those infants without
(39% vs 21%, P = 0.002). However, no such associations were found for
other bacterial species studied.
Conclusion: This study clearly shows thatM. catarrhalis colonizes more
often the nasopharynx of infants with TLR4 polymorphism Asp299Gly.
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O524 Trends in antimicrobial resistance in Acinetobacter spp.
from the European TEST programme
M. Hackel, D. Hoban, R. Badal, S. Bouchillon, B. Johnson, J. Johnson,
S. Hawser*, M. Dowzicky (Schaumburg, US; Epalinges, CH;
Collegeville, US)
Background: Acinetobacter spp. are a frequent cause of nosocomial
as well as community-acquired infections and represent increasingly
difﬁcult therapeutic challenges. The Tigecycline European Surveillance
Trial (T.E.S.T.) has been monitoring global resistance patterns of
signiﬁcant pathogens, including Acinetobacter spp., since 2004. This
report summarizes the susceptibility trends seen in Europe from 2004–
2010.
Methods: Clinically signiﬁcant Acinetobacter spp. were obtained from
27 European countries during 2004–2010. MICs for piperacillin-
tazobactam (PT), levoﬂoxacin (LVX), ceftriaxone (CAX), cefepime
(CPE), amikacin (AK), minocycline (MIN), ceftazidime (CAZ), tigecy-
cline (TIG), imipenem (IMI), and meropenem (MER) were determined
using supplied broth microdilution panels and interpreted according to
EUCAST guidelines.
Results: The % susceptible and MIC90 (mg/ml) for 5,455 Acinetobacter
spp. isolated in Europe over seven years are shown in the following table:
Conclusions: While the activity of all compounds tested (except
meropenem) decreased over time, only ceftriaxone, minocycline, and
piperacillin-tazobactam decreased signiﬁcantly (p< 0.001). Tigecycline
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exhibited the lowest MIC90 values for all years (1−2mg/ml), but has no
EUCAST breakpoint for Acinetobacter. Among drugs with breakpoints,
minocycline showed the highest %S each year tested.
O525 Molecular epidemiology of Acinetobacter baumannii in
Germany, 2005–2009
X. Schleicher*, P.G. Higgins, H. Wisplinghoff, D. Stefanik, M. Kresken,
H. Seifert (Cologne, Rheinbach, DE)
Objectives: Acinetobacter baumannii is one of the most prevalent
nosocomial pathogens contributing signiﬁcantly to morbidity and
mortality, mainly among patients in the ICU setting. Recent data suggest
a clonal population structure with several highly prevalent world-wide
clones. This study was conducted to evaluate the molecular epidemiology
of A. baumannii in Germany.
Methods: A total of 377 Acinetobacter isolates from three nationwide
surveillance studies prospectively collected from 17 centers between
2005 and 2009 (as part of the German Tigecycline Evaluation
Surveillance Trial, G-T.E.S.T.) were identiﬁed to species level using
reference methods. Among these, 140 A. baumannii were analyzed
using rep-PCR (DiversiLab®). A clonal cluster was deﬁned as >2
isolates from different centers showing >95% similarity. Antimicrobial
susceptibility was determined by broth microdilution. Presence of
carbapenem-hydrolyzing oxacillinases (OXA) was investigated by PCR.
Results: Acinetobacter genomic species 3 (GS3) was the most prevalent
species (n = 190; 50%), followed by A. baumannii (n = 140; 37%)
and Acinetobacter genomic species 13TU (GS13TU) (n = 8; 2%). 25
A. baumannii had an imipenem MIC 8mg/L and all had either
an OXA-58-like or OXA-23-like. The imipenem susceptibility rates
decreased from 96% in 2005 to 71% in 2007 and 76% in 2009.
Among imipenem-resistant A. baumannii the prevalence of OXA-58-like
decreased from 100% in 2005 to 0% in 2009 while the prevalence of
OXA-23-like increased to 31% in 2007 and to 100% in 2009. All GS3
and GS13TU isolates were susceptible to the carbapenems. However,
OXA-58-like (n = 5) and OXA-23-like (n = 2) genes were detected in
GS3 but not in GS13TU isolates.
Among A. baumannii isolates, world-wide clone 2 (WW2) was the most
frequently detected clonal lineage (n = 35) followed by WW1 (n = 6) and
WW4 (n = 4). However, the majority of isolates (n = 94) did not cluster
with any previously identiﬁed WW-clone and were found as either single
isolates or as small clusters of up to 4 isolates from a single center.
Carbapenem-resistance was signiﬁcantly more frequent among isolates
of WW2 (64% vs. 8%; p< 0.001).
Conclusion: The population structure of A. baumannii in Germany
is highly diverse. Among the few clonal clusters detected, WW2
was the most prevalent, geographically widespread and carbapenem-
resistant. These data underscore the high clonality of carbapenem-
resistant A. baumannii isolates.
O526 Aminoglycoside resistance and distribution of resistance
genes in sporadic and outbreak strains of Acinetobacter
baumannii isolated in Abu Dhabi
T. Pal*, A. Gazawi, A. Sonnevend, M. Ibrahim, S.E. Belal, M. Al-Haj
(Al Ain, AE)
Objectives: The aim was to investigate the differences in the level
of resistance and the distribution of aminoglycoside resistance genes
between sporadic and outbreak strains of Acinetobacter baumannii.
Methods: Sixty three non-repeat A. baumannii strains clustered into
seven distinct outbreak clones by macro-restriction and genotyping
were compared to 50 sporadic strains isolated in Abu Dhabi in
2008. Aminoglycoside resistance genes (aadA, aac(3)-Ia, aac(3)-Iia,
aac(6′)-Ih, aph(3’)-VI, ant(2’)-Ia, aph(3’)-Ia, aac(6′)-Ib, armA, strAB,
rmtA, rmtB, rmtC, rmtD, npmA) were detected by PCR. Antibiotic
susceptibility was tested against a wide range of drugs by disc diffusion
and to ceftazidime, imipenem, meropenem, ciproﬂoxacin, tigecycline,
colistin, gentamicin, amikacin, streptomycin, kanamycin, netilmicin,
spectinomycin and tobramycin by E-test.
Results: All outbreak strains and 48% of the sporadic isolates were
MDR (arbitrarily deﬁned as resistance to carbapenems and at least to
further two non-b lactam classes of drugs). The MIC values of different
aminoglycosides to different groups of strains are shown in Table 1. The
most frequent aminoglycoside resistance gene was armA among both
outbreak and sporadic isolates (61.9% and 52.0%, respectively) followed
by strAB (57.1% among outbreak strains) and by aadA and aph(3′)-VI
(38.0% each among sporadic isolates). The most common combination
of aminoglycoside resistance genes carried by members of the two largest
outbreak clones were: armA, strAB (with or without aac(3)-Iia) (Clone
D, N= 14) with high level of resistance to all aminoglycosides and
aph(3’)-VI, ant(2’)-Ia (with or without armA) (Clone F, N= 19) showing
high level of resistance to amikacin, gentamicin and kanamycin with
varying levels to other drugs.
Conclusion: Aminoglycoside resistance is wide-spread among local
outbreak isolates but also common among sporadic strains. In this latter
group it is also strongly linked to resistance to other antibiotic classes,
i.e. to multi-drug resistance. Particularly alarming is the wide-spread
distribution of armA, often localized on plasmids and spreading rapidly
in other parts of the world. Close monitoring of resistance clones and
resistance genes are needed to reveal the dynamics of rapidly increasing
aminoglycoside resistance in A. baumannii.
O527 Ceftazidime-resistance in Acinetobacter baumannii of clonal
complex 92 in Korea
Y. Lee*, Y. Kim, I.K. Bae, S.H. Jeong, K. Lee (Seoul, KR)
Objectives: The aim of this study was to deﬁne the epidemiological traits
of oxymino-cephalosporin-resistant Acinetobacter baumannii clinical
isolates from Korea.
Methods: A total of 378 non-duplicate clinical isolates of A. baumannii
were collected from 19 different hospitals in Korea in 2008.
Antimicrobial susceptibilities were tested by the disk diffusion assay.
PCR experiments were performed to detect genes encoding ESBLs, MBL
genes, and OXA carbapenemases. PCR products were subjected to direct
sequencing. Surrounding regions of the blaPER-1 gene was investigated
by sequencing overlapping PCR fragments. Southern blot experiments
were performed to identify location of the blaPER-1 gene. Strain typing
was performed by multilocus sequence typing (MLST) experiments.
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Results: 291/378 A. baumannii isolates were identiﬁed as clonal
complex (CC) 92, including sequence type (ST) 69, ST75, ST92, ST137,
and ST138, by MLST. Most (288/291) A. baumannii isolates of CC92
showed resistance to ceftazidime, in contrast to only 7/87 isolates of
non-CC92 did. The ISAba1 element upstream of the blaADC gene was
detected in 282/291 isolates of CC92 and 7/87 isolates of non-CC92.
The blaPER-1 gene was detected in 116/291 isolates of CC92 but not
in 87 isolates of non-CC92. The blaPER-1 gene was located in the
transposon Tn1213 (ISPa12-blaPER-1-Deltagst-ISPa13) in 93 isolates
and in a complex class 1 integron (orf513-blaPER-1-ATP binding protein
gene) in 6 isolates. The probe speciﬁc for blaPER-1 hybridized with
I-CeuI-digested fragments, which also hybridized with a probe speciﬁc
for 16S rRNA, suggesting the chromosomal location of the gene.
Conclusion: The present data show that A. baumannii isolates of CC92
are widely disseminated in Korea and they acquire ceftazidime-resistance
by production of PER-1 and/or overproduction of ADC enzymes.
O528 Endemic multidrug-resistant Acinetobacter baumannii from
animal specimens in German veterinary clinics
S. Kreder*, E. Prenger-Berninghoff, R. Weiss, T. van der Reijden,
P. van den Broek, G. Baljer, L. Dijkshoorn (Gießen, DE; Leiden, NL)
Objectives: Members of the genus Acinetobacter comprise well-known
nosocomial pathogens responsible for infections and epidemic spread
among critically ill human patients including multitrauma patients. The
main three clinically relevant species, A. baumannii, A. genomic species
(gen. sp.) 3 and A. gen. sp. 13TU, and one environmental species,
A. calcoaceticus form the so-called A. calcoaceticus-A. baumannii
(Acb) complex whose representatives cannot be distinguished well by
phenotypic attributes. Over recent years, an increase in the number of
multidrug-resistant Acinetobacter isolates from animal specimens was
recognized by the microbiology department of the Giessen Veterinary
Faculty. The aim of this study was to investigate the species and strain
diversity of these organisms and to compare them with a large set of
human Acinetobacter strains of the Leiden University Medical Center
collection.
Methods: From 2000 through 2008, 137 Acinetobacter isolates were
phenotypically identiﬁed as belonging to the Acb complex. Of these, 56
were selected for further investigation. The organisms were characterized
by three genotypic methods including ampliﬁed ribosomal restriction
analysis (ARDRA), macrorestriction analysis (PFGE) and AFLPTM
genomic ﬁngerprinting.
Results: Using ARDRA, 52 isolates were identiﬁed to A. baumannii,
three to A. gen. sp. 3 while one strain with a unique proﬁle remained
unclassiﬁed. With PFGE, three main clusters of strains with highly
similar proﬁles and six unique types were distinguished. These ﬁndings
were conﬁrmed by AFLP analysis. Moreover, by comparison to reference
strains included in the Leiden AFLP database, 19 isolates were identiﬁed
as belonging to the European clones that are notorious for their
association with outbreaks worldwide.
Conclusion: The study indicates persistence and spread of genotypically
related strains within and among the German veterinary clinics. The
occurrence of the European clones I-III might indicate that, like in
human medicine, A. baumannii is an upcoming opportunistic pathogen
in veterinary medicine. It also raises the question, whether the organisms
can spread from animals to humans or whether the animals have acquired
the organisms from humans.
Controlling MRSA
S535 Measures to be taken: hand hygiene, isolation, hospital
cleaning
B. Allegranzi* (Geneva, CH)
Background: MRSA is major problem worldwide both in healthcare
settings and in the community, causing an increasing burden of
morbidity, mortality and costs. Control of MRSA spread within
healthcare facilities is crucial to avoid complications threatening patient
safety during healthcare delivery. Relevant changes in some MRSA
national epidemiological trends have been detected over the last years.
Methods: The presentation will be based on systematic reviews of
the literature on the effectiveness of measures implemented for MRSA
control. In particular, aspects related to the relative impact on the
transmission risk, to cost-effectiveness and to implementation feasibility
in a range of healthcare settings and according to the available resources
and facilities, will be considered. The evaluation will cover both the
facility and the country levels.
Results: The best approach to MRSA control is based on multiple ac-
tions including early identiﬁcation and decolonization of carriers, careful
application of contact precautions, in particular optimal hand hygiene
practices and patient location in single room or cohorting according to
the local epidemiology and available facilities, environmental cleaning,
and locally tailored approaches to appropriate antibiotic use. Strategies
implemented by countries that were able to keep MRSA incidence at
low level and, more importantly, by countries that succeeded to reduce
high MRSA incidence, in particular bacteraemia, will be presented
along with the related results and trends. Controversies in the ﬁeld
of MRSA control will be highlighted; among these: universal versus
targeted screening; the advantages and limits of rapid screening methods;
the issue of antibiotic resistance following carriers’ decolonization;
challenges in the application of isolation precautions; the actual role
of environmental cleaning, given the relatively low potential role of
environmental reservoirs in MRSA transmission; the actual correlation
of MRSA incidence reduction and the consumption of alcohol-based
handrub.
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S539 Aminoglycosides
R. Moellering* (Boston, US)
The ﬁrst clinically useful aminoglycoside, streptomycin, was isolated
from a strain of Streptomyces griseus by Waksman and colleagues in
1943. This drug had remarkable activity against many species of Gram-
positive and Gram-negative bacteria as well as the tubercle bacillus.
However, when used as a single agent for treating tuberculosis, there was
rapid emergence of resistance. That was subsequently overcome by using
the drug in combination with other antituberculous agents. Over the
next quarter century, a number of other aminoglycosidic aminocyclitol
antibiotics were discovered, including neomycin (1949), kanamycin
(1957), gentamicin (1963), and tobramycin (1967). During this time,
extensive studies of the mechanism of action of the aminoglycosides
carried out, and based on detailed information concerning mechanisms
of enzymatic resistance, it became possible to provide a number
of chemical modiﬁcations of the basic aminoglycoside structure to
overcome resistance. Thus drugs such as amikacin (1972), dibekacin,
and others were developed speciﬁcally to overcome mechanisms of
enzymatic inactivation. Work in this arena has continued to the present,
with several aminoglycosides, including SPX-1212 and ACHN-490, in
preclinical or early clinical development for the treatment of infections
due to organisms resistant to standard aminoglycosides. The issue of
nephro- and ototoxicity has plagued all of the aminoglycosides, and
although the currently available agents vary in their toxicity, it has been
impossible thus far to design a compound in this class of antimicrobial
agents completely devoid of oto- and/or nephrotoxicity.
S540 From sulphonamides to ﬂuoroquinolones
A. Dalhoff* (Kiel, DE)
In the early 1930’s it was noted that azo dyes were active in vitro
against E coli and in vivo against b-hemolytic streptococci and that
a sulfonamide moiety para to the azo group mediated in vivo activity;
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the ﬁrst antibacterially active sulfonamide “prontosil” was synthesized
in November 1932. Shortly thereafter it was noted that an alkyl side
chain − indispensable for antiparasitic action of e.g. plasmoquine or
chloroquine − was not required for in vivo activity of sulfonamides. The
story of quinolones begins with chloroquine; nalidixic acid was identiﬁed
as a byproduct of chloroquine synthesis in 1962.
Both, sulfonamides and quinolones, presented opportunities for landmark
studies on protein binding (pb) and PK/PD of antibacterials. In 1942/3
Davis worked on the impact of pb on PK of sulfonamides and described
that “it is probable that only the unbound drug is bacteriostatically
active”. Analysis of the impact of pathology on and thermodynamics
of pb resulted in the formulation of an “efﬁcacy index” deﬁned as
free-drug AUC/MIC, being correlated to in vivo efﬁcacy. Using values
for the sulfonamide dissociation constant, pH, blood ﬂow at the focus
of infection, pb, metabolism and excretion an “area under the tissue
concentration vs time curve” was described as an indicator of probable
clinical success. A review on the “pharmacodynamics of sulfonamides”
was published in 1949.
In contrast to most antibacterials then available, nalidixic acid showed
a broad spectrum of activity against Gram negatives, but resistance
developed rapidly. The ﬁrst FQ, ﬂumequine bearing the F-atom at C-6,
was developed in 1976; it was active against nalidixic acid resistant
isolates. But till 1980 FQ development did not advance signiﬁcantly;
it was demonstrated then that the presence of a ﬂuorine at C-6 and
additional modiﬁcations at C-7, C-8 and N-1 improved antibacterial
activity and PK. Systematic population PK/PD analysis relating speed of
antibacterial action and FQ exposure to infectious outcome demonstrated
that pharmacodynamic endpoints “provide a new paradigm for clinical
trials”.
Both, sulfonamides and sulfones like sulfadiazine and dapsone, as
well as FQs like ciproﬂoxacin, levoﬂoxacin, moxiﬂoxacin are used
therapeutically; FQs like delaﬂoxacin, J&J Q2, WCK 771, ﬁnaﬂoxacin
and ciproﬂoxacin or levoﬂoxacin for inhalation are being developed
demonstrating that both drug classes are still indispensable for treatment
of infectious diseases.
Imaging infection
S542 Imaging microbes in vivo
A. Richter-Dahlfors* (Stockholm, SE)
A cornerstone of infection biology is the study of the complex
interplay between infecting organism and their host. Combining the
power of multiphoton-based live animal imaging with the precision
of micro-puncture, we have developed a system that allows us to
visually track a live infection from the ﬁrst interactions between
host and pathogen, within a living animal. Using GFP expressing
clinical uropathogenic E. coli (UPEC) we follow the progressing
pathophysiology of pyelonephritis, revealing previously un-described
vasal, immune and nephritic events. Isogenic GFP expressing UPEC
strains, carrying mutations in virulence factor genes such as Type 1
and P ﬁmbriae, alfa-haemolysin and LPS, have been used to address
their role for the kinetics of bacterial colonization in vivo as well
as the host’s immune and physiological responses. Furthermore, we
applied a hypothesis-free approach, based on transcriptional proﬁling and
comparative tissue transcriptomics, to identify components of the multi-
cellular tissue responses directing the host response. A core of genes
constituting a “General tissue response to early local bacterial infections”
was demonstrated, and revealed a marked role of IFN-g in prompt inter-
organ communication in early local tissue response to infection.
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Resistant superbugs: a comparative analysis
of Asia versus Europe
S547 ESBLs and carbapenemases
D. Livermore* (London, UK)
Europe and Asia are vast continents with great diversity, including
countries with very different infrastructures, public health systems,
patterns of antibiotic use and, so far as can be judged, resistance rates. A
few surveillance systems − MYSTIC, SMART and SENTRY examine
Gram-negative bacteria from both continents. Whilst their coverage is
tiny relative to total population, all point to higher rates of cephalosporin
resistance and ESBL production in much of Asia compared with Europe.
Several show India to have exceptionally high ESBL rates, at around
50−80% in both Klebsiella and E. coli, whereas ESBL rates of 20−50%
are widely seen across East Asia vs. 5−15% for most Western Europe.
CTX-M-15 is now the predominant ESBL in Europe except Iberia and
in Asia as far east as India, but is replaced by CTX-M-14 in the Far East
and, strangely, in Spain. One lineage of uropathogenic E. coli, Sequence
Type (ST)131, is particularly associated with cephalosporin resistance,
usually but not always mediated by CTX-M-15 enzyme; it occurs widely
across both continents, also in Africa, N. American and Australia. The
dissemination of carbapenemases across the two continents is at an
earlier stage than that of ESBLs and these enzymes remain extremely
rare in many countries. Nevertheless there is extensive dissemination
of NDM-1 metallo-carbapenemase in India and Pakistan, of VIM in
Greece, OXA-48 in Turkey and KPC (an enzyme that originated in
the US) in Greece. These are being introduced to further countries in
both continents by human migration, international lifestyles and medical
tourism, with cluster outbreaks of producers in, for example, China,
Poland, Italy and the UK. One of the most potentially disturbing, but least
clear, aspects is the extent to which resistant Enterobacteriaceae with
ESBLs and carbapenemases have entered the wider ecosystem in those
countries, largely in South Asia, where there is inadequate separation
of drinking and waste water and the extent to which this may drive the
problem by allowing gut colonisation of large numbers of residents.
Risk factors other than neutropenia for
developing infection in immunosuppressed
patients
S549 Toll-like receptors polymorphisms and fungal infections
L. Romani* (Perugia, IT)
Pro-inﬂammatory cytokines are an essential component of host defence
to fungi. Murine models and clinical evidence have revealed signiﬁcant
cytokine derangement in severe fungal diseases raising the suggestion of
a causative role for maladaptive cytokine release in the disease course. A
number of study is adding to the growing evidence that genetic variation
in pro-inﬂammatory cytokines has a role in susceptibility and survival
in many infectious disease. Several polymorphisms have been identiﬁed
in genes encoding for pro-inﬂammatory/anti-inﬂammatory cytokines,
such as TNF-a, IL-6, IL-10, INFg, IL-1Ra, IL-23R, IL-7Ra and
IL-10RB, and recently studies have shown association with susceptibility
to fungal infections in polymorphism at pattern recognition receptor
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(PRR) genes. Largely known for their role in inducing protective
immune responses, PRR engagement may paradoxically favour fungal
infections, by inducing inﬂammatory pathology and impairing antifungal
immunity. Although the dissection of complex genetic traits modulating
susceptibility to fungal infections is complex, the contribution of host
immune genetics may hold the key to elucidating new risk factors for
these severe, often fatal diseases.
Supported by FP7-HEALTH-2009 ALLFUN Project (Contract number
260338)
S550 Complement and fungal infections
C. Lass-Flo¨rl* (Innsbruck, AT)
Fungal infections are a serious complication in immunocompromised
patients such as human immunodeﬁciency virus-infected individuals,
patients with organ transplantations or with haematological neoplasia.
The lethality of opportunistic fungal infection is high despite a
growing arsenal of antimycotic drugs, implying the urgent need for
supportive immunological therapies to strengthen the current inefﬁcient
antimicrobial defences of the immunocompromised host. Therefore,
increasing effort has been directed to investigating the interplay between
fungi and the host immunity and thus to ﬁnd starting points for additional
therapeutic approaches. Important aspects include the activation of
the complement system by the fungal pathogen, the efﬁciency of
the complement-associated antimicrobial functions and the arsenal of
immune evasion strategies applied by the fungi. The broad spectrum
of complement-associated immune reactions includes the deposition
of complement products on the fungal surface to opsonise them for
phagocytosis, the activation and chemoattraction of immune cells, and
the stimulation of virtually the whole immunodefence network (humoral
immunity, T-cell response, and induction of cytokine and chemokine
expression). This central role of complement as the ﬁrst line of antifungal
defence could be demonstrated in many cases, e.g. by the fact that
complement-deﬁcient mice are extremely susceptible against several
fungal infections. The twin functions of complement as an interactive
player of the innate immunity and at the same time as a modulator of the
adaptive immunity make this defence weapon a particularly interesting
therapeutic candidate to mobilise a more effective immune response and
to strengthen in one fell swoop a broad spectrum of different immune
reactions. The ’Yin-Yang’ nature of the complement system in fungal
infections, as growing evidence assigns to complement a contributory
part in the pathogenesis of fungus-induced allergic manifestations.
S551 Mannose-binding lectin and bacterial infections in patients
with haematological cancer
M. Aoun* (Brussels, BE)
Genetic defects that impair the recognition of pathogens by the innate
immune system, may increase the risk of infectious diseases. Mannose-
binding lectin (MBL) an ancestral molecule that survived throughout the
evolution, is a C-type lectin receptor. It has a carbohydrate recognition
domain that binds to microbial polysaccharides of bacteria, fungi,
viruses and protozoa. It activates the complement system and facilitates
phagocytosis of microorganisms.
In humans, MBL is encoded by the gene MBL2 located on chromosome
10q25, Exon-1 structural mutations (O variant) and polymorphism
in promotor region (LX haplotype) result in low serum MBL
concentrations. MBL deﬁciency has been associated with an increased
risk of autoimmune diseases, cardiovascular diseases, cystic ﬁbrosis,
cancer and an increased risk of infection with more severe course. Low
serum levels of MBL are found in 30−40% of white people and very low
levels in about 8−10%. Because many components of the innate immune
system are redundant, MBL deﬁciency appears to be an important
risk of infection when it is combined with other immunodeﬁciencies.
These include early childhood with immune immaturity, primary
and secondary immunodeﬁciencies and oncology patients receiving
chemotherapy. Patients with haematological malignancies are at high
risk of developing chemotherapy-induced neutropenia and a variety
of bacterial and fungal infections with life-threatening complications.
During this period of immune paralysis of phagocytes and lymphocytes,
the non-cellular components of the innate immune systems, not affected
by the immunosuppressive drugs, may become an important alternative.
Several studies in children and adults tried to assess the role of
serum MBL deﬁciency in this setting. Heterogeneity of patients, small
numbers, different cut-off values for deﬁning MBL deﬁciency have
led to conﬂicting results. We recently reported in a large prospective
study that MBL-deﬁciency patients with haematological malignancy
have more severe infections including pneumonia, bacteremia, invasive
fungal infections or sepsis, after receiving chemotherapy.
These results have been conﬁrmed in another prospective trial in myelo-
ablative sibling allogeneic hematopoietic stem cell transplantation. These
reports suggest that MBL replacement therapy may be useful in patients
at high-risk of severe infections in post-chemotherapy period.
